State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

Filing at a Glance

Company: MVP Health Plan, Inc. Product Name: VT Small Group 2025

State: VermontGMCB

TOI: H16G Group Health - Major Medical Sub-TOI: H16G.003G Small Group Only - Other

Filing Type: GMCB Rate
Date Submitted: 05/13/2024

SERFF Tr Num: MVPH-134081005

SERFF Status: Assigned

State Tr Num: State Status: Co Tr Num:

Effective 01/01/2025

Date Requested:

Author(s): Eric Bachner, Julia Savasta, Nicholas Kender

Reviewer(s): Jacqueline Lee (primary), Michael Barber, Laura Beliveau, Tara Bredice

Disposition Date:
Disposition Status:
Effective Date:

State Filing Description:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

General Information

Project Name: Status of Filing in Domicile:
Project Number: Date Approved in Domicile:

Requested Filing Mode: Review & Approval Domicile Status Comments: Explanation for Combination/Other: Market Type: Group

Submission Type: New Submission Group Market Size: Small

Group Market Type: Employer, Other Explanation for Other Group Market Type: Small Group

Overall Rate Impact: 9.34% Filing Status Changed: 05/13/2024

State Status Changed:

Deemer Date: Created By: Julia Savasta

Submitted By: Julia Savasta Corresponding Filing Tracking Number:

PPACA: Non-Grandfathered Immed Mkt Reforms

PPACA Notes: null

Exchange Intentions: Plans are proposed to be sold on the state of Vermont's

exchange.

Filing Description:

These rates are for Small Group members purchasing coverage through the VT Exchange (or ACA-compliant plans directly from MVP) effective January 1, 2025.

Company and Contact

Filing Contact Information

Eric Bachner@mvphealthcare.com

625 State Street 518-991-3417 [Phone]

Schenectady, NY 12305

Filing Company Information

MVP Health Plan, Inc.CoCode: 95521State of Domicile: New York625 State StreetGroup Code: 1198Company Type: HealthSchenectady, NY 12305Group Name:Maintenance Organization

(518) 388-2469 ext. [Phone] FEIN Number: 14-1640868 State ID Number:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

Filing Fees

State Fees

Fee Required? No Retaliatory? No

Fee Explanation:

SERFF Tracking #: MVPH-134081005 State Tracking #: Company Tracking #: Company Tracking #:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

Rate Information

Rate data applies to filing.

Filing Method: SERFF

Rate Change Type: Increase

Overall Percentage of Last Rate Revision: 11.540% Effective Date of Last Rate Revision: 01/01/2024

Filing Method of Last Filing: SERFF

SERFF Tracking Number of Last Filing: MVPH-133660956

Company Rate Information

Company Name:	Company Rate Change:	Overall % Indicated Change:	Overall % Rate Impact:	Written Premium Change for this Program:	Number of Policy Holders Affected for this Program:	Premium for	Maximum % Change (where req'd):	Minimum % Change (where req'd):
MVP Health Plan, Inc.	Increase	9.340%	9.340%	\$12,581,628	1,209	\$134,638,660	11.700%	5.180%

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

Rate Review Detail

COMPANY:

Company Name: MVP Health Plan, Inc.

HHS Issuer Id: 77566

PRODUCTS:

Product Name	HIOS Product ID	HIOS Submission ID	Number of Covered Lives
VT Small Group HMO	77566VT005		15027

Trend Factors:

FORMS:

New Policy Forms: Affected Forms:

Other Affected Forms: VT EXCHANGE COC

REQUESTED RATE CHANGE INFORMATION:

Change Period: Annual
Member Months: 192,917
Benefit Change: Increase

Percent Change Requested: Min: 5.18 Max: 11.7 Avg: 9.34

PRIOR RATE:

Total Earned Premium: 134,638,660.00 Total Incurred Claims: 122,532,877.00

Annual \$: Min: 631.98 Max: 1,094.86 Avg: 746.65

REQUESTED RATE:

Projected Earned Premium: 147,220,288.00 Projected Incurred Claims: 133,097,371.00

Annual \$: Min: 702.04 Max: 1,183.81 Avg: 816.42

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

URRT

State Determination

Review Status: Incomplete

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

URRT Items

Item Name	Attachment(s)
Unified Rate Review Template	UnifiedRateReviewVTSG2025_2024050914457.xml
Actuarial Memorandum	2025-Federal-Act-Memo-Vermont-Exchange-Small.pdf
Actuarial Memorandum - Redacted	2025-Federal-Act-Memo-Vermont-Exchange-Small-Redacted.pdf
Consumer Justification Narrative	Consumer-Disclosure-Form-2025-VT-Exchange-Small.pdf
Other Supporting Documents	Unified-Rate-Review-VT-SG-2025.pdf

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number:

Attachment UnifiedRateReviewVTSG2025_2024050914457.xml is not a PDF document and cannot be reproduced here.



Contact Information

Company Identifying

<u>Information</u>

Company Legal Name: MVP Health Plan, Inc.

HIOS Issuer ID: 77566 NAIC Number: 95521

Primary Contact Information

Contact Name: Eric Bachner, ASA

Contact Title: Director, Commercial Market & Valuation Actuary

Primary Contact Phone #: 518-991-3417
Primary Contact Address: 625 State Street

Schenectady, NY 12305

Primary Contact E-mail: EBachner@mvphealthcare.com

ACTUARIAL MEMORANDUM

2025 Vermont Small Group Exchange Filing

General Information

This memorandum details the methods and assumptions underlying the proposed 2025 premium rates for the State of Vermont's small group ACA compliant market. These products will be issued by MVP Health Plan, Inc. (MVP), a non-profit subsidiary of MVP Health Care, Inc. The rate filing has been prepared to satisfy the requirements of 8 V.S.A §5104 as well as the requirements of the Federal ACA including 45 CFR Part 156, §156.80. The premium rates are effective between 1/1/2025 and 12/31/2025. There is one benefit plan being retired and one new benefit plans being added. MVP modified several of the benefits being offered, and the updated forms have been submitted in a separate SERFF filing as well as forms for the new plan. The proposed average rate increase (MVP's revenue increase) is 9.3%, with increases ranging from 5.2% to 11.7%.

Drivers of Rate Increase

The proposed premium rates reflect an increase over the prior rates due to single risk pool experience which is more adverse than assumed in the current rates and medical and pharmacy cost and utilization inflation. Premium rate increases are varying by plan due to benefit modifications of several benefits being offered as well as the impact of fixed PMPM non-claim costs on premiums that vary based on benefit level.

Market/Benefits

All benefit plans included in this rate filing are available to small employer groups. All Essential Health Benefits (EHBs) are covered. Only one EHB substitution was made as required by the Department of VHA, a substitution for the \$2,000 annual Private Duty Nursing benefit limit in the benchmark plan. MVP contracted Milliman to determine an actuarially equivalent visit limit, and the experience period data reflects this actuarially equivalent limit.

The non-standard plans proposed by MVP and included in this rate filing contain two benefits in excess of the EHBs: a wellness benefit and an acupuncture allowance of \$500. The wellness benefit and acupuncture allowance are included in all non-standard products and the wellness benefit is filed as a mandatory rider, form: FRVT366.

To inform consumers of the availability and details of the products included in this filing, MVP will provide community outreach support as well as offer web and print product content and other printed product materials for VT plans. MVP will also have a mass media presence to further educate health care customers in Vermont.

The book of business affected by this rate filing is 1,209 policyholders, 9,306 subscribers and 15,027 members based on February 2024 membership.

Experience Period Premium and Claims (Worksheet 1, Section 1 of Unified Rate Review Template)

Worksheet 1, Section 1 of the Unified Rate Review Template contains MVP Health Plan, Inc. small group data for Vermont members over the time period 1/1/2023 - 12/31/2023, completed through 3/31/2024.

MVP does not project to rebate consumers for 2023 dates of service, and therefore no adjustments were made to the earned premium amount reflected on Worksheet 1, Section 1 of the Unified Rate Review Template. The earned premium shown reflects the amount of premium MVP collected from groups over the experience period.

Allowed claim data includes claims from our fee for service (FFS) claim warehouses (medical and pharmacy) along with additional medical expenses not captured in the claim warehouse such as: payments associated with medical home, physician incentive payments, FFS write-offs and net reinsurance expenses.

An allowance for incurred but not reported paid claims (IBNR) was added to the experience period fee-for-service (FFS) medical claims. IBNR files were supplied directly from MVP's reserving actuary. MVP uses a combination PMPM and completion factor method to develop IBNR estimates, and Vermont specific data for the experience period was used to develop the factors. The fee-for-service experience period claims were reconciled with the IBNR lag triangles to ensure accuracy.

The Risk adjustment reflected in the experience period is for the merged market and includes High Cost Risk Pool recoveries per the URRT instructions.

A summary of experience period claims processed through MVP's claim system, experience period costs not processed through MVP's claims system, as well as an estimate of IBNR are summarized below for the claims shown in Worksheet I, Section I of the URRT.

	Allowed	Incurred
Claims Processed Through Claim System	\$140,395,018	\$115,973,687
Experience Period Costs Not Processed Through Claims System	\$3,719,476	\$3,719,476
IBNR	\$3,783,235	\$3,118,071
Total	\$147,897,729	\$122,811,234

Benefit Categories (Worksheet 1, Section 2 of Unified Rate Review Template)

MVP determines benefit category based on the type of claim form submitted in conjunction with the code and type of code attached to the claim form (i.e. ICD-9, ICD-10, Diagnosis Code, or HCPCS). The "Other Medical" category includes pediatric dental claims. The "Capitation" category includes capitated payments as well as all other claims not processed through MVP's claim warehouses.

Medical Trend Factors

The assumed unit cost trends reflect known and assumed price increases from MVP's provider network, weighted by benefit category. The Capitation unit cost trend reflects the expected change between the capitated and non-FFS claim expense between the experience period and the projection period.

MVP analyzed historical utilization patterns for the ACA-compliant business to determine whether there has been a utilization trend pattern in the recent past. Because of the rapid membership growth in this block in the past several years and COVID-19, the utilization trends produced by the model were not considered reliable. However, the regulatory actuary in the 2020 rate filing performed an analysis that found that "a reasonable range for market wide utilization trend to be 1% to 4%". MVP has maintained this same trend in the filing each year. Because MVP believes that their data still lacks necessary stability and L&E's view of utilization trend encompasses the entire market, MVP has built in a 1% annual utilization trend for this filing.

Rx Trend Factors

Annual allowed Rx trend factors split by generic, brand, and specialty drugs are provided by MVP's PBM and were determined using MVP specific data over the experience period by drug class. The forecast provided by MVP's PBM accounts for drugs coming off patent, changes in average wholesale price, new drugs being released to the market, and price competitiveness amongst generic and brand drug manufacturers.

Credibility Manual Rate Development (Worksheet 1, Section 2 of Unified Rate Review Template)

MVP is assuming that the small group market risk pool membership base of 192,917 member months in the experience period is fully credible for rating purposes. Therefore, the applied credibility percentage is 100.00% (0.00% weight on credibility manual).

Projection Factors (Worksheet 1, Section 2 of Unified Rate Review Template)

Morbidity Adjustment-Impact of COVID Vaccines

During the experience period, MVP was responsible for the administration cost of COVID-19 vaccines for all 12 months but began to be responsible for the full ingredient cost of those vaccines starting in September 2023. MVP is projecting the cost for 2025 to be: the 2023 utilization of COVID-19 vaccines for all 12 months multiplied by \$140, which represents the full amount for ingredient and administration costs. Therefore, the \$0.43 PMPM value found in line 12 represents the difference between the projected cost and the experience cost. The difference between the projected cost and the experience cost has an impact of 0.1%.

Plan Design Changes- Impact of Hearing Aids as EHB

Hearing aids were added as an essential health benefit in 2024. MVP analyzed historical experience in its New York population and determined this mandate would increase the experience period allowed claim cost by 0.04%.

Not Included- Adjustment for H.766

Vermont House Bill H.766 is "an act relating to prior authorization and step therapy requirements, health insurance claims, and provider contracts," and it has the potential to significantly raise the cost of medical claims in the Vermont commercial health insurance market. MVP is still analyzing the contents of the bill (and subsequent amendments that have been filed and approved), but our preliminary analysis suggests this would increase premium rates by 8-10%.

At the time of this filing (last action being taken on 5/3/24), the bill has been approved by both chambers of the Vermont Legislature and is awaiting signature or veto by the Governor.

Given the timing of this decision, the likelihood of a signature or override of the Governor's veto, and the magnitude of the bill in question, MVP is preparing to file an amendment to our rate filing shortly after submission to include the final impact of the bill in our premium rates.

Reinsurance (Worksheet 1, Section 2)

MVP is reflecting \$0.00 PMPM in reinsurance recoveries during the projection period.

Federal Risk Adjustment Program (Worksheet 1, Section 2)

MVP contracted with an external actuarial consultant to project expected transfer for 2023. MVP is expected to pay \$5,283,764 into the small group market transfer pool for 2023. This is \$27.39 on a PMPM basis or 4.3% of experience period claims prior to market-wide adjustments.

The URRT instructions state that the projected risk adjustment PMPM on Worksheet 1 is to be calculated on an allowed basis. Therefore, MVP has taken the projected risk adjustment PMPM on a net basis and divided by the projection period paid to allowed ratio to come up with the value shown (\$37.34 PMPM).

Exchange User Fees (Worksheet 1, Section 2)

Vermont's Exchange is not a Federally-Facilitated Exchange, therefore 0.00% of premium is built in to account for user fees during the projection period.

Market-Wide Adjusted Index Rate

The experience period index rate of \$766.64 is equal to the small group market allowed claim data for the time period, 1/1/2023 - 12/31/2023, completed through 3/31/2024.

The actual market adjusted index rate for the projection period equals \$890.94. This value was computed by adjusting the projection period index rate for the federal risk adjustment program, reinsurance and marketplace user fees.

Please see above for details on the computation of the projected value of the risk adjustment program. Note that this is a true expectation of allowed costs and is not equivalent to the adjusted claim cost for pricing on Exhibit 6 of the rate filing.

Actuarial Values and Cost Sharing Design of Plan (Worksheet 2, Section 3)

The AV Metal Level for each plan was determined using the Federally prescribed Actuarial Value Calculator. Adjustments for aggregate deductibles, the VT Rx OOPM, and safe harbor prescription Rx benefits were made to the calculator results for the non-standard Gold 3 and non-Standard Silver 2 plans. The actuarial certification of these adjustments has been included.

The Benefit Actuarial Value for each plan was determined using MVP's in-house benefit pricing tools. The pricing tools value the expected net paid claim cost associated with unique benefit plan designs from a starting single risk pool allowed amount. The AV is the ratio of the expected paid to allowed amount for each plan design. MVP did not reflect any induced utilization in the projection of the net paid amounts for each unique benefit plan.

The induced utilization factors used to set premium rates and compute the average in-force induced utilization factor are the HHS prescribed induced utilization factors of 1.00 for Bronze, 1.03 for Silver, 1.08 for Gold, and 1.15 for Platinum.

The actual paid to allowed ratio during the experience period and the assumed paid to allowed ratio used for pricing differ. The actual paid to allowed ratio (including assumed payments for cost sharing reductions) for the experience period is different than the pricing paid to allowed ratio produced by MVP's internal benefit relativity model. Because MVP prices using net claim expense instead of allowed claims, the allowed claims in the URRT need to be adjusted for the difference in the paid to allowed ratios to develop an equivalent Plan Adjusted Index Rate. The total of this adjustment is 1.7%.

The total adjustment made is the product of the three values (AV, induced demand, and difference in paid to allowed ratio).

Provider Network Adjustment (Worksheet 2, Section 3)

MVP only offers one provider network for its Vermont plans; therefore, no plan-level adjustment is necessary.

Benefits in Addition to EHB (Worksheet 2, Section 3)

Members purchasing a non-standard plan will receive MVP's Member Wellness Incentive (Form: FRVT366) and a \$500 acupuncture allowance. The wellness benefit provides subscribers with up to \$600 in wellness rewards per year, subject to certain guidelines. The cost of these benefits is included in the experience period claims as well as the plan AVs so an adjustment is not required.

Non-Claim Expense Plan Level Adjustments

Non claim expenses include both percent of premium loads and PMPM loads. The loads do not vary by plan. Each Standard and Non-Standard plan is being loaded with the same PMPM and Percent of Premium loads. The loads are outlined below:

Federal Taxes PMPM based

A total of \$0.44 PMPM is added for fees MVP must pay to the Federal Government per ACA regulations on a PMPM basis. This is comprised of \$0.17 PMPM for the risk adjustment user fee levied by the Department of Health and Human Services and \$0.27 PMPM for the Patient Centered Outcome Research Fee.

State Taxes PMPM Based

\$2.58 PMPM is added for fees MVP must pay to the State of Vermont to help fund expenses incurred by state agencies and other non-profit organizations on MVP's behalf, including the Green Mountain Care Board, the Vermont Program for Quality in Health Care, Inc., and the Office of the Health Care Advocate. This is found by using the best available information about the market-wide cost of each of the programs and then accounting for MVP's growth in market share from 2022 to 2025. We have not received updated expense information from the Green Mountain Care Board and we will seek to amend our filing once we receive this for FY 2024, should the expense be materially different from what is currently assumed.

State Taxes Premium based – VT Vaccine Assessment

Based on information provided by the Vermont Vaccine Purchasing Program (VVPP) in 2023, MVP's rates are estimated to be \$15.05 per covered child and \$3.00 per covered adult for 2025. Based on a blend of MVP's child and adult membership in the projection period, the total PMPM costs were determined, resulting in \$4.66 PMPM. This blended PMPM was then compared to the projection period premium PMPM before the assessment load to convert the assessment to a percent of premium load of 0.57%. These rates are subject to change at the VVPP annual assessment meeting on May 30, 2024, and we will seek to amend our filing if we receive updated data from the VVPP that is materially different from the current assumptions.

Federal Fees Premium based- National High Cost Reinsurance Pool (HCRP) Charge

In the 2025 Notice of Benefit and Payment Parameters issued by HHS, carriers will be compensated 60% for members' paid claims above \$1 million in a given plan year. The total reinsurance received across all states will be aggregated and compared to the national average premium PMPM to determine a percentage of premium charged to each issuer to fund the program.

Based on a national study performed by Wakely Consulting Group, the estimate of the load charged to small group market issuers in 2025 will be 0.77%.

General Administrative Expense Load (Including QI component)

The total administrative expense load included as a plan level adjustment equals \$51.44 PMPM and is used to cover SG&A expenses as well as Quality Improvement/Cost Containment Programs (QI). Based on an analysis of MVP's historical Supplemental Health Care Exhibit (SHCE) expenses, approximately 7% of MVP's total administrative expense was spent on QI. Therefore, \$3.60 PMPM of the \$51.44 PMPM administrative expense is attributable to QI.

MVP's projected administrative expense reflects the 2023 SHCE administrative expense on a PMPM basis trended at 3% per year annually for 2 years.

The following table summarizes the administrative expenses for small group and individual lines of business from the 2021, 2022, and 2023 SHCEs compared to the available admin expense built into the rates for the same time period.

Combined VT AR42 and AR44	Year	Exchange Available Admin PMPM	SHCE Admin PMPM*
Individual	2021	N/A	\$51.71
Small Group	2021	N/A	\$44.49
Combined	2021	\$43.75	\$47.44
Individual	2022	\$47.10	\$48.26
Small Group	2022	\$38.75	\$39.63
Combined	2022	\$42.20	\$43.07
Individual	2023	\$51.46	\$55.73
Small Group	2023	\$43.56	\$48.49
Combined	2023	\$46.74	\$51.41

*Reflects lines 1.7, 6.6, 8.3, 10.1, and 10.4 of SHCE, Part 1

Risk Margin

MVP is building a 1.5% risk margin into the VT Exchange premium rates for 2025. This charge is added to premium rates to meet statutory reserve requirements for MVP's VT block of business and protect against adverse experience relative to pricing assumptions.

Bad Debt Expense

A plan level adjustment equal to 0.17% of premium was added to account for non-payment of premium risk.

Age/Geographic/Tobacco Calibration (Worksheet 2, Section 3)

Per Vermont stating rating rules, variation in rates due to tobacco and age are not allowed. Therefore, all calibration factors are 1. Additionally, there is only 1 rating region in Vermont, so the geography calibration is also 1.

Consumer Adjusted Premium Rates

The Calibrated Plan Adjusted Index Rate PMPMs are converted to per contract premium rates using the computed single conversion factor and the prescribed standard load ratios. Please note that due to the rounding present in the URRT template, actual Plan Adjusted Index Rate PMPMs may vary from the URRT to the actual rates as filed.

The single conversion factor (SCF) was calculated using subscriber and member data by contract type for the eligible population enrolled with MVP as of February 2024. The SCF = weighted average contract size / weighted average load ratio.

Projection Period Membership

MVP's projection period membership equals the February 2024 enrollment of the population eligible to purchase these products, or 15,027 members. On Worksheet 2 of the URRT, members are mapped based on their February 2024 benefit to the same benefits for 2025. There is one exception: retired Gold 2 members who are mapped to the Gold 1 plan. This projected enrollment is used to calculate the rate increase on the Rate Increase Exhibit, while the current enrollment is used on the URRT, resulting in a different submission level rate increase.

New Products

MVP is offering one new base product to this market effective 1/1/25: Non-Standard Gold 4 (77566VT0050032). MVP utilized its proprietary benefit relativity model to value the benefits associated with the new plan and this is reflected in the premium rate.

Retired Products

MVP is retiring the following base product in Vermont in 2025: Non-Standard Gold 2 (77566VT0050004).

Loss Ratio Information

The traditional target loss ratio (claims cost / premium) for the rates proposed in this rate filing is 90.4%. After adjusting for taxes/assessments and expenses associated with quality improvements, the Federal target loss ratio for the rates proposed in this filing is 92.4%. Please see the following table for a calculation of these loss ratios based on MVP's projected starting claim cost in 2025:

Target Loss Ratio for 2025 VT Small Group								
A) Claims Expense	\$747.86							
B) Taxes/Assessments	\$14.10							
C) Quality Improvement	\$3.60							
D) Premium	\$827.22							
E) Traditional Loss Ratio	90.4%							
= A) / D)								
F) Federal Loss Ratio	92.4%							
= [A) + C)] / [D) - B)]								

Actuarial Certification

I, Kathleen Fish, am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. The projected Index Rate and Adjusted Paid Amount used in the development of these proposed premium rates is in compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80(d)(1)) and developed in compliance with the applicable Actuarial Standards of Practice. I have examined the assumptions and methods used in determining MVP's requested rates. Based on my review and examination, it is my opinion that the proposed premium rates are reasonable in relation to the benefits provided and that they are not excessive, nor inadequate, nor unfairly discriminatory. They are developed using only the permitted rating classifications. The Adjusted Paid Amount and only the allowable modifiers as described in 45 CFR 156.80(d)(1) and 45 CFR 156.80(d)(2) were used to generate plan level rates. The Standard AV Calculator was used to determine the Metal AV Value to be shown in Worksheet 2 of the Part I Unified Rate Review template for all the plans. The EHB portion of premium reflected in Worksheet 2, Sections 3 and 4 was calculated in accordance with actuarial standards of practice.

The URRT does not demonstrate the process that was used to develop premium rates. Rather it represents information required by Federal regulation to be provided in support of the review of rate increases and for certification that the Index rate is developed in accordance with Federal regulation and used consistently and only adjusted by the allowable modifiers.

I certify that I am knowledgeable as to the Vermont laws and regulations that apply to this filing and that, to the best of my knowledge and belief, this filing is in compliance with such laws and regulations and provides all required benefits.

I am of the opinion that this filing is in compliance with the applicable Federal and State Laws and Regulations concerning the PPACA and the HCERA of 2010.

I certify that each rate filing has been prepared in accordance with the following Actuarial Standards of Practice; ASOP #5, ASOP#8, ASOP #12, ASOP #23, ASOP #25, ASOP#41, ASOP#45, and ASOP#50.

______ <u>05/13/2024</u>
Kathleen Fish, FSA, MAAA Date

Senior Director, Actuarial Services / Chief Actuary

MVP Health Care, Inc.



Contact Information

Company Identifying

Information

Company Legal Name: MVP Health Plan, Inc.

HIOS Issuer ID: 77566 NAIC Number: 95521

Primary Contact Information

Contact Name: Eric Bachner, ASA

Contact Title: Director, Commercial Market & Valuation Actuary

Primary Contact Phone #: 518-991-3417
Primary Contact Address: 625 State Street

Schenectady, NY 12305

Primary Contact E-mail: EBachner@mvphealthcare.com

ACTUARIAL MEMORANDUM

2025 Vermont Small Group Exchange Filing

General Information

This memorandum details the methods and assumptions underlying the proposed 2025 premium rates for the State of Vermont's small group ACA compliant market. These products will be issued by MVP Health Plan, Inc. (MVP), a non-profit subsidiary of MVP Health Care, Inc. The rate filing has been prepared to satisfy the requirements of 8 V.S.A §5104 as well as the requirements of the Federal ACA including 45 CFR Part 156, §156.80. The premium rates are effective between 1/1/2025 and 12/31/2025. There is one benefit plan being retired and one new benefit plans being added. MVP modified several of the benefits being offered, and the updated forms have been submitted in a separate SERFF filing as well as forms for the new plan. The proposed average rate increase (MVP's revenue increase) is 9.3%, with increases ranging from 5.2% to 11.7%.

Drivers of Rate Increase

The proposed premium rates reflect an increase over the prior rates due to single risk pool experience which is more adverse than assumed in the current rates and medical and pharmacy cost and utilization inflation. Premium rate increases are varying by plan due to benefit modifications of several benefits being offered as well as the impact of fixed PMPM non-claim costs on premiums that vary based on benefit level.

Market/Benefits

All benefit plans included in this rate filing are available to small employer groups. All Essential Health Benefits (EHBs) are covered. Only one EHB substitution was made as required by the Department of VHA, a substitution for the \$2,000 annual Private Duty Nursing benefit limit in the benchmark plan. MVP contracted Milliman to determine an actuarially equivalent visit limit, and the experience period data reflects this actuarially equivalent limit.

The non-standard plans proposed by MVP and included in this rate filing contain two benefits in excess of the EHBs: a wellness benefit and an acupuncture allowance of \$500. The wellness benefit and acupuncture allowance are included in all non-standard products and the wellness benefit is filed as a mandatory rider, form: FRVT366.

To inform consumers of the availability and details of the products included in this filing, MVP will provide community outreach support as well as offer web and print product content and other printed product materials for VT plans. MVP will also have a mass media presence to further educate health care customers in Vermont.

The book of business affected by this rate filing is 1,209 policyholders, 9,306 subscribers and 15,027 members based on February 2024 membership.

Experience Period Premium and Claims (Worksheet 1, Section 1 of Unified Rate Review Template)

Worksheet 1, Section 1 of the Unified Rate Review Template contains MVP Health Plan, Inc. small group data for Vermont members over the time period 1/1/2023 - 12/31/2023, completed through 3/31/2024.

MVP does not project to rebate consumers for 2023 dates of service, and therefore no adjustments were made to the earned premium amount reflected on Worksheet 1, Section 1 of the Unified Rate Review Template. The earned premium shown reflects the amount of premium MVP collected from groups over the experience period.

Allowed claim data includes claims from our fee for service (FFS) claim warehouses (medical and pharmacy) along with additional medical expenses not captured in the claim warehouse such as: payments associated with medical home, physician incentive payments, FFS write-offs and net reinsurance expenses.

An allowance for incurred but not reported paid claims (IBNR) was added to the experience period fee-for-service (FFS) medical claims. IBNR files were supplied directly from MVP's reserving actuary. MVP uses a combination PMPM and completion factor method to develop IBNR estimates, and Vermont specific data for the experience period was used to develop the factors. The fee-for-service experience period claims were reconciled with the IBNR lag triangles to ensure accuracy.

The Risk adjustment reflected in the experience period is for the merged market and includes High Cost Risk Pool recoveries per the URRT instructions.

A summary of experience period claims processed through MVP's claim system, experience period costs not processed through MVP's claims system, as well as an estimate of IBNR are summarized below for the claims shown in Worksheet I, Section I of the URRT.

	Allowed	Incurred
Claims Processed Through Claim System	\$140,395,018	\$115,973,687
Experience Period Costs Not Processed Through Claims System	\$3,719,476	\$3,719,476
IBNR	\$3,783,235	\$3,118,071
Total	\$147,897,729	\$122,811,234

Benefit Categories (Worksheet 1, Section 2 of Unified Rate Review Template)

MVP determines benefit category based on the type of claim form submitted in conjunction with the code and type of code attached to the claim form (i.e. ICD-9, ICD-10, Diagnosis Code, or HCPCS). The "Other Medical" category includes pediatric dental claims. The "Capitation" category includes capitated payments as well as all other claims not processed through MVP's claim warehouses.

Medical Trend Factors

The assumed unit cost trends reflect known and assumed price increases from MVP's provider network, weighted by benefit category. The Capitation unit cost trend reflects the expected change between the capitated and non-FFS claim expense between the experience period and the projection period.

MVP analyzed historical utilization patterns for the ACA-compliant business to determine whether there has been a utilization trend pattern in the recent past. Because of the rapid membership growth in this block in the past several years and COVID-19, the utilization trends produced by the model were not considered reliable. However, the regulatory actuary in the 2020 rate filing performed an analysis that found that "a reasonable range for market wide utilization trend to be 1% to 4%". MVP has maintained this same trend in the filing each year. Because MVP believes that their data still lacks necessary stability and L&E's view of utilization trend encompasses the entire market, MVP has built in a 1% annual utilization trend for this filing.

Rx Trend Factors

Annual allowed Rx trend factors split by generic, brand, and specialty drugs are provided by MVP's PBM and were determined using MVP specific data over the experience period by drug class. The forecast provided by MVP's PBM accounts for drugs coming off patent, changes in average wholesale price, new drugs being released to the market, and price competitiveness amongst generic and brand drug manufacturers.

<u>Credibility Manual Rate Development (Worksheet 1, Section 2 of Unified Rate Review Template)</u>

MVP is assuming that the small group market risk pool membership base of 192,917 member months in the experience period is fully credible for rating purposes. Therefore, the applied credibility percentage is 100.00% (0.00% weight on credibility manual).

Projection Factors (Worksheet 1, Section 2 of Unified Rate Review Template)

Morbidity Adjustment-Impact of COVID Vaccines

During the experience period, MVP was responsible for the administration cost of COVID-19 vaccines for all 12 months but began to be responsible for the full ingredient cost of those vaccines starting in September 2023. MVP is projecting the cost for 2025 to be: the 2023 utilization of COVID-19 vaccines for all 12 months multiplied by \$140, which represents the full amount for ingredient and administration costs. Therefore, the \$0.43 PMPM value found in line 12 represents the difference between the projected cost and the experience cost. The difference between the projected cost and the experience cost has an impact of 0.1%.

Plan Design Changes- Impact of Hearing Aids as EHB

Hearing aids were added as an essential health benefit in 2024. MVP analyzed historical experience in its New York population and determined this mandate would increase the experience period allowed claim cost by 0.04%.

Not Included- Adjustment for H.766

Vermont House Bill H.766 is "an act relating to prior authorization and step therapy requirements, health insurance claims, and provider contracts," and it has the potential to significantly raise the cost of medical claims in the Vermont commercial health insurance market. MVP is still analyzing the contents of the bill (and subsequent amendments that have been filed and approved), but our preliminary analysis suggests this would increase premium rates by 8-10%.

At the time of this filing (last action being taken on 5/3/24), the bill has been approved by both chambers of the Vermont Legislature and is awaiting signature or veto by the Governor.

Given the timing of this decision, the likelihood of a signature or override of the Governor's veto, and the magnitude of the bill in question, MVP is preparing to file an amendment to our rate filing shortly after submission to include the final impact of the bill in our premium rates.

Reinsurance (Worksheet 1, Section 2)

MVP is reflecting \$0.00 PMPM in reinsurance recoveries during the projection period.

Federal Risk Adjustment Program (Worksheet 1, Section 2)

MVP contracted with an external actuarial consultant to project expected transfer for 2023. MVP is expected to pay \$5,283,764 into the small group market transfer pool for 2023. This is \$27.39 on a PMPM basis or 4.3% of experience period claims prior to market-wide adjustments.

The URRT instructions state that the projected risk adjustment PMPM on Worksheet 1 is to be calculated on an allowed basis. Therefore, MVP has taken the projected risk adjustment PMPM on a net basis and divided by the projection period paid to allowed ratio to come up with the value shown (\$37.34 PMPM).

Exchange User Fees (Worksheet 1, Section 2)

Vermont's Exchange is not a Federally-Facilitated Exchange, therefore 0.00% of premium is built in to account for user fees during the projection period.

Market-Wide Adjusted Index Rate

The experience period index rate of \$766.64 is equal to the small group market allowed claim data for the time period, 1/1/2023 - 12/31/2023, completed through 3/31/2024.

The actual market adjusted index rate for the projection period equals \$890.94. This value was computed by adjusting the projection period index rate for the federal risk adjustment program, reinsurance and marketplace user fees.

Please see above for details on the computation of the projected value of the risk adjustment program. Note that this is a true expectation of allowed costs and is not equivalent to the adjusted claim cost for pricing on Exhibit 6 of the rate filing.

Actuarial Values and Cost Sharing Design of Plan (Worksheet 2, Section 3)

The AV Metal Level for each plan was determined using the Federally prescribed Actuarial Value Calculator. Adjustments for aggregate deductibles, the VT Rx OOPM, and safe harbor prescription Rx benefits were made to the calculator results for the non-standard Gold 3 and non-Standard Silver 2 plans. The actuarial certification of these adjustments has been included.

The Benefit Actuarial Value for each plan was determined using MVP's in-house benefit pricing tools. The pricing tools value the expected net paid claim cost associated with unique benefit plan designs from a starting single risk pool allowed amount. The AV is the ratio of the expected paid to allowed amount for each plan design. MVP did not reflect any induced utilization in the projection of the net paid amounts for each unique benefit plan.

The induced utilization factors used to set premium rates and compute the average in-force induced utilization factor are the HHS prescribed induced utilization factors of 1.00 for Bronze, 1.03 for Silver, 1.08 for Gold, and 1.15 for Platinum.

The actual paid to allowed ratio during the experience period and the assumed paid to allowed ratio used for pricing differ. The actual paid to allowed ratio (including assumed payments for cost sharing reductions) for the experience period is different than the pricing paid to allowed ratio produced by MVP's internal benefit relativity model. Because MVP prices using net claim expense instead of allowed claims, the allowed claims in the URRT need to be adjusted for the difference in the paid to allowed ratios to develop an equivalent Plan Adjusted Index Rate. The total of this adjustment is 1.7%.

The total adjustment made is the product of the three values (AV, induced demand, and difference in paid to allowed ratio).

Provider Network Adjustment (Worksheet 2, Section 3)

MVP only offers one provider network for its Vermont plans; therefore, no plan-level adjustment is necessary.

Benefits in Addition to EHB (Worksheet 2, Section 3)

Members purchasing a non-standard plan will receive MVP's Member Wellness Incentive (Form: FRVT366) and a \$500 acupuncture allowance. The wellness benefit provides subscribers with up to \$600 in wellness rewards per year, subject to certain guidelines. The cost of these benefits is included in the experience period claims as well as the plan AVs so an adjustment is not required.

Non-Claim Expense Plan Level Adjustments

Non claim expenses include both percent of premium loads and PMPM loads. The loads do not vary by plan. Each Standard and Non-Standard plan is being loaded with the same PMPM and Percent of Premium loads. The loads are outlined below:

Federal Taxes PMPM based

A total of \$0.44 PMPM is added for fees MVP must pay to the Federal Government per ACA regulations on a PMPM basis. This is comprised of \$0.17 PMPM for the risk adjustment user fee levied by the Department of Health and Human Services and \$0.27 PMPM for the Patient Centered Outcome Research Fee.

State Taxes PMPM Based

\$2.58 PMPM is added for fees MVP must pay to the State of Vermont to help fund expenses incurred by state agencies and other non-profit organizations on MVP's behalf, including the Green Mountain Care Board, the Vermont Program for Quality in Health Care, Inc., and the Office of the Health Care Advocate. This is found by using the best available information about the market-wide cost of each of the programs and then accounting for MVP's growth in market share from 2022 to 2025. We have not received updated expense information from the Green Mountain Care Board and we will seek to amend our filing once we receive this for FY 2024, should the expense be materially different from what is currently assumed.

State Taxes Premium based – VT Vaccine Assessment

Based on information provided by the Vermont Vaccine Purchasing Program (VVPP) in 2023, MVP's rates are estimated to be \$15.05 per covered child and \$3.00 per covered adult for 2025. Based on a blend of MVP's child and adult membership in the projection period, the total PMPM costs were determined, resulting in \$4.66 PMPM. This blended PMPM was then compared to the projection period premium PMPM before the assessment load to convert the assessment to a percent of premium load of 0.57%. These rates are subject to change at the VVPP annual assessment meeting on May 30, 2024, and we will seek to amend our filing if we receive updated data from the VVPP that is materially different from the current assumptions.

Federal Fees Premium based- National High Cost Reinsurance Pool (HCRP) Charge

In the 2025 Notice of Benefit and Payment Parameters issued by HHS, carriers will be compensated 60% for members' paid claims above \$1 million in a given plan year. The total reinsurance received across all states will be aggregated and compared to the national average premium PMPM to determine a percentage of premium charged to each issuer to fund the program.

Based on a national study performed by Wakely Consulting Group, the estimate of the load charged to small group market issuers in 2025 will be 0.77%.

General Administrative Expense Load (Including QI component)

The total administrative expense load included as a plan level adjustment equals \$51.44 PMPM and is used to cover SG&A expenses as well as Quality Improvement/Cost Containment Programs (QI). Based on an analysis of MVP's historical Supplemental Health Care Exhibit (SHCE) expenses, approximately 7% of MVP's total administrative expense was spent on QI. Therefore, \$3.60 PMPM of the \$51.44 PMPM administrative expense is attributable to QI.

MVP's projected administrative expense reflects the 2023 SHCE administrative expense on a PMPM basis trended at 3% per year annually for 2 years.

The following table summarizes the administrative expenses for small group and individual lines of business from the 2021, 2022, and 2023 SHCEs compared to the available admin expense built into the rates for the same time period.

Combined VT AR42 and AR44	Year	Exchange Available Admin PMPM	SHCE Admin PMPM*
Individual	2021	N/A	\$51.71
Small Group	2021	N/A	\$44.49
Combined	2021	\$43.75	\$47.44
Individual	2022	\$47.10	\$48.26
Small Group	2022	\$38.75	\$39.63
Combined	2022	\$42.20	\$43.07
Individual	2023	\$51.46	\$55.73
Small Group	2023	\$43.56	\$48.49
Combined	2023	\$46.74	\$51.41

*Reflects lines 1.7, 6.6, 8.3, 10.1, and 10.4 of SHCE, Part 1

Risk Margin

MVP is building a 1.5% risk margin into the VT Exchange premium rates for 2025. This charge is added to premium rates to meet statutory reserve requirements for MVP's VT block of business and protect against adverse experience relative to pricing assumptions.

Bad Debt Expense

A plan level adjustment equal to 0.17% of premium was added to account for non-payment of premium risk.

Age/Geographic/Tobacco Calibration (Worksheet 2, Section 3)

Per Vermont stating rating rules, variation in rates due to tobacco and age are not allowed. Therefore, all calibration factors are 1. Additionally, there is only 1 rating region in Vermont, so the geography calibration is also 1.

Consumer Adjusted Premium Rates

The Calibrated Plan Adjusted Index Rate PMPMs are converted to per contract premium rates using the computed single conversion factor and the prescribed standard load ratios. Please note that due to the rounding present in the URRT template, actual Plan Adjusted Index Rate PMPMs may vary from the URRT to the actual rates as filed.

The single conversion factor (SCF) was calculated using subscriber and member data by contract type for the eligible population enrolled with MVP as of February 2024. The SCF = weighted average contract size / weighted average load ratio.

Projection Period Membership

MVP's projection period membership equals the February 2024 enrollment of the population eligible to purchase these products, or 15,027 members. On Worksheet 2 of the URRT, members are mapped based on their February 2024 benefit to the same benefits for 2025. There is one exception: retired Gold 2 members who are mapped to the Gold 1 plan. This projected enrollment is used to calculate the rate increase on the Rate Increase Exhibit, while the current enrollment is used on the URRT, resulting in a different submission level rate increase.

New Products

MVP is offering one new base product to this market effective 1/1/25: Non-Standard Gold 4 (77566VT0050032). MVP utilized its proprietary benefit relativity model to value the benefits associated with the new plan and this is reflected in the premium rate.

Retired Products

MVP is retiring the following base product in Vermont in 2025: Non-Standard Gold 2 (77566VT0050004).

Loss Ratio Information

The traditional target loss ratio (claims cost / premium) for the rates proposed in this rate filing is 90.4%. After adjusting for taxes/assessments and expenses associated with quality improvements, the Federal target loss ratio for the rates proposed in this filing is 92.4%. Please see the following table for a calculation of these loss ratios based on MVP's projected starting claim cost in 2025:

Target Loss Ratio for 2025 VT Small Group								
A) Claims Expense	\$747.86							
B) Taxes/Assessments	\$14.10							
C) Quality Improvement	\$3.60							
D) Premium	\$827.22							
E) Traditional Loss Ratio	90.4%							
= A) / D)								
F) Federal Loss Ratio	92.4%							
= [A) + C)] / [D) - B)]								

Actuarial Certification

I, Kathleen Fish, am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. The projected Index Rate and Adjusted Paid Amount used in the development of these proposed premium rates is in compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80(d)(1)) and developed in compliance with the applicable Actuarial Standards of Practice. I have examined the assumptions and methods used in determining MVP's requested rates. Based on my review and examination, it is my opinion that the proposed premium rates are reasonable in relation to the benefits provided and that they are not excessive, nor inadequate, nor unfairly discriminatory. They are developed using only the permitted rating classifications. The Adjusted Paid Amount and only the allowable modifiers as described in 45 CFR 156.80(d)(1) and 45 CFR 156.80(d)(2) were used to generate plan level rates. The Standard AV Calculator was used to determine the Metal AV Value to be shown in Worksheet 2 of the Part I Unified Rate Review template for all the plans. The EHB portion of premium reflected in Worksheet 2, Sections 3 and 4 was calculated in accordance with actuarial standards of practice.

The URRT does not demonstrate the process that was used to develop premium rates. Rather it represents information required by Federal regulation to be provided in support of the review of rate increases and for certification that the Index rate is developed in accordance with Federal regulation and used consistently and only adjusted by the allowable modifiers.

I certify that I am knowledgeable as to the Vermont laws and regulations that apply to this filing and that, to the best of my knowledge and belief, this filing is in compliance with such laws and regulations and provides all required benefits.

I am of the opinion that this filing is in compliance with the applicable Federal and State Laws and Regulations concerning the PPACA and the HCERA of 2010.

I certify that each rate filing has been prepared in accordance with the following Actuarial Standards of Practice; ASOP #5, ASOP#8, ASOP #12, ASOP #23, ASOP #25, ASOP#41, ASOP#45, and ASOP#50.

______ <u>05/13/2024</u>
Kathleen Fish, FSA, MAAA Date

Senior Director, Actuarial Services / Chief Actuary

MVP Health Care, Inc.



Consumer Disclosure about Proposed Health Insurance Rate Increase VT 2025 ACA Small Group Exchange Rate Filing

About Us

MVP Health Plan, Inc. is a non-profit health care payer operating in Vermont and New York. MVP's mission is to provide high quality and affordable health care with a focus on wellness to our members.

Why We Are Changing Our Premiums

MVP must obtain approval from the Green Mountain Care Board for the health insurance premium rates charged. MVP files annual premium rates for the Exchange which are guaranteed for 12 months. This rate filing seeks approval of MVP's 2025 Small Group Exchange rates for effective dates of coverage between January 1, 2025 and December 31, 2025. The premium rates filed reflect MVP's current estimate of the cost to provide health insurance for that coverage period. The filed premium rates may be higher or lower than the previously filed premium rates, however, premium rates generally increase over time. Changes in the filed premium rates (relative to previously approved rates) are driven by many factors, including:

- -Increases in base period experience. Premium rates are increasing by 4.8% because our estimate of 2024 claims are higher than expected compared to the previous year.
- -Increases in cost and utilization of services. The cost and utilization of medical and pharmacy services generally increase over time. Premium rates are increasing by 6.1% because of this estimated trend in 2025.
- -Impact of the Federal Risk Adjustment Program. The federal risk adjustment program seeks to "level the playing field" among insurers. MVP has enrolled a population of lower-risk members, so it is required to pay into the program. MVP's small group payment has gone down, decreasing premium rates by approximately 2.0%.
- -Changes in the cost of doing business. As the cost of doing business rises over time, MVP must collect a portion of the premium revenue to protect consumers by ensuring its solvency. MVP aligned its administrative costs with the expected cost of the small group market. These changes are worth approximately **0.5%** of a premium increase.

Conclusion

The proposed rates reflect an average rate adjustment to prior rates of 9.3%, ranging from 5.2% to 11.7%. There are 1,209 policyholders, 9,306 subscribers and 15,027 members impacted by this rate filing.

Vermonters can provide public comment on the proposed rate increases during the public comment period beginning on May 13th. For information about providing public comment, please visit: https://ratereview.vermont.gov/public-comment

A B	C	D	E	F		G	Н	l J	K L M N O P Q R !
Unified Rate Review v6.0									To add a product to Worksheet 2 - Plan Product Info, select the Add Product button or Ctrl + Shij
									To add a plan to Worksheet 2 - Plan Product Info, select the Add Plan button or Ctrl + Shift + L.
Company Legal Name:	MVP Health Plan, Inc.								To validate, select the Validate button or Ctrl + Shift + I.
HIOS Issuer ID:	77566	State:	VT						To finalize, select the Finalize button or Ctrl + Shift + F.
Effective Date of Rate Change	s): 1/1/2025	Market:	Small Group						,
	,		•						
Company Legal Name: HIOS Issuer ID: Effective Date of Rate Change									
	for all Plans)								
Market Level Calculations (Sam Section I: Experience Period Dat Experience Period: Allowed Claims Reinsurance Incurred Claims in Experience Pe Risk Adjustment									
Section I: Experience Period Dat	Ī								
Experience Period:		1/1/20		12/31/2023					
Allamed Claims			<u>Total</u>	PMPM A	766.64				
Allowed Claims Reinsurance			\$147,897,728.90 \$0.00		766.64 \$0.00				
Incurred Claims in Experience Pe	ind		\$122,811,234.00		636.60				
Risk Adjustment			-\$5,043,570.65		\$26.14				
Experience Period Premium			\$129,780,209.85		672.73				
Experience Period Member Mon	hs		192,917						
Section II: Projections									
			ar 1 Trend		Year 2 Trend				
Benefit Category	Experience Period Index						Trended EHB Allowed Claims		
	Rate PMPM	Cost	Utilization	Cost		Utilization	PMPM		
Inpatient Hospital	\$101.9				1.048	1.010	\$114.20		
Outpatient Hospital Professional	\$348.4 \$191.7				1.055	1.010 1.010	\$394.40 \$201.35		
Other Medical	\$3.:				1.000	1.010	\$3.19		
Capitation	\$19.3				1.070	1.000	\$22.09		
Prescription Drug	\$102.0				1.042	1.029	\$117.55		
Total	\$766.		'				\$852.79		
						•	-		
Morbidity Adjustment	·				1.001				
Demographic Shift					1.000				
Plan Design Changes					1.000				
Other	Inima DAADAA 6	. 1. 10.	27		1.000				
Adjusted Trended EHB Allowed (airris PIMPIM TOF	1/1/20)Z5	Ş	853.60				
Manual EHB Allowed Claims PM	M				\$0.00				
Applied Credibility %					00.00%				
F									
					Proje	ected Period Totals			
Projected Index Rate for		1/1/20	025		853.60	\$153,924,566.40			
Reinsurance					\$0.00	\$0.00			
Risk Adjustment Payment/Charg	:				\$37.34	-\$6,733,373.83			
KISK AUJUSTITIETIT PAYTTETIT/CITAIR					0.00%	\$0.00			
Exchange User Fees									
Exchange User Fees Market Adjusted Index Rate				\$	890.94	\$160,657,940.23			
Exchange User Fees Market Adjusted Index Rate						\$160,657,940.23			
Exchange User Fees					890.94 80,324	\$160,657,940.23			

Information Not Releasable to the Public Unless Authorized by Law: This information has not been publically disclosed and may be privileged and confidential. It is for internal government use only and must not be disseminated, distributed, or copied to persons not authorized to receive the information. Unauthorized disclosure may result in prosecution to the full extent of the law.

50 51

Product-Plan Data Collection

Product/Plan Level Calcula

Company Legal Name: HIOS Issuer ID: Effective Date of Rate Change(s): MVP Health Plan, inc. 77566 State: VT 1/1/2025 Market: Small Group

To add a product to Worksheet 2 - Plan Product Info, select the Add Plan button or Citi + Shift + P.

To add a plan to Worksheet 2 - Plan Product Info, select the Add Plan button or Citi + Shift + L.

To willotier, select the Violation button or Citi + Shift + L.

To fination, select the Fination button or Citi + Shift + F.

To remove a product, novigate to the corresponding Product Manu/Product ID field and select the Remove Product button or Citi + Shift + Q.

To remove a product, novigate to the corresponding Plan Manu/Plan ID field and select the Remove Plan button or Citi + Shift + Q.

	Producty Plant Level Calculations																			
	Field # Section I: General Product and Plan Information																			
ſ	1.1 Product Name										Small Gr	oup								
	1.2 Product ID										77566VT	005								
	1.3 Plan Name		FRVT-HMO-SP-001	FRVT-HMO-SG-001	FRVT-HMO-SG-004	FRVT-HMO-SG-002	FRVT-HMOH-SG-	FRVT-HMO-SS-003-	FRVT-HMOH-SS-	FRVT-HMOH-SS-	FRVT-HMO-SS-001- V	T-HMO-SS-003-S	VT-HMOH-SS-004- V	T-HMOH-SS-002-	VT-HMO-SS-001-N FF	RVT-HMO-SB-002	FRVT-HMOH-SB- FF	VT-HMO-SB-004-FR	VT-HMO-SB-005-	RVT-HMO-SB-001-
	1.4 Plan ID (Standard Component ID)		77566VT0050001	77566VT0050002	77566VT0050032	77566VT0050004	77566VT0050023	77566VT0050005	77566VT0050006	77566VT0050024	77566VT0050007 7	7566VT0050030	77566VT0050031	77566VT0050029	77566VT0050028 7	77566VT0050009	77566VT0050010 7	7566VT0050025 7	7566VT0050026	77566VT0050011
	1.5 Metal		Platinum	Gold	Gold	Gold	Gold	Silver	Silver	Silver	Silver	Silver	Silver	Silver	Silver	Bronze	Bronze	Bronze	Bronze	Bronze
	1.6 AV Metal Value		0.900	0.810			0.808		0.709	0.713	0.715	0.710		0.712		0.618	0.621	0.646	0.629	0.647
	1.7 Plan Category		Renewing	Renewing	New		Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing	Renewing
	1.8 Plan Type		нмо	HMO			HMO		нмо	HMO	HMO	HMO		HMC		HMO	нмо	HMO	HMO	HMO
	1.9 Exchange Plan?		Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	No		Yes	Yes	Yes	Yes	Yes
	1.10 Effective Date of Proposed Rates		1/1/2025	1/1/2025	1/1/2025		1/1/2025	1/1/2025	1/1/2025	1/1/2025	1/1/2025	1/1/2025		1/1/2025		1/1/2025	1/1/2025	1/1/2025	1/1/2025	1/1/2025
	1.11 Cumulative Rate Change % (over 12 mos prior)		8.12%	8.84%	0.00%	0.00%	9.24%	10.86%	9.85%	9.93%	10.74%	10.86%	9.86%	9.93%	10.74%	11.09%	10.48%	9.75%	10.77%	11.70%
-	1.12 Product Rate Increase %										9.46%									
Į.	1.13 Submission Level Rate Increase %										9.46%	•								
Worksheet 1 Totals	Section II: Experience Period and Current Plan Leve	d Information																		
WORKSHEEL 1 TOTALS	2.1 Plan ID (Standard Component ID)	Total	77E66V/T00E0004	775 661/7005 0002	275561/70050022	27566VT0050004	775 661/70050022	775661/70050005	77566\/T0050006 7	77566\/T0050034	775661/70050007 7	75661/70050020	77566VT0050024 7	75561/70050020	77566VT0050028 7	75561/70050000	755651/70050010 7	75661/70050035 73	EEE/TODEOD2E	77566\/T0050011
\$147.897.729		\$147.897.729	\$32.114.585	\$29.052.564			\$30.381.175		\$250.086	\$245	\$419.141	\$9.057.130		\$6.857.289		\$3,601,244	\$12.034.655	\$346,428	\$1.109.912	\$1.014.646
\$147,097,729		\$147,037,723	\$32,114,383 \$0	\$25,032,364	\$0		\$30,381,173	\$17,379	\$230,080	\$243 \$0	\$0	\$5,037,130	\$6,303,103	30,637,263 \$n	38,340,119	\$3,001,244	\$12,034,033	\$340,428	\$1,109,912	\$1,014,040
Ç	2.4 Member Cost Sharing	\$25,086,495	\$2,036,093	\$4,318,859			\$4,752,304	\$3,755	\$65,647	\$245	\$55,134	\$2,219,008	\$2,055,098	\$1,340,636	\$2,030,692	\$1,249,694	\$3,736,759	\$169,202	\$266,526	\$245,077
	2.5 Cost Sharing Reduction	\$0	\$0	\$0	SO SO		\$0	SO.	\$0	\$0		\$0		SO	SO	SO	\$0	SO	\$0	\$0
\$122,811,234	2.6 Incurred Claims	\$122,811,234	\$30,078,493	\$24,733,705	\$0		\$25,628,871	\$13,823	\$184,440	\$0	\$364,008	\$6,838,122	\$6,510,005	\$5,516,654	\$6,515,427	\$2,351,551	\$8,297,896	\$177,225	\$843,386	\$769,568
-\$5,043,571	2.7 Risk Adjustment Transfer Amount	-\$5,043,571	\$4,319,605	-\$32,605	\$0	\$74,949	\$2,324,629	\$6,339	-\$51,672	\$0	-\$100,523	-\$2,384,301	-\$2,064,312	-\$637,669		-\$809,489	-\$2,532,322	-\$294,732	-\$373,442	-\$252,855
\$129,780,210	2.8 Premium	\$129,780,210	\$26,236,497	\$25,600,456	\$0		\$23,569,678	\$6,015	\$297,755	\$0	\$352,593	\$9,438,833	\$8,489,166	\$5,104,178		\$4,201,656	\$11,103,576	\$584,125	\$890,176	\$964,610
192,917	2.9 Experience Period Member Months	192,917	30,662	35,951		4,395	32,846	9	448	0	592	15,462		8,374		7,769	21,713	1,102	1,669	1,854
	2.10 Current Enrollment	15,027	2,351	2,704		349	2,095		8	1	61	1,275		838		621	1,769	120	137	118
	2.11 Current Premium PMPM	\$746.65	\$973.10	\$817.16			\$820.64		\$734.06	\$740.87	\$652.63	\$660.74		\$667.54		\$585.70	\$561.97	\$578.84	\$591.72	\$573.71
	2.12 Loss Ratio	98.46%	98.44%	96.74%	#DIV/0!	116.29%	98.97%	111.90%	74.95%	#DIV/0!	144.41%	96.93%	101.33%	123.51%	88.63%	69.32%	96.81%	61.24%	163.21%	108.12%
	Per Member Per Month																			
	2.13 Allowed Claims	\$766.64	\$1,047.37	\$808.12		\$1,030.68	\$924.96		\$558.23	#DIV/0!	\$708.01	\$585.77	\$588.10	\$818.88		\$463.54	\$554.26	\$314.36	\$665.02	\$547.27
	2.14 Reinsurance	\$0.00	\$0.00	\$0.00	#DIV/0!	\$0.00	\$0.00	\$0.00	\$0.00	#DIV/0!	\$0.00	\$0.00		\$0.00		\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
	2.15 Member Cost Sharing	\$130.04	\$66.40	\$120.13	#DIV/0!	\$123.27	\$144.68	\$417.26	\$146.53	#DIV/0!	\$93.13	\$143.51		\$160.10	\$130.95	\$160.86	\$172.10	\$153.54	\$159.69	\$132.19
	2.16 Cost Sharing Reduction	\$0.00	\$0.00	\$0.00		\$0.00 \$907.41	\$0.00	\$0.00	\$0.00	#DIV/0!	\$0.00 \$614.88	\$0.00		\$0.00		\$0.00 \$302.68	\$0.00 \$382.16	\$0.00	\$0.00	\$0.00
	2.17 Incurred Claims 2.18 Risk Adjustment Transfer Amount	\$636.60 -\$26.14	\$980.97 \$140.88	\$687.98 -\$0.91	#DIV/0!	\$907.41 \$17.05	\$780.27 \$70.77	\$1,535.94 \$704.35	\$411.70 -\$115.34	#DIV/0!	\$614.88 -\$169.80	\$442.25 -\$154.20	\$446.99 -\$141.74	\$658.78 -\$76.15	\$420.16 -\$144.14	\$302.68 -\$104.19	\$382.16 -\$116.63	\$160.82 -\$267.45	\$505.32 -\$223.75	\$415.09 -\$136.38
	2.19 Premium	\$672.73	\$855.67	\$712.09		\$763.26	\$717.58	\$668.30	-\$115.34 \$664.63	#DIV/0!	-\$169.80 \$595.60	-\$154.20 \$610.45		\$609.53	\$618.20	-\$104.19 \$540.82	\$511.38	-\$267.45 \$530.06	\$533.36	\$520.29
	Plan ID (Standard Component ID) Z Market Adjusted Index Rate AV and Cost Sharing Design of Plan Provider Network Adjustment		77566VT0050001 1.0888 1.0000	77566VT0050002 0.9034 1.0000	0.8977	0.0000	77566VT0050023 0.9446 1.0000		77566VT0050006 7 0.7221 1.0000	0.7300 1.0000	77566VT0050007 7 \$890.9 0.7134 1.0000		0.7221	0.7293 1.0000		7566VT0050009 0.6208 1.0000	0.6269 1.0000	7566VT0050025 77 0.6352 1.0000	0.6254 1.0000	77566VT0050011 0.6301 1.0000
	3.5 Benefits in Addition to EHB		1.0000	1.0000			1.0000		1.0000	1.0000	1.0000	1.0000		1.0000		1.0000	1.0000	1.0000	1.0000	1.0000
L.	Administrative Costs							2.0000		2.0000								2.0000		
ſ	3.6 Administrative Expense		4.87%	5.81%	5.84%	0.00%	5.57%	7.22%	7.15%	7.08%	7.23%	7.22%	7.15%	7.08%	7.23%	8.21%	8.14%	8.04%	8.16%	8.10%
	3.7 Taxes and Fees		1.63%	1.68%	1.68%	0.00%	1.67%	1.76%	1.76%	1.76%	1.76%	1.76%	1.76%	1.76%	1.76%	1.82%	1.82%	1.81%	1.82%	1.82%
	3.8 Profit & Risk Load		1.67%	1.67%			1.67%		1.67%	1.67%	1.67%	1.67%		1.67%		1.67%	1.67%	1.67%	1.67%	1.67%
	3.9 Catastrophic Adjustment		1.0000	1.0000			1.0000	1.0000	1.0000	1.0000	1.0000	1.0000		1.0000		1.0000	1.0000	1.0000	1.0000	1.0000
	3.10 Plan Adjusted Index Rate		\$1,056.29	\$886.04	\$880.80	\$0.00	\$923.84	\$712.26	\$719.47	\$726.68	\$711.50	\$712.26	\$719.47	\$726.11	\$711.50	\$626.42	\$632.02	\$639.67	\$630.62	\$634.91
r																				
-	3.11 Age Calibration Factor	1.0000									1.000									
-	3.12 Geographic Calibration Factor 3.13 Tobacco Calibration Factor	1.0000									1.000									
H	3.14 Calibrated Plan Adjusted Index Rate	1.0000	\$1.056.29	\$886.04	\$880.80	\$0.00	\$923.84	\$712.26	\$719.47	\$726.68		\$712.26	\$719.47	\$726.11	\$711.50	\$626.42	\$632.02	\$639.67	\$630.62	\$634.91
	Section IV: Projected Plan Level Information 4.1 Plan ID (Standard Component ID)	Total													77566VT0050028 7					
ŀ	4.2 Allowed Claims	\$165,954,967	\$28,158,243	\$34,340,423			\$23,564,752		\$85,819	\$10,727	\$654,368	\$13,677,367		\$8,989,516		\$6,467,653	\$18,423,957	\$1,249,788	\$1,426,841	\$1,228,958
ŀ	4.3 Reinsurance	\$0	\$0	\$0	\$0	\$0	\$0,564,752	\$0	\$03,013	\$10,727	\$0	\$13,077,307	SO	SO	\$0	\$0,407,033	\$10,423,557	\$0	\$0	\$0
	4.4 Member Cost Sharing	\$38,321,196	\$1,920,392	\$6,067,953	\$0	\$0	\$3,280,213	\$10,218	\$26,604	\$3,245	\$208,285	\$4,342,564	\$4,422,885	\$2,724,722	\$4,257,899	\$2,515,917	\$7,056,376	\$468.421	\$548.620	\$466,881
	4.5 Cost Sharing Reduction	\$0	\$0	\$0	\$0		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
	4.6 Incurred Claims	\$127,633,771	\$26,237,851	\$28,272,471	\$0	\$0	\$20,284,538	\$21,964	\$59,215	\$7,482	\$446,083	\$9,334,803		\$6,264,794		\$3,951,736	\$11,367,582	\$781,367	\$878,221	\$762,077
	4.7 Risk Adjustment Transfer Amount	-\$5,491,247	-\$1,128,843	-\$1,216,380	\$0	\$0	-\$872,711	-\$945	-\$2,548	-\$322	-\$19,192	-\$401,616	-\$423,544	-\$269,533	-\$392,335	-\$170,017	-\$489,073	-\$33,617	-\$37,784	-\$32,787
	4.8 Premium	\$147,380,947	\$29,799,993	\$32,460,984		\$0	\$23,225,362	\$25,641	\$69,069	\$8,720	\$520,813	\$10,897,617		\$7,301,721		\$4,668,070	\$13,416,487	\$921,127	\$1,036,737	\$899,035
	4.9 Projected Member Months	180,324	28,212	36,636		0	25,140	36	96	12	732	15,300		10,056	14,964	7,452	21,228	1,440	1,644	1,416
	4.10 Loss Ratio	89.95%	91.51%	90.49%	#DIV/0!	#DIV/0!	90.75%	88.94%	89.02%	89.09%	88.93%	88.94%	89.02%	89.09%	88.93%	87.85%	87.93%	88.04%	87.91%	87.97%
	Per Member Per Month																			
	4.11 Allowed Claims	\$920.32	\$998.09	\$937.34		#DIV/0!	\$937.34		\$893.95	\$893.95	\$893.95	\$893.95	\$893.95	\$893.95	\$893.95	\$867.91	\$867.91	\$867.91	\$867.91	\$867.91
	4.12 Reinsurance	\$0.00	\$0.00	\$0.00	#DIV/0!	#DIV/0!	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
-	4.13 Member Cost Sharing	\$212.51	\$68.07 \$0.00	\$165.63 \$0.00	#DIV/0!	#DIV/0!	\$130.48	\$283.83	\$277.12	\$270.42	\$284.54 \$0.00	\$283.83		\$270.95	\$284.54	\$337.62 \$0.00	\$332.41 \$0.00	\$325.29 \$0.00	\$333.71	\$329.72
	4.14 Cost Sharing Reduction 4.15 Incurred Claims	\$0.00 \$707.80	\$0.00 \$930.02	\$0.00 \$771.71	#DIV/0!	#DIV/0!	\$0.00	\$0.00 \$610.12	\$0.00 \$616.82	\$0.00 \$623.53	\$0.00 \$609.40	\$0.00 \$610.12		\$0.00 \$622.99	\$0.00 \$609.40	\$0.00 \$530.29	\$0.00 \$535.50	\$0.00 \$542.62	\$0.00 \$534.20	\$0.00 \$538.19
-	4.15 Incurred Claims 4.16 Risk Adjustment Transfer Amount	\$707.80 -\$30.45	\$930.02 -\$40.01	\$//1./1 -\$33.20	#DIV/0!	#DIV/0!	-\$34.71	\$610.12 -\$26.25	\$616.82 -\$26.54	-\$26.83	\$609.40 -\$26.22	\$610.12 -\$26.25		\$622.99 -\$26.80	\$609.40 -\$26.22	\$530.29 -\$22.81	\$535.50 -\$23.04	\$542.62 -\$23.35	\$534.20 -\$22.98	\$538.19 -\$23.15
<u> </u>	4.16 Risk Adjustment Transfer Amount 4.17 Premium	-\$30.45 \$817.31	-\$40.01 \$1,056.29	-\$33.20 \$886.04	#DIV/0!	#DIV/0!	-\$34.71 \$923.84		-\$26.54 \$719.47	-\$26.83 \$726.68	-\$26.22 \$711.49	-\$26.25 \$712.26		-\$26.80 \$726.11	-\$26.22 \$711.49	-\$22.81 \$626.42	-\$23.04 \$632.02	-\$23.35 \$639.67	-\$22.98 \$630.62	-\$23.15 \$634.91
								\$/12.26	\$/19.4/	\$7.20.68	\$/11.49	\$/12.26	\$/19.4/	\$726.11	\$/11.49	\$020.42	\$032.02	\$039.0/	\$03U.bZ	\$034.91

Rating Area Data Collection

Specify the total number of Rating Areas in your State by selecting the Create Rating Areas button or Ctrl + Shift + R. Select only the Rating Areas you are offering plans within and add a factor for each area. To validate, select the Validate button or Ctrl + Shift + I. To finalize, select the Finalize button or Ctrl + Shift + F.

Rating Area	Rating Factor
Rating Area 1	1.000

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number: /

Supporting Document Schedules

Satisfied - Item:	Actuarial Memorandum and Certifications
Comments:	
Attachment(s):	Non-Standard AVC Screenshots 2025 VT.pdf Rate Increase Exhibit 2024-2025 SMALL_SERFF.pdf 2025 Actuarial Memorandum Vermont Exchange Small.pdf Actuarial Memo Dataset 2025 SMALL_SERFF.pdf Actuarial Memo Dataset 2025 SMALL_SERFF.xlsx Consumer-Disclosure-Form-2025-VT-Exchange-Small.pdf Federal AVC Actuarial Certification for Non-standard Plans - 2025_05092024.pdf Rate Increase Exhibit 2024-2025 SMALL_SERFF.xlsx Unified Rate Review VT SG 2025.xlsm VT 2025 Exchange Rate Filing SMALL_SERFF.pdf VT 2025 Exchange Rate Filing SMALL_SERFF.xlsx VT Rx Data 2025 SMALL_SERFF.pdf VT Rx Data 2025 SMALL_SERFF.xlsx Wakely - VT Standard Plan Designs - AV Certification_2024_03_06.pdf
Item Status:	
Status Date:	
Satisfied - Item:	Civil Union Rating Requirements
Comments:	MVP's rating rules satisfy 8 V.S.A. § 4724.
Attachment(s):	intri o rating rates satisfy o trema y mz m
Item Status:	
Status Date:	
Satisfied - Item:	Filing Compliance Certification
Comments:	
Attachment(s):	Certification of Compliance - 2025 VT.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Third Party Filing Authorization
Bypass Reason:	N/A
Attachment(s):	
Item Status:	
Status Date:	

SERFF Tracking #: MVPH-134081005 State Tracking #: Company Tracking #: Company Tracking #:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2025

Project Name/Number:

Attachment Actuarial Memo Dataset 2025 SMALL_SERFF.xlsx is not a PDF document and cannot be reproduced here.

Attachment Rate Increase Exhibit 2024-2025 SMALL_SERFF.xlsx is not a PDF document and cannot be reproduced here.

Attachment Unified Rate Review VT SG 2025.xlsm is not a PDF document and cannot be reproduced here.

Attachment VT 2025 Exchange Rate Filing SMALL_SERFF.xlsx is not a PDF document and cannot be reproduced here.

Attachment VT Rx Data 2025 SMALL_SERFF.xlsx is not a PDF document and cannot be reproduced here.

User Inputs for Plan Parameters	_									
Use Integrated Medical and Drug Deductible?	e? HSA/HRA Options				Tie	ered Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Em	nployer Contribution	n?	Tiere	Tiered Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Con	tribution Amount:		1st Tier Utilization:					
Use Separate MOOP for Medical and Drug Spending?	Gold ▼	Ailliaarcon	CIDATION AMOUNT.		2nd	Tier Utilization	:			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier										
Desired Metal Her	Tie	r 1 Plan Benefit	Design		Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$3,000.00							
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$3,000.00							
MOOP if Separate (\$)										
Click Here for Important Instructions			Tier 1				ier 2		Tier 1	Tier 2
	Subject to			f Copay, if	Subject to	Subject to	Coinsurance, i	if Copay, if		
Type of Benefit	Subject to Deductible?	Subject to All Coinsurance	? different	separate	Subject to V All Deductible?	Coinsurance?	different	separate		es only after d uttible?
Medical	V				Ÿ	- V				
Emergency Room Services	₩	<u></u>								
All Inpatient Hospital Services (inc. MH/SUD)	✓	✓			~	~				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-rays)	V	•			V	✓				
Specialist Visit	V	V			V	V			П	П
Mental/Behavioral Health and Substance Use Disorder Outpatient	<u> </u>	✓			<u>_</u>	~				
Services	<u> </u>	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				Y				
Imaging (CT/PET Scans, MRIs)					_					_
Speech Therapy	V	~			v	~				
									ì	
Occupational and Physical Therapy	<u> </u>					· · · · · · · · · · · · · · · · · · ·				
Preventive Care/Screening/Immunization	✓	✓	100%		~	~	100%	\$0.00		
Laboratory Outpatient and Professional Services	~	V				•				
X-rays and Diagnostic Imaging Skilled Nursing Facility	V	✓			V	V				П
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓ ✓ All	✓ ✓ All			✓ ✓ All	✓ ✓ All				All
Outpatient Surgery Physician/Surgical Services	V				- · · · · · · · · · · · · · · · · · · ·					
Drugs	<u> </u>				7					
Generics	<u>-</u>					<u>~</u>				
Preferred Brand Drugs	<u> </u>				v	~				
Non-Preferred Brand Drugs										
Specialty Drugs (i.e. high-cost) Options for Additional Benefit Design Limits:	<u> </u>		Dlan Dassvintian	. MAVE VE DITTE	GOLD 3 HDHP - Dr	oft Coloulator				
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	i. IVIVE VI FLOS	JOLD 3 HDHF - DI	art Calculator				
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	П									
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of		202	25 VT Exchange	1						
Copays?		AV	C Adjustments							
Calculate # Copays (1-10):			Plan		Ded / O	ОРМ	Factor	Federal AV B	efore Adi	Federal AV After Ad
Outpul									,	
Status/Error Messages:	Calculation Succes	eful	0.1101	IDIID DI	60.000	/			0.0451	
	81.31%	Januar.	Gold 3 F	HDHP Plus	\$3,000 1	Ded / OOPN	0.9939		0.8131	0.808
	Gold									
		re services are r	not subject to the de	eductible and hav	e no copay. Any	service with this	cost-sharing str	ucture is covered	at 100% bv th	e plan in the deductible
	range.									
. additional Hotes.	ū									
Calculation Time:	1.2969 seconds									

User Inputs for Plan Parameters

Use Integrated Medical and Drug Deductible?

Apply Inpatient Copay per Day?

Apply Skilled Nursing Facility Copay per Day?

Apply Skilled Nursing Facility Copay per Day?

Use Separate MOOP for Medical and Drug Spending?

Indicate if Plan Meets CSR or Expanded Bronze AV Standard?

ronze AV Standard?

HSA/HRA Options	Tiered Network Option
HSA/HRA Employer Contribution?	Tiered Network Plan?
Annual Contribution Amount:	1st Tier Utilization: 2nd Tier Utilization:

Desireu Metar Her	Cold								
	Tier 1 Plan Benefit Design								
	Medical	Combined							
Deductible (\$)	\$5,000.00	\$250.00							
Coinsurance (%, Insurer's Cost Share)	80.00%	100.00%							
MOOP (\$)									
MOOP if Separate (\$)	\$8,000.00	\$500.00							

Tier 2 Plan Benefit Design									
Medical Drug Combine									

Click Here for Important Instructions		Tie	r 1			Ti		Tier 1	Tier 2	
Type of Benefit	Subject to Deductible?	Subject to Coinsurance?	Coinsurance, if different	Copay, if separate	Subject to Deductible?	Subject to Coinsurance?	Coinsurance, if different	Copay, if separate	Copay applies only	after deductible?
Medical	□ All	□ All			☑ All	☑ All			☐ All	☐ All
Emergency Room Services	4			\$500.00	✓	D			2	
All Inpatient Hospital Services (inc. MH/SUD)	[3]	[2]			4	D.			11	
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-rays)				\$0.00	Z	•				
Specialist Visit				\$0.00	✓	ı.				
Mental/Behavioral Health and Substance Use Disorder Outpatient Services				\$0.00	Z	2				
Imaging (CT/PET Scans, MRIs)	[z]	11		\$500.00	2	<u> </u>			[2]	
Speech Therapy	ď	П		\$50.00	2				ы	
Occupational and Physical Therapy	П	Ц		\$25.00	Z	5			Ц	-
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	1	1.1		\$50.00	3	Ø			11	
X-rays and Diagnostic Imaging	11	11		\$50.00	✓	□			11	_
Skilled Nursing Facility	14	[7]			3	Ø			11	
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	∠			\$1,000.00	∠	E			4	
Outpatient Surgery Physician/Surgical Services	Z.	Ш		\$500.00		E .				
Drugs	□ All	□ All			☑ All	[□] All			□ All	□ All
Generics	11	11	·	\$0.00	4	D.			11	
Preferred Brand Drugs	[x]	H		\$40.00	 ✓	<u>□</u>			[2]	
Non-Preferred Brand Drugs	[2]	11		\$80.00	✓	D.			[2]	
Specialty Drugs (i.e. high-cost)	Ø		·	\$80.00	Ø	Ø.			Ø	

Options for Additional Benefit Design Limits:

Set a Maximum on Specialty Rx Coinsurance Payments? | |
Specialty Rx Coinsurance Maximum:
Set a Maximum Number of Days for Charging an IP Copay? | |

Days (1-10):

Begin Primary Care Cost-Sharing After a Set Number of Visits?

Visits (1-10):

Begin Primary Care Deductible/Coinsurance After a Set Number of Copays?

Copays (1-10):

Plan Description: MVP VT Plus Gold 4 - Draft Calculator

Name: Plan HIOS ID: Issuer HIOS ID:

AVC Version: 2025_1a

Output

Status/Error Messages: Calculation Successful.
Actuarial Value: 80.74%

Actuarial Value: 80.
Metal Tier: Gol

NOTE: One or more services are not subject to the deductible and have no copay. Any service with this cost-sharing structure is covered at 100% by the plan in the deductible range.

Additional Notes: NOTE: Service-specific cost-sharing is applying for service(s) with fac/prof components, overriding outpatient inputs for those service(s).

Calculation Time: 0.1562 seconds

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	•		HSA/HRA Options	5 _	Tie	ered Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Employer Contribution?				d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contr		t Tier Utilization:						
Use Separate MOOP for Medical and Drug Spending?					2nd	d Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Silver ▼									
Desired Metal Tier		- 1 Dlan Danafit D	a a law		Tion	. 2 Dlan Banafit I	Dasian			
	Medical	r 1 Plan Benefit D Drug	Combined	_	Medical	2 Plan Benefit I	Combined			
Deductible (\$)		Drug	\$5,775.00		iviedicai	Drug	Combined			
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$5,775.00	1						
MOOP if Separate (\$)			70,110100	⊒!						
			_			•	•			
Click Here for Important Instructions		Ti	er 1			T	ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Consu applies	only after deductible?
.,	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		
Medical	✓ All	✓ All			✓ All	V All			All	All
Emergency Room Services	<u> </u>	v			✓	<u>v</u>				
All Inpatient Hospital Services (inc. MH/SUD)	•	<u> </u>			Ψ.	Ψ)				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	✓	✓			✓	✓				
rays)	~	~			- ✓	V				······
Specialist Visit										
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓	✓			✓	✓				
Services Imaging (CT/PET Scans, MRIs)	<u> </u>	✓			- ✓	✓				
Speech Therapy	~	~			✓	✓				
Special merapy	V	✓			✓	V				
Occupational and Physical Therapy									-	
Preventive Care/Screening/Immunization			100%	**************			100%	\$0.00		•••••
Laboratory Outpatient and Professional Services	<u> </u>	<u> </u>			✓	V				
X-rays and Diagnostic Imaging	~	<u> </u>			✓	V				
Skilled Nursing Facility	V	V			✓	'				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓			✓	✓				
	~					✓				
Outpatient Surgery Physician/Surgical Services	✓ All	✓ All			✓ All	✓ All			□ AII	All
Drugs Generics	•				<u> </u>	<u>~</u>				
Preferred Brand Drugs	<u> </u>	<u> </u>			- ▼					
Non-Preferred Brand Drugs	V	v			₩	~				
Specialty Drugs (i.e. high-cost)	V	V			✓	✓				
Options for Additional Benefit Design Limits:	I		Plan Description	: MVP VT PLUS SI	VER 2 HDHP- Dr	raft Calculator				
Set a Maximum on Specialty Rx Coinsurance Payments?]	Name:							
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):			2025 VT Exc	hange						
Begin Primary Care Deductible/Coinsurance After a Set Number of			AVC Adjustr	nents						
Copays?			l l	Plan	Dec	l / OOPM	Factor	Federal AV	Before Adj	Federal AV After Adj
# Copays (1-10):										
Output Calculate			Silv	ver 2 HDHP Plu	s \$5,	775 Ded / OC	PM 1.0271		0.6940	0.7128
	Standard On-Eyeh	ange Individual S	ilver Plans must me	eet a [0, +2] nerce	nt de minimis ra	nge: Calculation	Successful			
	69.40%			0 (0, -2) perce	20					
	Silver Off-Exchang	e and Small Grou	ıp Market							
	,	•	•	ductible and have	no copay. Any	service with this	cost-sharing struct	ure is covered	at 100% by the	plan in the deductible
	range.		-				<u> </u>		,	
Calculation Time:	1.3438 seconds									

User Inputs for Plan Parameters	_									
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	s –	Tie	red Network O	otion—			
Apply Inpatient Copay per Day?			oyer Contribution			d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?					1st	Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?		Annual Contrib	oution Amount:		2nd	Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Silver ▼									
Desired Metal Tier	Silver									
	Tier	1 Plan Benefit De	sign		Tier	2 Plan Benefit [Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$2,500.00	\$850.00								
Coinsurance (%, Insurer's Cost Share)	50.00%	100.00%								
MOOP (\$)										
MOOP if Separate (\$)	\$7,600.00	\$1,600.00	<u>]</u>							
Click Here for Important Instructions		Tie	v 1			T	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only	y after deductible?
Medical		<u> </u>							7	
Emergency Room Services				\$400.00		<u>-</u>				
All Inpatient Hospital Services (inc. MH/SUD)										
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•			\$30.00	✓	✓			✓	
rays)	V				V	✓				
Specialist Visit				\$60.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓			\$30.00	✓	✓			✓	
Services	v				✓	✓			· · · · · · · · · · · · · · · · · · ·	
Imaging (CT/PET Scans, MRIs)				\$1,400.00	- v	✓				
Speech Therapy	•	П		\$60.00	. ✓	✓			v	-
	•			\$45.00	•	•				
Occupational and Physical Therapy			1000/				4000/	40.00		
Preventive Care/Screening/Immunization	V		100%	¢c0.00	~	✓	100%	\$0.00	V	
Laboratory Outpatient and Professional Services	V			\$60.00	✓	✓			✓	
X-rays and Diagnostic Imaging Skilled Nursing Facility		<u> </u>		\$150.00	✓	✓				
Skilled Nutsing Facility	•					✓			7	
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)				\$1,500.00		<u>~</u>				
Outpatient Surgery Physician/Surgical Services				\$300.00	Ţ All	▼ All			V All	
Drugs	V AII				V A	<u> </u>			V AII	
Generics				\$4.00	¥	·			7	
Preferred Brand Drugs				\$30.00	V	✓			V V	
Non-Preferred Brand Drugs	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			\$60.00	Ž	~			7	
Specialty Drugs (i.e. high-cost)	Ū			\$60.00					<u>. </u>	
Options for Additional Benefit Design Limits:			Plan Description:	: MVP VT Plus Silv	er 1 - Draft Calc	ulator				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:							
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):	~		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of	_		VBID - \$1							
Copays?										
# Copays (1-10):										
Outpu										
Status/Error Messages:	Calculation Succes	sful.								
	71.52%									
	Silver									
		e services are not	subject to the dec	ductible and have	no copav. Anv	service with this	cost-sharing struct	ure is covered	at 100% by the plan	n in the deductible
	range. NOTE: Serv		-				_			
	-			.,					• •	
Calculation Time:	0.125 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	<u> </u>		HSA/HRA Options		Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution?	Ш	Tiered	d Network Plan	, ⊔			
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:			Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?					2nd	Tier Utilization	:	ı		
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Silver ▼									
Desired Metal Tier		r 1 Plan Benefit De	a dan		Tion	2 Plan Benefit I	Danism	1		
	Medical	Drug	Combined		Medical	Drug	Combined	+		
Deductible (\$)		Drug	\$5,800.00		Weulcai	Drug	Combined	1		
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$5,800.00			•		†		
MOOP if Separate (\$)								-		
							_			
Click Here for Important Instructions		Tie					ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	• • •	Copay applies on	ly after deductible?
	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	- All	All
Medical	<u> </u>	<u></u>			~	~				
Emergency Room Services All Inpatient Hospital Services (inc. MH/SUD)	V	V			······	~				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	V	✓			.					
rays)						✓				
Specialist Visit	~	v			✓	✓				
Mental/Behavioral Health and Substance Use Disorder Outpatient	V	v			V	v				
Services					_					
Imaging (CT/PET Scans, MRIs)	V				.	~				
Speech Therapy	~	~			•	₹				
	~	~			✓	✓				
Occupational and Physical Therapy	П									
Preventive Care/Screening/Immunization	<u> </u>	~	100%		-		100%	\$0.00	——П	
Laboratory Outpatient and Professional Services	<u>-</u>	-			~	<u>~</u>			<u>-</u>	<u>-</u>
X-rays and Diagnostic Imaging	<u> </u>	<u> </u>			· 🔽	<u>~</u>				
Skilled Nursing Facility	v	✓			V	v				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)					_					
Outpatient Surgery Physician/Surgical Services	<u> </u>				'	<u>~</u>				
Drugs	✓ All	V All			✓ All	✓ All				All
Generics	v				~					
Preferred Brand Drugs	<u> </u>				· · ·	v				
Non-Preferred Brand Drugs	V	<u> </u>			•	∀				
Specialty Drugs (i.e. high-cost)	·									
Options for Additional Benefit Design Limits:		1	Plan Description:	MVP VT Plus Refl	lective Silver 2 H	IDHP - Draft Cal	culator			
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:							
Specialty Rx Coinsurance Maximum: Set a Maximum Number of Days for Charging an IP Copay?		-	Plan HIOS ID: Issuer HIOS ID:							
# Days (1-10):				2025 1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?			AVC version:	2025_1a						
# Visits (1-10):			2025 VT Exchang	e						
Begin Primary Care Deductible/Coinsurance After a Set Number of			AVC Adjustment							
Copays?			Plan		Ded / OO	PM	Factor Feder	al AV Before Ad	i Federal AV A	fter Adi
# Copays (1-10):					200,00				,	
Output Calculate	· ·		Silver 2 H	DHP Plus II	\$5.800 D	ed / OOPM	1.0271	0.693	3	0.7121
	Chandrad On 5	and the distribution of GC			. ,			2,000		
Status/Error Messages: Actuarial Value:	Standard On-Exch 69.33%	ange individual Sil	lver Plans must mee	ι a [U, +2] percen	it de minimis ra	rige; Calculation	successful.			
Metal Tier:	Silver Off-Exchang	e and Small Group	n Market							
	_		subject to the dedu	ctible and have i	no copav. Anv s	service with this	cost-sharing stri	cture is covered a	t 100% by the nla	n in the deductible
Additional Notes:	range.								, a.e più	
	=									
Calculation Time:	0.2266 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Options		Tie	red Network O	ntion			
Apply Inpatient Copay per Day?			oyer Contribution			d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?						Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	~	Annual Contrib	oution Amount:		-	Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier	Silver 🔻									
besired Wetal Her		1 Plan Benefit De	sign		Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined	1	Medical	Drug	Combined			
Deductible (\$)	\$2,500.00	\$850.00	Combined		Medical	2.06	Combined			
Coinsurance (%, Insurer's Cost Share)	50.00%	100.00%								
MOOP (\$)				1						
MOOP if Separate (\$)		\$1,600.00		-						
	41,000.00	7-,000.00	1			1	1			
Click Here for Important Instructions		Tie	r 1			T	er 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay applies only	after deductible?
туре от венени	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only	arter deductible:
Medical	V All	All			✓ All	▼ All			VAII	All
Emergency Room Services	<u> </u>			\$400.00	V	<u>~</u>				
All Inpatient Hospital Services (inc. MH/SUD)	•	•			•	<u> </u>				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	V			¢20.00	V	✓			✓	
rays)				\$30.00	_	_				
Specialist Visit	<u> </u>	<u>-</u>		\$60.00	✓	✓			V	
Mental/Behavioral Health and Substance Use Disorder Outpatient	•			420.00	V	✓			V	П
Services				\$30.00	_					
Imaging (CT/PET Scans, MRIs)	<u> </u>			\$1,400.00	₹	✓			<u> </u>	
Speech Therapy	<u> </u>			\$60.00	✓	✓			<u> </u>	
	•			445.00	~	✓			✓	
Occupational and Physical Therapy				\$45.00		_				
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	<u> </u>			\$60.00	<u> </u>	~			⊻	
X-rays and Diagnostic Imaging	<u> </u>			\$150.00	₹	✓			<u> </u>	
Skilled Nursing Facility	<u> </u>	<u> </u>		7-2-1-2	✓	✓				
	V				V	✓			✓	П
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)				\$1,500.00	_	_				
Outpatient Surgery Physician/Surgical Services	<u> </u>			\$300.00	<u> </u>	✓			<u> </u>	
Drugs	✓ All	All		7000.00	✓ All	✓ All			▼ All	
Generics	~			\$4.00	~	~			✓	
Preferred Brand Drugs	<u> </u>			\$30.00	✓	✓			<u> </u>	
Non-Preferred Brand Drugs	<u> </u>			\$60.00	<u> </u>	~			~	
Specialty Drugs (i.e. high-cost)		<u>-</u>		\$60.00	✓	✓			✓	
Options for Additional Benefit Design Limits:	_		Plan Description:		lective Silver 1 -	Draft Calculator				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:							
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of			VBID - \$1							
Copays?			•							
# Copays (1-10):										
Outnut										
Calculate										
Status/Error Messages:	Calculation Success	ful.								
Actuarial Value:	71.52%									
Metal Tier:	Silver									
	NOTE: One or more	services are not	subject to the ded	uctible and have	no copay. Any	service with this	cost-sharing struct	ure is covered	at 100% by the plan	in the deductible
Additional Notes:	range. NOTE: Servi	ce-specific cost-sl	haring is applying t	for service(s) with	fac/prof compo	onents, overridir	ig outpatient input	s for those ser	vice(s).	
Calculation Time:	0.1836 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option			ered Network O				
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	ı? □		d Network Plan				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:			t Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?	. 4	7 miliaar contar	Dation 7 mileanti		2nd	l Tier Utilization	:			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	D									
Desired Metal Tier										
		r 1 Plan Benefit De				2 Plan Benefit				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$9,200.00							
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$9,200.00							
MOOP if Separate (\$)										
			_							
Click Here for Important Instructions	0.11. 11		er 1		0.11.11		ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to	Subject to	Coinsurance, if	Copay, if	Copay applies only	after deductible?
** " 1	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	All	All
Medical	<u> </u>	<u> </u>			<u> </u>	<u> </u>			<u> </u>	
Emergency Room Services	v	<u> </u>				· · · · · · · · · · · · · · · · · · ·				<u>-</u>
All Inpatient Hospital Services (inc. MH/SUD)										
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•	✓			✓	✓				
rays)	~	~			₩	~				
Specialist Visit										
Mental/Behavioral Health and Substance Use Disorder Outpatient Services	•	✓			✓	✓				
Imaging (CT/PET Scans, MRIs)	v	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			- ✓	~				
Speech Therapy	~	~			~	v				
эреесп ппетару	V	✓			v	✓				П
Occupational and Physical Therapy	_	•			•	•				
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	✓	~	10070		✓	•	10070	\$0.00		
X-rays and Diagnostic Imaging	✓	<u> </u>			✓	✓				
Skilled Nursing Facility	✓	~			✓	•				
	V	V			V	✓				П
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)					_	_				_
Outpatient Surgery Physician/Surgical Services	<u> </u>	<u> </u>			V	✓				
Drugs	All	All			✓ All	✓ All			All	All
Generics				\$9.00	~	~				
Preferred Brand Drugs	~	✓			✓	✓				
Non-Preferred Brand Drugs	<u> </u>	<u> </u>			✓	~				
Specialty Drugs (i.e. high-cost)	~	~			✓	<u>~</u>				
Options for Additional Benefit Design Limits:			Plan Description	: MVP VT Plus Bro	onze 5 - Draft Ca	lculator				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:							
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	•									
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):										
Output Calculate										
Status/Error Messages:	Expanded Bronze	Standard (58% to	65%), Calculation	Successful.						
Actuarial Value:	62.92%	•								
Metal Tier:	Bronze									
	NOTE: One or mo	re services are not	subject to the de	ductible and have	no copay. Any	service with this	cost-sharing struct	ure is covered	at 100% by the plan	in the deductible
Additional Notes:	range.						<u> </u>			
Calculation Time:	0.2656 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	•	Tie	red Network O	ntion			
Apply Inpatient Copay per Day?			oyer Contribution			d Network Plan				
Apply Skilled Nursing Facility Copay per Day?						Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?		Annual Contrib	oution Amount:			Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	✓				2110	THE OTHER				
Desired Metal Tier	Bronze 🔻									
Desired Metal Her	Tio	1 Plan Benefit De	cian		Tion	2 Plan Benefit I	Docian			
	Medical		Combined		Medical		Combined			
Deductible (\$)	\$7,250.00	Drug \$700.00	Combined		iviedicai	Drug	Combined			
Coinsurance (%, Insurer's Cost Share)	50.00%	100.00%								
MOOP (\$)		00.00				1				
MOOP (\$) MOOP if Separate (\$)	\$6,40	00.00								
MOOP II Separate (\$)			1							
Click Here for Important Instructions		Tie	r 1			Т	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		after deductible?
Medical	✓ All	All			✓ All	✓ All			All	All
Emergency Room Services	•	~			✓	~				
All Inpatient Hospital Services (inc. MH/SUD)	>	~			✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	Y				✓	✓			V	
rays)				\$40.00						_
Specialist Visit	>			\$100.00	₹	✓			~	
Mental/Behavioral Health and Substance Use Disorder Outpatient										
Services	•			\$40.00	✓	✓			•	
Imaging (CT/PET Scans, MRIs)	>	Y			✓	✓				
Speech Therapy	Y	~			✓	✓				
Special Metapy	▼				✓	✓			7	
Occupational and Physical Therapy	•			\$50.00		•				
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	>	~	100/0		✓	✓	10070	30.00		
X-rays and Diagnostic Imaging	7	~			₹	✓				
Skilled Nursing Facility	7	~			✓	✓				
Skilled Ivarsing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	•	✓			₹.	✓				
Outpatient Surgery Physician/Surgical Services	>	V			✓	✓				
Drugs	All	All			✓ All	✓ All			All	All
Generics				\$9.00	✓	✓				
Preferred Brand Drugs	7			\$50.00	✓	✓			~	
Non-Preferred Brand Drugs	•			\$80.00	✓	✓			~	
Specialty Drugs (i.e. high-cost)	7			\$80.00	✓	✓			~	
Options for Additional Benefit Design Limits:			Plan Description	: MVP VT Plus Bro	nzo 1 Draft Ca	lculator				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	. IVIVE VI FIUS BIO	nize I - Diait Ca	iculatoi				
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025 10						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	V		AVC Version:	2025_1a						
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of	$\overline{}$		VBID - \$1							
Copays?			ν ο ΙΟ - Ψ1							
# Copays (1-10):										
Output # Copays (1-10).										
Calculate										
	Expanded Bronze	Standard (58% to	65%) Calculation	Successful						
· · · · · · · · · · · · · · · · · · ·	64.67%	3tadara (30% to	os,oj, carcalation	Saccessiui.						
	Bronze									
		re services are not	subject to the do-	ductible and have	no conav. Anv.	ervice with this	cost-sharing struct	ure is covered	at 100% by the plan	in the deductible
	range. NOTE: Offi		-			CI VICE WILLI LITS	cost-snaring struct	are is covered	at 100% by the plai	i iii die deductible
Additional Notes:	. a.igc. NOTE. OIII	ac visit specific to:	or straining is apply	, to x rays iii 011	securigs.					
- 1 · 1 · 1 · - 1										
Calculation Time:	0.1836 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	V	1	HSA/HRA Option	s _	Tie	red Network O	ption_			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	1?	Tiere	d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		A			1st	Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?		Annual Contrit	oution Amount:		2nd	Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier	Bronze 🔻									
Desired Wetal Her	Tie	r 1 Plan Benefit De	sign	T	Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined	 	Medical	Drug	Combined			
Deductible (\$)			\$9,200.00	-						
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$9,200.00	1						
MOOP if Separate (\$)		ľ	10,000	_		1				
			•							
Click Here for Important Instructions		Tie	r 1			Т	ier 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		6 1 1 1 1 2
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	The state of the s	after deductible?
Medical		L All		•	10000			•	□ All	- All
Emergency Room Services						~				
All Inpatient Hospital Services (inc. MH/SUD)		<u> </u>			~	~				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•	•			✓	✓				
rays)	_									
Specialist Visit	<u> </u>				✓	✓				
Mental/Behavioral Health and Substance Use Disorder Outpatient	•	V	the tall to the below to the below to the bolton to		V	✓				П
Services										
Imaging (CT/PET Scans, MRIs)					- ₹	<u>~</u>				
Speech Therapy	-				✓	<u>~</u>				
	•	•			✓	∠				
Occupational and Physical Therapy					_					
Preventive Care/Screening/Immunization			100%		1 2	_	100%	\$0.00	7-4	50000000000000000000000000000000000000
Laboratory Outpatient and Professional Services		~	000000000			~		•		
X-rays and Diagnostic Imaging					_	<u>~</u>				
Skilled Nursing Facility					~	~				
	~	v			V	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~	V			₩	<u>~</u>				
Outpatient Surgery Physician/Surgical Services		_								
Drugs	✓ All	— All			✓ All	✓ All			□ All	All
Generics			Ç.			~				
Preferred Brand Drugs					₹.	<u> </u>				
Non-Preferred Brand Drugs	V				V	> >				
Specialty Drugs (i.e. high-cost)		V				~				
Options for Additional Benefit Design Limits:			Plan Description	: MVP VT Secu	ıre				-43:	
Set a Maximum on Specialty Rx Coinsurance Payments?]	Name:							
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	•									
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):										
Outpu* Calculate										
Status/Error Messages:	Calculation Succes	ssful.								
Actuarial Value:	61.51%									
Metal Tier:	Bronze									
		re services are not	subject to the de	ductible and have	no copay. Any	service with this	cost-sharing struc	ure is covered	d at 100% by the plan	n in the deductible
Additional Notes:	range.						manus (Samus)		Was the same of the same of	
	1927									
Calculation Time:	0.2344 seconds									

Final 2025 AV Calculator

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	•	Tie	ered Network O	ation			
Apply Inpatient Copay per Day?			oyer Contribution	$\overline{}$		d Network Plan?	$\overline{}$			
Apply Skilled Nursing Facility Copay per Day?		113A) TIKA LIIIPI	oyer contribution			t Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	oution Amount:			l Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	✓				2110	i Hei Otilization.				
Desired Metal Tier	Silver ▼									
Desired Metal Her		r 1 Plan Benefit De	.alam		Ties	2 Plan Benefit [Na alam			
		1	Combined		Medical	1	Combined			
Deductible (\$)	Medical \$1,825.00	Drug \$650.00	Combined		iviedicai	Drug	Combined			
***	. ,									
Coinsurance (%, Insurer's Cost Share)	50.00%	100.00%								
MOOP (\$) MOOP if Separate (\$)	\$6,600.00	\$1,600.00								
WOOF II Separate (5)	30,000.00	\$1,000.00	1				J			
Click Here for Important Instructions		Tie	r 1			Ti	er 2		Tier 1	Tier 2
- (0.00)	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		6 1 1 1 11 2
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only a	
Medical	All	All			✓ All	✓ All			All	All
Emergency Room Services	~			\$350.00	~	~			<u> </u>	
All Inpatient Hospital Services (inc. MH/SUD)	~	~			✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-										
rays)	~			\$30.00	✓	✓			✓	
Specialist Visit	V			\$60.00	~	✓			<u> </u>	
Mental/Behavioral Health and Substance Use Disorder Outpatient				·						
Services	✓			\$30.00	✓	✓			✓	
Imaging (CT/PET Scans, MRIs)	V			\$1,400.00	✓	✓			<u> </u>	
Speech Therapy	~			\$60.00	V	✓			~	
Special metapy	V				✓	✓			V	П
Occupational and Physical Therapy	₩.			\$45.00	V	•				
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	✓		100%	\$60.00	✓	✓	100%	\$0.00	V	
X-rays and Diagnostic Imaging	<u> </u>			\$150.00	V	✓			<u> </u>	
Skilled Nursing Facility	~	<u> </u>		\$130.00	✓	✓				
Skilled Ivul Silig Facility					_	_				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓			\$1,500.00	✓	✓			~	
Outpatient Surgery Physician/Surgical Services	~			\$300.00	✓	✓			<u> </u>	
Drugs	✓ All	All		, , , , , , , , , , , , , , , , , , ,	✓ All	✓ All			✓ All	All
Generics	~			\$4.00	✓	✓			~	
Preferred Brand Drugs	~			\$30.00	✓	✓			~	
Non-Preferred Brand Drugs	~			\$60.00	✓	✓			~	
Specialty Drugs (i.e. high-cost)	✓			\$60.00	✓	✓			V	
Options for Additional Benefit Design Limits:			Plan Description	: MVP VT Plus Silv	er 1 CSR 73 - Dr.	aft Calculator				
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:		c. 1 co / o	art carcarator				
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?		-	Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025 1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	~	-		2025_20						
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of		1	VBID - \$1							
Copays?			, , , , , , , , , , , , , , , , , , ,							
# Copays (1-10):										
Output		1								
Calculate										
Status/Error Messages:	CSR Level of 73%	200-250% FPL), Ca	Iculation Successf	ul.						
	73.85%			-						
Metal Tier:	Silver									
		re services are not	subject to the de-	ductible and have	no copav Anve	service with this	cost-sharing struct	ure is covered	at 100% by the plan i	in the deductible
Additional Notes:			-	for service(s) with			_			s.c acadelible
Additional Notes:		5pcciiic cost-s				, 5 verriuii	o - acpasient inpu			
0.1.17										
Calculation Time:	0.2344 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible	· 🗆		HSA/HRA Options		Tie	red Network Op	otion			
Apply Inpatient Copay per Days	· 🗆	HSA/HRA Emplo	oyer Contribution?		Tiere	d Network Plan?				
Apply Skilled Nursing Facility Copay per Day		Annual Contrib	oution Amount:		1st	Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?		Ailliuai Colluit	dulon Amount.		2nd	Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tie										
		1 Plan Benefit De				2 Plan Benefit I				
5 L 31 L 46	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$		\$300.00								
Coinsurance (%, Insurer's Cost Share)	90.00%	100.00%								
MOOP (\$ MOOP if Separate (\$		\$800.00				T				
MOOF II Separate (5)	\$2,800.00	\$800.00	J				J			
Click Here for Important Instructions		Tie	r 1			Ti	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only a	fter deductible?
Medical	☐ All	All		·	✓ All	✓ All			☐ All	All
Emergency Room Services	~			\$50.00	V	✓			~	
All Inpatient Hospital Services (inc. MH/SUD)	~	~			V	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-				ćr 00						
rays)	✓			\$5.00	~	✓			✓	
Specialist Visit	~			\$30.00	✓	✓			✓	
Mental/Behavioral Health and Substance Use Disorder Outpatient				\$5.00						
Services	✓			\$5.00	~	✓			✓	
Imaging (CT/PET Scans, MRIs)	~			\$100.00	~	✓			~	
Speech Therapy	~			\$30.00	~	✓			v	
	✓			\$7.00	~	✓			✓	
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	<u> </u>			\$30.00	<u>~</u>	✓			<u> </u>	
X-rays and Diagnostic Imaging	>			\$30.00	V	₹			<u> </u>	
Skilled Nursing Facility	✓	✓			V	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~			\$200.00	✓	✓			✓	
Outpatient Surgery Physician/Surgical Services	7			\$100.00	V	✓			•	
Drugs	✓ All	All			✓ All	✓ All			✓ All	All
Generics	•			\$4.00	<u>~</u>	✓			✓	
Preferred Brand Drugs	~			\$20.00	<u>v</u>	⊻			<u> </u>	
Non-Preferred Brand Drugs	<u> </u>			\$50.00	<u> </u>	<u>v</u>			<u> </u>	
Specialty Drugs (i.e. high-cost)	✓		Non December	\$50.00	✓ V	oft Coloulaton				
Options for Additional Benefit Design Limits:		1	Plan Description:	MVP VI Plus Silv	er 1 CSR 87 - Dra	att Calculator				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name: Plan HIOS ID:							
Specialty Rx Coinsurance Maximum Set a Maximum Number of Days for Charging an IP Copay		ł	Issuer HIOS ID:							
# Days (1-10)				2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	· 🔻		AVC VEISIOII.	2025_18						
# Visits (1-10)										
Begin Primary Care Deductible/Coinsurance After a Set Number of			VBID - \$1							
Copays	_									
# Copays (1-10)										
Output		•								
Calculate										
Status/Error Messages:		150-200% FPL), Ca	lculation Successfu							
Actuarial Value:	87.48%									
Metal Tier:	Gold									
									at 100% by the plan i	n the deductible
Additional Notes:	range. NOTE: Ser	vice-specific cost-sl	haring is applying fo	or service(s) with	fac/prof compo	nents, overridir	ig outpatient input	s for those se	rvice(s).	
Calculation Time:	0.1836 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Options		Tie	ered Network O	ntion			
Apply Inpatient Copay per Day?			oyer Contribution			d Network Plan				
Apply Skilled Nursing Facility Copay per Day?						t Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?		Annual Contrib	oution Amount:			Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	1.4				2110	THE OTHER				
Desired Metal Tier	Platinum 🔻									
Desired Wetar Her	Tier	1 Plan Benefit De	cian		Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$0.00	\$0.00	Combined		ivieuicai	Diug	Combined			
Coinsurance (%, Insurer's Cost Share)	95.00%	100.00%								
MOOP (\$)	93.00%	100.00%								
MOOP (\$)	\$1,800.00	\$700.00		-		T				
woor ii separate (3)	\$1,000.00	\$700.00	1				J			
Click Here for Important Instructions		Tie	r 1			Т	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only	after deductible?
Medical	☐ All	All			✓ All	✓ All			All	All
Emergency Room Services				\$30.00	✓	~				
All Inpatient Hospital Services (inc. MH/SUD)		~			✓	~				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-										
rays)				\$5.00	✓	~				
Specialist Visit				\$10.00	✓	✓				
Mental/Behavioral Health and Substance Use Disorder Outpatient				·						
Services				\$5.00	✓	~				
Imaging (CT/PET Scans, MRIs)				\$25.00	✓	✓				
Speech Therapy				\$10.00	✓	✓				
Special includy						v			П	
Occupational and Physical Therapy				\$7.00	•	•				
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services			100%	\$20.00	✓	✓	100%	30.00		
X-rays and Diagnostic Imaging				\$20.00	▽	✓				
Skilled Nursing Facility		~		\$20.00	✓	✓				
January Tacing					✓	V				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)				\$50.00						
Outpatient Surgery Physician/Surgical Services				\$25.00		<u>~</u>				
Drugs	All	All			✓ All	✓ All			All	All
Generics				\$4.00	✓	~				
Preferred Brand Drugs				\$15.00	✓	✓				
Non-Preferred Brand Drugs				\$40.00	~	~				
Specialty Drugs (i.e. high-cost)				\$40.00	✓	~				
Options for Additional Benefit Design Limits:	_		Plan Description:	: MVP VT Plus Silv	er 1 CSR 94 - Dr	aft Calculator				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:							
Specialty Rx Coinsurance Maximum:	_		Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):	_		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	~									
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of			VBID - \$1							
Copays?										
# Copays (1-10):										
Output Calculate										
	0001	400 4500/ ==: \ - :								
	CSR Level of 94% (100-150% FPL), Cal	iculation Successfi	uı.						
Actuarial Value:	94.57%									
Metal Tier:	Platinum									
	NOTE: Service-spe	citic cost-sharing is	s applying for serv	rice(s) with fac/pro	of components,	overriding outp	itient inputs for th	ose service(s).		
Additional Notes:										
Calculation Time:	0.1992 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	,	Tie	red Network O	ntion			
Apply Inpatient Copay per Day?			oyer Contribution			d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?						Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	✓	Annual Contrib	oution Amount:			Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?					2110	THE OTHER				
Desired Metal Tier	Silver ▼									
Desired Metal Her	Tio	1 Plan Benefit De	cian		Tion	2 Plan Benefit I	Docian			
	Medical	1	Combined		Medical	Drug	Combined			
Deductible (\$)	\$950.00	Drug \$450.00	Combined		ivieuicai	Diug	Combined			
Coinsurance (%, Insurer's Cost Share)	70.00%	100.00%								
MOOP (\$)	70.00%	100.00%								
MOOP (\$) MOOP if Separate (\$)	\$6,000.00	\$1,600.00		_						
MOOP II Separate (\$)	\$6,000.00	\$1,000.00	1				1			
Click Here for Important Instructions		Tie	r 1			Т	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		y after deductible?
Medical	AII	All			✓ All	✓ All			All	All
Emergency Room Services	<u> </u>			\$150.00	~				<u> </u>	
All Inpatient Hospital Services (inc. MH/SUD)	•	✓			.	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•			\$15.00	✓	✓			•	
rays) Specialist Visit	~			\$40.00	· ·	✓			<u> </u>	
Mental/Behavioral Health and Substance Use Disorder Outpatient										
Services	Y			\$15.00	V	✓			V	
Imaging (CT/PET Scans, MRIs)	<u> </u>			\$500.00	<u>~</u>	✓			<u> </u>	
Speech Therapy	~			\$40.00	~	✓			~	
	•			\$19.00	V	✓			V	
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization	<u> </u>		100%		<u> </u>	✓	100%	\$0.00	~	
Laboratory Outpatient and Professional Services	<u> </u>			\$40.00	· •	✓			<u> </u>	
X-rays and Diagnostic Imaging				\$100.00	· •	✓				
Skilled Nursing Facility	>	Y			Y	~				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	•			\$800.00	✓	✓			✓	
Outpatient Surgery Physician/Surgical Services	~			\$200.00	✓	✓				
	✓ All	All		\$200.00	✓ All	✓ All			✓ All	All
Drugs Generics	~			\$4.00	~	✓			<u> </u>	
Preferred Brand Drugs	~			\$25.00	~	✓				
Non-Preferred Brand Drugs	~			\$50.00	V	✓				
		<u>-</u>		\$50.00	V	✓				
Specialty Drugs (i.e. high-cost)			Dian Danishian		1 CCD 77 D	-ft Calaulatau				
Options for Additional Benefit Design Limits:]		: MVP VT Plus Silv	er 1 CSK // - Dr	art Calculator				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:							
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of			VBID - \$1							
Copays?										
# Copays (1-10):										
Output Calculate										
Status/Error Messages:	Error: Result is ou	tside of [-2 +2] no	rcent de minimis	variation						
· · · · · · · · · · · · · · · · · · ·	77.85%	or [2, ·2] per	. cc uc mimilio							
Metal Tier:	//.03/0									
	NOTE: One or re-	o conject to	cubioct to the de-	ductible and barre	no consu. Are::	onvice with this	cost sharing street	uro is cover	at 100% butbarie	in the deductible
			-				_		at 100% by the plan	i iii tiie ueductible
Additional Notes:	range. NOTE: Serv	rice-specific cost-st	iai iiig is appiying	for service(s) with	rac/prof compo	ments, overridir	ig outpatient input	s ioi uiose ser	vice(S).	
Calculation Time:	0.1992 seconds									

User Inputs for Plan Parameters	•									
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	_		ered Netwo				
Apply Inpatient Copay per Day?	П	HSA/HRA Emp	loyer Contribution			d Network F				
Apply Skilled Nursing Facility Copay per Day?	П	Annual Contri	ibution Amount:			t Tier Utiliza				
Use Separate MOOP for Medical and Drug Spending?	▼				2nd	d Tier Utiliza	tion:			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier										
	Tier	1 Plan Benefit D	esign		Tier	r 2 Plan Ben	efit Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$4,700.00							
Coinsurance (%, Insurer's Cost Share)			100.00%			A.				
MOOP (\$)			\$4,700.00	_						
MOOP if Separate (\$)										
Click Here for Important Instructions		Tie	er 1				Tier 2		Tier 1	Tier 2
Type of Benefit	Subject to Deductible?	Subject to Coinsurance?	Coinsurance, if different	Copay, if separate		Subject Coinsurar		Copay, if separate		nly after deductible?
Medical	✓ All		unierene	Separate	V All		different	Separate	□ All	All
Emergency Room Services					V	~				
All Inpatient Hospital Services (inc. MH/SUD)		<u> </u>				~				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•	V			7	V				
rays)	200									
Specialist Visit	V	V			_	~				
Mental/Behavioral Health and Substance Use Disorder Outpatient	V	V	ten		V	✓				
Services	~					· ·				
Imaging (CT/PET Scans, MRIs)	7	V			V V	y				
Speech Therapy										
	•	7			V	✓				
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization	~		100%		7		100%	\$0.00		
Laboratory Outpatient and Professional Services	· •	· · · · · · · · · · · · · · · · · · ·				V			I	
X-rays and Diagnostic Imaging					~				<u> </u>	
Skilled Nursing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	V	V			V	v				
Outpatient Surgery Physician/Surgical Services	▼ All	V All			V All	V All			- All	
Drugs	V	V				V A				
Generics	▼	<u> </u>							I – H	
Preferred Brand Drugs	· •					V			ļ	
Non-Preferred Brand Drugs	<u> </u>				7	~			<u> </u>	
Specialty Drugs (i.e. high-cost)										
Options for Additional Benefit Design Limits:		ı	and the second s	MVP VT Plus	Silver 2 HDHP 73 - I	Draft Calcula	ator			
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:							
Specialty Rx Coinsurance Maximum:	_		Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID: AVC Version:	2025_1a						
# Days (1-10): Begin Primary Care Cost-Sharing After a Set Number of Visits?			Ave version.	2023_1a						
# Visits (1-10):		2025	VT Exchange							
Begin Primary Care Deductible/Coinsurance After a Set Number of			Adjustments							
Copays?		AVC	Plan	De	d / OOPM	Factor F	ederal AV Before Adj	Federal AV Af	ter Adi	
#Copays (1-10):					,		cuciui/iv belole/iuj			
Outpu Calculate		5	Silver 2 HDHP Plus 7	73% \$4	,700 Ded / OOPM	1.0179	0.7260		0.7390	
Status/Error Messages:	Error: Result is out	tside of [0 ±1] no	rcent de minimis ur	riation for CC	Rs					
	72.60%	o.uc or [o, 11] pe	. sent de minimis Ve	anation for Co.						
Metal Tier:										
	NOTE: One or mor	re services are no	t subject to the dec	luctible and ha	ive no copay. Any	service with	this cost-sharing struc	ture is covered	at 100% by the n	lan in the deductible
Additional Notes:	range.	_ services are no	- I suject to the det	unu III	copuy. Ally	vioc with	cost siluring struc			
Additional Notes:	J									
Calculation Time:	0.1758 seconds									

Here Investe for Disc. Decembers										
User Inputs for Plan Parameters	✓		LICA/LIDA C)ti	-:	lawa d Nationalis On	- * i · · ·			
Use Integrated Medical and Drug Deductible?			HSA/HRA C			iered Network Op ed Network Plan?				
Apply Inpatient Copay per Day?		HSA/HRA Emplo	oyer Contri	bution?						
Apply Skilled Nursing Facility Copay per Day?		Annual Contrib	bution Amo	unt:		st Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?					2n	d Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Gold ▼									
Desired Metal Tier										
		r 1 Plan Benefit De				r 2 Plan Benefit I				
	Medical	Drug	Combi	ned	Medical	Drug	Combined			
Deductible (\$)			\$1,650	0.00						
Coinsurance (%, Insurer's Cost Share)			100.0	0%						
MOOP (\$)			\$1,650	0.00						
MOOP if Separate (\$)										
Click Here for Important Instructions		Tie					er 2		Tier 1	Tier 2
Type of Benefit	Subject to D√uctible?	Subject to Coi√urance?	Coinsura differe		Subject to Ded thible?	Subject to Coin √rance?	Coinsurance, different	if Copay, if separate	Copay applies	only after deductible?
Medical	v	∀	u	- Jopanute	V V	✓				
Emergency Room Services	<u> </u>	<u> </u>			<u>v</u>	<u>v</u>				
All Inpatient Hospital Services (inc. MH/SUD)		•			Y				l	
	<u> </u>	V				✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-										
rays)	¥	~			V	✓				
Specialist Visit	~	<u> </u>				✓				
Mental/Behavioral Health and Substance Use Disorder Outpatient					_					
Services	V	~			✓	✓				
Imaging (CT/PET Scans, MRIs)	~	~			✓	✓				
Speech Therapy	V	V				₩				
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization	✓	✓	1009	%	✓	✓	100%	\$0.00		
Laboratory Outpatient and Professional Services	✓	✓			✓	✓				
X-rays and Diagnostic Imaging	y	✓			✓	✓				
Skilled Nursing Facility	V				-					
O. ttit [ilit. [/- A -ilit. [/- A -ilit. [/- A -ilit. [/- A -ilit. [/- A -ilit. [/- A	•	<u>v</u>				✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓			✓	✓				
Outpatient Surgery Physician/Surgical Services	✓ All	✓ All			✓ All	✓ All			All	☐ All
Drugs	V	<u> </u>			V	<u> </u>			i i	T T
Generics	7	<u> </u>			V	<u> </u>				
Preferred Brand Drugs	7	~			~	_ _				
Non-Preferred Brand Drugs	7	<u> </u>			V	<u>~</u>				- i
Specialty Drugs (i.e. high-cost)										
Options for Additional Benefit Design Limits:			Plan Descr	ription: MVP VT Plus Si	lver 2 CSR 87 - Di	raft Calculator				
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	iption: Wivi vi i las si	IVEL 2 CON O7 DI	rare carcarator				
Specialty Rx Coinsurance Maximum:			Plan HIOS	ID:						
Set a Maximum Number of Days for Charging an IP Copay?		-	Issuer HIO							
# Days (1-10):	П		AVC Version							
Begin Primary Care Cost-Sharing After a Set Number of Visits?		+	AVC Version	on: 2025_1a						
			20	25 VT Exchange						
# Visits (1-10): Begin Primary Care Deductible/Coinsurance After a Set Number of		+								
			A	/C Adjustments						
Copays?				Plan	Ded	/ OOPM	Factor Fe	deral AV Before A	dj Federal AV	After Adj
# Copays (1-10):		_								
Outpu Calculate				Silver 2 Plus 8	37% \$1,6	50 Ded / OOPM	1.0007	0.87	69	0.8775
Status/Error Messages:	CSR Level of 87%	(150-200% FPL), Ca	alculation Su	ıccessful						
Actuarial Value:	87.69%	(200 200/01 FL), Cd		icccoordi.						
Metal Tier:	87.69% Gold									
WELGI HEI.			aubiost t - t	the deducatible and be	. no conou	comico with this	anet charin+	wilatilka ja aali	at 1000/ butt-	nlan in the deduction
		re services are not	subject to t	the deductible and hav	e no copay. Any	service with this	cost-snaring st	ructure is covered	at 100% by the	plan in the deductible
Additional Notes:	range.									

Calculation Time: 0.3477 seconds
Draft 2025 AV Calculator

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	✓		HSA/HRA Option	S	Tie	red Network C	Option			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	i? 🗌	Tiered	d Network Plan	ı? 🗌			
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:		-	Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?		7 mmaar contra			2nd	Tier Utilization	า:			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	✓ Platinum ✓									
Desired Metal Tier		. 4 Dl D£+ D-	-1		T:	2 Dl D £4	D !			
	Medical	r 1 Plan Benefit De	Combined		Medical	2 Plan Benefit	Combin			
Deductible (\$)	ivieuicai	Drug	\$600.00		ivieuicai	Drug	Combi	ieu		
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$600.00							
MOOP if Separate (\$)			,	_						
		•	_			•				
Click Here for Important Instructions		Tie	er 1			-	Tier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to	Subject to	Coinsurar			only after deductible?
	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance	? differe	nt separate		
Medical	✓ All	✓ AII			✓ All	✓ All			All	All
Emergency Room Services	V	y			× ×	∀				
All Inpatient Hospital Services (inc. MH/SUD)	V	~			_	<u> </u>				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•	✓			✓	✓				
rays) Specialist Visit	V	<u> </u>			~	▽				П
Mental/Behavioral Health and Substance Use Disorder Outpatient										
Services	✓	~			✓	✓				
Imaging (CT/PET Scans, MRIs)	v	~			✓	V				
Speech Therapy	v	v			✓	✓				
	✓	V			✓	✓				
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	V	V			~	<u>~</u>				
X-rays and Diagnostic Imaging	▼	~				V				
Skilled Nursing Facility	~	~			✓	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	•	✓			✓	✓				
Outpatient Surgery Physician/Surgical Services	V	~			✓	✓				Ш
Drugs	✓ All	✓ AII			✓ All	✓ All			All	All
Generics	<u> </u>	~			V	<u> </u>				
Preferred Brand Drugs	V	V			V	▽				
Non-Preferred Brand Drugs	7	7			💆	✓				
Specialty Drugs (i.e. high-cost)	•	•	Dia - Danadatian	. MANDAT Dive Cile						
Options for Additional Benefit Design Limits: Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	: MVP VT Plus Sil	ver 2 CSR 94 - Dra	art Calculator				
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?				· · -						
# Visits (1-10):			2025 VT Exch	ange						
Begin Primary Care Deductible/Coinsurance After a Set Number of			AVC Adjustm	ents						
Copays?			PI	an	Ded / OO	PM	Factor F	ederal AV Before	Adj Federal AV A	After Adj
# Copays (1-10):										
Output			Sil	ver 2 Plus 94%	\$600 D	ed / OOPM	1.0001	0.9	9475	0.9476
Calculate Status / Error Mossages:	CCD Lovel of 040/ /	100 1E00/ FDI \ C-	Iculation Cooss4	ful.						
	94.75%	100-150% FPL), Ca	icuiation successi	ui.						
	Platinum									
		re services are not	subject to the de	ductible and have	no copay. Any s	ervice with this	s cost-sharin	g structure is cove	red at 100% by the	plan in the deductible
	range.		,					J		
	=									
Calculation Time:	0.3281 seconds									

User Inputs for Plan Parameters	✓										
Use Integrated Medical and Drug Deductible?			HSA/HRA Options		1	iered Netv	work Opt	tion			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution?			ed Networ					
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:			st Tier Util			1		
Use Separate MOOP for Medical and Drug Spending?	▽				21	nd Tier Util	lization:		J		
Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier	Silver ▼										
MAA MANON	Tier	r 1 Plan Benefit De	esign		Tie	er 2 Plan B	Benefit De	esign			
	Medical	Drug	Combined		Medical	Dr		Combined			
Deductible (\$)			\$3,400.00						1		
Coinsurance (%, Insurer's Cost Share)			100.00%				5				
MOOP (\$)			\$3,400.00								
MOOP if Separate (\$)											
Click Here for Important Instructions	X.	Tie	er 1				Tie	r 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subje		Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible:			different	separate		only after deductible?
Medical										□ All	All
Emergency Room Services			9		~	~					
All Inpatient Hospital Services (inc. MH/SUD)		<u> </u>			~	~					
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	V	₹			✓	V					
rays)											40000
Specialist Visit	V	<u> </u>			~	~					
Mental/Behavioral Health and Substance Use Disorder Outpatient	V	V			✓						П
Services	9230				S - 2					6	_
Imaging (CT/PET Scans, MRIs)						•					
Speech Therapy	~	<u> </u>			✓	✓					
	•	•			✓	✓					
Occupational and Physical Therapy											
Preventive Care/Screening/Immunization			100%					100%	\$0.00		
Laboratory Outpatient and Professional Services	Y	¥			- V	~				<u> </u>	
X-rays and Diagnostic Imaging					~	- V					
Skilled Nursing Facility						<u> </u>					
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	Y	~			~	✓					
Outpatient Surgery Physician/Surgical Services		<u> </u>			- ✓	₹					
Drugs	✓ All	✓ All			✓ All	<u>~</u>	All			□ All	- All
Generics	~	V			~	~					
Preferred Brand Drugs					✓	✓					
Non-Preferred Brand Drugs	<u> </u>				· •	<u>~</u>					
Specialty Drugs (i.e. high-cost)	_				✓	~					
Options for Additional Benefit Design Limits:			Plan Description:	MVP VT Plus Silv	er 2 HDHP 77	Draft Cald	culator				
Set a Maximum on Specialty Rx Coinsurance Payments?]	Name:								
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:								
Set a Maximum Number of Days for Charging an IP Copay?		1	Issuer HIOS ID:								
# Days (1-10):			AVC Version:	2025_1a							
Begin Primary Care Cost-Sharing After a Set Number of Visits?											
# Visits (1-10):		2025 VI	Exchange								
Begin Primary Care Deductible/Coinsurance After a Set Number of			justments								
Copays?			Plan	Ded / O	ОРМ	Factor	Federal A	AV Before Adi	Federal AV Afte	r Adi	
# Copays (1-10):					-						
Outpu* Calculate		Silv	er 2 HDHP Plus 77%	\$3,400	Ded / OOPM	1.0077		0.7723	0	.7783	
Status/Error Messages:	Error: Result is ou	tside of [0, +1] per	rcent de minimis var	iation for CSRs.							
Actuarial Value:	77.23%										
Metal Tier:											
	NOTE: One or mo	re services are not	subject to the dedu	ictible and have	no copay. Any	y service w	ith this c	ost-sharing stru	cture is covered	at 100% by the	plan in the deductible
Additional Notes:	range.										
Hill											
Calculation Time:	0.2227 seconds										

MVP Health Care Derivation of 2025 VT Exchange Rate increases by Contract and Benefit Plan for ACA Compliant Members in SG Market as of Febuary 2024

	GG	NON-STANDARD PLANS GOLD SILVER			BRONZE PLATINUM GOLD				STANDA SIL	RD PLANS VER			BRONZE								
			On Exchange	Reflective	On Exchange	Reflective					Shift from	On Exchange	Reflective	On Exchange	Reflective				Total Annual Premium	Average PMPM	Average Annua Premium
	HDHP	Non-HDHP	Non-HDHP	Non-HDHP	HDHP	HDHP	Non-HDHP	No RX OOP		Renewing	Retired Gold	Non-HDHP	Non-HDHP	HDHP	HDHP	HDHP	Non-HDHP	No RX OOP			
2025 Proposed Rates																					
Single Rate	\$1,035.37	\$987.13	\$797.39	\$797.39	\$814.41	\$813.77	\$711.56	\$706.75	\$1,183.81	\$993.01	\$993.01	\$798.25	\$798.25	\$806.33	\$806.33	\$708.32	\$702.04	\$716.90			
Couple Rate	\$2,070.74	\$1,974.26	\$1,594.78	\$1,594.78	\$1,628.82	\$1,627.54	\$1,423.12	\$1,413.50	\$2,367.62	\$1,986.02	\$1,986.02	\$1,596.50	\$1,596.50	\$1,612.66	\$1,612.66	\$1,416.64	\$1,404.08	\$1,433.80			
Adult and Child(ren) Rate	\$1,998.26	\$1,905.16	\$1,538.96	\$1,538.96	\$1,571.81	\$1,570.58	\$1,373.31	\$1,364.03	\$2,284.75	\$1,916.51	\$1,916.51	\$1,540.62	\$1,540.62	\$1,556.22	\$1,556.22	\$1,367.06	\$1,354.94	\$1,383.62			
Family Rate	\$2,909.39	\$2,773.84	\$2,240.67	\$2,240.67	\$2,288.49	\$2,286.69	\$1,999.48	\$1,985.97	\$3,326.51	\$2,790.36	\$2,790.36	\$2,243.08	\$2,243.08	\$2,265.79	\$2,265.79	\$1,990.38	\$1,972.73	\$2,014.49	\$147,220,288	\$816.42	\$9,797.05
2024 Approved Rates																					
Single Rate	\$947.82		\$720.03	\$720.03	\$740.87	\$740.27	\$637.04	\$638.01	\$1,094.86	\$912.32	\$944.14	\$720.03	\$720.03	\$734.06	\$733.96	\$641.13	\$631.98	\$653.19			
Couple Rate	\$1,895.64		\$1,440.06	\$1,440.06	\$1,481.74	\$1,480.54	\$1,274.08	\$1,276.02	\$2,189.72	\$1,824.64	\$1,888.28	\$1,440.06	\$1,440.06	\$1,468.12	\$1,467.92	\$1,282.26	\$1,263.96	\$1,306.38			
Adult and Child(ren) Rate	\$1,829.29		\$1,389.66	\$1,389.66	\$1,429.88	\$1,428.72	\$1,229.49	\$1,231.36	\$2,113.08	\$1,760.78	\$1,822.19	\$1,389.66	\$1,389.66	\$1,416.74	\$1,416.54	\$1,237.38	\$1,219.72	\$1,260.66			
Family Rate	\$2,663.37		\$2,023.28	\$2,023.28	\$2,081.84	\$2,080.16	\$1,790.08	\$1,792.81	\$3,076.56	\$2,563.62	\$2,653.03	\$2,023.28	\$2,023.28	\$2,062.71	\$2,062.43	\$1,801.58	\$1,775.86	\$1,835.46	\$134,638,660	\$746.65	\$8,959.78
2025 Proposed Rate Increases																					
Single Rate	9.2%		10.7%	10.7%	9.9%	9.9%	11.7%	10.8%	8.1%	8.8%	5.2%	10.9%	10.9%	9.8%	9.9%	10.5%	11.1%	9.8%			
Couple Rate	9.2%		10.7%	10.7%	9.9%	9.9%	11.7%	10.8%	8.1%	8.8%	5.2%	10.9%	10.9%	9.8%	9.9%	10.5%	11.1%	9.8%			
Adult and Child(ren) Rate	9.2%		10.7%	10.7%	9.9%	9.9%	11.7%	10.8%	8.1%	8.8%	5.2%	10.9%	10.9%	9.8%	9.9%	10.5%	11.1%	9.8%		n .	
Family Rate	9.2%		10.7%	10.7%	9.9%	9.9%	11.7%	10.8%	8.1%	8.8%	5.2%	10.9%	10.9%	9.8%	9.9%	10.5%	11.1%	9.8%	9.34%	Total Reve	nue Change
February 2024 Contracts																					
Single Rate	673		35	700	1	324	66	71	828	1,127	153	3	642	6	492	685	330	74			
Couple Rate	211		4	103	0	83	6	11	286	251	31	0	108	1	101	129	52	3			
Adult and Child(ren) Rate	58		2	28	0	27	3	6	69	92	7	0	35	0	45	44	18	2			
Family Rate	216 1.158		3 44	71 902	0	76	8	8 96	198 1.381	219 1.689	32	0	87 872	0	130	186 1.044	38 438	8 87			
Total	1,158		44	902	1	510	83	96	1,381	1,689	223	3	8/2		768	1,044	438	8/			
February 2024 Members																					
Single Rate	673		35	700	1	324	66	71	828	1,127	153	3	642	6	492	685	330	74			
Couple Rate	422		8	206	0	166	12	22	572	502	62	0	216	2	202	258	104	6			
Adult and Child(ren) Rate	153		6	71	0	62	6	13	178	229	17	0	90	0	115	109	43	9			
Family Rate	847		12	270	0	286	34	31	773	846	117	0	327	0	521	717	144	31			
Total	2,095		61	1,247	1	838	118	137	2,351	2,704	349	3	1,275	8	1,330	1,769	621	120			
2025 Proposed PMPY Revenue	\$10,757.37		\$8,672.99	\$8.897.65	\$9.772.92	\$8.805.84	\$7,689.91	\$7,865.67	\$12.625.93	\$10.673.17	\$10,872.35	\$9.579.00	\$8,790,29	\$9,675.96	\$8,338.43	\$7,450,36	\$7,807.50	\$7,623.52	, T		
2024 Approved PMPY Revenue	\$9.847.73		\$7.831.56	\$8.034.42	\$8,890.44	\$8,010.50	\$6,884.57	\$7,100,63	\$11,677,24	\$9.805.89	\$10,337.27	\$8,640,36	\$7,928.93	\$8.808.72		\$6,743.63		\$6,946.02			



Contact Information

Company Information

Company Legal Name: MVP Health Plan, Inc.

HIOS Issuer ID: 77566 NAIC Number: 95521

Primary Contact Information

Contact Name: Eric Bachner, ASA

Contact Title: Director, Commercial Market & Valuation Actuary

Primary Contact Phone #: 518-991-3417
Primary Contact Address: 625 State Street

Schenectady, NY 12305

Primary Contact E-mail: EBachner@mvphealthcare.com

ACTUARIAL MEMORANDUM 2025 Vermont Small Group Exchange Filing

Purpose and Scope of Filing

This memorandum details the methods and assumptions underlying the proposed 2025 premium rates for the State of Vermont's small group ACA compliant market. These products will be issued by MVP Health Plan, Inc. (MVP), a non-profit subsidiary of MVP Health Care, Inc. The rate filing has been prepared to satisfy the requirements of 8 V.S.A §5104 as well as the requirements of the Federal ACA including 45 CFR Part 156, §156.80. The premium rates are effective between 1/1/2025 and 12/31/2025. There is one benefit plan being retired and one new benefit plans being added. MVP modified several of the benefits being offered, and the updated forms have been submitted in a separate SERFF filing as well as forms for the new plan. The proposed average rate increase (MVP's revenue increase) is 9.3%, with increases ranging from 5.2% to 11.7%.

Market/Benefits

All benefit plans included in this rate filing are available to small employer groups.

A description of benefits is included in Exhibit 1 of the rate filing. As in 2024, MVP has filed Silver plans to be sold off exchange known as "reflective" Silver plans. These plans are equivalent to the corresponding on exchange plan with the exception of a \$5 copay or 5% coinsurance change to the ambulance benefit or a modification to the deductible/maximum out of pocket for the plan which has no cost sharing after the deductible.

Exhibit 1A of the filing provides an overview of benefit changes for renewing plans from 2024 to 2025. As noted in the rate filing document, design changes from the previous year's plan design are shaded in gray.

All Essential Health Benefits (EHBs) are covered. Only one EHB substitution was made as required by the DVHA, a substitution for the \$2,000 annual Private Duty Nursing benefit limit in the benchmark plan. MVP previously contracted Milliman to determine an actuarially equivalent visit limit, and the claim data in the experience period represents this actuarially equivalent limit.

The non-standard plans proposed by MVP and included in this rate filing contain two benefits in excess of the EHBs: a wellness benefit and an acupuncture allowance of \$500. The wellness benefit and acupuncture allowance are included in all non-standard products and the wellness benefit is filed as a mandatory rider, form: FRVT366.

To inform consumers of the availability and details of the products included in this filing, MVP will provide community outreach support as well as offer web and print product content and other printed product materials for VT plans. MVP will also have a mass media presence to further educate health care customers in Vermont.

The book of business affected by this rate filing is 1,209 policyholders, 9,306 subscribers and 15,027 members based on February 2024 membership.

Experience Period Claims

MVP historical claim data was the basis of the premium rate development. All ACA compliant small group data is included in the experience period data set. The claim data is assumed to be fully credible.

The experience period for the historical claims is incurred dates of service between 1/1/23 and 12/31/23, paid through 2/29/24. MVP has restated its incurred medical claim estimates to complete the claims through 3/31/24.

Please see Exhibit 3 for a summary of MVP's experience period claims, market-wide adjustments to experience period claims, and the development of the paid Index rate PMPM. Details of the market-wide adjustments and trend projections being made to MVP's experience period data are discussed below.

Line 1 of Exhibit 3 provides the member months for the experience period for the rating pool.

Line 2 of Exhibit 3 provides the experience period fee for service medical claim expense on a "per member per month" (PMPM basis). This includes all claims for medical services paid by MVP for the rating pool during the experience period.

Line 3 of Exhibit 3 provides the FFS claims paid by MVP for pediatric dental services provided to members in the rating pool during the experience period.

Line 4 reflects the assumption for claims Incurred but not Reported (IBNR) as of the latest date the claims data was paid through. We have completed the claims using an IBNR factor of 3.2% which is our best estimate of ultimate liabilities as of 3/31/24. MVP uses a combined trended PMPM and completion factor method to value its ultimate claim liabilities. Note that the model used to calculate IBNR for this block of business includes all Vermont business, so the paid and incurred claims below will not match the paid and incurred claims in the filing. Our emerging unpaid experience indicates that there are high-cost claims only attributable to small group, so we have modified the IBNR factor for the entire VT population to reflect these amounts specifically in the small group filing. Please see the following table comparing incurred and paid claim amounts by month for the experience period.

		Incurred	
Incurred Month	Paid Claims	Claims	IBNR Factor
202312	\$15,290,309	\$17,350,110	1.135
202311	\$16,637,866	\$17,401,828	1.046
202310	\$16,172,146	\$16,762,348	1.036
202309	\$16,238,927	\$16,611,553	1.023
202308	\$15,669,658	\$15,845,804	1.011
202307	\$14,087,163	\$14,181,084	1.007
202306	\$15,263,143	\$15,843,689	1.038
202305	\$15,679,643	\$15,774,380	1.006
202304	\$15,703,226	\$15,737,218	1.002
202303	\$17,603,896	\$17,643,311	1.002
202302	\$12,895,950	\$12,893,145	1.000
202301	\$13,884,444	\$13,901,258	1.001
Total	\$185,126,371	\$189,945,727	1.026

Line 5 reflects medical plus dental fee-for-service (FFS) claims, completed with IBNR. The formula is line 2 multiplied by line 4, then adding line 3. MVP is assuming that dental claims are fully complete with two months of run-out, and therefore IBNR is not applied to these claims.

Line 6 provides the experience period incurred pharmacy claims for the rating pool. Pharmacy claims include any claims which are paid through the pharmacy portion of the member's benefits.

Experience period Rx rebates are reflected in line 7 of Exhibit 3.

Line 8 of Exhibit 3 reflects MVP's ultimate liability for pharmacy claims during the experience period, which nets manufacturer rebates from the incurred claims paid by MVP.

Line 9 of Exhibit 3 reflects expenses for services such as capitations and other non-FFS medical expenses which come from MVP's General Ledger and are not processed through MVP's claims system. Please see the table below for detail on the items that comprise the capitation and non-FFS expenses reflected in MVP's experience period claims.

Please note the following changes from this table in the 2024 Actuarial Memorandum:

Well-Being Reimbursement

MVP offers a program where members can submit for up to \$600 in reimbursement for activities in the following four domains: Social, Surroundings, Physical, and Mind and Spirit. This iteration of MVP's wellness benefit began in 2023. In the 2024 rate filing, MVP included the claims incurred in 2022 under the old program in its fee for service paid medical claims and did not include any trend for the program. MVP saw a large increase in utilization under the new program as compared to the old one, and so we are reflecting the rewards in this table in the 2025 filing in order to account for them outside of our normal trend.

Claim Settlements to Providers

MVP paid \$1.3 million to providers in 2023 for claim settlements outside of our fee for service claim system. Because of the nature of these settlements, they should be considered claim expense and accounted for in our base period experience (and trended appropriately into the rating period).

Summary of Experience Period Non-FFS and Capitation								
Amounts								
Other Medical Expenses not in claim warehouse	\$2.67							
Net Reinsurance Expense	\$0.65							
Medical Home and PCP Incentive	\$3.77							
Wellstyle Rewards	\$1.28							
Claim Settlements to Providers	\$3.81							
Total Non-FFS and Capitation Amounts	\$12.19							

^{*}Note: VT Paid Claim Surcharge (0.999% of paid claims) and NY HCRA Surcharge (0.15% of paid claims) are not reflected in figures above. Line 9 of Exhibit 3 = (line 5 of Exhibit 3 + line 8 of Exhibit 3) * 1.149% + the applicable value shown above.

Line 10 of Exhibit 3 represents MVP's best estimate of the costs incurred to cover members in the rating pool during the experience period after making the adjustments described above. It is calculated by summing the medical and dental FFS incurred claims completed with IBNR (line 5 of Exhibit 3), the pharmacy incurred claims net of rebates (line 8 of Exhibit 3), and the capitation and non-FFS medical expenses (line 9 of Exhibit 3).

Market-Wide Adjustments to Experience Period Claims

Several adjustments to the experience period incurred claim costs were necessary to adjust for items not captured in the experience period. The adjustments are explained below.

Line 11- Adjustment for Waived Cost Share Due to COVID-19

MVP is removing \$0.27 PMPM to account for cost sharing related to the COVID-19 pandemic including treatment, visits, and testing that was waived during the experience period. Cost sharing shifted back to the members in 2024 with the unwinding of the public health emergency.

Line 12- Adjustment for COVID Vaccines

During the experience period, MVP was responsible for the administration cost of COVID-19 vaccines for all 12 months but began to be responsible for the full ingredient cost of those vaccines starting in September 2023. MVP is projecting the cost for 2025 to be: the 2023 utilization of COVID-19 vaccines for all 12 months multiplied by \$140, which represents

the full amount for ingredient and administration costs. Therefore, the \$0.40 PMPM value found in line 12 represents the difference between the projected cost and the experience cost.

Line 13- Adjustment for Hearing Aids as EHB

Hearing aids were added as an essential health benefit in 2024. MVP analyzed historical experience in its New York population and determined this mandate would result in an additional \$0.33 PMPM.

Line 14- Adjustment for Abortions Covered in Full

Vermont has mandated coverage of abortions without cost sharing except before the deductible on HDHPs. MVP analyzed its historical VT experience and determined this is worth \$0.03 PMPM.

Not Included- Adjustment for H.766

Vermont House Bill H.766 is "an act relating to prior authorization and step therapy requirements, health insurance claims, and provider contracts," and it has the potential to significantly raise the cost of medical claims in the Vermont commercial health insurance market. MVP is still analyzing the contents of the bill (and subsequent amendments that have been filed and approved), but our preliminary analysis suggests this would increase premium rates by 8-10%.

At the time of this filing (last action being taken on 5/3/24), the bill has been approved by both chambers of the Vermont Legislature and is awaiting signature or veto by the Governor.

Given the timing of this decision, the likelihood of a signature or override of the Governor's veto, and the magnitude of the bill in question, MVP is preparing to file an amendment to our rate filing shortly after submission to include the final impact of the bill in our premium rates.

Medical Trend Factors

The development of annual medical paid claim trend factors for 2024 and 2025 is illustrated in Exhibit 2a.

For VT providers whose contractual reimbursement changes are governed by the GMCB, MVP is reflecting the GMCB's most recently approved budgeted changes as the unit cost trend for 2024. We are using approved 2024 increases as the best estimate of future budgeted changes for 2025. For VT providers not governed by the GMCB and non-VT providers, MVP is reflecting its best estimate of unit cost changes. Total allowed unit cost trend is 4.1% for 2024 and 4.1% for 2025.

MVP analyzed historical medical utilization trends for its VT block of business and determined that the data has been too volatile in recent years to use for medical utilization trend purposes. MVP attributes this volatility to the significant membership growth for this block of business and COVID-19. During the 2020 filing, "L&E [Lewis & Ellis Actuaries and Consultants] performed a series of independent trend calculations using market wide utilization data from 2015 to 2018" and found that "After assessing all the market wide results, L&E believes that a reasonable range for market wide utilization trend to be 1% to 4%" (L&E Actuarial Memo, SERFF # MVPH-131934219, page 7). MVP has maintained this same trend in the filing each year. Because MVP believes that their data still lacks necessary stability and L&E's view of utilization trend encompasses the entire market, MVP has built in a 1% annual utilization trend for this filing.

In addition to the medical cost inflation rate assumed from the historical experience period to the rating period, an adjustment is needed to reflect the impact of cost share leveraging on the carrier's share of the medical cost. Leveraging is a result of the fixed nature of deductibles and copays in health benefit plans. When there are fixed member deductibles and copays, the carrier bears a greater portion of the cost of medical inflation. Therefore, an additional factor adjustment is made to the trend assumption to capture this cost.

The trend applied to the deductible portion of the experience period was derived using the distribution of claims for MVP's entire book of business (consistent with the data in MVP's benefit relativity model). Claims below the average deductible amount over the experience period were trended at the applicable allowed trend rate while claims greater than the deductible were held flat.

The average annual allowed trend factor applied to FFS medical claims in this filing is 5.1%. The annual paid leveraging factor is 0.6% which results in an average annual paid FFS medical trend of 5.7%. This can be found on line 16 of Exhibit 3.

Rx Trend Factors

Annual allowed Rx trend factors split by generic, brand, and specialty drugs are illustrated in Exhibit 2a. The trend forecast provided by MVP's PBM was determined using MVP's Vermont commercial data by drug class. The forecasts provided by MVP's PBM account for drugs coming off patent, changes in average wholesale price, new drugs being released to the market, and price competitiveness amongst generic and brand drug manufacturers. In addition to the market trend data provided by the PBM, MVP is also reflecting its best estimate of known contract changes for 2024 and 2025. Those contract changes are reflected in the unit cost trends shown on Exhibit 2a.

Supporting documentation illustrating how the Rx trends shown on Exhibit 2a were converted to paid trends for 2024 and 2025 can be found in Exhibit 2b.

To project rebates, MVP has taken the experience period rebates as a percentage of the experience period allowed claims (34.3%) and applied that percentage to the rating period allowed claims. This represents MVP's best estimate of future rebates that will be shared between the PBM and MVP.

The average annual allowed Rx trend in this filing is 7.3%, and the average annual paid Rx trend net of Rx rebates is 8.0% which can be found in line 17 of Exhibit 3.

The Annual FFS Claim Trend Projection factor shown in line 18 of Exhibit 3 represents the blended FFS annual trend projection. To arrive at the blended trend projection shown in line 21, the following calculation is performed: [line 5 * line 16 + line 8 * line 17] / [line 5 + line 8]. The annual trend is then applied for 24 months to move the experience period data from the experience period to the rating period, and the rating period FFS claim expense on a PMPM basis is reflected in line 20 of Exhibit 3.

Paid Claim Surcharges, Capitation, and Non-FFS PMPM Projection

The paid claim surcharges, capitation, and non-FFS expenses shown in lines 21 and 22 of Exhibit 3 represent MVP's best estimate of these costs in the projection period. A summary of the expenses driving the capitation and non-FFS expenses in line 22 can be found below. Expenses captured in the "Other Medical Expense not in warehouse" line include student out of area charges, a surcharge levied by the state of Massachusetts, and manual checks.

Summary of Rating Period Non-FFS and Capitation Amounts								
Other Medical Expenses not in claim warehouse	\$2.67							
Net Reinsurance Expense	\$1.79							
Medical Home and PCP Incentive	\$3.77							
Wellstyle Rewards	\$1.80							
Claim Settlements to Providers	\$4.08							
Total Non-FFS and Capitation Amounts	\$14.11							
· · · · · · · · · · · · · · · · · · ·								

Net Reinsurance Expense

MVP has experienced recoveries across all of its lines of business that have outpaced reinsurance premiums paid for the past couple of years. Because of this, MVP is anticipating that reinsurance premiums will be significantly increasing in 2025. The net reinsurance expense reflected here is the projected reinsurance premium paid for VT commercial members in 2025 less 2023 actual recoveries for VT commercial members.

Well-Being Reimbursement

As stated above, MVP instituted a new version of its wellness reward program starting in 2023. From 2022 to 2023, the expense related to this program has increased over 600% (from \$0.23 PMPM to \$1.47 PMPM). MVP's expectation is that the utilization of this program will continue to grow, given its initial popularity, the broad range of categories from which members can submit for reimbursement, and the method which MVP has chosen to allow members to submit for reimbursement. Therefore, MVP has assumed a 20% annual trend from 2023 to 2025 in this rate filing to account for increased utilization of the program.

Claim Settlements to Providers

As stated above, MVP has made settlements to providers outside of its claim system for 2023, settlements which should be considered medical claims (as they were for services which will flow through MVP's claim system in future time periods). MVP has trended the experience period PMPM using the unit cost trends for the providers to which the payments were made.

MVP is assuming that the VT paid claim surcharge will remain unchanged in 2025 and equal 0.999%. The NYS HCRA surcharge of 0.15% is also unchanged.

Federal Risk Adjustment Program

MVP contracted with an external actuarial consultant to project expected transfer for 2023. MVP is expected to pay \$5,283,764 into the small group market transfer pool for 2023. This is \$27.39 on a PMPM basis or 4.3% of experience period claims prior to market-wide adjustments. To calculate line 24 of Exhibit 3, MVP applied this risk adjustment payment as a percentage of claim expense to line 23 of Exhibit 3, which the best estimate of the rating period claim expense. This results in an estimated payment of \$30.85 PMPM or \$5,951,190 using experience period membership.

Plan Level Adjustments / Plan Specific Net and Gross Index PMPM rates

Line 25 of Exhibit 3 represents MVP's projected paid index rate after adjustments for 2025. This is the starting net claim cost that will be used to set 2025 premium rates. Gross Index rates and contract tier rates are calculated in Exhibit 6. The plan specific net claim cost for each plan is computed as follows on Exhibit 6:

Adjusted Claim Cost For Pricing	= _	Projected Paid Index Rate After Adjustments PMPM (line 25 of Exhibit 3)
(see Exhibit 6)		[Avg Inforce Actuarial Value * Induced Utilization Factor]

Plan Specific Net Claim Cost PMPM = Adjusted Claim Cost for Pricing * Benefit Actuarial Value * Plan Induced Utilization Factor (see Exhibit 6)

The Plan Specific Gross Claim Cost PMPM for each plan is derived by adjusting the Plan Specific Net Claim Cost PMPM which account for Benefits in Excess of EHBs, PMPM non-claim expense loads, and percent of premium non-claim expense loads.

Actuarial Values and Induced Utilization Factors

The AV Metal Level for each plan was determined using the Federally prescribed Actuarial Value Calculator. Adjustments for aggregate deductibles, the VT Rx OOPM, and safe harbor prescription Rx benefits were made to the

calculator results for the non-standard plans. The actuarial certification of these adjustments has been included as an attachment to this filing in SERFF.

The Benefit Actuarial Value for each plan was determined using MVP's in-house benefit relativity model. The pricing tools value the expected net paid claim cost associated with unique benefit plan designs from a starting single risk pool allowed amount. The AV is the ratio of the expected paid to allowed amount for each plan design.

The induced utilization factors used to set premium rates and compute the average in-force induced utilization factor are the HHS prescribed induced utilization factors of 1.00 for Bronze, 1.03 for Silver, 1.08 for Gold, and 1.15 for Platinum. The experience period actuarial value times induced demand factor (0.8261) can be found in Exhibit 6.

Non-Claim Expense Plan Level Adjustments

Non claim expenses include both percent of premium loads and PMPM loads. The loads do not vary by plan. Each Standard and Non-Standard plan is being loaded with the same PMPM and Percent of Premium loads. The loads are outlined below and summarized in Exhibit 5.

Federal Taxes PMPM based

A total of \$0.44 PMPM is added for fees MVP must pay to the Federal Government per ACA regulations on a PMPM basis. This is comprised of \$0.17 PMPM for the risk adjustment user fee levied by the Department of Health and Human Services and \$0.27 PMPM for the Patient Centered Outcome Research Fee.

State Taxes PMPM Based

\$2.58 PMPM is added for fees MVP must pay to the State of Vermont to help fund expenses incurred by state agencies and other non-profit organizations on MVP's behalf, including the Green Mountain Care Board, the Vermont Program for Quality in Health Care, Inc., and the Office of the Health Care Advocate. This is found by using the best available information about the market-wide cost of each of the programs and then accounting for MVP's growth in market share from 2022 to 2025. We have not received updated expense information from the Green Mountain Care Board and we will seek to amend our filing once we receive this for FY 2024, should the expense be materially different from what is currently assumed.

State Taxes Premium based – VT Vaccine Assessment

Based on information provided by the Vermont Vaccine Purchasing Program (VVPP) in 2023, MVP's rates are estimated to be \$15.05 per covered child and \$3.00 per covered adult for 2025. Based on a blend of MVP's child and adult membership in the projection period, the total PMPM costs were determined, resulting in \$4.66 PMPM. This blended PMPM was then compared to the projection period premium PMPM before the assessment load to convert the assessment to a percent of premium load of 0.57%. These rates are subject to change at the VVPP annual assessment meeting on May 30, 2024, and we will seek to amend our filing if we receive updated data from the VVPP that is materially different from the current assumptions.

Federal Fees Premium based – National High Cost Reinsurance Pool (HCRP) Charge

In the 2025 Notice of Benefit and Payment Parameters issued by HHS, carriers will be compensated 60% for members' paid claims above \$1 million in a given plan year. The total reinsurance received across all states will be aggregated and compared to the national average premium PMPM to determine a percentage of premium charged to each issuer to fund the program.

Based on a national study performed by Wakely Consulting Group, the estimate of the load charged to small group market issuers in 2025 will be 0.77%.

General Administrative Expense Load (Including QI component)

The total administrative expense load included as a plan level adjustment equals \$51.44 PMPM and is used to cover SG&A expenses as well as Quality Improvement/Cost Containment Programs (QI). Based on an analysis of MVP's historical Supplemental Health Care Exhibit (SHCE) expenses, approximately 7% of MVP's total administrative expense was spent on QI. Therefore, \$3.60 PMPM of the \$51.44 PMPM administrative expense is attributable to QI.

MVP's projected administrative expense reflects the 2023 SHCE administrative expense on a PMPM basis trended at 3% per year annually for 2 years.

The following table summarizes the administrative expenses for small group and individual lines of business from the 2021, 2022, and 2023 SHCEs compared to the available admin expense built into the rates for the same time period.

Combined VT AR42 and AR44	Year	Exchange Available Admin PMPM	SHCE Admin PMPM*		
Individual	2021	N/A	\$51.71		
Small Group	2021	N/A	\$44.49		
Combined	2021	\$43.75	\$47.44		
Individual	2022	\$47.10	\$48.26		
Small Group	2022	\$38.75	\$39.63		
Combined	2022	\$42.20	\$43.07		
Individual	2023	\$51.46	\$55.73		
Small Group	2023	\$43.56	\$48.49		
Combined	2023	\$46.74	\$51.41		

*Reflects lines 1.7, 6.6, 8.3, 10.1, and 10.4 of SHCE, Part 1

Risk Margin

MVP is building a 1.5% risk margin into the VT Exchange premium rates for 2025. This charge is added to premium rates to meet statutory reserve requirements for MVP's VT block of business and protect against adverse experience relative to pricing assumptions.

Bad Debt Expense

A plan level adjustment equal to 0.17% of premium was added to account for non-payment of premium risk.

Rider FRVT366 (Wellness Benefit in Addition to EHBs)

Members purchasing a non-standard plan will receive MVP's Member Wellness Incentive (Form: FRVT366). This is an enhancement to the current wellness benefit whereby primary subscribers can earn up to \$600 in reimbursements for wellness-related activities. The cost of this benefit is included in the experience period claims as well as the plan AVs so an adjustment is not required on Exhibit 6.

Acupuncture Allowance (Benefit in Addition to EHBs)

MVP is including a \$500 acupuncture allowance in its benefits in 2025. The cost of this benefit is included in the experience period claims as well as the plan AVs so an adjustment is not required on Exhibit 6.

Per Contract Premium Rates

The Plan Specific Gross Claim Cost PMPMs computed in Exhibit 6 are converted to per contract premium rates using the computed single conversion factor and the prescribed standard load ratios. The single conversion factor (SCF) was calculated using subscriber and member data by contract type for the eligible population enrolled with MVP as of

February 2024. The SCF = weighted average contract size / weighted average load ratio. Please see Exhibit 4 for the derivation of the SCF.

Loss Ratio Information

The traditional target loss ratio (claims cost / premium) for the rates proposed in this rate filing is 90.4%. After adjusting for taxes/assessments and expenses associated with quality improvements, the Federal target loss ratio for the rates proposed in this filing is 92.4%. Please see the following table for a calculation of these loss ratios based on MVP's projected starting claim cost in 2025:

Target Loss Ratio for 2025 VT Small Group								
A) Claims Expense	\$747.86							
B) Taxes/Assessments	\$14.10							
C) Quality Improvement	\$3.60							
D) Premium	\$827.22							
E) Traditional Loss Ratio	90.4%							
= A) / D)								
F) Federal Loss Ratio	92.4%							
= [A) + C)] / [D) - B)]								

MVP does not anticipate having to rebate members for 2023 per the ACA minimum MLR requirements.

Actuarial Dataset, Rate Increase Exhibit, URRT, and Federal Memorandum

Also included with this rate filing are L&E's Actuarial Dataset, a projection of rate increases for ACA compliant subscribers as of February 2024, the Federal URRT, and the Federal Actuarial Memorandum.

Projection Period Enrollment

MVP's projection period membership equals the February 2024 enrollment of the population eligible to purchase these products, or 15,027 members. On Worksheet 2 of the URRT, members are mapped based on their February 2024 benefit to the same benefits for 2025. There is one exception: retired Gold 2 members who are mapped to the Gold 1 plan.

New Products

MVP is offering one new base product to this market effective 1/1/25: Non-Standard Gold 4 (77566VT0050032). MVP utilized its proprietary benefit relativity model to value the benefits associated with the new plan and this is reflected in the premium rate.

Retired Products

MVP is retiring the following base product in Vermont in 2025: Non-Standard Gold 2 (77566VT0050004).

Actuarial Certification

I, Kathleen Fish, am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. The projected Index Rate and Adjusted Paid Amount used in the development of these proposed premium rates is in compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80(d)(1)) and developed in compliance with the applicable Actuarial Standards of Practice. I have examined the assumptions and methods used in determining MVP's requested rates. Based on my review and examination, it is my opinion that the proposed premium rates are reasonable in relation to the benefits provided and that they are not excessive, nor inadequate, nor unfairly discriminatory. They are developed using only the permitted rating classifications. The Adjusted Paid Amount

and only the allowable modifiers as described in 45 CFR 156.80(d)(1) and 45 CFR 156.80(d)(2) were used to generate plan level rates. The Standard AV Calculator was used to determine the Metal AV Value to be shown in Worksheet 2 of the Part I Unified Rate Review template for all the plans.

I certify that I am knowledgeable as to the Vermont laws and regulations that apply to this filing and that, to the best of my knowledge and belief, this filing is in compliance with such laws and regulations and provides all required benefits.

I am of the opinion that this filing is in compliance with the applicable Federal and State Laws and Regulations concerning the PPACA and the HCERA of 2010. The proposed premium rates were developed based on currently approved State and Federal regulations and statutes. If modifications are made to State or Federal regulations or statutes for the 2025 plan year after this filing is submitted, including but not limited to changes to the enforcement of the individual mandate, changes to rules around selling across state lines or association groups, the proposed premium rates may not be reasonable relative to the benefits being offered and could result in inadequate premium rates. If such modifications are made, MVP will pursue an adjustment to the proposed premium rates to reflect the regulations and statutes that will be in place for the 2025 plan year.

I certify that each rate filing has been prepared in accordance with the following Actuarial Standards of Practice; ASOP #5, ASOP#8, ASOP #12, ASOP #23, ASOP #25, ASOP #26, ASOP#41, ASOP#42, ASOP#45, and ASOP#50.

Kathleen Fish, FSA, MAAA

05/13/2024

Senior Director, Actuarial Services / Chief Actuary

MVP Health Care, Inc.

Actuarial Memorandum Dataset Supplement - Plan Year 2025

Please provide Company specific inputs for any cells shaded in blue.

Purpose, Scope, and Reason for Rate Increase

Insurance Company Name HIOS ID SERFF Filing Number Date of Submission Proposed Effective Date

Before Rate Change After Rate Change

MVP Health Plan, Inc. MVPH-134081005 5/13/2024 1/1/2025

Average Annual Premium \$747 \$816

Amount in SERFF's Rate
Review Detail Section

Explanation for differences

Instructions:

help illustrate what should be provided).

•The issuer must complete the Actuarial Memorandum Dataset Supplement and submit with the filing.

•This includes cells where the spreadsheet contains sample input (red entries are just proxy values that

Enter data for all blue shaded cells consistent with the issuer's Part III Actuarial Memorandum.

This document applies to all issuers, new and existing.
Please submit in Excel format under the Supporting Documentation Tab in the Form/Rate filing.
Remember to scroll to the right - there is information requested through Column N.

Proposed Overall Rate Change 9.34% 9.34% Proposed Minimum Rate Change Proposed Maximum Rate Change 11.70% 11.70% N/A

If the difference between the maximum and minimum rate increase is greater than 10%, Provide a statement and clear delineation of contributing factors explaining why certain individual will receive a rate

decrease as low as the minimum while others will face rate increases as high as the maximum

Relationship of Proposed Rate Scale to Current Rate Scale:

Provide a detailed breakdown of the average rate change from the previous approved filing by using the chart below to itemize the drivers of the average rate change. The table should include the previous assumption, current assumption, and the resulting change. Include additional lines as necessary.

change. Include additional lines as necessary.		Current Filing	Dolothida	7
Source of Change	Previous filing	Current Filing Assumption	Relativity Current Filing / Previous filing	
Base Period Experience	Assumption 1.000	1.150	1.150	e.g. previous filing experience period index rate compared to the current filing experience index rate
Adjustment for COVID Testing	0.997	1.000	1.003	le.g. previous filling experience period index rate compared to the current filling experience index rate
Adjustment for Telemedicine Benefit Expansion		1.000	1.000	
Adjustment for Leap Year	1.003	1.000	0.997	
Adjustment for Waived Cost Share Due to CO		1.000	1.003	
Adjustment for COVID Vaccines	1.003	1.001	0.998	
Adjustment for Hearing Aids as EHB	1.003	1.001	1.000	
Adjustment for Abortions Covered in Full	1.000	1.000	1.000	
Adjustment for H.766	1.000	1.000	1.000	
Pricing Trend	1.196	1.125	0.941	The change in this factor is based on the change the trend assumption in previous filing and current filing (e.g. 1.075 ² / 1.08 ²)
Risk Adjustment Recoveries	1.065	1.043	0.980	The change in this factor is based on the change in the risk adjustment recoveries assumptions between previous filing and current filing.
Experience Period Benefit and AV Change	0.977	1.000	1.024	The orange in the factor is based on the original trice has adjustment resevenes assumptions between previous ming and current ming.
SG&A	1.053	1.057	1.004	
Total PMPM Taxes/Assessments	1.003	1.003	1.000	
Total % of Premium Taxes/Assessments	1.013	1.014	1.001	
Margin	1.016	1.017	1.001	
Single Conversion Factor	1.119	1.121	1.002	
			1.000	
			1.000	
			1.000	
			1.000	
			1.000	
			1.000	
			1.000	
Total Rate Change			1.093	
If applicable, Provide an explanation for differe average rate change in cell B18	nce between the Calculate	d Rate change and the	1.093	
N/A				

Annual Rate Change Distribution

	Impacted # of Contracts	Impacted # of Members	Impacted # of Groups, If applicable
Reduction of 15.00% or more	0	0	0
Reduction of 10.01% to 14.99%	0	0	0
Reduction of 5.01% to 10.00%	0	0	0
Reduction of 0.01% to 5.00%	0	0	0
No Change	0	0	0
Increase of 0.01% to 5.00%	0	0	0
Increase of 5.01% to 10.00%	5,824	9,796	792
Increase of 10.01% to 14.99%	3,482	5,231	417
Increase of 15.00% or more	0	0	0
Total	0.306	15 027	1 200

History of Rate Changes

Thistory of Nate Offariges		
For Voor	Average Annual Proposed	Average Annual Approved
<u>For Year</u>	Rate Change	Rate Change
2021	7.30%	2.70%
2022	4.97%	0.83%
2023	16.61%	18.25%
2024	12.50%	11.54%

Rev. 4/30/2019

Retention

	PMPM in effect during the experience period	PMPM from Most Recent Approved Rate Filing	Proposed PMPM for Effective Date	Proposed Change in PMPM Compared to Prior 12 months	Proposed Change in PMPM Compared to Most Recently Approved Filing
Dates	1/1/2023 - 12/31/2023	1/1/2024 - 12/31/2024	1/1/2025 - 12/31/2025		
Commissions & Brokers Fees	\$0.00	\$0.00	\$0.00		
Taxes, Licenses & Fees	\$4.78	\$11.49	\$13.96	192.09%	21.46%
Exchange Fee	\$0.00	\$0.00	\$0.00		
Reinsurance	\$0.00	\$0.00	\$0.00		
All Other Admin Expense	\$43.56	\$44.62	\$51.44	18.08%	15.28%
Profit/Risk Margin	-\$0.34	\$10.93	\$13.63	-4092.21%	24.76%
Total	\$48.00	\$67.04	\$79.03	64.64%	17.89%
Variable	\$13.34	\$26.81	\$32.15	140.91%	19.89%
Non-Variable	\$34.66	\$40.23	\$46.88	35.28%	16.55%
Total	\$48.00	\$67.04	\$79.03	64.64%	6 17.89%
Check	TRUE	TRUE	TRUF	-	

	As % of Premium during the experience period	As % of Premium from Most Recent Approved Rate Filing	Proposed As % of Premium for Effective Date	Proposed Change in %	Proposed Change in % or Premium Compared to Most Recently Approved Filing
Commissions & Brokers Fees	0.00%	0.00%	0.00%		
Taxes, Licenses & Fees	0.70%	1.68%	1.71%	144.38%	1.62%
Exchange Fee	0.00%	0.00%	0.00%		
Reinsurance	0.00%	0.00%	0.00%		
All Other Admin Expense	6.38%	6.53%	6.30%	-1.21%	-3.55%
Profit/Risk Margin	-0.05%	1.60%	1.67%	-3440.00%	4.38%
Total	7.03%	9.81%	9.68%	37.75%	-1.37%
Variable	1.95%	3.93%	3.94%	101.55%	0.31%
Non-Variable	5.07%	5.89%	5.74%	13.18%	-2.49%
Total	7.03%	9.81%	9.68%	37.75%	-1.37%
Check	TRUE	TRUE	TRUE		

Trend & Projection Assumptions

(1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed"). Historical Experience (ACA Only):

	Historical Experience (ACA Only):	Basis? ⁽¹⁾ :	Hiodrica	(1) Choose the option bases	i on now phong is deve	iopod (i.o., ii diiowod trorido	aro adoa iir projections, de	sioot riiiowod j.					
Model Tool Model & Book Loo			Marath Language Lole's and	Δ.	and the LD allian O.M.	A		A		Normalized Monthly	No constituti Dallino 40 Ma	NI P I A P I	Nicola Para I Arra de Para I
Monthly Trend Analysis Based on	N.A. d.	Maria Maria	Monthly Incurred Claims \$		_	Annualized Rolling 3 Mo		Average Age/Gender	04 - 5	Incurred Claims \$	Normalized Rolling 12 Mo		Normalized Annualized
Experience Data Time Period	Month	Member Months	PMPM*	Rolling 12 Mo Trend	Trend	Trend	Average Benefit Factor	Factor	Other Factor	PMPM*	Trend	Rolling 6 Mo Trend	Rolling 3 Mo Trend
Used for Rate Development (ACA Only	·	21,795	\$373.07				1.00	1.00	1.00	\$373.07			
	Feb-2021	21,855	\$409.36				1.00	1.00	1.00	\$409.53			
	Mar-2021	21,817	\$484.43				1.00	1.00	1.00	\$484.08			
	Apr-2021	21,757	\$477.90	-			1.00	1.00	1.00	\$477.18			
	May-2021	21,667	\$466.65	-		70.740/	1.00	1.00	1.00	\$464.97			74.040/
	Jun-2021	21,722	\$516.10	-		76.71%	1.00	1.00	1.00	\$513.99			74.64%
	Jul-2021	21,773	\$473.36	+		27.04%	1.00	1.00	1.00	\$471.59			25.44%
	Aug-2021	21,797	\$469.83			8.71%	1.00	1.00	1.00	\$468.28			7.93%
	Sep-2021	21,751	\$656.47			43.77%	1.00	1.00	1.00	\$653.77			43.38%
	Oct-2021	21,721	\$536.29			69.90%	1.00	1.00	1.00	\$533.95			69.79%
	Nov-2021	21,623	\$596.47		40.400/	126.09%	1.00	1.00	1.00	\$593.97		45 500/	125.64%
	Dec-2021	21,514	\$568.62		46.46%	27.99%	1.00	1.00	1.00	\$566.31		45.79%	27.76%
	Jan-2022	20,922	\$434.13		33.36%	-13.71%	1.00	1.00	1.00	\$433.76		33.00%	-13.46%
	Feb-2022	20,903	\$414.49		23.86%	-60.34%	1.00	1.01	1.00	\$413.96		23.72%	-60.03%
	Mar-2022	20,868	\$526.02		1.37%	-57.39%	1.00	1.01	1.00	\$524.84		1.46%	-56.93%
	Apr-2022	20,891	\$509.99		-4.08%	-32.86%	1.00	1.01	1.00	\$508.14		-3.89%	-32.64%
	May-2022	20,800	\$501.14		-17.15%	37.33%	1.00	1.01	1.00	\$499.50		-16.93%	36.91%
	Jun-2022	20,771	\$562.51		-20.23%	71.76%	1.00	1.01	1.00	\$560.86		-19.98%	70.55%
	Jul-2022	20,755	\$555.52		-11.66%	55.29%	1.00	1.01	1.00	\$554.30		-11.48%	55.08%
	Aug-2022	20,796	\$616.43		3.58%	62.11%	1.00	1.00	1.00	\$615.57		3.74%	62.69%
	Sep-2022	20,772	\$527.80		12.84%	36.18%	1.00	1.01	1.00	\$526.08		12.91%	36.74%
	Oct-2022	20,659	\$670.34		26.34%	57.64%	1.00	1.01	1.00	\$668.27		26.40%	57.78%
	Nov-2022	20,611	\$600.50		42.78%	15.52%	1.00	1.01	1.00	\$598.32		42.76%	14.98%
	Dec-2022	20,552	\$637.56	8.73%	49.78%	58.90%	1.00	1.01	1.00	\$634.64	8.75%	49.60%	57.94%
	Jan-2023	16,394	\$492.31	8.76%	34.97%	-13.67%	0.98	1.02	1.00	\$494.10	8.81%	35.03%	-13.57%
	Feb-2023	16,230	\$472.27	9.89%	10.48%	-32.99%	0.98	1.02	1.00	\$474.07	9.98%	10.63%	-32.11%
	Mar-2023	16,178	\$649.95	10.94%	18.08%	-48.88%	0.98	1.02	1.00	\$652.08	11.10%	18.53%	-47.37%
	Apr-2023	16,065	\$627.44	12.17%	3.80%	0.05%	0.98	1.02	1.00	\$630.39	12.43%	4.47%	2.56%
	May-2023	16,033	\$629.45	13.60%	-0.69%	88.72%	0.98	1.02	1.00	\$633.34	13.94%	0.34%	92.33%
	Jun-2023	16,012	\$627.24	13.78%	-6.09%	85.84%	0.98	1.02	1.00	\$631.76	14.20%	-4.59%	87.69%
	Jul-2023	15,975	\$550.40	12.38%	-0.54%	14.00%	0.97	1.02	1.00	\$554.64	12.86%	1.05%	15.40%
	Aug-2023	16,031	\$643.88	10.12%	17.61%	-16.72%	0.97	1.02	1.00	\$649.10	10.66%	19.51%	-15.73%
	Sep-2023	16,018	\$666.62	14.74%	10.87%	-4.80%	0.97	1.02	1.00	\$672.18	15.41%	12.63%	-4.02%
	Oct-2023	15,984	\$698.10	12.55%	19.01%	52.56%	0.97	1.02	1.00	\$703.75	13.32%	20.70%	53.28%
	Nov-2023	16,036	\$678.45	13.73%	20.53%	58.23%	0.97	1.02	1.00	\$684.52	14.64%	21.90%	58.72%
Last Month in Experience Period	Dec-2023	15,961	\$676.45	13.06%	25.35%	48.07%	0.97	1.02	1.00	\$681.68	14.12%	26.17%	48.18%

Last Month in Experience Period

Add more rows if needed. If applicable, please provide an explanation for the Other normalization factor.

The Department is requesting each carrier provide additional trend exhibits, in excel with working formulas, that are similar to the aggregate information provided above. These exhibits should provide the data by Service Category, Metal Tier, etc. that are used by the Company in the trend development. Please state where in the filing it is located.

Please see the tabs "Med Trends by Category" and "Rx Trend by Category" for the historical incurred claims by Med category (IP/OP/PHY) and Rx category (Generic/Brand/Specialty).

Solvency

Most Recent Quarterly Most Recent Annual Financial Statement Financial Statement Total Adjusted Capital 422,836,319 422,836,319 101,515,430 **Authorized Control Level** 101,515,430 **RBC** Ratio 416.52% 416.52%

Loss Ratio

					Formed	Lana
					Earned	Loss
Time Period	Period Beginning Date	Period Ending Date	Member Months	Incurred Claims	Premium	Ratio
Historical Year -4	1/1/2019	12/31/2019	190,666	87,826,336	93,565,302	93.9%
Historical Year -3	1/1/2020	12/31/2020	247,662	114,541,370	135,732,258	84.4%
Historical Year -2	1/1/2021	12/31/2021	260,792	150,031,701	148,057,941	101.3%
Historical Year -1	1/1/2022	12/31/2022	249,300	147,698,521	143,443,945	103.0%
Historical Year 0	1/1/2023	12/31/2023	192,917	128,593,889	129,780,210	99.1%
Historical Totals			1,141,337	628,691,817	650,579,657	96.6%

Interim Time Period	1/1/2024	2/29/2024	30,020	19,169,392	22,383,980	85.6%
Future Year 1	1/1/2025	12/31/2025	180,324	133,097,371	147,220,288	90.4%
-						

	Expected	A-to-E
	Incurred Claims	Claims Ratio
	84,687,557	103.7%
	121,091,426	94.6%
	134,664,905	111.4%
	131,032,739	112.7%
	120,762,624	106.5%
	592,239,252	106.2%
,		
	20,371,366	94.1%
	133 097 371	100.0%

Quality		
Improvement	Adjustments	Adj Medical
Expenses	to Earned Premium	Loss Ratio
758,851	202,106	94.9%
624,108	2,284,978	86.3%
676,912	1,030,333	102.5%
579,623	1,251,313	104.3%
504,256	913,038	100.2%
3,143,750	5,681,768	98.0%
93,764	368,822	87.5%

2,516,758

649,303

92.4%

Anticipated Pricing Loss Ratio (no adjustments)	90%
Anticipated LR using Federally-prescribed MLR methodology	92%
Note:	

The historical time periods should represent calendar years since the inception date of the plan type through the most recent date available allowing for the appropriate amount of run-out.

The interim time period the time periods available in the current year.

The future year should represent the 12 months immediately following the rate effective date.

Consumer Adjusted Premium Rate Development

Section III of WS2 of the 2022 URRT requires that the Issuer provide the Actuarial Value and cost-sharing design of the plan. The Department requires that the issuer provide the breakdown of this value between Cost Sharing Only and Induced Utilization for every plan in the URRT. (Add additional columns as needed to include all plans shown on the URRT.)

Please see the example below.

Actuarial value and Cost-Sharing Design of the Plan (add additional columns as needed to include all plans shown in Section III of WS2 of the 2022 URRT)

Plan ID (Standard Component ID)	77566VT0050001	77566VT0050002	77E66VT00E0022	77566VT0050004	77566VT0050022	77566VT0050005	77566VT0050006	77566VT0050024	77566VT0050007	77566VT0050020	77566VT0050024	77566VT0050020	77E66VT00E0029	77566VT0050000	77566VT0050040	77566VT0050025	77566VT0050026	77566VT0050011
(From Line 3.1 of the URRT)	77566V10050001	77566V10050002	77566V10050032	77566V10050004	77566V10050025	77566V10050005	77566VT0050006	77506V10050024	77566VT0050007	77566VT0050030	77566VT0050031	77566V10050029	77500V10050028	77566710050009	77566VT0050010	77560 10050025	77566V10050026	77566 V 100500 11
AV and Cost-Sharing Design of Plan	1.090	0.003	0.909	NI/A	0.045	0.714	0.722	0.720	0.712	0.744	0.722	0.720	0.712	0.621	0.627	0.635	0.635	0.630
(From Line 3.3 of the URRT)	1.069	0.903	0.696	IN/A	0.945	0.714	0.722	0.730	0.713	0.714	0.722	0.729	0.713	0.621	0.627	0.635	0.625	0.630
Paid/Allowed Ratio (Cost-Sharing only)	0.932	0.823	0.818	N/A	0.861	0.683	0.690	0.698	0.682	0.683	0.690	0.697	0.682	0.611	0.617	0.625	0.616	0.620
Used Induced utilization factors	1.150	1.080	1.080	N/A	1.080	1.030	1.030	1.030	1.030	1.030	1.030	1.030	1.030	1.000	1.000	1.000	1.000	1.000
Calculated	1.072	0.880	0.994	#VALUE!	0.930	0.703	0.711	0.718	0.702	0.703	0.711	0.718	0.702	0.611	0.617	0.635	0.616	0.620
(This value should equal value on Row 192)	1.072	0.669	0.004	#VALUE!	0.930	0.703	0.711	0.718	0.702	0.703	0.711	0.718	0.702	0.611	0.617	0.625	0.616	0.620

In the text box, please state where in the filing it is located.

Please see the columns "Benefit Actuarial Value" and "Induced Utilization Factor" on Exhibit 7 of the rate filing. The "Calculated" value above does not tie out to the "AV and Cost Sharing Design" line item of WS2 of the URRT because this includes the paid-to-allowed normalization factor, as ordered.

Risk Adjustment

					Proposed Change in
				Proposed Change in	PMPM Compared to
	Actual Risk Adjustment	Assumed in Most Recent	Assumed in Current Rate	PMPM Compared to	Most Recently Approved
	Received	Approved Rate Filing	Filing	Prior 12 months	Filing
Time Period	1/1/2023	1/1/2024	1/1/2025		
Total Risk adjustment (Dollar amount)	(\$5,043,571)	(\$8,376,737)	(\$5,562,716)		
Membership Member Months	192,917	195,144	180,324	-6.53%	-7.59%
PMPM	(\$26.14)	(\$42.93)	(\$30.85)	18.00%	-28.14%
Premium	\$129,780,210	\$147,686,411	\$147,220,288	13.44%	-0.32%
As a % of Premium	-4%	-6%	-4%	-2.77%	-33.38%

If the actual risk adjustment payable/receivable was more than 20% different than what was estimated in the previous filing, please provide details on how the current risk adjustment estimate has addressed prior results.

CSR Enrollment

CSR Enrollment			
		Emerging Enrollment	
	Enrollment (member	(member months) in Most	Projected Enrollment
	months) During the	Recent Approved Rate	(member months) Assumed
	Experience Period	Filing	in Current Rate Filing
Time Period	01/01/2023-12/31/2023	01/01/2024-02/29/2024	01/01/2025-12/31/2025
94% AV Variant	0	0	0
87% AV Variant	0	0	0
77% AV Variant (if applicable)	0	0	0
73% AV Variant	0	0	0
70% AV Variant	1 049	73	876

rrend & Projection Assumptions For inpatient Claims		(1)		┑									
	Historical Experience (ACA Or	nly): owed Basis?(1):	Incurred	(1) Choose the α	option based on h	ow pricing is dev	eloped (i.	e., if allow	ed trend.	s are used in pi	ojections, s	elect "Allow	red").
			Monthly				Averag	Average		Monthly	ed	d	Normalized
			Incurred		Annualized	Annualized	e	Age/Gen		Incurred	_		Annualized
		Member	Claims \$	-	Rolling 6 Mo	Rolling 3 Mo		der	Other	Claims \$			Rolling 3 Mo
Monthly Trend Analysis Based on Experience Data Time Perio		Months	PMPM*	Trend	Trend	Trend	Factor	Factor	Factor	PMPM*	Trend	Mo Trend	Trend
used for Rate Development (ACA Only	· ·	21,795	\$80.43				1.00	1.00	1.00	\$80.43	<u> </u>		
	Feb-2021	21,855	\$96.81				1.00	1.00	1.00	\$96.85			
	Mar-2021	21,817	\$77.13				1.00	1.00	1.00	\$77.08	<u> </u>		
	Apr-2021	21,757	\$97.26				1.00	1.00	1.00	\$97.12			
	May-2021	21,667	\$81.09				1.00	1.00	1.00	\$80.80	<u> </u>		
	Jun-2021	21,722	\$113.96			74.42%	1.00	1.00	1.00	\$113.50	<u> </u>		72.33%
	Jul-2021	21,773	\$97.38			35.28%	1.00	1.00	1.00	\$97.02			33.53%
	Aug-2021	21,797	\$76.19			60.27%	1.00	1.00	1.00	\$75.93	ļ		59.10%
	Sep-2021	21,751	\$217.84			220.73%	1.00	1.00	1.00	\$216.94			219.73%
	Oct-2021	21,721	\$88.60			192.73%	1.00	1.00	1.00	\$88.22			192.52%
	Nov-2021	21,623	\$124.04			403.77%	1.00	1.00	1.00	\$123.52			402.90%
	Dec-2021	21,514	\$85.29		59.09%	-66.37%	1.00	1.00	1.00	\$84.94		58.35%	-66.42%
	Jan-2022	20,922	\$80.01		42.73%	-67.01%	1.00	1.00	1.00	\$79.94		42.32%	-66.91%
	Feb-2022	20,903	\$67.04		50.43%	-91.50%	1.00	1.01	1.00	\$66.96		50.25%	-91.43%
	Mar-2022	20,868	\$85.74		-39.50%	-62.74%	1.00	1.01	1.00	\$85.55		-39.44%	-62.34%
	Apr-2022	20,891	\$101.19		-35.00%	-41.13%	1.00	1.01	1.00	\$100.83		-34.87%	-40.96%
	May-2022	20,800	\$67.84		-53.93%	44.19%	1.00	1.01	1.00	\$67.62		-53.80%	43.67%
	Jun-2022	20,771	\$89.81		-49.16%	53.03%	1.00	1.01	1.00	\$89.55		-49.00%	51.93%
	Jul-2022	20,755	\$100.63		-42.14%	6.91%	1.00	1.01	1.00	\$100.41		-42.02%	6.83%
	Aug-2022	20,796	\$121.98		-27.46%	125.90%	1.00	1.00	1.00	\$121.81		-27.32%	126.79%
	Sep-2022	20,772	\$50.20		-0.04%	23.31%	1.00	1.01	1.00	\$50.03		0.03%	23.93%
	Oct-2022	20,659	\$171.09		21.98%	211.07%	1.00	1.01	1.00	\$170.56		22.06%	211.35%
	Nov-2022	20,611	\$97.76		67.78%	8.34%	1.00	1.01	1.00	\$97.40		67.77%	7.82%
	Dec-2022	20,552	\$74.03	-10.45%	56.82%	150.19%	1.00	1.01	1.00	\$73.69	-10.42%	56.68%	148.66%
	Jan-2023	16,394	\$95.73	-9.25%	42.81%	-63.75%	0.98	1.02	1.00	\$96.08	-9.19%	42.94%	-63.62%
	Feb-2023	16,230	\$63.35	-6.84%	-3.28%	-71.75%	0.98	1.02	1.00	\$63.59	-6.74%	-3.14%	-71.30%
	Mar-2023	16,178	\$142.91	-3.52%	49.35%	-40.14%	0.98	1.02	1.00	\$143.38	-3.36%	49.94%	-38.43%
	Apr-2023	16,065	\$130.18	-1.92%	-1.61%	154.58%	0.98	1.02	1.00	\$130.79	-1.66%	-0.85%	160.35%
	May-2023	16,033	\$99.26	1.94%	-10.19%	560.41%	0.98	1.02	1.00	\$99.87	2.27%	-9.17%	570.76%
	Jun-2023	16,012	\$78.58	3.48%	-1.87%	8.62%	0.98	1.02	1.00	\$79.15	3.87%	-0.38%	9.62%
	Jul-2023	15,975	\$65.00	0.57%	-10.36%	-72.74%	0.97	1.02	1.00	\$65.50	1.00%	-9.04%	-72.41%
	Aug-2023	16,031	\$93.97	-5.75%	19.79%	-83.45%	0.97	1.02	1.00	\$94.73	-5.28%	21.61%	-83.24%
	Sep-2023	16,018	\$128.89	17.49%	-15.86%	-23.73%	0.97	1.02	1.00	\$129.96	18.15%	-14.57%	-23.03%
	Oct-2023	15,984	\$105.44	2.08%	-8.24%	233.67%	0.97	1.02	1.00	\$106.30	2.79%	-7.05%	235.37%
	Nov-2023	16,036	\$81.89	3.18%	-14.28%	213.67%	0.97	1.02	1.00	\$82.63	4.02%	-13.39%	214.56%
Last Month in Experience Perio	od Dec-2023	15,961	\$60.73	3.57%	-22.75%	-44.88%	0.97	1.02	1.00	\$61.20	4.50%	-22.20%	-44.84%
·													

	Historical Experience (ACA Only)):	Incurred	(1) Choose the o	option based on h	now pricing is dev	eloped (i.	e., if allow	ed trends	s are used in pr	rojections, s	select "Allow	ed").
			Monthly				Averag	Average		Monthly	ed	d	Normalized
			Incurred		Annualized	Annualized	e	Age/Gen		Incurred	Rolling	Annualize	Annualized
		Member	Claims \$	Rolling 12 Mo	-	Rolling 3 Mo		der	Other	Claims \$		_	Rolling 3 Mo
Monthly Trend Analysis Based on Experience Data Time Period		Months	PMPM*	Trend	Trend	Trend	Factor	Factor	Factor	PMPM*	Trend	Mo Trend	Trend
used for Rate Development (ACA Only)	Jan-2021	21,795	\$163.36				1.00	1.00	1.00	\$163.36			
	Feb-2021	21,855	\$165.42				1.00	1.00	1.00	\$165.49			
	Mar-2021	21,817	\$217.78				1.00	1.00	1.00	\$217.62			
	Apr-2021	21,757	\$194.19				1.00	1.00	1.00	\$193.90			
	May-2021	21,667	\$207.75				1.00	1.00	1.00	\$207.00			
	Jun-2021	21,722	\$214.70			62.01%	1.00	1.00	1.00	\$213.82			60.12%
	Jul-2021	21,773	\$195.07			30.85%	1.00	1.00	1.00	\$194.34			29.21%
	Aug-2021	21,797	\$205.18			-3.08%	1.00	1.00	1.00	\$204.50			-3.77%
	Sep-2021	21,751	\$238.88			15.40%	1.00	1.00	1.00	\$237.90			15.11%
	Oct-2021	21,721	\$234.58			45.86%	1.00	1.00	1.00	\$233.56			45.77%
	Nov-2021	21,623	\$254.13			95.95%	1.00	1.00	1.00	\$253.06			95.55%
	Dec-2021	21,514	\$260.65		42.43%	88.89%	1.00	1.00	1.00	\$259.59		41.78%	88.54%
	Jan-2022	20,922	\$213.72		38.78%	33.46%	1.00	1.00	1.00	\$213.54		38.43%	33.87%
	Feb-2022	20,903	\$197.72		28.84%	-26.71%	1.00	1.01	1.00	\$197.47		28.72%	-26.13%
	Mar-2022	20,868	\$251.92		26.79%	-38.57%	1.00	1.01	1.00	\$251.35		26.91%	-37.90%
	Apr-2022	20,891	\$229.12		18.12%	-25.01%	1.00	1.01	1.00	\$228.29		18.37%	-24.78%
	May-2022	20,800	\$248.80		9.19%	38.16%	1.00	1.01	1.00	\$247.98		9.48%	37.73%
	Jun-2022	20,771	\$266.34		2.81%	58.41%	1.00	1.01	1.00	\$265.56		3.13%	57.30%
	Jul-2022	20,755	\$262.32		7.00%	72.14%	1.00	1.01	1.00	\$261.74		7.20%	71.89%
	Aug-2022	20,796	\$277.20		20.05%	48.68%	1.00	1.00	1.00	\$276.81		20.23%	49.19%
	Sep-2022	20,772	\$271.35		20.93%	40.99%	1.00	1.01	1.00	\$270.46		20.98%	41.55%
	Oct-2022	20,659	\$261.29		26.98%	17.78%	1.00	1.01	1.00	\$260.48		27.01%	17.88%
	Nov-2022	20,611	\$260.58		29.99%	-6.11%	1.00	1.01	1.00	\$259.63		29.97%	-6.55%
	Dec-2022	20,552	\$311.32	19.59%	36.44%	11.40%	1.00	1.01	1.00	\$309.90	19.61%	36.27%	10.71%
	Jan-2023	16,394	\$231.42	18.15%	23.97%	0.63%	0.98	1.02	1.00	\$232.26	18.21%	24.02%	0.76%
	Feb-2023	16,230	\$239.22	18.44%	6.85%	0.39%	0.98	1.02	1.00	\$240.13	18.55%	7.01%	1.72%
	Mar-2023	16,178	\$289.37	18.20%	6.06%	-30.85%	0.98	1.02	1.00	\$290.32	18.37%	6.49%	-28.78%
	Apr-2023	16,065	\$271.68	18.29%	3.17%	-5.33%	0.98	1.02	1.00	\$272.96	18.55%	3.84%	-2.97%
	May-2023	16,033	\$286.87	17.88%	5.09%	30.05%	0.98	1.02	1.00	\$288.64	18.22%	6.16%	32.55%
	Jun-2023	16,012	\$301.33	16.85%	-3.03%	64.11%	0.98	1.02	1.00	\$303.51	17.27%	-1.48%	65.77%
	Jul-2023	15,975	\$250.10	13.80%	2.15%	20.52%	0.97	1.02	1.00	\$252.02	14.28%	3.77%	22.01%
	Aug-2023	16,031	\$299.57	11.63%	14.58%	1.49%	0.97	1.02	1.00	\$302.00	12.17%	16.43%	2.69%
	Sep-2023	16,018	\$297.00	11.23%	13.58%	-5.94%	0.97	1.02	1.00	\$299.48	11.88%	15.35%	-5.19%
	Oct-2023	15,984	\$320.61	12.23%	18.56%	43.22%	0.97	1.02	1.00	\$323.21	13.00%	20.24%	43.89%
	Nov-2023	16,036	\$327.60	14.36%	20.06%	52.13%	0.97	1.02	1.00	\$330.54	15.27%	21.46%	52.62%
Last Month in Experience Period	Dec-2023	15,961	\$344.02	13.33%	29.05%	88.51%	0.97	1.02	1.00	\$346.68	14.39%	29.89%	88.65%

	Historical Experience (ACA (Only): owed Basis? ⁽¹⁾ :	Incurred	(1) Choose the o	pption based on h	ow pricing is dev	veloped (i.	e., if allow	ved trends	are used in p	rojections, s	select "Allow	ed").
			Monthly				_	Average		Monthly	ed	d	Normalized
			Incurred		Annualized	Annualized		Age/Gen		Incurred		Annualize	
		Member	Claims \$	Rolling 12 Mo	_	Rolling 3 Mo			Other	Claims \$			Rolling 3 Mo
Monthly Trend Analysis Based on Experience Data Time Perio		Months	PMPM*	Trend	Trend	Trend	Factor			PMPM*	Trend	Mo Trend	Trend
used for Rate Development (ACA Only	´ 	21,795	\$97.87				1.00	1.00	1.00	\$97.87			
	Feb-2021	21,855	\$94.29				1.00	1.00	1.00	\$94.33			
	Mar-2021	21,817	\$123.15				1.00	1.00	1.00	\$123.07			
	Apr-2021	21,757	\$127.07				1.00	1.00	1.00	\$126.88			
	May-2021	21,667	\$117.49				1.00	1.00	1.00	\$117.06			
	Jun-2021	21,722	\$123.01			84.74%	1.00	1.00	1.00	\$122.51			82.63%
	Jul-2021	21,773	\$109.87			7.04%	1.00	1.00	1.00	\$109.46			5.72%
	Aug-2021	21,797	\$117.24			-17.84%	1.00	1.00	1.00	\$116.85			-18.43%
	Sep-2021	21,751	\$125.68			-15.16%	1.00	1.00	1.00	\$125.17			-15.40%
	Oct-2021	21,721	\$136.90			38.08%	1.00	1.00	1.00	\$136.30			38.00%
	Nov-2021	21,623	\$141.12			76.70%	1.00	1.00	1.00	\$140.53			76.34%
	Dec-2021	21,514	\$139.52		27.21%	96.19%	1.00	1.00	1.00	\$138.95		26.63%	95.82%
	Jan-2022	20,922	\$95.57		18.69%	-2.78%	1.00	1.00	1.00	\$95.49		18.36%	-2.53%
	Feb-2022	20,903	\$92.38		4.28%	-56.23%	1.00	1.01	1.00	\$92.26		4.15%	-55.90%
	Mar-2022	20,868	\$113.95		0.28%	-72.67%	1.00	1.01	1.00	\$113.70		0.34%	-72.38%
	Apr-2022	20,891	\$105.85		-10.70%	-53.05%	1.00	1.01	1.00	\$105.46		-10.53%	-52.89%
	May-2022	20,800	\$110.87		-23.55%	2.87%	1.00	1.01	1.00	\$110.51		-23.35%	2.60%
	Jun-2022	20,771	\$126.28		-29.90%	66.56%	1.00	1.01	1.00	\$125.91		-29.68%	65.40%
	Jul-2022	20,755	\$113.23		-23.41%	58.72%	1.00	1.01	1.00	\$112.99		-23.25%	58.48%
	Aug-2022	20,796	\$127.15		-9.52%	51.21%	1.00	1.00	1.00	\$126.97		-9.37%	51.73%
	Sep-2022	20,772	\$121.65		-4.49%	24.21%	1.00	1.01	1.00	\$121.25		-4.43%	24.70%
	Oct-2022	20,659	\$153.28		18.87%	73.21%	1.00	1.01	1.00	\$152.80		18.93%	73.35%
	Nov-2022	20,611	\$146.95		43.10%	75.03%	1.00	1.01	1.00	\$146.42		43.07%	74.22%
	Dec-2022	20,552	\$152.14	0.37%	59.41%	143.74%	1.00	1.01	1.00	\$151.44	0.38%	59.20%	142.29%
	Jan-2023	16,394	\$107.68	1.53%	51.14%	11.29%	0.98	1.02	1.00	\$108.07	1.57%	51.18%	11.39%
	Feb-2023	16,230	\$108.54	2.97%	31.87%	-37.25%	0.98	1.02	1.00	\$108.96	3.06%	32.03%	-36.45%
	Mar-2023	16,178	\$136.23	5.06%	34.13%	-63.22%	0.98	1.02	1.00	\$136.68	5.21%	34.60%	-62.13%
	Apr-2023	16,065	\$133.24	8.59%	11.33%	-29.79%	0.98	1.02	1.00	\$133.87	8.82%	12.01%	-28.00%
	May-2023	16,033	\$144.65	11.43%	-0.18%	48.09%	0.98	1.02	1.00	\$145.54	11.75%	0.84%	51.03%
	Jun-2023	16,012	\$150.90	12.80%	-8.07%	119.41%	0.98	1.02	1.00	\$151.99	13.21%	-6.58%	121.64%
	Jul-2023	15,975	\$136.10	14.31%	-1.24%	70.24%	0.97	1.02	1.00	\$137.15	14.80%	0.37%	72.35%
	Aug-2023	16,031	\$149.84	15.12%	12.93%	23.89%	0.97	1.02	1.00	\$151.05	15.69%	14.80%	25.34%
	Sep-2023	16,018	\$149.40	17.58%	12.02%	6.31%	0.97	1.02	1.00	\$150.65	18.26%	13.84%	7.14%
	Oct-2023	15,984	\$175.83	17.56%	30.48%	46.64%	0.97	1.02	1.00	\$177.25	18.37%	32.38%	47.31%
	Nov-2023	16,036	\$179.99	19.29%	43.08%	78.86%	0.97	1.02	1.00	\$181.60	20.26%	44.75%	79.43%
Last Month in Experience Perio		15,961	\$177.22	19.88%	53.93%	124.71%	0.97	1.02	1.00	\$178.59	21.03%	54.93%	124.90%

Historical Experience (ACA Only): d Basis?⁽¹⁾: Incurred (1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed"). Monthly d Monthly Normalize Normalized Normalized Annualize d Rolling Annualize Average Average Incurred d Rolling Annualized Annualized Incurred Rolling Member Claims \$ 6 Mo d Rolling 3 Benefit Age/Gend Other Claims \$ 12 Mo Rolling 6 Rolling 3 Monthly Trend Analysis Based on Experience Data Time Period Month Months PMPM* Mo Trend Factor er Factor Factor PMPM* Trend Trend Mo Trend Mo Trend Trend used for Rate Development (ACA Only) Jan-2021 21,795 \$8.27 1.00 1.00 1.00 \$8.27 21,855 \$7.94 \$7.94 Feb-2021 1.00 1.00 1.00 \$9.42 21,817 1.00 1.00 \$9.41 Mar-2021 1.00 Apr-2021 21,757 \$9.19 1.00 1.00 1.00 \$9.18 May-2021 21,667 \$10.26 1.00 1.00 1.00 \$10.23 21,722 \$9.86 \$9.82 1.00 1.00 Jun-2021 71.42% 1.00 69.40% 21,773 \$11.00 89.09% 1.00 1.00 \$10.96 Jul-2021 1.00 86.72% 21,797 \$11.29 Aug-2021 53.87% 1.00 1.00 \$11.25 52.82% 21,751 \$10.88 \$10.83 Sep-2021 63.86% 1.00 1.00 1.00 63.46% 21,721 \$11.72 40.49% 1.00 1.00 1.00 \$11.67 40.42% Oct-2021 21,623 \$11.81 \$11.76 Nov-2021 31.10% 1.00 1.00 30.82% 21,514 \$13.34 1.00 \$13.29 Dec-2021 62.52% 52.65% 1.00 1.00 61.79% 52.36% Jan-2022 20,922 \$7.80 34.77% -9.61% 1.00 1.00 \$7.79 1.00 34.41% -9.40% 20,903 \$8.01 -47.75% 1.00 \$8.00 Feb-2022 9.06% 1.01 1.00 8.94% -47.38% 20,868 \$9.79 \$9.77 Mar-2022 0.54% -76.76% 1.00 1.01 1.00 0.60% -76.51% 20,891 \$10.32 -47.54% \$10.29 Apr-2022 -11.34% 1.00 1.01 -11.18% -47.35% May-2022 20,800 \$11.56 -16.25% 37.42% 1.00 1.01 \$11.52 37.08% -16.05% 20,771 \$11.49 1.00 Jun-2022 -29.12% 188.74% 1.01 \$11.46 -28.91% 186.73% 1.00 20,755 \$12.13 Jul-2022 -10.63% 144.87% 1.01 \$12.11 -10.45% 144.57% 1.00 1.00 20,796 \$14.00 \$13.98 Aug-2022 18.21% 99.22% 1.00 1.00 1.00 18.42% 99.99% Sep-2022 20,772 \$14.02 37.67% 109.70% 1.00 1.01 1.00 \$13.97 37.77% 110.53% 20,659 \$15.08 \$15.03 Oct-2022 63.46% 125.23% 1.00 1.01 63.55% 125.41% 20,611 \$14.56 81.23% 1.00 1.01 \$14.51 80.35% Nov-2022 78.04% 1.00 78.04% 20,552 Dec-2022 \$14.25 103.18% 42.76% \$14.18 14.38% 1.00 1.01 14.40% 102.96% 41.93% 1.00 16,394 \$9.47 \$9.51 Jan-2023 16.52% 68.95% -32.94% 0.98 1.02 1.00 16.57% 68.99% -32.91% Feb-2023 16,230 \$10.47 18.72% 30.64% -59.35% 0.98 1.02 1.00 \$10.51 18.83% 30.77% -58.84% Mar-2023 16,178 \$13.10 -67.99% -67.04% 21.00% 13.12% \$13.14 21.17% 13.50% 0.981.02 1.00 16,065 \$10.88 \$10.83 -39.50% 0.98 1.02 -37.94% Apr-2023 20.69% -11.12% 1.00 20.93% -10.60% 16,033 \$12.21 20.15% 15.57% 1.02 \$12.28 20.47% -23.05% 17.85% May-2023 -23.80% 0.98 1.00 Jun-2023 16,012 \$9.27 -39.56% -8.29% 0.98 1.02 1.00 \$9.34 17.77% -7.39% 17.40% -38.61% 15,975 \$8.27 0.97 Jul-2023 13.89% -39.13% -43.98% 1.02 1.00 \$8.34 14.30% -38.17% -43.30% Aug-2023 16,031 \$8.94 7.82% -37.41% -71.18% 0.97 \$9.01 -36.40% -70.83% 1.02 1.00 8.26% 16,018 \$8.62 -59.13% 0.97 1.02 1.00 \$8.69 -58.80% Sep-2023 1.24% -44.69% 1.75% -43.81%

Oct-2023

Nov-2023

Dec-2023

15,984

16,036

15,961

\$10.21

\$11.16

\$12.40

-5.19%

-10.03%

-12.55%

-39.23%

-36.64%

-16.78%

Trend & Projection Assumptions For RX Brand Claims

Last Month in Experience Period

Historical Experience (ACA Only): d Basis?⁽¹⁾: Incurred (1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed").

-24.18%

64.32%

191.96%

0.97

0.97

0.97

1.02

1.02

1.00

1.00

1.00

\$10.30

\$11.26

\$12.50

-4.61%

-9.35%

-11.74%

-38.34%

-35.89%

-16.22%

-23.80%

64.86%

192.19%

		•			-	_				Normalize	-		
			Monthly		Annualize					d Monthly	Normalize	Normalized	Normalized
			Incurred	Rolling	d Rolling	Annualize	Average	Average		Incurred	d Rolling	Annualized	Annualized
		Member	Claims \$	12 Mo	6 Mo	d Rolling 3	Benefit	Age/Gend	Other	Claims \$	12 Mo	Rolling 6	Rolling 3
Monthly Trend Analysis Based on Experience Data Time Period	Month	Months	PMPM*	Trend	Trend	Mo Trend	Factor	er Factor	Factor	PMPM*	Trend	Mo Trend	Mo Trend
used for Rate Development (ACA Only)	Jan-2021	21,795	\$19.66				1.00	1.00	1.00	\$19.66			
	Feb-2021	21,855	\$23.43				1.00	1.00	1.00	\$23.44			
	Mar-2021	21,817	\$28.40				1.00	1.00	1.00	\$28.38			
	Apr-2021	21,757	\$27.98				1.00	1.00	1.00	\$27.94			
	May-2021	21,667	\$27.97				1.00	1.00	1.00	\$27.87			
	Jun-2021	21,722	\$29.99			108.83%	1.00	1.00	1.00	\$29.87			106.40%
	Jul-2021	21,773	\$31.26			56.38%	1.00	1.00	1.00	\$31.15			54.42%
	Aug-2021	21,797	\$31.56			46.66%	1.00	1.00	1.00	\$31.46			45.62%
	Sep-2021	21,751	\$31.87			47.47%	1.00	1.00	1.00	\$31.74			47.09%
	Oct-2021	21,721	\$32.27			32.34%	1.00	1.00	1.00	\$32.13			32.27%
	Nov-2021	21,623	\$32.64			18.21%	1.00	1.00	1.00	\$32.51			17.97%
	Dec-2021	21,514	\$36.51		55.21%	31.46%	1.00	1.00	1.00	\$36.36		54.52%	31.21%
	Jan-2022	20,922	\$26.64		28.59%	1.00%	1.00	1.00	1.00	\$26.62		28.26%	1.29%
	Feb-2022	20,903	\$28.07		12.90%	-20.49%	1.00	1.01	1.00	\$28.03		12.80%	-19.87%
	Mar-2022	20,868	\$36.86		14.28%	-33.56%	1.00	1.01	1.00	\$36.77		14.39%	-32.85%
	Apr-2022	20,891	\$31.92		8.65%	3.77%	1.00	1.01	1.00	\$31.80		8.87%	4.11%
	May-2022	20,800	\$34.61		5.46%	63.77%	1.00	1.01	1.00	\$34.50		5.73%	63.29%
	Jun-2022	20,771	\$37.62		-0.42%	67.40%	1.00	1.01	1.00	\$37.51		-0.12%	66.26%
	Jul-2022	20,755	\$37.19		15.79%	63.01%	1.00	1.01	1.00	\$37.11		16.01%	62.77%
	Aug-2022	20,796	\$37.46		31.22%	39.05%	1.00	1.00	1.00	\$37.41		31.40%	39.52%
	Sep-2022	20,772	\$40.47		28.88%	49.31%	1.00	1.01	1.00	\$40.33		28.93%	49.88%
	Oct-2022	20,659	\$40.05		39.14%	35.12%	1.00	1.01	1.00	\$39.93		39.17%	35.22%
	Nov-2022	20,611	\$43.04		46.66%	46.67%	1.00	1.01	1.00	\$42.88		46.63%	45.98%
	Dec-2022	20,552	\$47.06	24.69%	57.03%	63.34%	1.00	1.01	1.00	\$46.85	24.71%	56.83%	62.36%
	Jan-2023	16,394	\$38.95	25.58%	43.97%	47.16%	0.98	1.02	1.00	\$39.09	25.65%	44.04%	47.44%
	Feb-2023	16,230	\$39.90	27.19%	34.84%	12.10%	0.98	1.02	1.00	\$40.05	27.31%	35.08%	13.68%
	Mar-2023	16,178	\$46.46	26.60%	36.32%	-14.15%	0.98	1.02	1.00	\$46.61	26.79%	36.91%	-11.59%
	Apr-2023	16,065	\$42.86	28.19%	29.95%	-2.22%	0.98	1.02	1.00	\$43.06	28.48%	30.81%	0.17%
	May-2023	16,033	\$49.07	29.57%	26.28%	40.42%	0.98	1.02	1.00	\$49.38	29.96%	27.61%	43.01%
	Jun-2023	16,012	\$53.49	30.85%	21.73%	81.53%	0.98	1.02	1.00	\$53.87	31.35%	23.70%	83.39%
	Jul-2023	15,975	\$51.91	32.57%	31.33%	104.29%	0.97	1.02	1.00	\$52.31	33.17%	33.44%	106.86%
	Aug-2023	16,031	\$59.68	36.08%	46.82%	102.53%	0.97	1.02	1.00	\$60.16	36.79%	49.19%	104.92%
	Sep-2023	16,018	\$53.02	36.43%	46.67%	64.32%	0.97	1.02	1.00	\$53.46	37.28%	48.96%	65.58%
	Oct-2023	15,984	\$56.94	38.17%	56.35%	45.44%	0.97	1.02	1.00	\$57.40	39.15%	58.55%	46.09%
	Nov-2023	16,036	\$51.56	37.11%	51.93%	-8.39%	0.97	1.02	1.00	\$52.02	38.23%	53.64%	-8.11%
Last Month in Experience Period	Dec-2023	15,961	\$55.59	35.92%	47.63%	-1.32%	0.97	1.02	1.00	\$56.02	37.22%	48.58%	-1.24%

Historical Experience (ACA Only): d Basis?⁽¹⁾: Incurred (1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed"). Monthly d Monthly Normalize Normalized Normalized Annualize Incurred Rolling d Rolling Annualize Average Average Incurred d Rolling Annualized Annualized Member Claims \$ 12 Mo 6 Mo d Rolling 3 Benefit Age/Gend Other Claims \$ 12 Mo Rolling 6 Rolling 3 Monthly Trend Analysis Based on Experience Data Time Period Month Months PMPM* Trend Mo Trend Factor er Factor Factor PMPM* Trend Mo Trend Mo Trend Trend used for Rate Development (ACA Only) Jan-2021 21,795 \$35.00 \$35.00 1.00 1.00 1.00 21,855 \$52.98 1.00 \$53.00 Feb-2021 1.00 1.00 21,817 \$59.91 Mar-2021 \$59.96 1.00 1.00 1.00 \$53.44 Apr-2021 21,757 \$53.52 1.00 1.00 May-2021 21,667 \$53.30 1.00 1.00 1.00 \$53.11 21,722 \$55.67 \$55.44 Jun-2021 45.44% 1.00 1.00 1.00 43.75% 21,773 \$60.01 \$59.79 Jul-2021 6.25% 1.00 1.00 1.00 4.90% 21,797 \$59.33 \$59.13 Aug-2021 21.22% 1.00 1.00 1.00 20.34% 21,751 \$62.77 \$62.51 Sep-2021 57.75% 1.00 1.00 1.00 57.34% Oct-2021 21,721 \$63.09 44.17% 1.00 1.00 1.00 \$62.82 44.09% Nov-2021 21,623 37.58% \$63.43 \$63.69 1.00 1.00 37.30% 21,514 \$63.54 1.00 1.00 1.00 \$63.28 Dec-2021 43.92% 19.31% 43.26% 19.08% Jan-2022 20,922 \$50.05 -15.49% 1.00 1.00 \$50.01 -15.24% 16.98% 1.00 16.66% 20,903 Feb-2022 \$60.93 -27.90% 1.00 1.01 \$60.85 -27.31% 13.66% 1.00 13.56% 20,868 \$67.30 -23.05% 1.01 \$67.15 Mar-2022 14.51% 1.00 1.00 14.62% -22.22% 20,891 \$71.05 58.66% 1.00 1.01 \$70.79 Apr-2022 13.04% 13.29% 59.15% May-2022 20,800 \$66.51 89.25% 1.00 1.01 \$66.29 88.59% 8.28% 8.57% 20,771 \$70.21 1.00 1.01 \$70.00 Jun-2022 7.42% 84.58% 1.00 7.75% 83.28% 20,755 \$69.31 14.24% \$69.15 Jul-2022 24.78% 1.00 1.01 25.02% 14.08% 1.00 20,796 \$77.14 \$77.03 Aug-2022 33.78% 25.10% 1.00 1.00 1.00 33.96% 25.56% Sep-2022 20,772 \$69.60 32.07% 16.91% 1.00 1.01 1.00 \$69.37 32.12% 17.40% 20,659 \$68.64 1.01 \$68.43 Oct-2022 25.22% 19.50% 1.00 25.26% 19.62% Nov-2022 20,611 \$75.85 -4.71% 1.00 1.01 \$75.58 -5.16% 28.93% 1.00 28.91% 20,552 Dec-2022 \$77.04 28.51% 10.50% 1.00 \$76.69 28.36% 9.83% 20.59% 1.01 20.61% 1.00 16,394 \$61.22 1.72% 1.02 \$61.44 Jan-2023 19.81% 13.46% 0.98 1.00 19.86% 13.51% 1.85% Feb-2023 16,230 \$62.98 18.99% -1.43% -18.15% 0.98 1.02 1.00 \$63.22 19.09% -1.27% -17.02% Mar-2023 16,178 \$73.76 18.64% -0.77% -36.31% \$74.00 18.80% -0.37% -34.41% 0.98 1.02 1.00 16,065 \$90.59 \$90.17 20.76% 0.98 1.02 1.00 18.27% 10.85% 23.80% Apr-2023 18.00% 10.11% May-2023 16,033 \$89.62 18.74% 11.42% 140.12% 0.98 1.02 1.00 \$90.17 19.10% 12.61% 144.69%

\$84.63

\$90.62

\$83.67

\$81.92

\$81.29

\$78.75

\$78.07

18.62%

19.85%

17.87%

18.58%

19.60%

18.32%

16.65%

12.91%

31.01%

51.16%

52.88%

34.04%

20.73%

13.74%

219.02%

84.73%

6.82%

-13.16%

-25.14%

-23.73%

-25.39%

1.00

1.00

1.00

1.00

1.00

1.00

1.00

16,012

15,975

16,031

16,018

15,984

16,036

15,961

\$84.03

\$89.93

\$83.00

\$81.24

\$80.64

\$78.06

\$77.47

18.17%

19.31%

17.26%

17.86%

18.78%

17.37%

15.56%

11.12%

28.93%

48.75%

50.54%

32.21%

19.43%

13.01%

215.93%

82.51%

5.61%

-13.86%

-25.48%

-23.97%

-25.46%

0.98

0.97

0.97

0.97

0.97

0.97

0.97

1.02

1.02

1.02

1.02

1.02

1.02

1.02

Jun-2023

Jul-2023

Aug-2023

Sep-2023

Oct-2023

Nov-2023

Dec-2023

Last Month in Experience Period



Consumer Disclosure about Proposed Health Insurance Rate Increase VT 2025 ACA Small Group Exchange Rate Filing

About Us

MVP Health Plan, Inc. is a non-profit health care payer operating in Vermont and New York. MVP's mission is to provide high quality and affordable health care with a focus on wellness to our members.

Why We Are Changing Our Premiums

MVP must obtain approval from the Green Mountain Care Board for the health insurance premium rates charged. MVP files annual premium rates for the Exchange which are guaranteed for 12 months. This rate filing seeks approval of MVP's 2025 Small Group Exchange rates for effective dates of coverage between January 1, 2025 and December 31, 2025. The premium rates filed reflect MVP's current estimate of the cost to provide health insurance for that coverage period. The filed premium rates may be higher or lower than the previously filed premium rates, however, premium rates generally increase over time. Changes in the filed premium rates (relative to previously approved rates) are driven by many factors, including:

- -Increases in base period experience. Premium rates are increasing by 4.8% because our estimate of 2024 claims are higher than expected compared to the previous year.
- -Increases in cost and utilization of services. The cost and utilization of medical and pharmacy services generally increase over time. Premium rates are increasing by 6.1% because of this estimated trend in 2025.
- -Impact of the Federal Risk Adjustment Program. The federal risk adjustment program seeks to "level the playing field" among insurers. MVP has enrolled a population of lower-risk members, so it is required to pay into the program. MVP's small group payment has gone down, decreasing premium rates by approximately 2.0%.
- -Changes in the cost of doing business. As the cost of doing business rises over time, MVP must collect a portion of the premium revenue to protect consumers by ensuring its solvency. MVP aligned its administrative costs with the expected cost of the small group market. These changes are worth approximately **0.5%** of a premium increase.

Conclusion

The proposed rates reflect an average rate adjustment to prior rates of 9.3%, ranging from 5.2% to 11.7%. There are 1,209 policyholders, 9,306 subscribers and 15,027 members impacted by this rate filing.

Vermonters can provide public comment on the proposed rate increases during the public comment period beginning on May 13th. For information about providing public comment, please visit: https://ratereview.vermont.gov/public-comment



ACTUARIAL CERTIFICATION FEDERAL ACTUARIAL VALUE ADJUSTMENT VERMONT EXCHANGE Gold 3 HDHP Plus Silver 2 HDHP Plus Silver 2 HDHP Plus II

MVP Health Plan, Inc., a fully owned subsidiary of MVP Health Care, offers a range of products on the Vermont Exchange as well as Silver metal plans off the Exchange. One standard plan is offered at the Platinum and Catastrophic metal levels, while standard and non-standard plans are offered at the remaining levels. Standard plans are prescribed by the State of Vermont and are separately certified where necessary. Non-standard plans are filed at the discretion of MVP. MVP offers three non-standard benefit plans, Gold 3 HDHP Plus, Silver 2 HDHP Plus, and Silver 2 HDHP Plus II, with benefit features that don't fit into the parameters of the Federal Actuarial Value Calculator and therefore are being certified herein. The purpose of this memorandum is to document the actuarial analysis and adjusted actuarial values output from the 2025 Federal Actuarial Value calculator exhibiting compliance with the metal level requirements outlined in 45 CFR 156.140(b).

MVP's benefit pricing model is populated with allowed claim utilization from approximately 140,000 covered MVP commercial members. The data reflects claims paid for 2022 incurred dates, paid as of December 31st, 2023. MVP combines data from all its commercial products and states to increase the credibility in the data set. This data set is considered fully credible and appropriate for use as a benefit pricing tool for MVP's fully insured commercial members. The underlying data is appropriate relative to the Vermont Essential Health Benefit Package.

The model uses traditional continuance table logic to value plan deductibles and OOP maximums as well as average utilization per 1,000 and average unit cost per service data for all the significant services that drive member cost sharing. Specific factor adjustments are included in the methodology to account for family deductible and OOP limits, aggregate deductible types, and the State of Vermont maximum Rx OOP regulation. While reduced copays for 90-day supplies of mail order prescriptions also does not fit into the Federal Actuarial Value calculator, the impact on the Actuarial Value is negligible for all plans and is not reflected in the factors presented. The factor adjustments were derived based on modeling the net plan liabilities from this subscriber/member based historical allowed claim data set both with and without these benefit features.

The methodology of MVP's benefit pricing tool is consistent with the methodology underlying the Federal calculator with regard to the following factors: continuance tables that reflect membership enrolled for a full 12 months, out of network costs are not considered in the actuarial values, and the model reflects the anticipated utilization of the standard population buying products at these metal levels without consideration for induced demand.

Pursuant to 45 CFR 156.135(b) one of two permitted alternative methods must be used to determine any final adjusted Federal AV. MVP used the AV Calculator to determine the Federal AV for the plan provisions that fit within the calculator parameters and then calculated an actuarial adjustment factor to apply to the calculator produced AV to account for the plan features that materially deviate from the calculator parameters. The product of the Federal Calculator produced AV times the actuarial adjustment factor is the final Federal AV for the benefit plan. I certify that the adjustments made are appropriate and in accordance with generally accepted actuarial principles and methodologies.

The following 3 benefit features for the Gold 3 HDHP Plus were determined to not fit the Federal Calculator:

VT secondary Rx OOP max

Aggregate Family Deductible

Safe harbor prescription drug benefits excluded from the plan deductible

The following 2 benefit features for the Silver 2 HDHP Plus and Silver 2 HDHP II Plus were determined to not fit the Federal Calculator:

VT secondary Rx OOP max

Safe harbor prescription drug benefits excluded from the plan deductible

The following 2 benefit features for the Silver 2 HDHP Plus 73%, 77%, and 87% cost-sharing reduction plans were determined to not fit the Federal Calculator:

VT secondary Rx OOP max

Safe harbor prescription drug benefits excluded from the plan deductible

The following benefit feature for the Silver 2 Plus 94% cost-sharing reduction plan was determined to not fit the Federal Calculator:

Safe harbor prescription drug benefits excluded from the plan deductible

To determine the adjustment factors, I used MVP's proprietary benefit pricing tool to value the AV for these plans first excluding the above features that don't fit the calculator and a second time with the above benefit changes. The ratio of the two AVs is the actuarial adjustment factor used to modify the Federal Calculator computed AV.

Plan Description	MVP determined AV	Federal AV before/after adjustment			
Gold 3 HDHP Plus with no secondary Rx OOP max, with embedded single deductibles and with no safe harbor drug benefit	86.61%	81.31%			
Gold 3 HDHP Plus including the secondary Rx OOP max, the aggregate family deductible and the safe harbor drug benefit	86.08%	80.81%			
Silver 2 HDHP Plus with no secondary Rx OOP max and with no safe harbor drug benefit	67.91%	69.40%			
Silver 2 HDHP Plus including the secondary Rx OOP max and the safe harbor drug benefit	69.75%	71.28%			
Silver 2 HDHP Plus 73% CSR with no secondary Rx OOP max and with no safe harbor drug benefit	70.91%	72.60%			
Silver 2 HDHP Plus 73% CSR including the secondary Rx OOP max and the safe harbor drug benefit	72.18%	73.90%			
Silver 2 HDHP Plus 77% CSR with no secondary Rx OOP max and with no safe harbor drug benefit	75.16%	77.23%			
Silver 2 HDHP Plus 77% CSR including the secondary Rx OOP max and the safe harbor drug benefit	75.74%	77.83%			
Silver 2 Plus 87% CSR with no secondary Rx OOP max and with no safe harbor drug benefit	82.48%	87.69%			
Silver 2 Plus 87% CSR including the secondary Rx OOP max and the safe harbor drug benefit	82.54%	87.75%			
Silver 2 Plus 94% CSR with no safe harbor drug benefit	88.38%	94.75%			
Silver 2 Plus 94% CSR including the safe harbor drug benefit	88.39%	94.76%			
Silver 2 HDHP Plus II with no secondary Rx OOP max and with no safe harbor drug benefit	67.84%	69.33%			
Silver 2 HDHP Plus II including the secondary Rx OOP max and the safe harbor drug benefit	69.68%	71.21%			

Actuarial Adjustment factor for Gold 3 Plan: 0.9939 = 86.08% / 86.61%Final Federal AV for Gold 3 Plan: $81.31\% \times 0.9939 = 80.81\%$

Actuarial Adjustment factor for Silver 2 Plan: 1.0271 = 69.75% / 67.91%Final Federal AV for Silver 2 Plan: $69.40\% \times 1.0271 = 71.28\%$

Actuarial Adjustment factor for Silver 2 73% Plan: 1.0179 = 72.18% / 70.91% Final Federal AV for Silver 2 73% Plan: 72.60% x 1.0179 = 73.90%

Actuarial Adjustment factor for Silver 2 77% Plan: 1.0077 = 75.74% / 75.16% Final Federal AV for Silver 2 77% Plan: 77.23% x 1.0077 = 77.83%

Actuarial Adjustment factor for Silver 2 87% Plan: 1.0007 = 82.54% / 82.48% Final Federal AV for Silver 2 87% Plan: $87.69\% \times 1.0007 = 87.75\%$

Actuarial Adjustment factor for Silver 2 94% Plan: 1.0001 = 88.39% / 88.38% Final Federal AV for Silver 2 94% Plan: 94.75% x 1.0001 = 94.76%

Actuarial Adjustment factor for Silver 2 II Plan: 1.0271 = 69.68% / 67.84% Final Federal AV for Silver 2 II Plan: $69.33\% \times 1.0271 = 71.21\%$

CERTIFICATION

I, Kathleen Fish, Chief Actuary for MVP Health Care, am a Member of the American Academy of Actuaries and a Fellow of the Society of Actuaries, and I meet its qualification standards to provide this certification. I have used the 2025 Actuarial Value Calculator to determine the actuarial value for the plan provisions that fit within the calculator and have determined the actuarially appropriate adjustment factors to apply where necessary for the identified plan features that, in my opinion, deviates substantially from the allowable inputs of the Federal calculator. The development of the actuarial value adjustment factor was determined in accordance with generally accepted actuarial principles and practices and conforms with the exception methodology outlined in 45 CFR 156.135 (b)(3).

The final actuarial values reported for each of these benefit plans, those from the Federal Calculator alone, and the adjusted plans, meet the required actuarial values for each respective metal level as outlined in 45 CFR 156.140(b).

Kathleen Fish, FSA, MAAA

Senior Director, Actuarial Services / Chief Actuary

MVP Health Care

<u>5/9/2024</u> Date



MVP Health Care -- 2025 Small Group Exchange Rate Filing

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

Exhibit 1 -- Summary of Medical Coplans Offered

Exhibit 1a -- Comparison of 2024 to 2025 Benefits

Exhibit 2a -- Pricing Trend Assumptions

Exhibit 2b -- Support for Rx Trend Assumptions used in Development of Index Rate

Exhibit 3 -- Index Rate Development

Exhibit 4 -- Conversion Factor and Tier Ratios

Exhibit 5 -- Retention Loads and Paid Claim Surcharges

Exhibit 6 -- 2025 Premium Rates

Exhibit 1 -- Summary of Medical Coplans Offered

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

												In-Netwo	rk Benefits									
											Med						Med OOP	Med OOP	Rx OOP	Rx OOP		
			Standard/Non-	On/Off			IP				Ded	Med Dec	Deductible		Med OOP	Rx OOP	Max	Max	Max	Max	OOP Max	
Form ID	Product Type	Metal Level	Standard	Exchange	PCP	SCP	(Med/Surg)	ER	OP Surg	Amb	Single	Family	Туре	Coins.	Туре	Туре	Single	Family	Single	Family	Туре	Pharmacy
FRVT-HMO-SP-001-S (2025)	HyHMO	Platinum	Standard	On Exchange	\$15 No DD*	\$40 No DD	10%	\$100	10%	\$60 No DD	\$450	\$900	Embedded	10%	Embedded	Embedded	\$1,600	\$3,200	\$1,600	\$3,200	Separate	\$10/\$50/50%
FRVT-HMO-SG-001-S (2025)	НуНМО	Gold	Standard	On Exchange	\$20 No DD*	\$55 No DD	30%	\$150	30%	\$75 No DD	\$1,400	\$2,800	Embedded	30%	Embedded	Embedded	\$5,600	\$11,200	\$1,600	\$3,200	Separate	\$15/\$60/50%, \$200/\$400 Brand Ded
FRVT-HMOH-SG-003-N (2025)	HDHMO	Gold	Non-Standard	On Exchange	\$0	\$0	0%	\$0	0%	\$0	\$3,000	\$6,000	Aggregate	0%	Aggregate	Aggregate	\$3,000	\$6,000	\$1,650	\$3,300	Integrated	0% / 0% / 0%, Subject to Med Deductible
, ,									\$1,000 (Fac)							55 5						·
FRVT-HMO-SG-004-N (2025)	HyHMO	Gold	Non-Standard	On Exchange	\$0 No DD	\$0 No DD	20%	\$500	\$500 (Phys)	\$150	\$5,000	\$10,000	Embedded	20%	Embedded	Embedded	\$8,000	\$16,000	\$500	\$1,000	Separate	\$0 No DD/\$40/\$80, \$250/\$500 Brand Ded
FRVT-HMO-SS-003-S (2025)	HyHMO	Silver	Standard	On Exchange	\$40 No DD*	\$90 No DD	50%	\$250	50%	\$100 No DD	\$3,500	\$7,000	Embedded	50%	Embedded	Embedded	\$9,200	\$18,400	\$1,600	\$3,200	Integrated	\$15 / \$70 / 50%, \$500/\$1,000 Brand Ded
FRVT-HMOH-SS-004-S (2025)	HDHMO	Silver	Standard	On Exchange	10%	35%	35%	35%	35%	35%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,650	\$3,300	Integrated	\$10/\$40/50%, Subject to Med Deductible
FRVT-HMOH-SS-002-N (2025)	HDHMO	Silver	Non-Standard	On Exchange	0%	0%	0%	0%	0%	0%	\$5,775	\$11,550	Embedded	0%	Embedded	Aggregate	\$5,775	\$11,550	\$1,650	\$3,300	Integrated	0% / 0% / 0%, Subject to Med Deductible
, , ,									\$1,500 (Fac)							55 5						\$850/\$1700 Ded then \$5/\$30/\$60,
FRVT-HMO-SS-001-N (2025)	HyHMO	Silver	Non-Standard	On Exchange	\$30*	\$60	50%	\$400	\$300 (Phys)	\$100	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,600	\$15,200	\$1,600	\$3,200	Separate	VBID = \$1 #
VT-HMO-SS-003-S II (2025)	HyHMO	Silver	Standard	Off Exchange	\$40 No DD*	\$90 No DD	50%	\$250	50%	\$105 No DD	\$3,500	\$7,000	Embedded	50%	Embedded	Embedded	\$9,200	\$18,400	\$1,600	\$3,200	Integrated	\$15 / \$70 / 50%, \$500/\$1,000 Brand Ded
VT-HMOH-SS-004-S II (2025)	HDHMO	Silver	Standard	Off Exchange	10%	35%	35%	35%	35%	40%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,650	\$3,300	Integrated	\$10/\$40/50%, Subject to Med Deductible
VT-HMOH-SS-002-N II (2025)	HDHMO	Silver	Non-Standard	Off Exchange	0%	0%	0%	0%	0%	0%	\$5,800	\$11,600	Embedded	0%	Embedded	Aggregate	\$5,800	\$11,600	\$1,650	\$3,300	Integrated	0% / 0% / 0%, Subject to Med Deductible
` ,									\$1,500 (Fac)			' '										\$850/\$1700 Ded then \$5/\$30/\$60,
VT-HMO-SS-001-N II (2025)	HyHMO	Silver	Non-Standard	Off Exchange	\$30*	\$60	50%	\$400	\$300 (Phys)	\$105	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,600	\$15,200	\$1,600	\$3,200	Separate	VBID = \$1 #
FRVT-HMO-SB-002-S (2025)	HyHMO	Bronze	Standard	On Exchange	\$35	\$90	50%	50%	50%	\$100	\$6,450	\$12,900	Embedded	50%	Embedded	Embedded	\$9,200	\$18,400	\$1,600	\$3,200	Integrated	\$1100/\$2200 Brand Ded then \$15/\$85/60%
FRVT-HMOH-SB-003-S (2025)	HDHMO	Bronze	Standard	On Exchange	50%	50%	50%	50%	50%	50%	\$5,800	\$11,600	Aggregate	50%	Stacked	Aggregate	\$7,100	\$14,200"	\$1,650	\$3,300	Integrated	\$12/40%/60%, Subject to Med Deductible
FRVT-HMO-SB-004-S (2025)	HyHMO	Bronze	Standard	On Exchange	\$40 No DD*	\$100 No DD	0%	0%	0%	0%	\$9,200	\$18,400	Embedded	0%	Embedded	Embedded	\$9,200	\$18,400	N/A	N/A	N/A	\$25 No DD/0%/0%, Subject to Med Deductible
` '	•			ľ																		\$10 No DD / \$0 / \$0, Subject to Med Deductible, VBID =
FRVT-HMO-SB-005-N (2025)	HMO	Bronze	Non-Standard	On Exchange	0%**	0%	0%	0%	0%	0%	\$9,200	\$18,400	Embedded	0%	Embedded	Embedded	\$9,200	\$18,400	N/A	N/A	N/A	\$1 #
FRVT-HMO-SB-001-N (2025)	HvHMO	Bronze	Non-Standard	On Exchange	\$40*	\$100	50%	50%	50%	\$100	\$7.250	\$14,500	Embedded	50%	Embedded	Embedded	\$8,400	\$16,800	N/A	N/A	N/A	\$10/\$50/\$80, \$700/\$1400 Brand Ded, VBID = \$1 #

Services subject to deductible (DD) unless otherwise stated.

**First 3 PCP Office Visits are not subject to deductible

*First 3 PCP Office Visits are covered in full

Generic Drugs are Covered in full up to age 10, after Pharmacy deductible is met

" Family structure is \$9,200 for each member up to family limit

Note: MVP's Non-Standard Plan Designs also have a Member Wellness Rider (Form: FRVT366) attached which provides up to \$598 per contract per year.

Exhibit 1a -- Comparison of 2024 to 2025 Benefits by Plan

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

											In-Netwo	rk Benefits									
										Med						Med OOP	Med OOP	Rx OOP	Rx OOP		
			Standard/Non-			IP				Ded	Med Ded	Deductible		Med OOP	Rx OOP	Max	Max	Max	Max	OOP Max	
Form ID	Product Type	Metal Level	Standard	PCP	SCP	(Med/Surg)	ER	OP Surg	Amb	Single	Family	Туре	Coins.	Type	Type	Single	Family	Single	Family	Туре	Pharmacy
FRVT-HMO-SP-001-S (2024)	НуНМО	Platinum	Standard	\$15 No DD*	\$40 No DD	10%	\$100	10%	\$60 No DD	\$450	\$900	Embedded	10%	Embedded	Embedded	\$1,500	\$3,000	\$1,500	\$3,000	Separate	\$10/\$50/50%
FRVT-HMO-SP-001-S (2025)	НуНМО	Platinum	Standard	\$15 No DD*	\$40 No DD	10%	\$100	10%	\$60 No DD	\$450	\$900	Embedded	10%	Embedded	Embedded	\$1,600	\$3,200	\$1,600	\$3,200	Separate	\$10/\$50/50%
FRVT-HMO-SG-001-S (2024)	НуНМО	Gold	Standard	\$20 No DD*	\$55 No DD	30%	\$150	30%	\$75 No DD	\$1,400	\$2,800	Embedded	30%	Embedded	Embedded	\$5,600	\$11,200	\$1,500	\$3,000	Separate	\$15/\$60/50%, \$200/\$400 Brand Ded
FRVT-HMO-SG-001-S (2025)	НуНМО	Gold	Standard	\$20 No DD*	\$55 No DD	30%	\$150	30%	\$75 No DD	\$1,400	\$2,800	Embedded	30%	Embedded	Embedded	\$5,600	\$11,200	\$1,600	\$3,200	Separate	\$15/\$60/50%, \$200/\$400 Brand Ded
FRVT-HMOH-SG-003-N (2024)	HDHMO	Gold	Non-Standard	0%	0%	0%	\$0	0%	\$0	\$3,000	\$6,000	Aggregate	0%	Aggregate	Aggregate	\$3,000	\$6,000	\$1,600	\$3,200	Integrated	0% / 0% / 0%, Subject to Med Deductible
FRVT-HMOH-SG-003-N (2025)	HDHMO	Gold	Non-Standard	0%	0%	0%	\$0	0%	\$0	\$3,000	\$6,000	Aggregate	0%	Aggregate	Aggregate	\$3,000	\$6,000	\$1,650	\$3,300	Integrated	0% / 0% / 0%, Subject to Med Deductible
								\$1,000 (Fac)													
FRVT-HMO-SG-004-N (2025)	HyHMO	Gold	Non-Standard	\$0 No DD	\$0 No DD	20%	\$500	\$500 (Phys)	\$150	\$5,000	\$10,000	Embedded	20%	Embedded	Embedded	\$8,000	\$16,000	\$500	\$1,000	Separate	\$0 No DD/\$40/\$80, \$250/\$500 Brand Ded
FRVT-HMO-SS-003-S (2024)	НуНМО	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$100 No DE	\$4,000		Embedded	50%	Embedded	Embedded	\$9,300	\$18,600	\$1,500	\$3,000	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
FRVT-HMO-SS-003-S (2025)	HyHMO	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$250	50%	\$100 No DD	\$3,500	\$7,000	Embedded	50%	Embedded	Embedded	\$9,200	\$18,400	\$1,600	\$3,200	Integrated	\$15 / \$70 / 50%, \$500/\$1,000 Brand Ded
FRVT-HMOH-SS-004-S (2024)	HDHMO	Silver	Standard	15%	35%	35%	35%	35%	35%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,600	\$3,200	Integrated	\$10/\$40/50%, Subject to Med Deductible
FRVT-HMOH-SS-004-S (2025)	HDHMO	Silver	Standard	10%	35%	35%	35%	35%	35%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,650	\$3,300	Integrated	\$10/\$40/50%, Subject to Med Deductible
FRVT-HMOH-SS-002-N (2024)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5,775	\$11,550	Embedded	0%	Embedded	Aggregate	\$5,775	\$11,550	\$1,600	\$3,200	Integrated	0% / 0% / 0%, Subject to Med Deductible
FRVT-HMOH-SS-002-N (2025)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5,775	\$11,550	Embedded	0%	Embedded	Aggregate	\$5,775	\$11,550	\$1,650	\$3,300	Integrated	0% / 0% / 0%, Subject to Med Deductible
								\$1,400 (Fac)													
FRVT-HMO-SS-001-N (2024)	HyHMO	Silver	Non-Standard	\$30**	\$60	50%	\$400	\$300 (Phys)	\$100	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,500	\$15,000	\$1,500	\$3,000	Separate	\$850/\$1700 Ded then \$5/50%/50%, VBID = \$1 #
								\$1,500 (Fac)													
FRVT-HMO-SS-001-N (2025)	HyHMO	Silver	Non-Standard	\$30*	\$60	50%	\$400	\$300 (Phys)	\$100	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,600	\$15,200	\$1,600	\$3,200	Separate	\$850/\$1700 Ded then \$5/\$30/\$60, VBID = \$1 #
VT-HMO-SS-003-S II (2024)	НуНМО	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$105 No DD	\$4,000	\$8,000	Embedded	50%	Embedded	Embedded	\$9,300	\$18,600	\$1,500	\$3,000	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
VT-HMO-SS-003-S II (2025)	HyHMO	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$250	50%	\$105 No DD	\$3,500	\$7,000	Embedded	50%	Embedded	Embedded	\$9,200	\$18,400	\$1,600	\$3,200	Integrated	\$15 / \$70 / 50%, \$500/\$1,000 Brand Ded
VT-HMOH-SS-004-S II (2024)	HDHMO	Silver	Standard	15%	35%	35%	35%	35%	40%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,600	\$3,200	Integrated	\$10/\$40/50%, Subject to Med Deductible
VT-HMOH-SS-004-S II (2025)	HDHMO	Silver	Standard	10%	35%	35%	35%	35%	40%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,650	\$3,300	Integrated	\$10/\$40/50%, Subject to Med Deductible
VT-HMOH-SS-002-N II (2024)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5,800	\$11,600	Embedded	0%	Embedded	Aggregate	\$5,800	\$11,600	\$1,600	\$3,200	Integrated	0% / 0% / 0%, Subject to Med Deductible
VT-HMOH-SS-002-N II (2025)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5,800	\$11,600	Embedded	0%	Embedded	Aggregate	\$5,800	\$11,600	\$1,650	\$3,300	Integrated	0% / 0% / 0%, Subject to Med Deductible
								\$1,400 (Fac)													
VT-HMO-SS-001-N II (2024)	HyHMO	Silver	Non-Standard	\$30**	\$60	50%	\$400	\$300 (Phys)	\$105	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,500	\$15,000	\$1,500	\$3,000	Separate	\$850/\$1700 Ded then \$5/50%/50%, VBID = \$1 #
								\$1,500 (Fac)													
VT-HMO-SS-001-N II (2025)	HyHMO	Silver	Non-Standard	\$30*	\$60	50%	\$400	\$300 (Phys)	\$105	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,600	\$15,200	\$1,600	\$3,200	Separate	\$850/\$1700 Ded then \$5/\$30/\$60, VBID = \$1 #
FRVT-HMO-SB-002-S (2024)	HMO	Bronze	Standard	\$35	\$90	50%	50%	50%	\$100		\$12,900	Embedded	50%	Embedded	Embedded	\$9,450	\$18,900	\$1,500	\$3,000	Integrated	\$1100/\$2200 Brand Ded then \$20/\$85/60%
FRVT-HMO-SB-002-S (2025)	НуНМО	Bronze	Standard	\$35	\$90	50%	50%	50%	\$100	\$6,450		Embedded	50%	Embedded	Embedded	\$9,200	\$18,400	\$1,600	\$3,200	Integrated	\$1100/\$2200 Brand Ded then \$15/\$85/60%
FRVT-HMOH-SB-003-S (2024)	HDHMO	Bronze	Standard	50%	50%	50%	50%	50%	50%	\$5,800	\$11,600	Aggregate	50%	Stacked	Aggregate	\$7,200	\$14,400"	\$1,600	\$3,200	Integrated	\$12/40%/60%, Subject to Med Deductible
FRVT-HMOH-SB-003-S (2025)	HDHMO	Bronze	Standard	50%	50%	50%	50%	50%	50%	\$5,800	\$11,600	Aggregate	50%	Stacked	Aggregate	\$7,100	\$14,200"	\$1,650	\$3,300	Integrated	\$12/40%/60%, Subject to Med Deductible
FRVT-HMO-SB-004-S (2024)	HMO	Bronze	Standard	\$40 No DD*	\$100 No DD	0%	0%	0%	0%	\$9,400	+ -,	Embedded	0%	Embedded	Embedded	\$9,400	\$18,800	N/A	N/A	N/A	\$30 No DD/0%/0%, Subject to Med Deductible
FRVT-HMO-SB-004-S (2025)	НуНМО	Bronze	Standard		\$100 No DD	0%	0%	0%	0%	\$9,200	+ -,	Embedded	0%	Embedded	Embedded	\$9,200	\$18,400	N/A	N/A	N/A	\$25 No DD/0%/0%, Subject to Med Deductible
FRVT-HMO-SB-005-N (2024)	HMO	Bronze	Non-Standard	0%**	0%	0%	0%	0%	0%	\$9,450	\$18,900	Embedded	0%	Embedded	Embedded	\$9,450	\$18,900	N/A	N/A	N/A	\$35 No DD / \$0 / \$0, Subject to Med Deductible, VBID = \$3 #
FRVT-HMO-SB-005-N (2025)	HMO	Bronze	Non-Standard	0%**	0%	0%	0%	0%	0%	\$9,200	\$18,400	Embedded	0%	Embedded	Embedded	\$9,200	\$18,400	N/A	N/A	N/A	\$10 No DD / \$0 / \$0, Subject to Med Deductible, VBID = \$1 #
FRVT-HMO-SB-001-N (2024)	HMO	Bronze	Non-Standard	\$40	\$100	50%	50%	50%	\$100	\$7,250	\$14,500	Embedded	50%	Embedded	Embedded	\$8,400	\$16,800	N/A	N/A	N/A	\$25/\$100/60%, \$700/\$1400 Brand Ded, VBID = \$3 #
FRVT-HMO-SB-001-N (2025)	НуНМО	Bronze	Non-Standard	\$40*	\$100	50%	50%	50%	\$100	\$7,250	\$14,500	Embedded	50%	Embedded	Embedded	\$8,400	\$16,800	N/A	N/A	N/A	\$10/\$50/\$80, \$700/\$1400 Brand Ded, VBID = \$1 #

Changes in benefits from 2024 to 2025 are shown in gray shading.

Exhibit 2a -- Pricing Trend Assumptions

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

E	xperience Period:	January 1, 2023 - December 31, 2023
	Rating Period:	January 1, 2025 - December 31, 2025

	2024	2025	Total
Months of Trend	12	12	24

Medical Trend Summary

	2024 Annual Trend					
	% of Allowed Claims	Unit Cost	Utilization	Total		
IP	15.9%	4.8%	1.0%	5.8%		
OP	54.3%	5.2%	1.0%	6.2%		
PHY	29.9%	1.7%	1.0%	2.7%		
Medical Total		4.1%	1.0%	5.1%		

	2025 Annual Trend					
	% of Allowed Claims	Unit Cost	Utilization	Total		
IP	16.0%	4.8%	1.0%	5.9%		
OP	54.9%	5.5%	1.0%	6.5%		
PHY	29.2%	1.3%	1.0%	2.3%		
Medical Total		4.1%	1.0%	5.2%		

Annual Allowed Medical Trend 5.1%

Leveraging Impact - Fee-For-Service Medical Claims										
	Allowed-COB	Coinsurance	Copay	Deductible	Paid*					
Rating Period:	\$622.53	\$18.80	\$9.22	\$81.43	\$513.07					
24 Months of Trend:	1.106	1.106	1.020	1.036	1.118					
Projection Period:	\$688.28	\$20.79	\$9.41	\$84.39	\$573.69					
Allowed Trend (Annual)	5.1%									
Paid Trend (Annual)	5.7%									
Leveraging (Annual)	0.6%									

Rx Trend Summary

	2024	<u>Trend</u>	2025	Trend	Annualized Trend		
	Unit Cost	Utilization	Unit Cost	Utilization	Unit Cost	Utilization	
Generic	-7.6%	3.9%	1.3%	2.6%	-3.2%	3.2%	
Brand	10.8%	-6.7%	4.5%	3.7%	7.6%	-1.7%	
Specialty	-0.8%	9.5%	3.8%	7.1%	1.5%	8.3%	

Exhibit 2b -- Rx Trend Development

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

Rx Claim Information	Generic	Brand	Specialty	Total
Experience Period Scripts / 1000	13,775	1,074	169	15,018
Experience Period Allowed Cost per Script	\$16.11	\$616.84	\$5,802.05	\$124.13
Experience Period Deductible Per Script	\$2.37	\$28.26	\$83.15	\$5.13
Experience Period Copay Per Script	\$3.77	\$22.27	\$20.65	\$5.28
Experience Period Coinsurance Per Script	\$0.91	\$8.53	\$64.49	\$2.17
Experience Period Paid Cost Per Script	\$9.07	\$557.78	\$5,633.76	\$111.55
Experience Period Allowed PMPM	\$18.50	\$55.20	\$81.65	\$155.35
Experience Period Deductible PMPM	\$2.72	\$2.53	\$1.17	\$6.42
Experience Period Copay PMPM	\$4.33	\$1.99	\$0.29	\$6.61
Experience Period Coinsurance PMPM	\$1.04	\$0.76	\$0.91	\$2.72
Experience Period Paid PMPM	\$10.41	\$49.91	\$79.29	\$139.61
Experience Period Rx Rebates PMPM				(\$53.26)
Annual Util Trend	1.032	0.983	1.083	1.029
Annual Unit Cost Trend	0.968	1.076	1.015	1.042
Annual Allowed Trend	0.999	1.058	1.099	1.073
Annual Deductible Trend	1.018	1.018	1.018	1.041
Annual Paid Trend	0.970	1.064	1.099	1.077
Annual Paid Trend Net of Rebates	n/a	n/a	n/a	1.080
Months of Trend	24	24	24	24
Projected Scripts / 1000	14,681	1,038	198	15,917
Projected Allowed Cost per Script	\$15.09	\$714.23	\$5,974.13	\$134.85
Projected Deductible Per Script	\$2.45	\$29.28	\$86.18	\$5.24
Projected Copay Per Script	\$3.77	\$22.27	\$20.65	\$5.18
Projected Coinsurance Per Script	\$0.85	\$9.88	\$66.40	\$2.26
Projected Paid Cost Per Script	\$8.02	\$652.80	\$5,800.90	\$122.16
Projected Allowed PMPM	\$18.46	\$61.79	\$98.62	\$178.87
Projected Deductible PMPM	\$3.00	\$2.53	\$1.42	\$6.96
Projected Copay PMPM	\$4.61	\$1.93	\$0.34	\$6.88
Projected Coinsurance PMPM	\$1.04	\$0.85	\$1.10	\$2.99
Projected Paid PMPM	\$9.81	\$56.48	\$95.76	\$162.04
Projected Rx Rebates				(\$61.32)
Net Projected Paid PMPM				\$100.72

Development of Index PMPM Claim Rate

Experience Period Incurred DOS: Jan 2023 - Dec 2023

Completed Through: 3/31/24

	ACA Compliant Small Group
1 Member Months	192,917
2 FFS Paid Medical Claims	\$513.07
3 FFS Paid Pediatric Dental Claims	\$1.73
4 IBNR Factor	1.032
5 FFS Incurred Paid Medical Claims	\$530.97
6 FFS Incurred Rx Claims	\$139.61
7 Experience Period Rx Rebates	(\$53.26)
8 FFS Incurred Rx Claims (Net of Rebates)	\$86.35
9 Experience Period Capitation and Non-FFS Medical Costs	\$19.28
10 Adjusted Experience Period Claim Expense	\$636.60
Market-Wide Adjustments to Experience Period Claims	
11 Adjustment for Waived Cost Share Due to COVID-19	(\$0.27)
12 Adjustment for COVID Vaccines	\$0.40
13 Adjustment for Hearing Aids as EHB	\$0.33
14 Adjustment for Abortions Covered in Full	\$0.03
15 Experience Period Claim Expense After All Adjustments	\$637.08
16 Annual FFS Medical projection factor	1.057
17 Annual FFS Rx projection factor	1.080
18 Annual FFS Claim trend projection factor	1.061
19 Months of Trend	24
20 Projection Period FFS Claim Expense PMPM Prior to Adjustments for Federal Programs	\$694.92
21 Projection Period VT Paid Claim Surcharge + NYS HCRA	\$7.98
22 Projection Period Capitation and Non-FFS Medical Costs	\$14.11
23 Paid Index Rate PMPM Prior to Adjustments for Federal Programs	\$717.01
Federal Reinsurance and Risk Adjustment Programs	
24 Federal Risk Adjustment Program Impact	\$30.85
25 Paid Index Rate PMPM After Adjustments for Federal Programs	\$747.86

Exhibit 4 -- Conversion Factor and Tier Ratios

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

-				Avg Contrac	t
Tier	Contract Type	Subscribers	Members	Size	Load Factor
4	Single	6,210	6,210	1.000	1.000
4	Double	1,380	2,760	2.000	2.000
4	Parent/Child(ren)	436	1,101	2.525	1.930
4	Family	1,280	4,956	3.872	2.810

Single Conversion Factor 1.121

Exhibit 5 -- Retention Loads, Taxes/Assessments, and Paid Claim Surcharges

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

0/ of December Defend	
% of Premium Retention Compone	ents
Draker Lood	0.000/
Broker Load	0.00%
Bad Debt	0.17%
Risk Margin	1.50%
Total % of Premium Retention Components	1.67%
PMPM Retention Components	}
General Administrative Load	\$51.44
% of Premium Taxes and Assessm	ents
December Too	0.000/
Premium Tax	0.00%
VT Vaccine Pilot	0.57%
National High Cost Reinsurance Pool Charge	0.77%
Total % of Premium Taxes/Assessments	1.34%
% of Paid Claim Taxes and Assessr	nents
Vermont Paid Claim Surcharge	0.999%
New York State HCRA Surcharge	0.150%
Total % of Paid Claim Taxes/Assessments	1.149%
PMPM Taxes and Assessment	s
HHS Risk Adjustment User Fee	\$0.17
PCORI Fee	\$0.27
18 VSA 9374(h) Billback	\$2.58
Total PMPM Taxes/Assessments	\$3.02

Exhibit 6 -- 2025 Small Group Exchange Premium Rates

MVP Health Plan, Inc. 2025 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2025 - December 31, 2025

\$747.86	2025 Adjusted Paid Claim Cost (Exhibit 3, Line 25)
0.8261	Benefit Relativity * Induced Demand Reflected in Index Rate
\$905.25	Adjusted Claim Cost for Pricing

					Federal and State		Induced			Administrative	% of Premium	PMPM Taxes	Gross					Increase over 2024	Increase over 2024	Increase	Increase over 2024
	Product		Standard/Non-		Combined	Actuarial		Net Claim Cost	CTR (% of	Expense	Taxes and	and	Claim Cost			Parent/Child(Single	Double	over 2024	Family
Coplan	Туре	Metal Level	Standard	Exchange	Subsidy	Value	Factor*	PMPM	Premium)	(PMPM)	Assessments	Assessments	PMPM	Single***	Double	ren)	Family	Rate	Rate	P/C Rate	Rate
FRVT-HMO-SP-001-S (2025)	НуНМО	Platinum	Standard	On Exchange	Non-Subsidized	0.932	1.150	\$970.04	\$17.64	\$51.44	\$14.15	\$3.02	\$1,056.29	\$1,183.81	\$2,367.62	\$2,284.75	\$3,326.51	8.1%	8.1%	8.1%	8.1%
FRVT-HMO-SG-001-S (2025)	НуНМО	Gold	Standard	On Exchange	Non-Subsidized	0.823	1.080	\$804.91	\$14.80	\$51.44	\$11.87	\$3.02	\$886.04	\$993.01	\$1,986.02	\$1,916.51	\$2,790.36	8.8%	8.8%	8.8%	8.8%
FRVT-HMOH-SG-003-N (2025)	HDHMO	Gold	Non-Standard	On Exchange	Non-Subsidized	0.861	1.080	\$841.58	\$15.43	\$51.44	\$12.38	\$3.02	\$923.84	\$1,035.37	\$2,070.74	\$1,998.26	\$2,909.39	9.2%	9.2%	9.2%	9.2%
FRVT-HMO-SG-004-N (2025)	HyHMO	Gold	Non-Standard	On Exchange	Non-Subsidized	0.818	1.080	\$799.83	\$14.71	\$51.44	\$11.80	\$3.02	\$880.80	\$987.13	\$1,974.26	\$1,905.16	\$2,773.84	N/A	N/A	N/A	N/A
FRVT-HMO-SS-003-S (2025)	HyHMO	Silver	Standard	On Exchange	Non-Subsidized	0.683	1.030	\$636.37	\$11.89	\$51.44	\$9.54	\$3.02	\$712.26	\$798.25	\$1,596.50	\$1,540.62	\$2,243.08	10.9%	10.9%	10.9%	10.9%
FRVT-HMOH-SS-004-S (2025)	HDHMO	Silver	Standard	On Exchange	Non-Subsidized	0.690	1.030	\$643.36	\$12.02	\$51.44	\$9.64	\$3.02	\$719.47	\$806.33	\$1,612.66	\$1,556.22	\$2,265.79	9.8%	9.8%	9.8%	9.8%
FRVT-HMOH-SS-002-N (2025)	HDHMO	Silver	Non-Standard	On Exchange	Non-Subsidized	0.698	1.030	\$650.35	\$12.14	\$51.44	\$9.74	\$3.02	\$726.68	\$814.41	\$1,628.82	\$1,571.81	\$2,288.49	9.9%	9.9%	9.9%	9.9%
FRVT-HMO-SS-001-N (2025)	HyHMO	Silver	Non-Standard	On Exchange	Non-Subsidized	0.682	1.030	\$635.62	\$11.88	\$51.44	\$9.53	\$3.02	\$711.49	\$797.39	\$1,594.78	\$1,538.96	\$2,240.67	10.7%	10.7%	10.7%	10.7%
VT-HMO-SS-003-S II (2025)	HyHMO	Silver	Standard	Off Exchange	Non-Subsidized	0.683	1.030	\$636.37	\$11.89	\$51.44	\$9.54	\$3.02	\$712.26	\$798.25	\$1,596.50	\$1,540.62	\$2,243.08	10.9%	10.9%	10.9%	10.9%
VT-HMOH-SS-004-S II (2025)	HDHMO	Silver	Standard	Off Exchange	Non-Subsidized	0.690	1.030	\$643.36	\$12.02	\$51.44	\$9.64	\$3.02	\$719.47	\$806.33	\$1,612.66	\$1,556.22	\$2,265.79	9.9%	9.9%	9.9%	9.9%
VT-HMOH-SS-002-N II (2025)	HDHMO	Silver	Non-Standard	Off Exchange	Non-Subsidized	0.697	1.030	\$649.79	\$12.13	\$51.44	\$9.73	\$3.02	\$726.11	\$813.77	\$1,627.54	\$1,570.58	\$2,286.69	9.9%	9.9%	9.9%	9.9%
VT-HMO-SS-001-N II (2025)	HyHMO	Silver	Non-Standard	Off Exchange	Non-Subsidized	0.682	1.030	\$635.62	\$11.88	\$51.44	\$9.53	\$3.02	\$711.49	\$797.39	\$1,594.78	\$1,538.96	\$2,240.67	10.7%	10.7%	10.7%	10.7%
FRVT-HMO-SB-002-S (2025)	HÝHMO	Bronze	Standard	On Exchange	Non-Subsidized	0.611	1.000	\$553.11	\$10.46	\$51.44	\$8.39	\$3.02	\$626.42	\$702.04	\$1,404.08	\$1,354.94	\$1,972.73	11.1%	11.1%	11.1%	11.1%
FRVT-HMOH-SB-003-S (2025)	HĎHMO	Bronze	Standard	On Exchange	Non-Subsidized	0.617	1.000	\$558.54	\$10.55	\$51.44	\$8.47	\$3.02	\$632.02	\$708.32	\$1,416.64	\$1,367.06	\$1,990.38	10.5%	10.5%	10.5%	10.5%
FRVT-HMO-SB-004-S (2025)	HyHMO	Bronze	Standard	On Exchange	Non-Subsidized	0.625	1.000	\$565.96	\$10.68	\$51.44	\$8.57	\$3.02	\$639.67	\$716.90	\$1,433.80	\$1,383.62	\$2,014.49	9.8%	9.8%	9.8%	9.8%
FRVT-HMO-SB-005-N (2025)	HMO	Bronze	Non-Standard	J	Non-Subsidized	0.616	1.000	\$557.18	\$10.53	\$51.44	\$8.45	\$3.02	\$630.62	\$706.75	\$1,413.50	\$1,364.03	\$1,985.97	10.8%	10.8%	10.8%	10.8%
FRVT-HMO-SB-001-N (2025)	НуНМО	Bronze	Non-Standard	J		0.620	1.000	\$561.34	\$10.60	\$51.44	\$8.51	\$3.02	\$634.91	\$711.56	\$1,423.12	\$1,373.31	\$1,999.48	11.7%	11.7%	11.7%	11.7%

^{***}Child Only Rate = Single Rate per Child

Please provide Company specific inputs for any cells shaded in blue.

Field Name	Description	Input
Insurance Company Name	Company Name	MVP Health Care
HIOS ID	5 digit HIOS ID (if applicable)	77566
SERFF Filing Number	Filing number assigned by SERFF	MVPH-134081005
Market	Market type: Individual, Small Group, Large Group etc.	Small Group
Product Name	Product name entered in SERFF	VT Small Group 2025
Period Prior to Experience Period Start Date	Beginning date for the 12 month period preceding the base period experience (MM/DD/YYYY)	1/1/2022
Period Prior to Experience Period End Date	End date for the 12 month period preceding the base period experience (MM/DD/YYYY)	12/31/2022
Experience Period Start Date	Beginning date for base period experience (MM/DD/YYYY)	1/1/2023
Experience Period End Date	End date for base period experience (MM/DD/YYYY)	12/31/2023
Projection Period Start Date	Beginning effective date for proposed rates (MM/DD/YYYY)	1/1/2025
Projection Period End Date	Ending effective date for proposed rates (MM/DD/YYYY)	12/31/2025

Insurance Company Name MVP Health Care
HIOS ID 77566
SERFF Filing Number MVPH-134081005
Market Small Group
Product Name VT Small Group 2025

Prescription Drug Costs as Percentage of Premium¹

Enter PMPM drug costs incurred during the below periods for the following prescription drug tiers dispensed only at a pharmacy, network pharmacy, or mailorder pharmacy. Additionally, enter the total premium PMPM and member months for each period.

	Gross of Member	Cost Sharing and	Rebates (Allov	ved Basis)				
		Experience	e Period -1	Experien	ce Period	Projection Period		
		01/01/2022	-12/31/2022	01/01/2023	-12/31/2023	01/01/2025-12/31/202		
		Retail	Mail	Retail	Mail	Retail	Mail	
	Non-Specialty Generic PMPM	\$19.47	\$0.53	\$18.06	\$0.44	\$18.02	\$0.44	
(III)	Non-Specialty Brand PMPM	\$38.97	\$1.63	\$52.81	\$2.39	\$59.12	\$2.67	
	Specialty PMPM	\$70.18	\$0.08	\$81.65	\$0.00	\$98.61	\$0.00	
(B)	Medical Rx PMPM	\$6	.02	\$6	.64	\$7	.34	
	Total (Medical and Rx) Premium PMPM	\$57	5.39	\$67	2.73	\$816.42		
	Non-Specialty Generic % of Premium	3.38%	0.09%	2.68%	0.07%	2.21%	0.05%	
(1)	Non-Specialty Brand % of Premium	6.77%	0.28%	7.85%	0.35%	7.24%	0.33%	
	Specialty Total % of Premium	12.20%	0.01%	12.14%	0.00%	12.08%	0.00%	
(B)	Medical Rx PMPM	1.0	5%	0.9	99%	0.9	90%	
	Non-Specialty Generic % of Premium Change vs Prior Period			-0.70%	-0.03%	-0.48%	-0.01%	
(11)	Non-Specialty Brand % of Premium Change vs Prior Period			1.08%	0.07%	-0.61%	-0.03%	
	Specialty % of Premium Change vs Prior Period			-0.06%	-0.01%	-0.06%	0.00%	
(B)	Medical Rx % of Premium Change vs Prior Period			-0.	06%	-0.0	09%	

	Net of Member Cost Sharing (Paid Amount), Gross of Rebates								
		,	e Period -1		ce Period	Projection	on Period		
		01/01/2022	-12/31/2022	01/01/2023	-12/31/2023	01/01/2025-12/31/202			
		Retail	Mail	Retail	Mail	Retail	Mail		
	Non-Specialty Generic PMPM	\$11.54	\$0.37	\$10.11	\$0.30	\$9.52	\$0.29		
(III)	Non-Specialty Brand PMPM	\$35.17	\$1.55	\$47.63	\$2.28	\$53.90	\$2.58		
	Specialty PMPM	\$68.53	\$0.08	\$79.28	\$0.00	\$95.75	\$0.00		
(B)	Medical Rx PMPM	\$5	.94	\$6	.53	\$7	'.30		
	Total Medical and Rx Premium PMPM	\$57	5.39	\$67	2.73	\$816.42			
		•		•		•			
	Non-Specialty Generic % of Premium	2.00%	0.06%	1.50%	0.05%	1.17%	0.04%		
(1)	Non-Specialty Brand % of Premium	6.11%	0.27%	7.08%	0.34%	6.60%	0.32%		
	Specialty Total % of Premium	11.91%	0.01%	11.79%	0.00%	11.73%	0.00%		
(B)	Medical Rx PMPM	1.0	3%	0.9	97%	0.8	39%		
	Non-Specialty Generic % of Premium Change vs Prior Period			-0.50%	-0.02%	-0.34%	-0.01%		
(11)	Non-Specialty Brand % of Premium Change vs Prior Period			0.97%	0.07%	-0.48%	-0.02%		
	Specialty % of Premium Change vs Prior Period			-0.13%	-0.01%	-0.06%	0.00%		
(B)	Medical Rx % of Premium Change vs Prior Period			-0.	06%	-0.0	08%		

¹ Vermont Statute 8 V.S.A. § 4062

 $(2) (A) \ In \ conjunction \ with \ a \ rate \ filing \ required \ by \ subsection \ (a) \ of \ this \ section, \ an \ insurer \ shall \ disclose \ to \ the \ Board:$

- (i) for all covered prescription drugs, including generic drugs, brand-name drugs excluding specialty drugs, and specialty drugs dispensed at a pharmacy, network pharmacy, or mail-order pharmacy for outpatient use:
- (I) the percentage of the premium rate attributable to prescription drug costs for the prior year for each category of prescription drugs;
- (II) the year-over-year increase or decrease, expressed as a percentage, in per-member, per-month total health plan spending on each category of prescription drugs; and
- (III) the year-over-year increase or decrease in per-member, per-month costs for prescription drugs compared to other components of the premium rate.
- (B) The insurer shall provide, if available, the percentage of the premium rate attributable to prescription drugs administered by a health care provider in an outpatient setting that are part of the medical benefit as separate from the pharmacy benefit.

Insurance Company Name MVP Health Care
HIOS ID 77566
SERFF Filing Number MVPH-134081005
Market Small Group
Product Name VT Small Group 2025

Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board:
(ii) the specialty tier formulary list.

Specialty Formulary List

Provide the specialty formulary information listed below.

Drug Name	Drug Tier	Formulary Name (if multiple formularies are used)
ACTEMRA INJ 162/0.9	Tier 3	MarketPlace
ACTEMRA INJ ACTPEN	Tier 3	MarketPlace
ACTIMMUNE INJ 2MU/0.5	Tier 3	MarketPlace
ADALIMU-ADAZ INJ 40/0.4ML	Tier 2	MarketPlace
ADCIRCA TAB 20MG	Tier 3	MarketPlace
ADEFOV DIPIV TAB 10MG	Tier 1	MarketPlace
ADEMPAS TAB 0.5MG	Tier 3	MarketPlace
ADEMPAS TAB 1.5MG	Tier 3	MarketPlace
ADEMPAS TAB 1MG	Tier 3	MarketPlace
ADEMPAS TAB 2.5MG	Tier 3	MarketPlace
ADEMPAS TAB 2MG	Tier 3	MarketPlace
ALYQ TAB 20MG	Tier 2	MarketPlace
AMBRISENTAN TAB 10MG	Tier 2	MarketPlace
AMBRISENTAN TAB 5MG	Tier 2	MarketPlace
AMPYRA TAB 10MG	Tier 3	MarketPlace
APOKYN INJ 10MG/ML	Tier 3	MarketPlace
APOMORPHINE INJ 30MG/3ML	Tier 2	MarketPlace
AUBAGIO TAB 14MG	Tier 3	MarketPlace
AUBAGIO TAB 7MG	Tier 3	MarketPlace
AUSTEDO TAB 12MG	Tier 2	MarketPlace
AUSTEDO TAB 6MG	Tier 2	MarketPlace
AUSTEDO TAB 9MG	Tier 2	MarketPlace
AUSTEDO XR TAB 12MG	Tier 2	MarketPlace
AUSTEDO XR TAB 24MG	Tier 2	MarketPlace
AUSTEDO XR TAB 6MG	Tier 2	MarketPlace
AUSTEDO XR TAB TITR KIT	Tier 2	MarketPlace
AVONEX PEN KIT 30MCG	Tier 2	MarketPlace
AVONEX PREFL KIT 30MCG	Tier 2	MarketPlace
BAFIERTAM CAP 95MG	Tier 2	MarketPlace
BARACLUDE SOL	Tier 3	MarketPlace
BARACLUDE TAB 0.5MG	Tier 3	MarketPlace
BARACLUDE TAB 1MG	Tier 3	MarketPlace
BENLYSTA INJ 200MG/ML	Tier 3	MarketPlace
BETASERON INJ 0.3MG	Tier 2	MarketPlace
BETHKIS NEB 300/4ML	Tier 3	MarketPlace
BOSENTAN TAB 125MG	Tier 2	MarketPlace
BOSENTAN TAB 62.5MG	Tier 2	MarketPlace
BRONCHITOL CAP 40MG	Tier 3	MarketPlace
BRONCHITOL CAP TOL TEST	Tier 3	MarketPlace
CARBAGLU TAB 200MG	Tier 3	MarketPlace
CARGLUMIC TAB 200MG	Tier 2	MarketPlace
CAYSTON INH 75MG	Tier 3	MarketPlace
CERDELGA CAP 84MG	Tier 3	MarketPlace
CETRORELIX INJ 0.25MG	Tier 2	MarketPlace

_		
CETRORELIX KIT 0.25MG	Tier 2	MarketPlace
CETROTIDE KIT 0.25MG	Tier 3	MarketPlace
CHOR GONADOT INJ 10000UNT	Tier 3	MarketPlace
CINACALCET TAB 30MG	Tier 2	MarketPlace
CINACALCET TAB 60MG	Tier 2	MarketPlace
CINACALCET TAB 90MG	Tier 2	MarketPlace
COPAXONE INJ 20MG/ML	Tier 2	MarketPlace
•		
COPAXONE INJ 40MG/ML	Tier 2	MarketPlace
COSENTYX INJ 150MG/ML	Tier 2	MarketPlace
COSENTYX INJ 300DOSE	Tier 2	MarketPlace
COSENTYX INJ 75MG/0.5	Tier 2	MarketPlace
COSENTYX PEN INJ 150MG/ML	Tier 2	MarketPlace
COSENTYX PEN INJ 300DOSE	Tier 2	MarketPlace
CUPRIMINE CAP 250MG	Tier 3	MarketPlace
CYSTAGON CAP 150MG	Tier 2	MarketPlace
CYSTAGON CAP 50MG	Tier 2	MarketPlace
DALFAMPRIDIN TAB 10MG ER	Tier 2	MarketPlace
DEFERASIROX GRA 180MG	Tier 2	MarketPlace
DEFERASIROX GRA 360MG	Tier 2	MarketPlace
DEFERASIROX GRA 90MG	Tier 2	MarketPlace
DEFERASIROX TAB 125MG	Tier 2	MarketPlace
DEFERASIROX TAB 180MG	Tier 2	MarketPlace
DEFERASIROX TAB 250MG	Tier 2	MarketPlace
DEFERASIROX TAB 360MG	Tier 2	MarketPlace
DEFERASIROX TAB 500MG	Tier 2	MarketPlace
DEFERASIROX TAB 90MG	Tier 2	MarketPlace
DEFERIPRONE TAB 1000MG	Tier 2	MarketPlace
DEFERIPRONE TAB 500MG	Tier 2	MarketPlace
DEFLAZACORT TAB 18MG	Tier 2	MarketPlace
DEFLAZACORT TAB 30MG	Tier 2	MarketPlace
DEFLAZACORT TAB 36MG	Tier 2	MarketPlace
DEFLAZACORT TAB 6MG	Tier 2	MarketPlace
DEPEN TITRA TAB 250MG	Tier 3	MarketPlace
DESMOPRESSIN SOL 1.5MG/ML	Tier 2	MarketPlace
DIMETHYL FUM CAP 120MG DR	Tier 2	MarketPlace
DIMETHYL FUM CAP 240MG DR	Tier 2	MarketPlace
DIMETHYL FUM CAP STARTER	Tier 2	MarketPlace
DOFETILIDE CAP 125MCG	Tier 2	MarketPlace
DOFETILIDE CAP 250MCG	Tier 2	MarketPlace
DOFETILIDE CAP 500MCG	Tier 2	MarketPlace
DOJOLVI LIQ 100%	Tier 3	MarketPlace
		MarketPlace
	Tier 3	
DROXIDOPA CAP 2004C	Tier 2	MarketPlace
DROXIDOPA CAP 200MG	Tier 2	MarketPlace
DROXIDOPA CAP 300MG	Tier 2	MarketPlace
DUOPA SUS 4.63-20	Tier 3	MarketPlace
DUPIXENT INJ 100/0.67	Tier 2	MarketPlace
DUPIXENT INJ 200/1.14	Tier 2	MarketPlace
DUPIXENT INJ 200MG	Tier 2	MarketPlace
DUPIXENT INJ 300/2ML	Tier 2	MarketPlace
EGRIFTA SV INJ 2MG	Tier 3	MarketPlace
EMFLAZA TAB 18MG	Tier 3	MarketPlace
EMFLAZA TAB 30MG	Tier 3	MarketPlace
EMFLAZA TAB 36MG	Tier 3	MarketPlace
EMFLAZA TAB SOMG	Tier 3	MarketPlace
ENBREL INJ 25/0.5ML	Tier 2	MarketPlace
ENBREL INJ 25MG	Tier 2	MarketPlace
ENBREL INJ 50MG/ML	Tier 2	MarketPlace
ENBREL MINI INJ 50MG/ML	Tier 2	MarketPlace
ENBREL SRCLK INJ 50MG/ML	Tier 2	MarketPlace
ENDARI POW 5GM	Tier 3	MarketPlace

ENSPRYNG INJ	Tier 3	MarketPlace
ENTECAVIR TAB 0.5MG	Tier 2	MarketPlace
ENTECAVIR TAB 1MG	Tier 2	MarketPlace
EPCLUSA PAK 150-37.5	Tier 2	MarketPlace
EPCLUSA PAK 200-50MG	Tier 2	MarketPlace
EPCLUSA TAB 200-50MG	Tier 2	MarketPlace
EPCLUSA TAB 400-100	Tier 2	MarketPlace
EPIDIOLEX SOL 100MG/ML	Tier 3	MarketPlace
ESBRIET CAP 267MG	Tier 3	MarketPlace
ESBRIET TAB 267MG	Tier 3	MarketPlace
ESBRIET TAB 801MG	Tier 3	MarketPlace
EXJADE TAB 125MG	Tier 3	MarketPlace
EXJADE TAB 250MG	Tier 3	MarketPlace
EXJADE TAB 500MG	Tier 3	MarketPlace
FASENRA PEN INJ 30MG/ML	Tier 2	MarketPlace
FERRIPROX TAB 1000MG	Tier 3	MarketPlace
FERRIPROX TAB 500MG	Tier 3	MarketPlace
FINGOLIMOD CAP 0.5MG	Tier 2	MarketPlace
FIRAZYR INJ 30MG/3ML	Tier 3	MarketPlace
FOLLISTIM AQ INJ 300UNIT	Tier 2	MarketPlace
FOLLISTIM AQ INJ 600UNIT	Tier 2	MarketPlace
FOLLISTIM AQ INJ 900UNIT	Tier 2	MarketPlace
FORTEO INJ 600/2.4	Tier 2	MarketPlace
FYREMADEL SOL 250/0.5	Tier 2	MarketPlace
GANIRELIX AC INJ 250/0.5	Tier 3	MarketPlace
GATTEX KIT 5MG	Tier 3	MarketPlace
GILENYA CAP 0.25MG	Tier 3	MarketPlace
GILENYA CAP 0.5MG	Tier 3	MarketPlace
GLATIRAMER INJ 20MG/ML	Tier 2	MarketPlace
GLATIRAMER INJ 40MG/ML	Tier 2	MarketPlace
GLATOPA INJ 20MG/ML	Tier 2	MarketPlace
GLATOPA INJ 40MG/ML	Tier 2	MarketPlace
GONAL-F INJ 1050UNIT	Tier 3	MarketPlace
GONAL-F INJ 450UNIT	Tier 3	MarketPlace
GONAL-F INJ 4300N11 GONAL-F RFF INJ 300/0.5		
·	Tier 3	MarketPlace
GONAL-F RFF INJ 450/0.75	Tier 3	MarketPlace
GONAL-F RFF INJ 75UNIT	Tier 3	MarketPlace
GONAL-F RFF INJ 900/1.5	Tier 3	MarketPlace
HAEGARDA INJ 2000UNIT	Tier 3	MarketPlace
HAEGARDA INJ 3000UNIT	Tier 3	MarketPlace
HARVONI PAK	Tier 2	MarketPlace
HARVONI PAK 45-200MG	Tier 2	MarketPlace
HARVONI TAB 45-200MG	Tier 2	MarketPlace
HARVONI TAB 90-400MG	Tier 2	MarketPlace
HEPAGAM B INJ	Tier 2	MarketPlace
HEPSERA TAB 10MG	Tier 3	MarketPlace
HETLIOZ CAP 20MG	Tier 3	MarketPlace
HUMATROPE INJ 12MG	Tier 3	MarketPlace
HUMATROPE INJ 24MG	Tier 3	MarketPlace
HUMATROPE INJ 6MG	Tier 3	MarketPlace
HUMIRA INJ 10/0.1ML	Tier 2	MarketPlace
HUMIRA INJ 20/0.2ML	Tier 2	MarketPlace
HUMIRA INJ 40/0.4ML	Tier 2	MarketPlace
•		MarketPlace
	Tier 2	
HUMIRA PEDIA INJ CROHNS	Tier 2	MarketPlace
HUMIRA PEN INJ 40/0.4ML	Tier 2	MarketPlace
HUMIRA PEN INJ 40MG/0.8	Tier 2	MarketPlace
HUMIRA PEN INJ 80/0.8ML	Tier 2	MarketPlace
HUMIRA PEN INJ CD/UC/HS	Tier 2	MarketPlace
HUMIRA PEN INJ PS/UV	Tier 2	MarketPlace
HUMIRA PEN KIT 80/0.8ML	Tier 2	MarketPlace

HUMIRA PEN KIT CD/UC/HS	Tier 2	MarketPlace
HUMIRA PEN KIT PED UC	Tier 2	MarketPlace
HUMIRA PEN KIT PS/UV	Tier 2	MarketPlace
HYPERHEP B INJ	Tier 2	MarketPlace
HYRIMOZ INJ 40/0.4ML	Tier 2	MarketPlace
ICATIBANT INJ 30MG/3ML	Tier 2	MarketPlace
<u>'</u>		
INGREZZA CAP 40-80MG	Tier 3	MarketPlace
INGREZZA CAP 40MG	Tier 3	MarketPlace
INGREZZA CAP 60MG	Tier 3	MarketPlace
INGREZZA CAP 80MG	Tier 3	MarketPlace
INTRON A INJ 10MU	Tier 3	MarketPlace
INTRON A INJ 18MU	Tier 3	MarketPlace
INTRON A INJ 50MU	Tier 3	MarketPlace
JADENU TAB 180MG	Tier 3	MarketPlace
JADENU TAB 360MG	Tier 3	MarketPlace
JADENU TAB 90MG	Tier 3	MarketPlace
JADENU SPRKL GRA 180MG		
	Tier 3	MarketPlace
JADENU SPRKL GRA 360MG	Tier 3	MarketPlace
JADENU SPRKL GRA 90MG	Tier 3	MarketPlace
JAVYGTOR PAK 100MG	Tier 2	MarketPlace
JAVYGTOR POW 500MG	Tier 2	MarketPlace
JAVYGTOR TAB 100MG	Tier 2	MarketPlace
JYNARQUE TAB 15MG	Tier 3	MarketPlace
JYNARQUE TAB 30MG	Tier 3	MarketPlace
KESIMPTA INJ 20/.4ML	Tier 3	MarketPlace
KITABIS PAK NEB 300/5ML	Tier 3	MarketPlace
KORLYM TAB 300MG	Tier 3	MarketPlace
KUVAN POW 100MG	Tier 3	MarketPlace
KUVAN POW 500MG	Tier 3	MarketPlace
KUVAN TAB 100MG	Tier 3	MarketPlace
KYNMOBI MIS 10MG	Tier 3	MarketPlace
KYNMOBI MIS 15MG	Tier 3	MarketPlace
KYNMOBI MIS 20MG	Tier 3	MarketPlace
KYNMOBI MIS 25MG	Tier 3	MarketPlace
KYNMOBI MIS 30MG	Tier 3	MarketPlace
LAMIVUDINE TAB 100MG	Tier 2	MarketPlace
LANREOTIDE INJ 120/.5ML	Tier 3	MarketPlace
LEDIP-SOFOSB TAB 90-400MG	Tier 2	MarketPlace
LETAIRIS TAB 10MG	Tier 3	MarketPlace
LETAIRIS TAB 5MG	Tier 3	MarketPlace
LEUPROLIDE INJ 14 DAY	Tier 2	MarketPlace
LEUPROLIDE INJ 1MG/0.2	Tier 2	MarketPlace
LEUPROLIDE KIT 14 DAY		MarketPlace
	Tier 2	
LEUPROLIDE KIT 1MG/0.2	Tier 2	MarketPlace
LIQREV SUS 10MG/ML	Tier 3	MarketPlace
LITFULO CAP 50MG	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(10)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(4)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(5)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(6)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(7)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(8)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(9)	Tier 3	MarketPlace
MAVYRET PAK 50-20MG	Tier 2	MarketPlace
MAVYRET TAB 100-40MG	Tier 2	MarketPlace
MAYZENT PAK STARTER	Tier 2	MarketPlace
MAYZENT TAB 0.25MG	Tier 2	MarketPlace
MAYZENT TAB 1MG	Tier 2	MarketPlace
MAYZENT TAB 2MG	Tier 2	MarketPlace
MENOPUR INJ 75UNIT	Tier 2	MarketPlace
MIFEPRISTONE TAB 300MG	Tier 2	MarketPlace

MIGLUSTAT CAP 100MG	Tier 2	MarketPlace
MOZOBIL INJ	Tier 3	MarketPlace
MULPLETA TAB 3MG	Tier 3	MarketPlace
MYCAPSSA CAP 20MG	Tier 3	MarketPlace
NABI-HB INJ	Tier 2	MarketPlace
NATPARA INJ 100MCG	Tier 3	MarketPlace
NATPARA INJ 25MCG	Tier 3	MarketPlace
NATPARA INJ 50MCG	Tier 3	MarketPlace
NATPARA INJ 75MCG	Tier 3	MarketPlace
NGENLA INJ 24/1.2ML	Tier 3	MarketPlace
NGENLA INJ 60/1.2ML	Tier 3	MarketPlace
NITISINONE CAP 10MG	Tier 2	MarketPlace
NITISINONE CAP 2MG	Tier 2	MarketPlace
NITISINONE CAP 5MG	Tier 2	MarketPlace
NORDITROPIN INJ 10/1.5ML	Tier 2	MarketPlace
NORDITROPIN INJ 15/1.5ML	Tier 2	MarketPlace
NORDITROPIN INJ 30/3ML	Tier 2	MarketPlace
NORDITROPIN INJ 5/1.5ML	Tier 2	MarketPlace
NORTHERA CAP 100MG	Tier 3	MarketPlace
NORTHERA CAP 200MG	Tier 3	MarketPlace
NORTHERA CAP 300MG	Tier 3	MarketPlace
NOVAREL INJ 5000UNIT	Tier 3	MarketPlace
NUCALA INJ 100MG/ML	Tier 2	MarketPlace
NUCALA INJ 40MG/0.4	Tier 2	MarketPlace
NUPLAZID CAP 34MG	Tier 3	
		MarketPlace
NUPLAZID TAB 10MG	Tier 3	MarketPlace
NUTROPIN AQ INJ 10MG/2ML	Tier 2	MarketPlace
NUTROPIN AQ INJ 20MG/2ML	Tier 2	MarketPlace
NUTROPIN AQ INJ NUSPIN 5	Tier 2	MarketPlace
OCALIVA TAB 10MG	Tier 3	MarketPlace
OCALIVA TAB 5MG	Tier 3	MarketPlace
OFEV CAP 100MG	Tier 3	MarketPlace
OFEV CAP 150MG	Tier 3	MarketPlace
	1	MarketPlace
	Tier 3	
OLPRUVA PAK 3GM	Tier 3	MarketPlace
OLPRUVA PAK 4 GM	Tier 3	MarketPlace
OLPRUVA PAK 5GM	Tier 3	MarketPlace
OLPRUVA PAK 6.67GM	Tier 3	MarketPlace
OLPRUVA PAK 6GM	Tier 3	MarketPlace
OMNITROPE INJ 10/1.5ML	Tier 3	MarketPlace
OMNITROPE INJ 5.8MG	Tier 3	MarketPlace
OMNITROPE INJ 5/1.5ML	Tier 3	MarketPlace
ONCASPAR INJ 750/ML	Tier 3	MarketPlace
•		
ONUREG TAB 200MG	Tier 3	MarketPlace
ONUREG TAB 300MG	Tier 3	MarketPlace
OPSUMIT TAB 10MG	Tier 3	MarketPlace
ORENITRAM TAB 0.125MG	Tier 3	MarketPlace
ORENITRAM TAB 0.25MG	Tier 3	MarketPlace
ORENITRAM TAB 1MG	Tier 3	MarketPlace
ORENITRAM TAB 2.5MG	Tier 3	MarketPlace
ORENITRAM TAB 5MG	Tier 3	MarketPlace
ORENITRAM TAB MONTH 1	Tier 3	MarketPlace
	1	
ORENITRAM TAB MONTH 2	Tier 3	MarketPlace
ORENITRAM TAB MONTH 3	Tier 3	MarketPlace
ORFADIN CAP 10MG	Tier 3	MarketPlace
ORFADIN CAP 20MG	Tier 3	MarketPlace
ORFADIN CAP 2MG	Tier 3	MarketPlace
ORFADIN CAP 5MG	Tier 3	MarketPlace
OTEZLA TAB 10/20/30	Tier 2	MarketPlace
OTEZLA TAB 30MG	Tier 2	MarketPlace
OTREXUP INJ 10MG	Tier 3	MarketPlace
OTHEROT IN TOMO	TICI 3	Widthett lace

OTREXUP INJ 12.5/0.4	Tier 3	MarketPlace
OTREXUP INJ 15MG	Tier 3	MarketPlace
OTREXUP INJ 17.5/0.4	Tier 3	MarketPlace
OTREXUP INJ 20MG	Tier 3	MarketPlace
OTREXUP INJ 22.5/0.4	Tier 3	MarketPlace
OTREXUP INJ 25MG	Tier 3	MarketPlace
OVIDREL INJ	Tier 3	MarketPlace
OXBRYTA TAB 300MG	Tier 3	MarketPlace
OXBRYTA TAB 500MG	Tier 3	MarketPlace
PALYNZIQ INJ 10/0.5ML	Tier 3	MarketPlace
PALYNZIQ INJ 2.5/0.5	Tier 3	MarketPlace
PALYNZIQ INJ 20MG/ML	Tier 3	MarketPlace
PEGASYS INJ	Tier 2	MarketPlace
PEGASYS INJ 180MCG/M	Tier 2	MarketPlace
PENICILLAMIN CAP 250MG	Tier 2	MarketPlace
PENICILLAMIN TAB 250MG	Tier 2	MarketPlace
PHENYLBUTYRA POW SODIUM	Tier 2	MarketPlace
PIRFENIDONE CAP 267MG	Tier 2	MarketPlace
PIRFENIDONE TAB 267MG	Tier 2	MarketPlace
PIRFENIDONE TAB 801MG	Tier 2	MarketPlace
PLEGRIDY INJ	Tier 2	MarketPlace
PLEGRIDY INJ PEN	Tier 2	MarketPlace
PLEGRIDY INJ STARTER	Tier 2	MarketPlace
PLEGRIDY PEN INJ STARTER	Tier 2	MarketPlace
PLERIXAFOR INJ 24/1.2ML	Tier 2	MarketPlace
PONVORY TAB 20MG		
	Tier 3	MarketPlace
PONVORY TAB STARTER	Tier 3	MarketPlace
PREGNYL INJ 10000UNT	Tier 3	MarketPlace
PROMACTA PAK 25MG	Tier 3	MarketPlace
PROMACTA POW 12.5MG	Tier 3	MarketPlace
PROMACTA TAB 12.5MG	Tier 3	MarketPlace
PROMACTA TAB 25MG	Tier 3	MarketPlace
PROMACTA TAB 50MG	Tier 3	MarketPlace
PROMACTA TAB 75MG	Tier 3	MarketPlace
PULMOZYME SOL 1MG/ML	Tier 3	MarketPlace
RADICAVA ORS SUS 105/5ML	Tier 3	MarketPlace
RADICAVA ORS SUS STARTER	Tier 3	MarketPlace
RASUVO INJ 10MG	Tier 3	MarketPlace
RASUVO INJ 12.5MG	Tier 3	MarketPlace
RASUVO INJ 15MG	Tier 3	MarketPlace
RASUVO INJ 17.5MG	Tier 3	MarketPlace
RASUVO INJ 20MG	Tier 3	Market Place
RASUVO INJ 22.5MG	Tier 3	MarketPlace
RASUVO INJ 25MG	Tier 3	
		MarketPlace MarketPlace
RASUVO INJ 30MG	Tier 3	Market Place
RASUVO INJ 7.5MG	Tier 3	MarketPlace
RAVICTI LIQ 1.1GM/ML	Tier 3	MarketPlace
REBIF INJ 22/0.5	Tier 2	MarketPlace
REBIF INJ 44/0.5	Tier 2	MarketPlace
REBIF REBIDO INJ 22/0.5	Tier 2	MarketPlace
REBIF REBIDO INJ 44/0.5	Tier 2	MarketPlace
REBIF REBIDO INJ TITRATN	Tier 2	MarketPlace
REBIF TITRTN INJ PACK	Tier 2	MarketPlace
RELEUKO INJ 300MCG	Tier 3	MarketPlace
RELEUKO INJ 480MCG	Tier 3	MarketPlace
RELYVRIO PAK 3-1GM	Tier 3	MarketPlace
REVATIO SUS 10MG/ML	Tier 3	MarketPlace
REVATIO TAB 20MG	Tier 3	MarketPlace
RHOPHYLAC INJ 1500/2ML	Tier 2	MarketPlace
· · · · · · · · · · · · · · · · · · ·		
RIBAVIRIN CAP 200MG	Tier 2	Market Place
RIBAVIRIN TAB 200MG	Tier 2	MarketPlace

RINVOQ TAB 15MG ER Tier 2 MarketPlace RINVOQ TAB 3MG ER Tier 2 MarketPlace RINVOQ TAB 45MG ER Tier 2 MarketPlace SABRIL POW 500MG Tier 3 MarketPlace SABRIL TAB 500MG Tier 3 MarketPlace SABRIL TAB 500MG Tier 3 MarketPlace SAIZEN INJ 8.MG Tier 3 MarketPlace SAIZEN INJ 8.MG Tier 3 MarketPlace SAIZEN INJ 8.MMG Tier 3 MarketPlace SAIZEN TAB 15MG Tier 3 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 2 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 2 MarketPlace SEROSTIM INJ 5MG Tier 2 MarketPlace SEROSTIM INJ 5MG Tier 2 MarketPlace SEROSTIM INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 3 MarketPlace SCOMATULINE INJ 150MG Tier 3 MarketPlace SOMAVERT INJ 150MG Tier 3 MarketPlace SOMAVERT INJ 150MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOVALDI PAR 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace			
RINVOQ TAB 45MG ER	RINVOQ TAB 15MG ER	Tier 2	MarketPlace
SABRIL POW 500MG Tier 3 MarketPlace SABRIL TAB 500MG Tier 3 MarketPlace SAIZEN IN JSMG Tier 3 MarketPlace SAIZEN IN JSMG Tier 3 MarketPlace SAIZEN IN JS.8MG Tier 3 MarketPlace SAIZEN IN JSMG/SML Tier 2 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM IN JAMG Tier 2 MarketPlace SILDENAFIL USL JOMG/ML Tier 2 MarketPlace SILDENAFIL USL JOMG/ML Tier 2 MarketPlace SKYRIZI IN J 1500DOSE Tier 2 MarketPlace SKYRIZI IN J 1500MG/ML Tier 2 MarketPlace SOMATULINE IN J 1500MG/ML Tier 3 MarketPlace SOMATULINE IN J 1500MG/ML Tier 3 MarketPlace SOMATULINE IN J 1500MG/ML Tier 3 MarketPlace SOMAVERT IN J 150MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 250MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA I	RINVOQ TAB 30MG ER	Tier 2	MarketPlace
SABRIL TAB SOOMG Tier 3 MarketPlace SAIZEN IN IS SMG Tier 3 MarketPlace SAIZEN SAIZEN IN SMG Tier 3 MarketPlace SAIZEN SAIZEN SMG Tier 3 MarketPlace SAIZEN SMSCA TAB SMG Tier 3 MarketPlace SAMSCA TAB SMG Tier 3 MarketPlace SAMSCA TAB SMG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM IN SMG Tier 3 MarketPlace SILDENAFIL TAB 20MG Tier 3 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI IN J 15000SE Tier 2 MarketPlace SKYRIZI IN J 150MG/ML Tier 2 MarketPlace SOPOS/YELPAT TAB 400-100 Tier 2 MarketPlace SOPOS/YELPAT TAB 50MG Tier 3 MarketPlace SOMATULINE IN J 150MG/ML Tier 3 MarketPlace SOMATULINE IN J 150MG/ML Tier 3 MarketPlace SOMATULINE IN J 150MG Tier 3 MarketPlace SOMAVERT IN J 15MG Tier 3 MarketPlace SOVALDI PAK 15MMG Tier 3 MarketPlace SOVALDI TAB 20MMG Tier 3 MarketPlace STELARA IN J 45MG/OS TIER 3 MarketPlace TADLIQ SUS 20MG/SML	RINVOQ TAB 45MG ER	Tier 2	MarketPlace
SAIZEN INJ 5MG Tier 3 MarketPlace SAIZEN INJ 8.8MG Tier 3 MarketPlace SAIZEN INJ 30MG/3ML Tier 2 MarketPlace SAIZEN INJ 30MG/3ML Tier 2 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 3 MarketPlace SAPROPTERIN TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 2 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHEMY TAB 500MG Tier 2 MarketPlace SODIUM PHEMY TAB 500MG Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SM	SABRIL POW 500MG	Tier 3	MarketPlace
SAIZEN INJ 8.8MG Tier 3 MarketPlace SAIZENREP INJ 8.8MG Tier 3 MarketPlace SAALZI NIJ 30MG/3ML Tier 2 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 2 MarketPlace SAPROPTERIN TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 1500OSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOOMATULINE IN 90/0.3 ML Tier 3 MarketPlace SOMATULINE IN 90/0.3 ML Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace TABLIZYRO INJ 300/2ML Tier 3	SABRIL TAB 500MG	Tier 3	MarketPlace
SAIZEN INJ 8.8MG Tier 3 MarketPlace SAIZENREP INJ 8.8MG Tier 3 MarketPlace SAARAZA INJ 30MG/3ML Tier 2 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 90MC Tier 3 MarketPlace SENSIPAR TAB 90MC Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 150MG/ML Tier 3 MarketPlace SOMATULINE INJ 150MG Tier 3 MarketPlace SOMATULINE INJ 150MG Tier 3 MarketPlace SOMATULINE INJ 150MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace TABALAFIL TAB 20MG TIER 3 M	SAIZEN INJ 5MG	Tier 3	MarketPlace
SAIZENPREP INJ 8.8MG SAIAZIR INJ 30MG/3ML Tier 2 SAMSCA TAB 15MG SAMSCA TAB 30MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 2 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SKYRIZI INJ 1500MG/ML Tier 2 MarketPlace SKYRIZI INJ 1500MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 3 MarketPlace SOPOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 60/0.2ML Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOVALDI PAK 15MG Tier 3 MarketPlace SOVALDI PAK 20MG Tier 3 MarketPlace SOVALDI PAK 20MG Tier 3 MarketPlace SOVALDI TAB 20MG Tier 3 MarketPlace SOVALDI TAB 20MG Tier 3 MarketPlace SOVALDI TAB 20MG Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TARLEYRO INJ 30MG/ML Tier 2 MarketPlace			MarketPlace
SAJAZIR INJ 30MG/3ML SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOVALDI PAK 15MG Tier 3 MarketPlace SOVALDI PAK 20MG Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier			
SAMSCA TAB 15MG Tier 3 MarketPlace SAMSCA TAB 30MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 2 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 6MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOPOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/SML Tier 3 MarketPlace SOMATULINE INJ 120/SML Tier 3 MarketPlace SOMATULINE INJ 120/SML Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STILARA INJ 90MG/ML Tier 2 MarketPlace TALHZYRO INJ 350MG/ML Tier 3 MarketPlace TALHZYRO INJ 350MG/ML Tier			
SAMSCA TAB 30MG Tier 3 MarketPlace SAPROPTERIN POW 100MG Tier 2 MarketPlace SAPROPTERIN POW 500MG Tier 2 MarketPlace SAPROPTERIN TAB 100MG Tier 2 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 60/0.2ML Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 Marke			
SAPROPTERIN POW 100MG SAPROPTERIN POW 500MG Tier 2 SAPROPTERIN TAB 100MG Tier 3 SAPROPTERIN TAB 100MG Tier 3 SENSIPAR TAB 30MG Tier 3 SENSIPAR TAB 50MG Tier 3 MarketPlace SENSIPAR TAB 50MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 6MG Tier 3 MarketPlace SEROSTIM INJ 6MG Tier 3 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 180/1.2 Tier 2 MarketPlace SKYRIZI INJ 180/1.2 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOMATULINE INJ 100/.2ML Tier 3 MarketPlace SOMATULINE INJ 100/.2ML Tier 3 MarketPlace SOMATULINE INJ 100/.3ML Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 95MG/ML Tier 2 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace			
SAPROPTERIN POW 500MG SAPROPTERIN TAB 100MG Tier 2 SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 60MG Tier 3 MarketPlace SENSIPAR TAB 60MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 6MG Tier 3 MarketPlace SEROSTIM INJ 6MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150MOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI PEN INJ 150MG/ML Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 190/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOWALDI PAK 150MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADLIAE INJ 150MG/ML Tier 3 MarketPlace			
SAPROPTERIN TAB 100MG SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 30MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 15000SE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI PEN INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 20MMG Tier 3 MarketPlace SOVALDI TAB 40MMG Tier 3 MarketPlace SOVALDI TAB 20MMG Tier 3 MarketPlace SOVALDI TAB 40MMG Tier 3 MarketPlace SOVALDI TAB 40MMG Tier 3 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADLIAL TAB 20MG Tier 3 MarketP			
SENSIPAR TAB 30MG SENSIPAR TAB 60MG Tier 3 MarketPlace SENSIPAR TAB 90MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 6MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 SOMATULINE INJ 60/0.2ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace			
SENSIPAR TAB 60MG SENSIPAR TAB 90MG Tier 3 MarketPlace SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace			
SENSIPAR TAB 90MG SEROSTIM INJ 4MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 SOMATULINE INJ 10/0.5ML Tier 3 MarketPlace SOMATULINE INJ 10/0.3ML Tier 3 MarketPlace SOMATULINE INJ 10/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace		Tier 3	MarketPlace
SEROSTIM INJ 4MG SEROSTIM INJ 5MG Tier 3 MarketPlace SEROSTIM INJ 5MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 SILDENAFIL SUS 10MG/ML Tier 2 SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 45MG/.5 Tier 2 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace	SENSIPAR TAB 60MG	Tier 3	MarketPlace
SEROSTIM INJ 5MG SEROSTIM INJ 6MG Tier 3 MarketPlace SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/6.4 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 10MGO.2ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace	SENSIPAR TAB 90MG	Tier 3	MarketPlace
SEROSTIM INJ 6MG SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 190/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace	SEROSTIM INJ 4MG	Tier 3	MarketPlace
SEROSTIM INJ 6MG SILDENAFIL SUS 10MG/ML Tier 2 MarketPlace SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace	SEROSTIM INJ 5MG	Tier 3	MarketPlace
SILDENAFIL SUS 10MG/ML SILDENAFIL TAB 20MG Tier 2 MarketPlace SKYRIZI INJ 150DOSE Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 10J.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace	SEROSTIM INJ 6MG	Tier 3	
SILDENAFIL TAB 20MG Tier 2 SKYRIZI INJ 150MG/ML Tier 2 SKYRIZI INJ 150MG/ML Tier 2 SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 180/1.2 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI PEN INJ 150MG/ML Tier 2 SODIUM PHENY TAB 500MG Tier 2 SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace	SILDENAFIL SUS 10MG/ML		MarketPlace
SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 180/1.2 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI PEN INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 50MG/ML Tier 2 MarketPlace TABALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TABALAFIL TAB 20MG Tier 3 MarketPlace TABALAFIL TAB 20MG Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace	,		
SKYRIZI INJ 150MG/ML Tier 2 MarketPlace SKYRIZI INJ 180/1.2 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI PEN INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.2ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TACHUR SUS 20MG/SML Tier 3 MarketPlace			
SKYRIZI INJ 180/1.2 Tier 2 MarketPlace SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI PEN INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TACHATARA MARKETPLACE TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace			
SKYRIZI INJ 360/2.4 Tier 2 MarketPlace SKYRIZI PEN INJ 150MG/ML Tier 2 MarketPlace SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.2ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	•		
SKYRIZI PEN INJ 150MG/ML SODIUM PHENY TAB 500MG Tier 2 MarketPlace SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.2ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TACHARA INJ 150MG/ML Tier 3 MarketPlace TACHARA INJ 150MG/ML Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace	·		
SODIUM PHENY TAB 500MG SOFOS/VELPAT TAB 400-100 Tier 2 MarketPlace SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 60/0.2ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TACHARA INJ 150MG/ML Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TACHARA INJ 150MG/ML Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace	,		
SOFOS/VELPAT TAB 400-100 Tier 2 SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 90/0.2ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	•		
SOMATULINE INJ 120/.5ML Tier 3 MarketPlace SOMATULINE INJ 60/0.2ML Tier 3 MarketPlace SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace			
SOMATULINE INJ 60/0.2ML SOMATULINE INJ 90/0.3ML Tier 3 MarketPlace SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	•	Tier 2	MarketPlace
SOMATULINE INJ 90/0.3ML SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADLIQ SUS 20MG/SML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	SOMATULINE INJ 120/.5ML	Tier 3	MarketPlace
SOMAVERT INJ 10MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	SOMATULINE INJ 60/0.2ML	Tier 3	MarketPlace
SOMAVERT INJ 15MG Tier 3 MarketPlace SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TACHARA INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	SOMATULINE INJ 90/0.3ML	Tier 3	MarketPlace
SOMAVERT INJ 20MG Tier 3 MarketPlace SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	SOMAVERT INJ 10MG	Tier 3	MarketPlace
SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	SOMAVERT INJ 15MG	Tier 3	MarketPlace
SOMAVERT INJ 25MG Tier 3 MarketPlace SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	SOMAVERT INJ 20MG	Tier 3	MarketPlace
SOMAVERT INJ 30MG Tier 3 MarketPlace SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace		Tier 3	MarketPlace
SOVALDI PAK 150MG Tier 3 MarketPlace SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADALAFIL TAB 20MG Tier 3 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace		Tier 3	MarketPlace
SOVALDI PAK 200MG Tier 3 MarketPlace SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
SOVALDI TAB 200MG Tier 3 MarketPlace SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
SOVALDI TAB 400MG Tier 3 MarketPlace STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
STELARA INJ 45MG/0.5 Tier 2 MarketPlace STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
STELARA INJ 90MG/ML Tier 2 MarketPlace STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
STIMATE SOL 1.5MG/ML Tier 2 MarketPlace SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
SYPRINE CAP 250MG Tier 3 MarketPlace TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	-		
TADALAFIL TAB 20MG Tier 2 MarketPlace TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
TADLIQ SUS 20MG/5ML Tier 3 MarketPlace TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace			
TAKHZYRO INJ 150MG/ML Tier 3 MarketPlace TAKHZYRO INJ 300/2ML Tier 3 MarketPlace		Tier 2	MarketPlace
TAKHZYRO INJ 300/2ML Tier 3 MarketPlace	-		
	TAKHZYRO INJ 150MG/ML	Tier 3	MarketPlace
TASIMELTEON CAP 20MG Tier 2 MarketPlace	TAKHZYRO INJ 300/2ML	Tier 3	MarketPlace
	TASIMELTEON CAP 20MG	Tier 2	MarketPlace
TERIFLUNOMID TAB 14MG Tier 1 MarketPlace	TERIFLUNOMID TAB 14MG	Tier 1	MarketPlace
TERIFLUNOMID TAB 7MG Tier 1 MarketPlace			
TERIPARATIDE INJ 600/2.4 Tier 2 MarketPlace			
TERIPARATIDE INJ 620/2.48 Tier 2 Market Place			
TETRABENAZIN TAB 12.5MG Tier 2 Market Place	-		
THALOMID CAP 100MG Tier 3 MarketPlace			
THALOMID CAP 150MG Tier 3 MarketPlace			
THALOMID CAP 200MG Tier 3 MarketPlace			
THALOMID CAP 50MG Tier 3 MarketPlace			
THIOLA TAB 100MG Tier 3 MarketPlace	THIOLA TAB 100MG	Tier 3	MarketPlace

	•	
TIKOSYN CAP 125MCG	Tier 3	MarketPlace
TIKOSYN CAP 250MCG	Tier 3	MarketPlace
TIKOSYN CAP 500MCG	Tier 3	MarketPlace
TIOPRONIN TAB 100MG	Tier 2	MarketPlace
TOBI NEB 300/5ML	Tier 3	MarketPlace
TOBI PODHALR CAP 28MG	Tier 3	MarketPlace
TOBRAMYCIN NEB 300/4ML	Tier 2	MarketPlace
•		
TOBRAMYCIN NEB 300/5ML	Tier 2	MarketPlace
TOLVAPTAN TAB 15MG	Tier 2	MarketPlace
TOLVAPTAN TAB 30MG	Tier 2	MarketPlace
TRACLEER TAB 125MG	Tier 3	MarketPlace
TRACLEER TAB 32MG	Tier 3	MarketPlace
TRACLEER TAB 62.5MG	Tier 3	MarketPlace
TREMFYA INJ 100MG/ML	Tier 2	MarketPlace
TRIENTINE CAP 250MG	Tier 2	MarketPlace
TRIENTINE CAP 500MG	Tier 2	MarketPlace
TYMLOS INJ	Tier 2	MarketPlace
TYVASO SOL 0.6MG/ML	Tier 3	MarketPlace
TYVASO DPI POW 16-32-48	Tier 3	MarketPlace
TYVASO DPI POW 16-32MCG	Tier 3	MarketPlace
TYVASO DPI POW 16MCG	Tier 3	MarketPlace
TYVASO DPI POW 32-48MCG	Tier 3	MarketPlace
TYVASO DPI POW 32MCG	Tier 3	MarketPlace
TYVASO DPI POW 48MCG	Tier 3	MarketPlace
TYVASO DPI POW 64MCG	Tier 3	MarketPlace
TYVASO REFIL SOL 0.6MG/ML	Tier 3	MarketPlace
TYVASO KETTE SOE 0.6MG/ME TYVASO START SOL 0.6MG/ML	Tier 3	MarketPlace
· · · · · · · · · · · · · · · · · · ·		
UPTRAVI TAB 1000MCG	Tier 3	MarketPlace
UPTRAVI TAB 1200MCG	Tier 3	MarketPlace
UPTRAVI TAB 1400MCG	Tier 3	MarketPlace
UPTRAVI TAB 1600MCG	Tier 3	MarketPlace
UPTRAVI TAB 200MCG	Tier 3	MarketPlace
UPTRAVI TAB 400MCG	Tier 3	MarketPlace
UPTRAVI TAB 600MCG	Tier 3	MarketPlace
UPTRAVI TAB 800MCG	Tier 3	MarketPlace
UPTRAVI PACK TAB 200/800	Tier 3	MarketPlace
VEMLIDY TAB 25MG	Tier 3	MarketPlace
VENTAVIS SOL 10MCG/ML	Tier 3	MarketPlace
VENTAVIS SOL 20MCG/ML	Tier 3	MarketPlace
VIGABATRIN PAK 500MG	Tier 2	MarketPlace
VIGABATRIN TAB 500MG	Tier 2	MarketPlace
VIGADRONE POW 500MG	Tier 2	Market Place
VIGADRONE TAB 500MG	Tier 2	MarketPlace
		MarketPlace
VIGPODER POW 500MG	Tier 2	
VIJOICE TAB 125MG	Tier 3	MarketPlace
VIJOICE TAB 250MG	Tier 3	MarketPlace
VIJOICE TAB 50MG	Tier 3	MarketPlace
VOSEVI TAB	Tier 2	MarketPlace
VOXZOGO INJ 0.4MG	Tier 3	MarketPlace
VOXZOGO INJ 0.56MG	Tier 3	MarketPlace
VOXZOGO INJ 1.2MG	Tier 3	MarketPlace
VUMERITY CAP 231MG	Tier 2	MarketPlace
VYNDAMAX CAP 61MG	Tier 3	MarketPlace
VYNDAQEL CAP 20MG	Tier 3	MarketPlace
WINRHO SDF INJ 15000UNT	Tier 2	MarketPlace
WINRHO SDF INJ 1500UNIT	Tier 2	MarketPlace
WINRHO SDF INJ 2500UNIT	Tier 2	MarketPlace
WINRHO SDF INJ 5000UNIT	Tier 2	MarketPlace
XELJANZ SOL 1MG/ML	Tier 2	MarketPlace
XELJANZ TAB 10MG	Tier 2	MarketPlace
XELJANZ TAB 5MG	Tier 2	MarketPlace

Processing the state of the sta		
XELJANZ XR TAB 11MG	Tier 2	MarketPlace
XELJANZ XR TAB 22MG	Tier 2	MarketPlace
XENAZINE TAB 12.5MG	Tier 3	MarketPlace
XENAZINE TAB 25MG	Tier 3	MarketPlace
XOLAIR INJ 150MG/ML	Tier 2	MarketPlace
XOLAIR INJ 300/2ML	Tier 2	MarketPlace
XOLAIR INJ 75/0.5	Tier 2	MarketPlace
YARGESA CAP 100MG	Tier 2	MarketPlace
ZAVESCA CAP 100MG	Tier 3	MarketPlace
ZEPOSIA CAP .92MG	Tier 3	MarketPlace
ZEPOSIA CAP STR KIT	Tier 3	MarketPlace
ZEPOSIA 7DAY CAP STR PACK	Tier 3	MarketPlace
ZOKINVY CAP 50MG	Tier 3	MarketPlace
ZOKINVY CAP 75MG	Tier 3	MarketPlace
ZORBTIVE INJ 8.8MG	Tier 3	MarketPlace

Insurance Company Name	MVP Health Care
HIOS ID	77566
SERFF Filing Number	MVPH-134081005
Market	Small Group
Product Name	VT Small Group 2025

Pharmacy Benefit Manager Information²

Please list any pharmacy benefit managers utilized for the following periods. Include additional lines as necessary.

	Experience Period -1	Experience Period	Projection Period
	01/01/2022-12/31/2022	01/01/2023-12/31/2023	1/01/2025-12/31/202
Pharmacy Benefit Manager #1	CVS/Caremark	CVS/Caremark	CVS/Caremark
Pharmacy Benefit Manager #2			
Pharmacy Benefit Manager #3			
Pharmacy Benefit Manager #4			

For each period, enter the PBM, if applicable, administering pharmacy benefits at a pharmacy, network pharmacy, or mail-order pharmacy for each drug tier.

	Experience Period -1		Experience Period		Projection Period	
	01/01/2022-12/31/2022		01/01/2023-12/31/2023		1/01/2025-12/31/202	
	Retail	Mail	Retail	Mail	Retail	Mail
Non-Specialty Generic PMPM						
Non-Specialty Brand PMPM						
Specialty PMPM						

For each period, enter the PBM, if applicable, administering drug benefits by a health care provider in an outpatient setting as part of the medical benefit as separate from the pharmacy benefit for each drug tier.

	Experience Period -1		Experience Period		Projection Period	
	01/01/2022-12/31/2022		01/01/2023-12/31/2023		1/01/2025-12/31/202	
	Retail	Mail	Retail	Mail	Retail	Mail
Non-Specialty Generic PMPM						
Non-Specialty Brand PMPM						
Specialty PMPM						

² Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board:
(C) The insurer shall include information on its use of a pharmacy benefit manager, if any, including which components of the prescription drug coverage described in subdivisions (A) and (B) of this subdivision (2) are managed by the pharmacy benefit manager, as well as the name of the pharmacy benefit manager or managers used.



State of Vermont

Actuarial Value Certification for 2025 Standard Plan Designs

March 6, 2024

Prepared by:

Wakely Consulting Group, LLC, an HMA Company

Darren Johnson, ASA, MAAAConsulting Actuary II

Julie Peper, FSA, MAAA Principal



Table of Contents

Executive Summary	1
Regulatory Background	2
CSR Loading	3
Chiropractic and Physical Therapy Copays	4
Limiting Out-of-Pocket Expenses for Insulin	4
Addition of Hearing Aid Coverage to EHBs	4
Actuarial Value Considerations	5
Methodology	9
Vermont-Specific Adjustment Model	9
Adjusted AV Calculations	11
Mental Health/Substance Abuse Office Limits with \$0 Cost Sharing	13
Insulin Out-of-Pocket Limit	14
Disclosures and Limitations	15
Appendix A: Actuarial Certification	18
Appendix B: Summary of Plan Design Changes from 2024 Designs	20
Appendix C: On and Off-Exchange Reflective Silver Standard Plan Designs	21
Appendix D: Comments Relative to Applicable ASOPs	22
Appendix E: Standard Plan Designs	26
Appendix F: Summary of Adjustments Considered and Final Adjusted AVs	30
Appendix G: Screen Shots and AV Development	31



Executive Summary

The Affordable Care Act (ACA) requires that health care coverage provided by issuers to non-grandfathered individual and small groups must cover all Essential Health Benefits (EHBs) and have plan designs that have Actuarial Values (AVs) that fall under the Platinum (90% AV), Gold (80% AV), Silver (70% AV), or Bronze (60% AV) tiers.

The State of Vermont (State) standardizes several plan designs that all issuers offering plans in the Exchange, Vermont Health Connect, must offer. Issuers must offer the standard plan designs in the individual and small group markets. In 2024, there was one Platinum, one Gold, two Silver, and three Bronze standard plan designs for Vermont Health Connect. There was a traditional deductible plan at each of the Platinum, Gold, and Silver metal levels, with two at the Bronze level, and a High Deductible Health Plan (HDHP) at each of the Silver and Bronze levels. The 2024 standard plan designs are all continuing in 2025 with minor changes.

For each of the Silver standard plan designs, the cost-sharing reduction plan designs are also standard. Cost-sharing reduction (CSR) plan designs were developed at each of the 73% (Federal), 77% (Vermont specific), 87% (Federal), and 94% (Federal) AV levels.

The State contracted with Wakely Consulting Group, LLC, an HMA Company (Wakely), to assist in the development of the 2025 standard plan designs and to provide an actuarial certification of the actuarial values of the state's standard plan designs that do not fit within the parameters of the Federal calculator and require adjustment. This memo documents the approved 2025 standard plan designs as well as the process for developing the corresponding actuarial values. The actuarial certification is provided in Appendix A.

The 2025 Notice of Benefit and Payment Parameters (NBPP) and Federal Actuarial Value Calculator (AVC) Model are still in draft form. Should there be changes between the draft and final versions, the plan designs reflected here may require changes. In addition, the IRS limits for HDHPs have not been released yet for 2025 though the plan designs shown here were based on Mercer's preliminary predictions for those limits that have always been accurate. Additional changes may be required to the Silver and Bronze HDHPs, should the plan designs presented here not comply with federal or state requirements. Note that in order to comply with Vermont regulations and the anticipated HDHP minimum deductible, some plan designs have been changed since the presentation and approval of the Green Mountain Care Board.

A detailed list of the changes from the 2024 standard plan designs is in Appendix B. At a high level the changes for each base standard plan are:

- Platinum The medical and pharmacy Maximum Out of Pocket (MOOP) were increased.
- Gold The pharmacy MOOP was increased.



- Silver Deductible The combined deductible and medical/pharmacy MOOP were decreased. The pharmacy only MOOP was increased. In addition, generic drug and ER copays were both decreased.
- Bronze Deductible with Pharmacy Limit The combined medical/pharmacy MOOP decreased while the pharmacy only MOOP was increased. The generic drug copay also decreased.
- Bronze Deductible without Pharmacy Limit The combined deductible and combined MOOP were decreased. The generic drug copay was also decreased.
- Silver HDHP The embedded individual combined medical/pharmacy MOOP was decreased. In addition, primary care and mental health/substance abuse office visit coinsurance was decreased.
- Bronze HDHP The combined medical/pharmacy MOOP and the embedded individual combined medical/pharmacy MOOP were decreased.

In addition to the standard plans, the State of Vermont requests that issuers offer a Gold plan where the deductible and MOOP are set at the same amount. This means that once the deductible is met, the plan pays 100% of all services. Unlike the standard plans, it is not required that issuers offer this plan, but it is highly recommended. The issuer may determine the amount at which to set the deductible and MOOP, as long as they are equal and the resulting plan falls in the Gold tier. Since the amounts are to be determined by the issuers, these plans are not included within this memo.

Regulatory Background

The ACA allows for a de minimis range around the target AVs for each metal level. The 2025 draft NBPP included a range of -2% to +2% for most plans. For example, any plan design that has an AV from 78% to 82% is considered a Gold plan. Consistent with the final 2024 NBPP, the 2025 draft NBPP included a smaller range for On-Exchange Silver plans of 0% to +2% (or an AV between 70% and 72%). Off-Exchange Silver plans would continue to be subject to the -2% to +2% range. The plan designs presented here comply with the draft AV ranges. Bronze plan designs meeting certain criteria are eligible for an expanded range of +5% on the higher end, allowing an AV up to 65% compared to a high end at 62%. Plans that meet these criteria include HDHPs and plans that cover at least one major service, other than preventive, prior to the deductible. All three Bronze standard plans qualify for the expanded range.



The Center for Consumer Information and Insurance Oversight (CCIIO) released the draft 2025 Actuarial Value Calculator (AVC)¹ that issuers must use to determine the AV of a plan. The 2025 plan designs presented in this report are compliant with the draft 2025 AVC.

The Annual Limitation on Cost Sharing was released in a separate guidance letter and has been finalized for 2025. The limitation will be \$9,200 for 2025, a decrease of \$250 from the \$9,450 limit in 2024. This is the first time this limit has decreased which necessitated a number of plan design changes to ensure compliance.

While CCIIO anticipates that most plans will be able to use the AVC without modification, some plan designs have features which are not supported by the AVC. In these instances, an actuary can either modify the inputs to most closely represent the plan design or an actuary can modify the results of the AVC to account for the features not supported by the AVC. An actuarial certification documenting the development of the AV for these designs is required.

The federal HDHP minimum deductible and MOOP limits are anticipated to be \$1,650 and \$8,250, respectively, for 2025, based on Mercer's early projections.² The 2024 minimum deductible and MOOP were \$1,600 and \$8,050, respectively. The 2025 increases are higher than the historical averages, where the deductible has increased \$50 every two to three years and the MOOP has increased around \$100 a year. Due to the higher minimum deductible for 2025, adjustments have been made to both HDHPs (and corresponding Silver CSR HDHPs). Note that there were similarly large increases in 2024, with increases the last few years heavily driven by high inflation. Should the HDHP minimum deductible be finalized at an amount other than \$1,650, changes to some plan designs would be required.

CSR Loading

As of 2020, Act No. 88 (Bill S.19) requires the premiums of the Silver on-Exchange plans to reflect the cost of funding for CSR subsidies, following the announcement that federal funding would cease. This resulted in a "CSR load" to these plans such that the Silver premiums are higher than they would have been without the CSR load. For individuals who are not eligible for premium subsidies (and are therefore not protected from the CSR load), issuers offer "reflective" off-Exchange Silver plans whose premiums have not been increased for the CSR load and have only a minor difference in plan design compared to their on-Exchange counterparts. These plans will continue in 2025.

The Off-Exchange "reflective" plans will have a \$5 copay or 5% coinsurance increase on ambulance services compared to the on-Exchange plans. These differentials apply to both standard and non-standard Silver plans. A comparison of the standard Silver on and off-Exchange plan designs are shown in Appendix C. As ambulance services are not explicitly included in the

¹ http://www.cms.gov/CCIIO/Resources/Regulations-and-guidance/index.html

² Mercer projects 2025 HSA, HDHP and excepted-benefit HRA figures



AVC and the differences in cost sharing are minimal, there is no difference in the calculation of the federal AV for these plans. Unless otherwise noted, in the Appendices the cost sharing for ambulance services represents the on-Exchange plan design.

In the event there is a Silver plan approved with 100% coinsurance, the off-Exchange "reflective" plan will have a \$25 deductible and MOOP increase compared to the on-Exchange plan. Unlike the ambulance cost sharing above, this difference will impact the AV. The issuer submitting such a plan will need to ensure that both the on and off-Exchange plan designs fit within the AV requirements. Since this is for non-standard plans only, these plans are not included within this memo.

Chiropractic and Physical Therapy Copays

Act No. 7³ requires that the copay for chiropractic and physical therapy services for Silver and Bronze metal level plans be between 125% and 150% of the copay applicable to services provided by a primary care provider (PCP). All of the Silver and Bronze Deductible plans are in compliance. HDHPs are exempt from the requirement since they are deductible, and coinsurance based.

Limiting Out-of-Pocket Expenses for Insulin

Bill S.296⁴, an act relating to limiting out-of-pocket expenses for prescription insulin drugs, was introduced and passed by the senate in 2020. This act limits a member's total out-of-pocket responsibility to \$100 per 30-day supply for insulin prescriptions, regardless of the amount, type, or number of insulin medications prescribed for the beneficiary. This change cannot be accommodated by the Federal AVC as it does not allow for separate cost-sharing inputs for insulin drugs. These prescriptions would be included with non-insulin prescriptions in the data underlying the AVC. Therefore, we reviewed utilization, costs, and member cost sharing for insulin prescriptions for issuers in Vermont Health Connect to determine the impact of this limit. We have not adjusted the AVs reflected here for this change. However, we did confirm that all plan designs will continue to be within the required de minimis range for 2025. Additional information on the methodology used to determine the impact on AV is included in the Methodology section below.

Addition of Hearing Aid Coverage to EHBs

The Vermont EHBs were expanded for the 2024 year to include one set of prescription hearing aids every three years as well as annual hearing exams.⁵ The cost sharing for these benefits is

https://legislature.vermont.gov/Documents/2018.1/Docs/ACTS/ACT007/ACT007%20As%20Enacted.pdf

⁴ https://legislature.vermont.gov/bill/status/2020/S.296

⁵https://governor.vermont.gov/press-release/federal-government-approves-expanded-coverage-vermont%E2%80%99s-essential-health-benefits



to be standardized such that the hearing aids are covered with the same cost sharing as durable medical equipment (DME), and the annual exam is covered the same as a specialist office visit. This was determined to not impact actuarial values sufficiently to warrant an adjustment, but we continue to recommend issuers add an explicit line for DME (which aligns with Outpatient Coinsurance) to assist in transparency.

Actuarial Value Considerations

A summary of Vermont's standard plan designs is in Appendix E. Five of the standard plan designs (and the cost-sharing reduction plan designs) have features not supported by the AVC and thus an actuarial certification is required. The remaining standard plan designs have features that may warrant an AV adjustment, but no explicit adjustment or actuarial certification has been done for these plans. In developing these standard plan designs and the resulting actuarial certification, Wakely also followed applicable Actuarial Standards of Practice (ASOP) as detailed in Appendix D and including:

- ASOP No. 23 Data Quality;
- ASOP No. 25 Credibility Procedures;
- ASOP No. 41 Actuarial Communications;
- ASOP No. 50 Determining Minimum Value and Actuarial Value under the Affordable Care Act; and
- ASOP No. 56 Modeling.

Both Silver plans and all three Bronze plans have design features that are both significant and not supported by the AVC. The Silver cost-sharing reduction plan designs have similar features. While most plans have some subtleties in their design that are not supported by the AVC, CCIIO has stated and regulations dictate that modifications should be made only for substantial differences. The five potential substantial differences that Wakely considered include:

 Family deductible and MOOPs. There are two common types of applications for deductibles and MOOPs, commonly referred to in Vermont as stacked and aggregate.⁶
 The data supporting the AVC is only at the member level, and thus most closely resembles

⁶ Stacked deductibles and MOOPs are typical in traditional deductible plans where the individual deductible and MOOP apply to each member of a contract and the family deductible and MOOP is used as a protection for contracts where multiple members have claims. For example, if the family MOOP is two times the individual MOOP but three members of a contract all would have reached their individual MOOP, it limits the family's liability to two times the individual MOOP.

Aggregate deductible and MOOPs are typical in HDHPs where all claims for all members of a non-single contract accumulate to the family deductible and MOOP. For two person or family contracts where only one member has significant claims, the member still must reach the higher deductible and MOOP amounts which makes the average member liability higher under an aggregate deductible.



the stacked application of deductibles and MOOPs, although the family stacked AV will be higher in most instances. Most HDHPs use the aggregate application of deductible and MOOPs, which can significantly lower the AV since a family of two would need to accumulate to a deductible that is twice that of a single contract. Note that if the family MOOP is more than the 2025 single limit of \$9,200, the MOOP must either be stacked or there must be an embedded individual MOOP of \$9,200. Wakely developed a model to account for aggregate family deductibles and has modified this model to account for stacked and embedded MOOPs for HDHPs. Thus, a specific adjustment has been made to the appropriate AVs for HDHPs.

• Vermont implemented a statute (H.559 Sec. 32. 8 V.S.A. § 4089) for prescription drug deductibles and MOOPs. The requirement mandates, in part, that the MOOP for prescription drug costs in any plan design shall not exceed the minimum deductible amount for HDHPs per Section 223(c)(2)(A)(i) of the Internal Revenue Code of 1986 (projected at \$1,650 and \$3,300 for individual and family coverage in 2025). The requirement also states that for HDHPs the cost sharing benefit for prescription drugs must start after the minimum deductible amount for HDHPs (same \$1,650 and \$3,300 for individual and family coverage in 2025) is met, but the amount may be met with either medical or prescription drug claims. This means that for all HDHPs, for purposes of prescription drug coverage, the deductible is considered met when accumulated medical and drug claims reach \$1,650 for individual or \$3,300 for family, regardless of what the medical deductible amount is. Similarly, the MOOP for only drug claims (including amounts used to accumulate to the deductible) is \$1,650 or \$3,500, regardless of the amount of the overall MOOP which will include both drug and medical claims.

Since for an integrated deductible and MOOP, only one amount is able to be input in the AVC, the value of the lower drug deductible and MOOP cannot be modeled in the AVC. This statute has a significant impact on AV, particularly at the lower AV tiers where the difference between the medical and prescription drug deductible and MOOP is greater. Wakely has developed a model to account for Vermont's prescription drug regulation and thus, where appropriate, a specific adjustment has been made to the AVs using this model.

• The 2025 plan designs for all plans except the HDHPs and the Bronze Deductible plan with Pharmacy Limit include three free PCP or MH/SA office visits prior to application of member cost sharing. The AVC allows an input to begin primary care cost sharing after a set number of visits. However, the plan designs for 2025 include a combination of PCP and/or MH/SA office visits to ensure compliance with the requirements of the Mental Health Parity and Addiction Equity Act (MHPAEA). Since the AVC does not allow input for a number of free MH/SA visits, an adjustment to the output of the calculator is necessary. Therefore, we reviewed utilization of PCP and MH/SA office visits to determine the impact of the free visits. This review found that the impact was negligible for Platinum and Gold plans, as well as the CSR 87% and 94% plans, and therefore no adjustment was made for these plans. The impact to the Silver and Bronze without pharmacy limit plans and was



worth up to 0.1%. Therefore, a specific adjustment has been made to the AVs for those plans.

• In the current market, most Vermont HDHPs waive the deductible for preventive prescription drugs. This is another plan feature not currently supported by the AVC. Wakely has not analyzed the exact portion of drugs this represents, and this may vary by issuer. The impact to AV would only apply to drug costs that would normally be incurred prior to the member reaching the deductible. Any costs after the deductible and MOOP are met would be similar to the AVC. It is possible that this design feature could have a significant impact on the AV. Based on high-level estimates, Wakely believes the impact to AV for this design feature is likely around 0.5%. Since Wakely did not quantify the exact adjustment of the preventive drug difference for HDHPs, Wakely did not make a specific adjustment but did make sure that any AVs developed for HDHPs were at least 0.5% below the high end of the de minimis range in order to account for this increased benefit. It is expected that the impact for these drugs would be highest for the Bronze plan where the deductible is highest, and the impact would decrease as deductibles decrease (and AVs increase).

Given the issuers now have credible data on the portion of claims that are preventive prescription drugs, we requested that they review the appropriateness of this adjustment for the 2024 plan designs. Both issuers indicated that 0.5% was adequate and appropriate. Wakely is relying on the issuer's assessment and continues to make sure that any AVs developed for HDHPs are at least 0.5% below the high end of the de minimis range to account for this increased benefit.

• Bill S.296, an act relating to limiting out-of-pocket expenses for prescription insulin drugs. This act limits a member's total out-of-pocket responsibility to \$100 per 30-day supply for insulin prescriptions, regardless of the amount, type, or number of insulin medications prescribed for the beneficiary. This change cannot be accommodated by the Federal AVC as it does not allow for separate cost sharing inputs for insulin drugs. These prescriptions would be included with non-insulin prescriptions in the data underlying the AVC. Therefore, we reviewed utilization, costs, and member cost sharing for insulin prescriptions for issuers in Vermont Health Connect to determine the impact of this limit. This review found that the impact was negligible for Platinum, Gold, and Silver plans and was worth up to 0.1% for Bronze plans.

Wakely did not make a specific adjustment for this requirement but did make sure that any AVs developed for Bronze plans were at least 0.1% below the high end of the de minimis range in order to account for this increased benefit. No adjustments were made to the de minimis range for the other metal levels. Additional information on the methodology used to determine the impact on AV is included in the Methodology section below.



There are other potential design features for which adjustments could be made. However, given the expectation that adjustments be made for only the most substantive deviations, Wakely does not believe additional adjustments are warranted. It is also important to note that the bucketing of claims and the methodology used to calculate the AVC are not always clearly defined. Thus, at times it is difficult to ascertain whether an adjustment is warranted and how that adjustment would be estimated.

As stated, Wakely made explicit adjustments to account for the stacked and aggregate family deductible/MOOP, the three free PCP and MH/SA office visits, and Vermont's prescription drug regulation. These adjustments are described in detail in the Methodology section. For the preventive prescription drug benefits, Wakely did not make an explicit adjustment but did allow cushion in the AV such that an increase of up to 0.5% would not result in the AV falling outside of the required range. For the insulin limitations on cost sharing, Wakely did not make an explicit adjustment but did allow cushion in the Bronze AVs such that an increase of up to an additional 0.1% would not result in the AV falling outside of the required range. The table below shows the acceptable range for each standard plan design after accounting for this cushion where an explicit adjustment was not made.

Table 1: Adjusted Acceptable Federal Actuarial Values

	Plan	Acceptable Range ¹	Final Adjusted AV
	Platinum	88.0%-92.0%	90.0%
	Gold	78.0%-82.0%	81.0%
Deductible Plans	Silver	70.0%-72.0%	71.0%
	Bronze (with drug limit)	58.0%-64.9%	61.8%
	Bronze (without drug limit)	58.0%-64.9%	64.6%
	Silver - Embedded OOPM ⁷	70.0%-71.5%	70.9%
HDHPs	Bronze - Embedded OOPM	58.0%-64.4%	62.1%
	250-300% FPL (73% AV)	73.0%-74.0%	73.9%
Cost Sharing Reduction	` ,		
Plan Designs -	200-250% FPL (77% AV)	77.0%-78.0%	78.0%
Deductible Plans	150-200% FPL (87% AV)	87.0%-88.0%	87.8%
	133-150% FPL (94% AV)	94.0%-95.0%	94.8%
	250-300% FPL (73% AV)	73.0%-73.5%	73.4%
Cost Sharing Reduction	200-250% FPL (77% AV)	77.0%-77.5%	77.5%
Plan Designs - HDHPs	150-200% FPL (87% AV)	87.0%-87.5%	87.2%
	133-150% FPL (94% AV)	94.0%-94.5%	94.4%

¹ Based on revised de minimis ranges in the draft 2025 NBPP

The table in Appendix F shows all plan designs for which adjustments were made, the adjustments considered, the original AV from the AVC, and the final adjusted AV.

⁷ Out of pocket maximum (OOPM) and MOOP are used interchangeably in this report



Methodology

Since several of the standard plan designs have features not supported by the AVC, Wakely developed a model to capture the impact of these features on the AV. It was anticipated that the AVC would not accommodate all of the Vermont plan design features.

If a plan has substantive differences from what the AVC allows, there are two allowed approaches defined in the federal regulations. The first allows the actuary to adjust the inputs of the plan design to "fit" it into the AVC. The second allows the actuary to put in as many of the design features as possible into the AVC and then adjust the resulting AV to account for the unique design features. Wakely determined the second approach was most appropriate for the Vermont plan design differences. Thus, for the plan designs where adjustments were made, Wakely first input as much of the plan design as possible into the AVC and then modified the resulting AV to account for the unique features.

The following discusses the model that Wakely developed and the process used to adjust the actuarial values from the AVC.

Vermont-Specific Adjustment Model

Anticipating the need to quantify some of Vermont's unique plan design features, Wakely developed a model that would account for both aggregate deductibles and MOOPs as well as quantify the impact of Vermont's prescription drug regulation. This model is updated every few years to capture recent Vermont-specific data. The current model was updated during the 2024 plan design cycle and includes Vermont-specific ACA data incurred in 2019. While 2020 data was available at the time of the update, given the COVID impact on claims for that year, it was decided that 2019 data would be a better dataset to use. This model will be updated in future years with more recent data as needed.

In developing the model, Wakely was provided with membership and medical and pharmacy claims data extracts from the Vermont Healthcare Claims Uniform Reporting and Evaluation System (VHCURES). Filters were then applied to the data to target the most appropriate population for the model and reduce the number of records included. The data used included:

- Small group and individual ACA markets
- Allowed medical and prescription drug data that was incurred in 2019
- Product types HMO (non-Medicare risk), PPO, POS and EPO
- Excluded claims marked as denied, out-of-state, and duplicates



The methodology developed for the model does not use the traditional approach of continuance tables. When determining the paid claims and resulting actuarial value of the plan designs where the prescription drug regulation is a factor, the order in which the claims occur is important. Continuance tables fail to recognize the impact of the order of the claims on actuarial values. Thus, the model re-prices the claims based on the inputs provided in the model rather than rely on continuance tables.

The model allows a user to enter the following:

- Medical and Prescription drug deductible amounts for both individual and family contracts.
 These amounts can differ but the model assumes the amounts are always integrated, or that both medical and drug claims will accumulate to both deductibles, even if different amounts.
- Medical and prescription drug maximum out of pocket amounts for both individual and family contracts. These amounts can differ and the model allows for different treatment of the MOOPs as noted below.
- Medical and prescription drug coinsurance amounts. If the plan design includes copays, an effective coinsurance needs to be input.
- The structure of the deductibles and MOOPs. As can be seen in the table below, the model can distinguish between aggregate and stacked deductibles and MOOPs. It also allows for different accumulations of claims to the medical and prescription drug MOOPs. There are six structural selections available in the model, described in the table below. Option 5 is most closely aligned to the federal AVC. Option 6 represents the design of the Vermont HDHPs.



Table 2: Model Structures

Options	C Deductible	Deductible / MOOP Type		
		Medical	Rx	
1	Medical & Rx	Medical & Rx	Rx Only	Aggregate
2	Medical & Rx	Medical & Rx	Rx Only	Stacked
3	Medical & Rx	Medical Only	Rx Only	Aggregate
4	Medical & Rx	Medical Only	Rx Only	Stacked
5	Medical & Rx	Medical & Rx	Medical & Rx	Stacked
6	Medical & Rx	Medical & Rx	Rx Only	Aggregate Deductible /Aggregate MOOP with Embedded Ind MOOP (can also be used for Stacked MOOP)

Adjusted AV Calculations

Using the federal AV calculator and the model as outlined above, the following methodology was used to develop the adjusted AV calculations for the HDHPs:

- The plan designs were entered into the AVC ignoring the separate prescription drug deductible and MOOP thresholds. The resulting AV is the unadjusted value, which does not account for the prescription drug regulations or the aggregate family deductible and MOOP levels.
- The model was used to determine the revised AV.
- 3. The same plan design input into the AVC was input into the model. The model only allows for coinsurance. Since the HDHP designs include copays and/or different coinsurance amounts, an effective coinsurance was developed for each plan design. The effective coinsurance amounts were developed separately for medical and prescription drug services using the allowed weights and average cost per service from the federal AVC continuance tables for the relevant metal tier.
- 4. The model was normalized to the AVC for each plan design. This means the same plan design, ignoring the prescription drug thresholds and assuming a stacked family deductible and MOOP, was input into the model and the underlying data was adjusted to arrive at the same AV as the AVC. This was done to ensure the same starting AV in both models and to try to mirror the induced utilization in the AVC. The normalization factors were reviewed for reasonability and deemed reasonable given they are accounting for trend, regional differences in cost and utilization and induced utilization.



- 5. The plan design in the model was adjusted to lower the prescription drug deductible and MOOP inputs (if applicable) to the appropriate plan design amounts and also to adjust the prescription drug MOOP to only consider prescription drug claims (the medical MOOP amount continues to use both medical and prescription drug claims). The application of deductible and MOOP was also changed to use an aggregate family deductible and family MOOP with an embedded individual MOOP equal to \$9,200.
- 6. The resulting AV from the model is used as the final AV for tier placement.

The model was intended only for HDHPs where medical and drug claims both accumulate to the deductible. The Bronze plan with the pharmacy limit⁸ and Silver deductible plans (and associated CSR plans) need to be adjusted to account for the lower prescription drug MOOP, but the deductible plan has separate medical and drug deductibles. Thus, the model was used but with a slight variation in methodology. The following highlight the differences in methodology used only for the Bronze and Silver Deductible plans.

- 1. Same as for HDHPs, as much of the plan design as possible was entered into the AVC. This is the unadjusted AV. The Bronze and Silver Deductible plans then need to be adjusted for the lower and separate prescription drug MOOP.
- 2. The model was used to develop the AV adjustments in a slightly different process than for the HDHPs.
 - a. Instead of normalizing the model to the AVC, the normalization factor for the Bronze or Silver HDHP was used.
 - b. The model cannot accommodate plan designs where both medical and drug claims do not accumulate to the deductible. Thus, the same plan design was entered into the model as in the AVC but the model selection indicated that both medical and drug claims accumulated to the deductible amounts.
 - c. The model was then re-run with the lower drug MOOP and to adjust the prescription drug MOOP to only consider prescription drug claims (the medical MOOP amount continues to use both medical and prescription drug claims). The model continued to use a stacked application for deductible and MOOP since it is a traditional deductible plan.
- 3. The final AV is the ratio of the AV from 2c and 2b applied to the AV from the AVC in 1.

⁸ Only the Bronze plan with the pharmacy limit needs to be adjusted. The Bronze plan without the pharmacy limit is not subject to the lower prescription drug MOOP and as such does not require an explicit adjustment to the AVC results.



Mental Health/Substance Abuse Office Limits with \$0 Cost Sharing

The 2025 plan designs for all plans except the Bronze Deductible plan with Pharmacy Limit and HDHPs include three free PCP or MH/SA office visits prior to application of member cost sharing. The AVC allows an input to begin primary care cost sharing after a set number of visits. However, the plan designs for 2025 include a combination of PCP and/or MH/SA office visits to ensure compliance with the requirements of the Mental Health Parity and Addiction Equity Act (MHPAEA). Since the AVC does not allow input for a number of free MH/SA visits, an adjustment to the output of the calculator is necessary. The table below reflects the adjustment made to each of the standard plan designs.

Table 3: Estimated Impact of 3 Free PCP and/or MH/SA Visits

Metal	Increase to AV
Silver Deductible	1.001
Bronze Deductible w/o Pharmacy Limit	1.001
Silver Deductible CSR – 73%	1.001
Silver Deductible CSR – 77%	1.001

The impact was also calculated for the Platinum, Gold, 87% Silver CSR, and 94% Silver CSR plans but given the lower copays, the impact the determined to be negligible. The following methodology was used to develop the impacts.

- Wakely developed a continuance table based on the number of office visits a member incurred in the year. Wakely utilized similar VHCURES data as described above, except the data reflects claims incurred in the 2018 calendar year. The same filters were applied as described above and the summary reflects the experience of almost 900,000 member months.
- Wakely identified PCP and MH/SA office visits based primarily on a list of CPT codes. It was assumed that only the PCP and MH/SA office visit payments would be subject to the first 3 free visits. Specifically, we assumed that for any other services that may have the same cost sharing as PCP and MH/SA office visits, the reduced cost sharing would not apply (i.e., no changes for cost sharing for these services). Consistent with the AV Calculator, we also did not include other services that may happen in conjunction with an office visit (e.g. lab work) in our AV adjustment. It is our understanding that only the office visit copay would be waved and any copays for additional services incurred at the same time may still apply (e.g. copay stacking) based on the carrier's adjudication practices.
- Two separate continuance tables were developed. The first reflects only claims identified
 as a PCP office visit and is consistent with the methodology of the AVC. The second is a
 combination of both PCP and MH/SA visits.



- Based on the continuance tables, the cost share and paid claim amounts were calculated, assuming no member cost sharing applies for the first 3 visits. The difference between the paid amounts calculated utilizing the PCP only continuance table and PCP and MH/SA combined tables reflects the adjustment made to the AVC outputs.
- Two AVs were calculated. The first was based on the unadjusted high level allowed and paid costs of the VHCURES data. This was done in total including both medical and pharmacy claims. The second, adjusted AV, added the additional paid costs from step 2 to the high level total paid claim amounts. The ratio of the two AVs is the increase applied to the federal AV. This was done separately for each standard plan design.

Appendix G includes screen shots from the AVC and the model for each plan design with an adjusted actuarial value. Also included is a summary of the AVs and in the instance of the Bronze and Silver Deductible plans, a calculation of the adjustment.

Insulin Out-of-Pocket Limit

As mentioned above, a bill has been introduced that would limit a member's total out-of-pocket responsibility to \$100 per 30-day supply for insulin prescriptions. The AVs reflected here have not been adjusted for this requirement. However, we did review the impact of the requirement and determined that all plan designs presented here would continue to meet the de minimis requirements.

Since insulin drugs only represent a portion of the claims in a given drug tier and only one input can be made in the AVC for each drug tier, the value of the cost sharing limit cannot be modeled in the AVC. This statute has a larger impact on AV at the lower AV tiers where the drug deductibles are higher. The estimated impact by metal tier is shown in the table below.

Table 4: Estimated Impact of Insulin Out-of-Pocket Limit

Metal	Increase to AV
Bronze	0.1%
Silver	0.0%
Gold	0.0%
Platinum	0.0%

The following methodology was used to develop the impacts:

 Both carriers, BCBS VT and MVP, provided claim-level data for insulin prescriptions based on their individual and small group experience in Vermont in 2019 and 2020. The data included metal tier, allowed and paid costs, days' supply, and member cost sharing. Each carrier also provided high-level market information for 2019 and 2020, including metal tier, member months, and total allowed and paid costs for medical and pharmacy.



- Based on the claim-level data, the cost share and paid claim amounts were recalculated, assuming a limit of \$100 per prescription for a 30-day supply. The difference between the cost sharing in the experience data and the new cost sharing incorporating the limit was added to the paid claim costs.
- Two AVs were calculated. The first based on the unadjusted high level allowed and paid costs. This was done in total including both medical and pharmacy claims. The second, adjusted AV, added the additional paid costs from step 2 to the high level total paid claim amounts. The difference in AV between these two is the increase to AV. This was done separately for each metal level.

Based on this analysis, the impact on all metal levels except Bronze is negligible. For the Bronze plans, all plan designs presented here are more than 0.1% below the high end of the de minimis range, therefore, will continue to be within the range.

Disclosures and Limitations

Responsible Actuary. Julie Peper and Darren Johnson are the actuaries responsible for this communication. Julie and Darren are both Members of the American Academy of Actuaries and a Fellows of the Society of Actuaries. Both meet the Qualification Standards of the American Academy of Actuaries to issue this report. Jared Asprer also contributed significantly to this report.

Intended Users. This information has been prepared for the sole use of the State of Vermont and issuers within that state that will be submitting standard plan designs. Distribution to such parties should be made in its entirety. This report cannot be distributed to or relied on by any third party without the prior written permission of Wakely.

Risks and Uncertainties. The assumptions and resulting estimates included in this report and produced by the model are inherently uncertain. Users of the results should be qualified to use it and understand the results and the inherent uncertainty. Actual results may vary, potentially materially, from our estimates. Wakely does not warrant or guarantee that actual experience will tie to the AV estimated for the placement of plan designs into tiers. The developed actuarial values are for the purposes of classifying plan designs of similar value and do not represent the expected actuarial value of a plan or pricing AV used to determine premium rates. Actual AVs will vary based on a plan's specific population, utilization, unit cost, and other variables.

Conflict of Interest. Wakely provides actuarial services to a variety of clients throughout the health industry. Our clients include commercial, Medicare, and Medicaid health plans, the federal government and state governments, medical providers, and other entities that operate in the domestic and international health insurance markets. Wakely has implemented various internal practices to reduce or eliminate conflict of interest risk in serving our various clients. Except as noted here, the responsible actuaries are financially independent and free from conflict



concerning all matters related to performing the actuarial services underlying this analysis. In addition, Wakely is organizationally and financially independent to the state of Vermont.

Data and Reliance. We have relied on others for data and information used in the actuarial value adjustments. We have reviewed the data for reasonableness but have not performed any independent audit or otherwise verified the accuracy of the data/information. If the underlying information is incomplete or inaccurate, our estimates may be impacted, potentially significantly. Below is a list of data and assumptions provided by others and assumptions required by law.

- The draft 2025 Federal AVC Model was relied on for the original AV. While reasonability
 tests have shown there are some assumptions and methodologies that are not consistent
 with expectations, the AVC was developed for plan classification and not pricing. Thus,
 the model is being used as such and we make no warranties for the accuracy of the AVs
 that result from the AVC.
- VHCURES data supplied by the state was used in the development of the HDHP model.
- Adjustment to the high-end of the de minimis AV range for HDHPs to account for prescription drugs for which the deductible is waived. This was reviewed by both issuers, BCBS VT and MVP, based on their internal experience and claims data.
- Insulin prescription claim experience. This was provided by both issuers, BCBS VT and MVP, based on their internal experience and claims data.
- Mercer's projections of the likely federal HDHP minimum deductible and MOOP limits.⁹

Subsequent Events. There are no known relevant events subsequent to the date of information received that would impact the results of this report, other than those discussed in the report and below.

- The federal HDHP minimum deductible and MOOP limits are anticipated to be \$1,650 and \$8,250, respectively, for 2025, based on Mercer's early projections. The 2024 minimum deductible and MOOP are \$1,600 and \$8,050, respectively. We performed the plan modelling in this certification using the projected amounts, but should the minimum deductible differ when the limits are released, changes may be required to both HDHPs (and corresponding Silver CSR HDHPs).
- The 2025 Notice of Benefits and Payment Parameters (NBPP) is still in draft form. The
 plan designs presented are compliant with the 2025 draft NBPP and may need to change
 if there are differences between the draft and final versions.

⁹ Mercer projects 2025 HSA, HDHP and excepted-benefit HRA figures



- The 2025 Federal AVC Model is also still in draft form. The plan designs presented are compliant with the 2025 draft Federal AVC and may need to change if there are changes to the final model from the draft version.
- Other changes to regulations passed subsequent to this report.

Contents of Actuarial Report. This document and the supporting exhibits constitute the entirety of actuarial report and supersede any previous communications on the project.

Deviations from ASOPS. Wakely completed the analysis using sound actuarial practice. To the best of my knowledge, the report and methods used in the analysis are in compliance with the appropriate Actuarial Standards of Practice (ASOP) with no known deviations. A summary of ASOP compliance is listed in Exhibit D.

Exhibit A contains the formal actuarial certification. If you have any questions regarding this letter or the certification, please contact us.



Appendix A: Actuarial Certification

Actuarial Certification State of Vermont Actuarial Value of Standard Plan Designs Effective January 1, 2025

I, Darren Johnson, am associated with the firm of Wakely Consulting Group, LLC (Wakely), an HMA company, am a Fellow of the Society of Actuaries and a member of the American Academy of Actuaries and meet its Qualification Standards for Statements of Actuarial Opinion. Wakely was retained by the State of Vermont to provide a certification of the actuarial value of the state's standard plan designs that are effective January 1, 2025, on Vermont Health Connect. This certification may not be appropriate for other purposes.

To the best of my information, knowledge and belief, the actuarial values provided with this certification are considered actuarially sound for purposes of § 156.135(b), according to the following criteria:

- The 2025 federal Actuarial Value Calculator was used to determine the AV for the plan provisions that fit within the calculator parameters;
- Appropriate adjustments were calculated, to the AV identified by the calculator, for plan design features that deviate substantially from the parameters of the AV calculator;
- The actuarial values have been developed in accordance with generally accepted actuarial principles and practices; and
- The actuarial values meet the requirements of § 156.135(b).

The assumptions and methodology used to develop the actuarial values have been documented in my correspondence with the State of Vermont. The actuarial values associated with this certification are for standard plan designs (Silver HDHP, Bronze HDHP, Bronze Deductible with Pharmacy Limit, Bronze Deductible without Pharmacy Limit, Silver Deductible, Silver HDHP CSR 73%, Silver HDHP CSR 77%, Silver HDHP CSR 87%, Silver HDHP CSR 94%, Silver Deductible CSR 73%, Silver Deductible CSR 77%, Silver Deductible CSR 87%, and Silver Deductible CSR 94%) that will be effective as of January 1, 2025 for individual and group coverage sold on Vermont Health Connect.

The developed actuarial values are for the purposes of classifying plan designs of similar value and do not represent the expected actuarial value of a plan. Actual AVs will vary based on a plan's specific population, utilization, unit cost and other variables.

In developing the actuarial values, I have relied upon the federal Actuarial Value calculator and data from the Vermont Healthcare Claims Uniform Reporting and Evaluation System



(VHCURES). I did not audit the data provided; however, I did review the data for reasonableness and consistency.

Actuarial methods, considerations, and analyses used in forming my opinion conform to the appropriate Standards of Practice as promulgated from time-to-time by the Actuarial Standards Board, whose standards form the basis of this Statement of Opinion.

Darren Fohnson

Darren Johnson, FSA, MAAA February 29, 2024



Appendix B: Summary of Plan Design Changes from 2024 Designs

Deductible Plans						
Platinum	Gold					
Increase pharmacy MOOP from \$1,500 to \$1,600	Increase pharmacy MOOP from \$1,500 to \$1,600					
Increase medical MOOP from \$1,500 to \$1,600	Leave medical MOOP at \$5,600					
Silver	Bronze w/ Rx Limit					
Decrease medical deductible from \$4,000 to \$3,500	Decrease medical MOOP from \$9,450 to \$9,200					
Decrease medical MOOP from \$9,300 to \$9,200	Increase pharmacy MOOP from \$1,500 to \$1,600					
Increased pharmacy MOOP from \$1,500 to \$1,600	Decrease generic Rx copay from \$20 to \$15					
Decrease generic Rx copay from \$20 to \$15						
Decrease ER copay from \$500 to \$250						
Bronze w/o Rx Limit						
Decrease medical deductible from \$9,400 to \$9,200						
Decrease medical MOOP from \$9,400 to \$9,200						
Decrease generic pharmacy copy from \$30 to \$25						

HDHPs HDHPs								
Silver - Embedded MOOP	Bronze - Embedded MOOP							
Decrease embedded single MOOP from \$9,450 to \$9,200	Decrease embedded single MOOP from \$9,450 to \$9,200							
Decrease PCP Office visit coinsurance from 15% to 10%	Decreased combined MOOP from \$7,200 to \$7,100							
Decrease MH/SA Office visit coinsurance from 15% to 10%								
Leave medical MOOP at \$7,050								



Appendix C: On and Off-Exchange Reflective Silver Standard Plan Designs

	2025 Plan Designs – S	ilver Deductible Plan	2025 Plan Designs – Silver HDHP			
Deductible/OOP Max	On the Exchange	Off the Exchange	On the Exchange	Off the Exchange		
Type of Plan	Deductible	Deductible	HSA Q/HDHP	HSA Q/HDHP		
Medical Ded	\$3,500	\$3,500	\$2,100	\$2,100		
Pharmacy Ded	\$500	\$500	\$1,600	\$1,600		
Integrated Ded	No	No	Yes	Yes		
Medical OOPM	\$9,200	\$9,200	\$7,050	\$7,050		
Pharmacy OOPM	\$1,600	\$1,600	\$1,600	\$1,600		
Integrated OOPM	Pharmacy -No, Medical - Yes	Pharmacy -No, Medical - Yes	Yes	Yes		
Family Deductible / OOP	Stacked, 2x Individual	Stacked, 2x Individual	Aggregate with Combined Medical/Pharmacy embedded \$9,200 Single OOPM; 2x Individual	Aggregate with Combined Medical/Pharmacy embedded \$9,200 Single OOPM; 2x Individual		
Medical Deductible waived for:	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Preventive	Preventive		
Drug Deductible waived for:	Generic scripts	Generic scripts	Wellness scripts	Wellness scripts		
Service Category	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance		
Inpatient	50%	50%	35%	35%		
Outpatient	50%	50%	35%	35%		
ER	\$250	\$250	35%	35%		
Radiology (MRI, CT, PET)	50%	50%	35%	35%		
Preventive	\$0	\$0	0%	0%		
PCP Office Visit	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$40	10%	10%		
MH/SA Office Visit	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$40	10%	10%		
Specialist Office Visit	\$90	\$90	35%	35%		
Physical Therapy/Chiropractic	\$50	\$50	35%	35%		
Urgent Care	\$100	\$100	35%	35%		
Ambulance	\$100	\$105	35%	40%		
Pharmacy Generic	\$15	\$15	\$10	\$10		
Pharmacy Preferred Brand	\$70	\$70	\$40	\$40		
Pharmacy Non-Preferred Brand	50%	50%	50%	50%		
Pharmacy Specialty	50%	50%	50%	50%		
Actuarial Value						
2025 DRAFT Federal AVC, Adjusted if Necessary	71.0%	71.0%	70.9%	70.9%		



Appendix D: Comments Relative to Applicable ASOPs

This appendix includes comments relative to the following applicable Actuarial Standards of Practice (ASOP).

- ASOP No. 23, Data Quality;
- ASOP No. 25, Credibility Procedures;
- ASOP No. 41, Actuarial Communications; and
- ASOP No. 50 Determining Minimum Value and Actuarial Value under the Affordable Care Act.
- ASOP No. 56 Modeling

ASOP 23: DATA QUALITY

- <u>3.1 Overview</u> VHCURES data was used as the basis for the HDHP model and Vermont-specific insulin prescription data was used as the basis for the insulin limit impact. This data source was deemed reasonable for the analysis discussed in the management report.
- 3.2 Selection of Data The data was considered reasonable for our analysis subject to the following considerations
 - a. The data sources contained all material data elements.
 - b. The following considerations were reviewed as part of our analysis:
 - 1. Data was appropriate and sufficiently current.
 - 2. Data was reasonable and comprehensive of the necessary data elements.
 - 3. There were no known, material limitations of the data.
 - 4. No alternative data sets were reasonably available. The reliability of the data underlying our analysis did not require support from alternative data sets.
 - 5. Alternative data sets were not deemed necessary to complete the analysis.
 - 6. Sampling methods were not required.
- <u>3.3 Reliance on Data Supplied by Others</u> Reliance is discussed in the management report to which this appendix is attached.



- <u>3.4 Reliance on Other Information Relevant to the Use of Data</u> We relied on information contained in the report. We did not detect any material errors in the data provided and relied upon the data as part of our analysis.
- <u>3.5 Review of Data</u> We reviewed the data. Data definitions were included as part of the VHCURES data. Ultimately the data was reasonable with the adjustments discussed in our management report.
- 3.6 Limitation of the Actuary's Responsibility We did not audit the data.
- <u>3.7 Use of Data</u>– Use and adjustments to the data are discussed in this management report. In addition:
 - a. We deem that the data are of sufficient quality to perform the analysis;
 - b. The data did not require enhancement before the analysis could be performed
 - c. The data was reasonable for the analysis and did not require adjustment beyond that discussed in the management report;
 - d. We did not detect any material defects in any data source;
 - e. The data were adequate to perform our analysis.

ASOP 25: CREDIBILITY PROCEDURES

The HDHP model uses data as its starting point. The experience used is fully credible and therefore no credibility blending or adjustments were necessary.

ASOP 41: ACTUARIAL COMMUNICATIONS

This report and the actuarial memorandum submitted are consistent with the guidance in ASOP 41.

3.1 General Requirements for Actuarial Communications

- 3.1.1 Principal and Scope of Engagement These results were developed to comply with § 156.135(b) and should not be used for any other purpose. The distribution of this report to other users is limited to the State of Vermont
- <u>3.1.2 Form and Content</u> The State of Vermont was the principal for this engagement and the scope of the engagement included developing and certifying the actuarial values for the standard plan designs as discussed in the management report.
- <u>3.1.3 Timing of Communication</u> This report is provided in conjunction with the actuarial certification of the submitted actuarial values.



- 3.1.4 Identification of Responsible Actuary The responsible actuary is identified in the attestation and this management report.
- <u>3.2 Actuarial Report</u> This management report is an Actuarial Report as defined in this ASOP. Correspondence between Wakely and the State of Vermont as part of this engagement should also be considered part of the Actuarial Report.
- <u>3.3 Specific Circumstances</u> No constraints apply beyond any discussed in the attachment management report.
- <u>3.4 Disclosures Within an Actuarial Report</u> all relevant disclosures have been made in the management report. Consistent with this ASOP, we make specific mention to the following items here:
 - 3.4.1 Uncertainty or Risk Uncertainty is discussed in the management report.
 - <u>3.4.2 Conflict of Interest</u> Wakely is financially, organizationally, and otherwise independent from the State of Vermont and any reliant parties.
 - <u>3.4.3 Reliance on Other Sources for Data and Other Information</u> Reliance regarding data and assumptions are discussed in this management report.
 - <u>3.4.4 Responsibility for Assumptions and Methods</u> Assumptions and methods are discussed in the management report and the parties associated with the assumptions and methods have been delineated. Therefore, pursuant to this ASOP, no additional disclosure is necessary.
 - <u>3.4.5 Information Date of Report</u> -The management report lists the applicable dates for the analysis and correspondence.
 - <u>3.4.6 Subsequent Events</u> Subsequent events are listed in the Limitations and Disclosures section.
- <u>3.5 Explanation of Material Differences</u> Wakely has issued no other report regarding the development of these actuarial values. No comparison to prior results is necessary.
- <u>3.6 Oral Communications</u> No oral communication is considered part of this actuarial report. Any material assumptions or methods discussed in oral communications have been documented in written form as well.
- <u>3.7 Responsibility to Other Users</u> Intended users of this report have been specifically noted in the document.

ASOP 50: DETERMINING MINIMUM VALUE AND ACTUARIAL VALUE UNDER THE AFFORDABLE CARE ACT

- 3.1 Use of AVC or MVC The federal AVC was used.
- <u>3.2 Exceptions to the AVC</u> The federal AV was determined by making adjustments to the results of the federal AVC based on provisions that could not be appropriate modeled in the AVC.



- 3.3 Exceptions to the MVC Not applicable.
- 3.4 Evaluating Non-Standard Plan Designs The HDHP model was normalized to the federal AVC.
- <u>3.5 Reasonableness of Assumptions for Non-Standard Plan Designs</u> The assumptions used to modify the federal AVs were reviewed for reasonability.
- 3.6 Unreasonable Results Not applicable.
- 3.7 Documentation See ASOP 41 documentation above.



Appendix E: Standard Plan Designs

Deductible Plan Designs

Deductible/OOP Max	Platinum	Gold	Silver	Bronze w/ Pharmacy Limit	Bronze w/o Pharmacy Limit
Type of Plan	Deductible	Deductible	Deductible	Deductible	Deductible
Medical Ded	\$450	\$1,400	\$3,500	\$6,450	\$9,200
Pharmacy Ded	\$0	\$200	\$500	\$1,100	N/A
Integrated Ded	No	No	No	No	Yes
Medical OOPM	\$1,600	\$5,600	\$9,200	\$9,200	\$9,200
Pharmacy OOPM	\$1,600	\$1,600	\$1,600	\$1,600	N/A
Integrated OOPM	No	No	Pharmacy -No, Medical - Yes	Pharmacy -No, Medical - Yes	Yes
Family Deductible / OOP	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual
Medical Deductible waived for:	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Preventive	Preventive, OV
Drug Deductible waived for:	N/A	Generic scripts	Generic scripts	Generic Scripts	Generic Scripts
Service Category	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance
Inpatient	10%	30%	50%	50%	0%
Outpatient	10%	30%	50%	50%	0%
ER	\$100	\$150	\$250	50%	0%
Radiology (MRI, CT, PET)	10%	30%	50%	50%	0%
Preventive	\$0	\$0	\$0	0%	0%
PCP Office Visit	First 3 Visits \$0, Then \$15	First 3 Visits \$0, Then \$20	First 3 Visits \$0, Then \$40	\$35	First 3 Visits \$0, Then \$40
MH/SA Office Visit	First 3 Visits \$0, Then \$15	First 3 Visits \$0, Then \$20	First 3 Visits \$0, Then \$40	\$35	First 3 Visits \$0, Then \$40
Specialist Office Visit	\$40	\$55	\$90	\$90	\$100
Physical Therapy/Chiropractic	\$20	\$35	\$50	\$45	\$50
Urgent Care	\$50	\$65	\$100	\$100	0%
Ambulance	\$60	\$75	\$100	\$100	0%
Pharmacy Generic	\$10	\$15	\$15	\$15	\$25
Pharmacy Preferred Brand	\$50	\$60	\$70	\$85	0%
Pharmacy Non-Preferred Brand	50%	50%	50%	60%	0%
Pharmacy Specialty	50%	50%	50%	60%	0%
Actuarial Value					
2025 Federal AVC, Adjusted if Necessary	90.0%	81.0%	71.0%	61.8%	64.6%



Deductible Plan Designs – Cost Sharing Reduction Plans

Deductible/OOP Max		• • • • • • • • • • • • • • • • • • • •			133-150% FPL (94% AV)
	2025 Plan Design	2025 Plan Design	2025 Plan Design	2025 Plan Design	2025 Plan Design
Type of Plan	Deductible	Deductible	Deductible	Deductible	Deductible
Medical Ded	\$3,500	\$3,150	\$2,950	\$1,275	\$300
Pharmacy Ded	\$500	\$450	\$350	\$250	\$0
Integrated Ded	No	No	No	No	No
Medical OOPM	\$9,200	\$6,950	\$6,350	\$2,500	\$1,100
Pharmacy OOPM	\$1,600	\$1,300	\$1,200	\$450	\$250
Integrated OOPM	Pharmacy -No, Medical - Yes	Pharmacy -No, Medical - Yes	Pharmacy -No, Medical - Yes	Pharmacy -No, Medical - Yes	Pharmacy -No, Medical - Yes
Family Deductible / OOP	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual
Medical Deductible waived for:	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb
Drug Deductible waived for:	Generic scripts	Generic scripts	Generic scripts	Generic scripts	N/A
Service Category	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance
Inpatient	50%	50%	50%	40%	10%
Outpatient	50%	50%	50%	40%	10%
ER	\$250	\$250	\$200	\$125	\$75
Radiology (MRI, CT, PET)	50%	50%	50%	40%	10%
Preventive	\$0	\$0	\$0	\$0	\$0
PCP Office Visit	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$30	First 3 Visits \$0, Then \$10	First 3 Visits \$0, Then \$5
MH/SA Office Visit	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$30	First 3 Visits \$0, Then \$10	First 3 Visits \$0, Then \$5
Specialist Office Visit	\$90	\$90	\$60	\$30	\$15
Physical Therapy/Chiropractic	\$50	\$50	\$35	\$12	\$6
Urgent Care	\$100	\$100	\$70	\$40	\$25
Ambulance	\$100	\$100	\$100	\$100	\$50
Pharmacy Generic	\$15	\$15	\$15	\$10	\$5
Pharmacy Preferred Brand	\$70	\$70	\$60	\$50	\$20
Pharmacy Non-Preferred Brand	50%	50%	50%	50%	30%
Pharmacy Specialty	50%	50%	50%	50%	30%
Actuarial Value					
2025 DRAFT Federal AVC, Adjusted if Necessary	71.0%	73.9%	78.0%	87.8%	94.8%



HDHP Plan Designs

	•	
Deductible/OOP Max	Silver	Bronze
Type of Plan	HSA Q/HDHP	HSA Q/HDHP
Medical Ded	\$2,100	\$5,800
Pharmacy Ded	\$1,650	\$1,650
Integrated Ded	Yes	Yes
Medical OOPM	\$7,050	\$7,100
Pharmacy OOPM	\$1,650	\$1,650
Integrated OOPM	Yes	Pharmacy -No, Medical - Yes
Family Deductible / OOP	Aggregate with Combined Medical/Pharmacy embedded \$9,200 Single OOPM; 2x Individual	Aggregate with Combined Medical/Pharmacy embedded \$9,200 Single OOPM; 2x Individual
Medical Deductible waived for:	Preventive	Preventive
Drug Deductible waived for:	Wellness scripts	Wellness scripts
Service Category	Copay / Coinsurance	Copay / Coinsurance
Inpatient	35%	50%
Outpatient	35%	50%
ER	35%	50%
Radiology (MRI, CT, PET)	35%	50%
Preventive	0%	0%
PCP Office Visit	10%	50%
MH/SA Office Visit	10%	50%
Specialist Office Visit	35%	50%
Physical Therapy/Chiropractic	35%	50%
Urgent Care	35%	50%
Ambulance	35%	50%
Pharmacy Generic	\$10	\$12
Pharmacy Preferred Brand	\$40	40%
Pharmacy Non-Preferred Brand	50%	60%
Pharmacy Specialty	50%	60%
Actuarial Value		



HDHP Plan Designs - Cost Sharing Reduction Plans

Deductible/OOP Max	70% AV Silver 2025 Plan Design	250-300% FPL (73% AV) 2025 Plan Design	200-250% FPL (77% AV) 2025 Plan Design	150-200% FPL (87% AV) 2025 Plan Design	133-150% FPL (94% AV) 2025 Plan Design
Type of Plan	HSA Q/HDHP	HSA Q/HDHP	HSA Q/HDHP	HSA Q/HDHP	Deductible (NOT HSAQ)
Medical Ded	\$2,100	\$1,800	\$1,800	\$1,650	\$650
Pharmacy Ded	\$1,650	\$1,650	\$1,650	N/A	N/A
Integrated Ded	Yes	Yes	Yes	Yes	Yes
Medical OOPM	\$7,050	\$5,850	\$4,700	\$1,650	\$650
Pharmacy OOPM	\$1,650	\$1,650	\$1,650	N/A	N/A
Integrated OOPM	Yes	Pharmacy -No, Medical - Yes	Pharmacy -No, Medical - Yes	Yes	Yes
Family Deductible / OOP	Aggregate with Combined Medical/Pharmacy embedded \$9,200 Single OOPM; 2x Individual	Aggregate with Combined Medical/Pharmacy embedded \$9,200 Single OOPM; 2x Individual	Aggregate with Combined Medical/Pharmacy embedded \$9,200 Single OOPM; 2x Individual	Aggregate, 2x Individual	Aggregate, 2x Individual
Medical Deductible waived for:	Preventive	Preventive	Preventive	Preventive	Preventive
Drug Deductible waived for:	Wellness scripts	Wellness scripts	Wellness scripts	Wellness scripts	Wellness scripts
Service Category	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance
Inpatient	35%	30%	30%	0%	0%
Outpatient	35%	30%	30%	0%	0%
ER	35%	30%	30%	0%	0%
Radiology (MRI, CT, PET)	35%	30%	30%	0%	0%
Preventive	0%	0%	0%	0%	0%
PCP Office Visit	10%	10%	10%	0%	0%
MH/SA Office Visit	10%	10%	10%	0%	0%
Specialist Office Visit	35%	30%	30%	0%	0%
Physical Therapy/Chiropractic	35%	30%	30%	0%	0%
Urgent Care	35%	30%	30%	0%	0%
Ambulance	35%	30%	30%	0%	0%
Pharmacy Generic	\$10	\$10	\$10	\$0	\$0
Pharmacy Preferred Brand	\$40	\$40	\$40	\$0	\$0
Pharmacy Non-Preferred Brand	50%	50%	50%	0%	0%
Pharmacy Specialty	50%	50%	50%	0%	0%
Actuarial Value					
2025 DRAFT Federal AVC, Adjusted if Necessary	70.9%	73.5%	77.5%	87.2%	94.4%



Appendix F: Summary of Adjustments Considered and Final Adjusted AVs

Adjustments Considered	Aggregate Ded	Aggregate MOOP, Embedded \$9,200	Stacked MOOP	Drug Regulation	Preventive Drugs	Insulin Cost Sharing Limit	\$0 Cost Share on PCP/MHSA Visits	AV from AVC	Final Adjusted AV
Bronze Deductible (without pharmacy limit)	No	No	No	No	No	Yes	Yes	64.6%	64.6%
Silver HDHP	Yes	Yes	No	Yes	Yes	No	No	72.9%	70.9%
Bronze HDHP	Yes	Yes	No	Yes	Yes	Yes	No	64.2%	62.1%
Silver Deductible	No	No	No	Yes	No	No	Yes	69.9%	71.0%
Bronze Deductible (with pharmacy limit)	No	No	Yes	Yes	No	Yes	No	60.9%	61.8%
Silver HDHP - CSR 73%	Yes	Yes	No	Yes	Yes	No	No	75.7%	73.5%
Silver HDHP - CSR 77%	Yes	No	No	Yes	Yes	No	No	79.5%	77.5%
Silver HDHP - CSR 87%	Yes	No	No	No	Yes	No	No	87.7%	87.2%
Silver HDHP - CSR 94%	Yes	No	No	No	Yes	No	No	94.4%	94.4%
Silver Deductible CSR - 73%	No	No	Yes	Yes	No	No	Yes	73.0%	73.9%
Silver Deductible CSR – 77%	No	No	Yes	Yes	No	No	Yes	77.1%	78.0%
Silver Deductible CSR - 87%	No	No	Yes	Yes	No	No	Yes	87.4%	87.8%
Silver Deductible CSR - 94%	No	No	Yes	Yes	No	No	Yes	94.6%	94.8%



Appendix G: Screen Shots and AV Development

- 1. Bronze Deductible Plan (without pharmacy limit)
- 2. Silver HDHP Embedded MOOP
- 3. Bronze HDHP Embedded MOOP
- 4. Silver Deductible Plan
- 5. Bronze Deductible Plan (with pharmacy limit)
- 6. Silver HDHP Embedded MOOP CSR 73%
- 7. Silver HDHP Embedded MOOP CSR 77%
- 8. Silver HDHP Embedded MOOP CSR 87%
- 9. Silver HDHP Embedded MOOP CSR 94%
- 10. Silver Deductible CSR 73%
- 11. Silver Deductible CSR 77%
- 12. Silver Deductible CSR 87%
- 13. Silver Deductible CSR 94%



BRONZE DEDUCTIBLE (WITHOUT PHARMACY LIMIT)

AV from AVC = 64.6%

Adjusted AV = 64.6% * 1.001(MH/SA Copay Adj) = 64.6%

Oser inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	✓	1	HSA/HRA Option	s	Tie	red Network Op	otion			
Apply Inpatient Copay per Day?		HSA/HRA Employ	er Contribution?	? 🗆	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?				40.00	1st T	ier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contrit	oution Amount:	\$0.00	2nd 7	ier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?							-			
Desired Metal Tier										
		1 Plan Benefit De	sign		Tier	2 Plan Benefit D	lesign			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$9,200.00				\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			100.00%				60.00%			
MOOP (\$)			\$9,200.00	+			\$8,700.00			
MOOP (5)		I	35,200.00				\$8,700.00			
WOOF II Separate (3)			ı							
Click Here for Important Instructions		Tie	r1			Tie	er 2		Tier 1	Tier 2
CHECK THE TOT THIS DISCUSSION OF THE THIS CHECK THE THE THIS CHECK THE THE THIS CHECK THE THIS CHECK THE	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to		Coinsurance, if	Copay, if	Copay applies	
Type of Benefit	Deductible?	Coinsurance?	different	separate		Coinsurance?	different		deducti	
Medical	□ All	□ All	anterent	separate	All	All	anterent	separate	☐ All	All
	✓ ×									
Emergency Room Services										
All Inpatient Hospital Services (inc. MH/SUD)	V									
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$40.00						
X-rays)	_				_					
Specialist Visit				\$100.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient				\$40.00						
Services		⊔		Ş40.00	_					
Imaging (CT/PET Scans, MRIs)	V									
Speech Therapy				\$100.00						
				ć50.00						
Occupational and Physical Therapy		ш		\$50.00						
Preventive Care/Screening/Immunization			100%							
Laboratory Outpatient and Professional Services	☑									
X-rays and Diagnostic Imaging	☑									
Skilled Nursing Facility	⊽				Ō					Ē
										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓									
Outpatient Surgery Physician/Surgical Services	✓									
Drugs	☐ All	☐ All			All	□ All			☐ All	☐ All
Generics				\$25.00						
Preferred Brand Drugs	v	ä		\$25.00		Ä				Ä
Non-Preferred Brand Drugs	V	ä			1 H	H			ö	
	Z				1 H	H			H	H
Specialty Drugs (i.e. high-cost)	V									
Options for Additional Benefit Design Limits:		1	Plan Description			_				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:		RX Limit Optio					
Specialty Rx Coinsurance Maximum:	\$0	1	Plan HIOS ID:	2025 Bronze No	RX Limit Optio	n 2				
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0									
Output										
Calculate										
Status/Error Messages:	Expanded Bronze	e Standard (58% t	o 65%), Calculatio	on Successful.						
Actuarial Value:	64.57%									
Metal Tier:	Bronze									
		ore services are n	ot subject to the	deductible and h	nave no conav	Any service wit	h this cost-sharir	ng structure is o	overed at 100% by	the plan in the
Additional Notes:									inputs for those se	
Additional Notes.	accioic idilge			12 app. 1.118 I	(5) WII			o outputient		
Coloridation Trans	4.5004									
Calculation Time:	1.5664 seconds									
Draft 2025 AV Calculator										



SILVER HDHP - EMBEDDED MOOP

AV from AVC = 72.9%

Adjusted AV = 70.9%

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	✓		HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Employ	yer Contribution?	· 🗆		Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contril	oution Amount:	\$0.00	1st 7	Tier Utilization	100%			
Use Separate MOOP for Medical and Drug Spending?		Alliluai Collulii	dution Amount.	30.00	2nd 1	Tier Utilization	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier	Silver ▼			_						
		1 Plan Benefit De				2 Plan Benefit				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$2,100.00				\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			65.00%	1			60.00%			
MOOP (\$)			\$7,050.00]			\$8,700.00			
MOOP if Separate (\$)										
Click Here for Important Instructions		Tie	-1			-	ier 2		Tier 1	Tier 2
CHECK HETE TOT IMPORTANT MISTIGLIONS	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay appli	
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?		separate		tible?
Medical	☐ All	☐ All	unierent	3c parate	All	All	unierent	Separate	□ All	All
Emergency Room Services	✓	✓								
All Inpatient Hospital Services (inc. MH/SUD)	V	V			Ō	Ō				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and			90%							
X-rays)	✓	V	90%							
Specialist Visit	V	☑								
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓	•	90%							
Services	_	_	30/6						_	
Imaging (CT/PET Scans, MRIs)	✓	₹								
Speech Therapy	V	V								
	✓	✓								П
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization			100%							_
Laboratory Outpatient and Professional Services	V	V			-					
X-rays and Diagnostic Imaging	<u> </u>	Z .								
Skilled Nursing Facility	V	V			ļ					
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
Outpatient Surgery Physician/Surgical Services	Ø	Ø								
Drugs	☐ All	☐ All			All	□ All			☐ All	All
Generics	V		"	\$10.00					V	
Preferred Brand Drugs	V			\$40.00					☑	
Non-Preferred Brand Drugs	v	✓	50%							
Specialty Drugs (i.e. high-cost)	V	☑	50%							
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Silver HDH	HP Option 2					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2025 Silver HDH	HP Option 2					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
#Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays? # Copays (1-10):	0									
	U									
Output										
Calculate Status/Error Messages:	Error: Pocultic a	steido of [2 : 2]	norcont do minim	sic variation						
Actuarial Value:	Error: Result is or 72.90%	utside 01 [-2, +2]	percent de minin	ııs vdildülli.						
Metal Tier:	12.30/0									
Wictal fiel.	NOTE: One or mo	re cenices are n	ot subject to the	deductible and b	ave no consu	Any service wi	th this cost-sharin	ia structura is s	overed at 100% by	u the plan in the
Additional Notes:	deductible range						ar ans cost-sildill	ig scructure IS U	overeu at 100% D	y are plan in the
Additional roces.					J ,					
Calculation Time:	1.4023 seconds									
Draft 2025 AV Calculator	525 5000.103									



Silver HDHP – Embedded MOOP, Continued

HDHP Model – Normalization:

ress 'Calculate' anytime an	input or dr	opdown s	election is (changed.	
Note that the model run-tir	ne will vary	based on	the comp	iters processing	speed.
A message box will appear	to indicate	that the c	alculations	are done.	
	Medical	Rx			
Individual Deductible	2,100	2,100			
Family Deductible	4,200	4,200			
Individual Out-of-Pocket	7,050	7,050			
Family Out-of-Pocket	14,100	14,100			
Coinsurance (50% or Less)	30%	36%			
	Costs	that Accun			
			OP	Deductible /	
	Deductibl		Rx	OOP Type	
Settings	Medical &	Medical &	Medical 8		
				Normalization	Factor
	Calcu	ulate			
		_			
	Medical	Rx	Total	Value to Norm	nalize To
Allowed PMPM				72.90%	
Plan PMPM					



Silver HDHP – Embedded MOOP, Continued

HDHP Model – Adjusted Actuarial Value:

	alculate' anytime an inp					down box, and press 'Calculate'.
	nat the model run-time				_	na speed.
	age box will appear to	-		•	•	.9
	- J					
		Medical	Rx			
	Individual Deductible	2,100	1,650			
	Family Deductible	4,200	3,300			
			-			
Inc	lividual Out-of-Pocket	7,050	1,650			
	Family Out-of-Pocket	14,100	3,300			
Coi	nsurance (50% or Less)	30%	36%			
		Costs	that Accun	nulate		
			00	OP [Deductible	/
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical &	Medical &	Rx Only	Aggregate	
					Normaliza	tion Factor
		Calc	ulate			
Results						
		Medical	Rx	Total	Value to N	Normalize To
	Allowed PMPM					
	Plan PMPM					
	Actuarial Value			70.78%	1.008875	



BRONZE HDHP - EMBEDDED MOOP

AV from AVC = 64.2%

Adjusted AV = 62.1%

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	•		HSA/HRA Option	•	Tie	red Network O	ntion			
Apply Inpatient Copay per Day?			yer Contribution			Network Plan?				
Apply Skilled Nursing Facility Copay per Day?						Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	bution Amount:	\$0.00	2nd	Tier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?							<i></i>			
Desired Metal Tier										
besited Wetal Her		1 Plan Benefit D	esign		Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$5,800.00				\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			50.00%				60.00%			
MOOP (\$)			\$7,100.00	7			\$8,700.00			
MOOP if Separate (\$)										
			-			•	•			
Click Here for Important Instructions		Tie	er 1			Ti	er 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to		Coinsurance, if	Copay, if	Copay applie	
	Deductible?	Coinsurance?	different	separate	Deductible?		different	separate	deduc	
Medical	□ All	☐ All			All	AII			□ All	☐ All
Emergency Room Services	V	▽								
All Inpatient Hospital Services (inc. MH/SUD)	M	V							Ш	
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	✓	✓								
X-rays)	- ✓	_								
Specialist Visit	<u> </u>	V								
Mental/Behavioral Health and Substance Use Disorder Outpatient Services	✓	✓								
	✓	<u> </u>								
Imaging (CT/PET Scans, MRIs) Speech Therapy	<u>V</u>	V								
эрееси петару										
Occupational and Physical Therapy	✓	\checkmark								
Preventive Care/Screening/Immunization		П	100%							
Laboratory Outpatient and Professional Services	V	v v	100/0		1 8					
X-rays and Diagnostic Imaging	Ū	Ž			l H	H				H
Skilled Nursing Facility	V	V			Ē				ä	Ä
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
Outpatient Surgery Physician/Surgical Services	☑	V								
Drugs	☐ All	☐ All			☐ All	☐ All			☐ All	☐ All
Generics	✓			\$12.00					~	
Preferred Brand Drugs	☑	✓	60%							
Non-Preferred Brand Drugs	☑	✓	40%			Ō				
Specialty Drugs (i.e. high-cost)	V	✓	40%							
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Bronze HD	OHP Option 2					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2025 Bronze HD	OHP Option 2					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0									
Output										
Calculate										
Status/Error Messages:	Expanded Bronze	e Standard (58% t	o 65%), Calculati	on Successful.						
Actuarial Value: Metal Tier:	64.21% Propage									
ivictal fiel.	Bronze	aro condess see	ot cubio et te th	doductible ca 11		Anyconies	h this cost sho	or chrisch '-	covered at 1000/ I	the plan in the
A different Market	deductible range		iot subject to the	ueuuctible and h	lave no copay.	Any service wit	in unis cost-sharir	ig structure is	covered at 100% by	uie pian in the
Additional Notes:	ueuuctibie range	:.								
Calculation Time:	1.5391 seconds									
Draft 2025 AV Calculator										



Bronze HDHP – Embedded MOOP, Continued

HDHP Model – Normalization:

Orose ICa	lculate' anytime a			ng option fi		
		•				
	at the model run-t		-		-	ssing speea.
A messo	age box will appea	r to inaicat	e tnat tne d	aiculations	are aone.	
			_			
		Medical	Rx			
	vidual Deductible	5,800	5,800			
F	amily Deductible	11,600	11,600			
Individu	ual Out-of-Pocket	7,100	7,100			
Fam	ily Out-of-Pocket	14,200	14,200			
Coinsura	nce (50% or Less)	46%	53%			
		Costs	that Accun	nulate		
			00	OP [Deductible	/
		Deductible	Medical	Rx	OOP Type	_
	Settings	Medical &	Medical &	Medical &		5
		Calcu	ulate			
					64.21%	
				64.21%	0.992	



Bronze HDHP – Embedded MOOP, Continued

HDHP Model – Adjusted Actuarial Value:

Press 'Calculate' anytime a	n input or d	lropdown s	election is a	hanged.	
Note that the model run-t	ime will var	y based on	the compu	iters proces	sing speed.
A message box will appea	r to indicat	e that the c	alculations	are done.	
	Medical	Rx			
Individual Deductible	5,800	1,650			
Family Deductible	11,600	3,300			
Individual Out-of-Pocket	7,100	1,650			
Family Out-of-Pocket	14,200	3,300			
Coinsurance (50% or Less)	46%	53%			
	Costs	that Accun	nulate		
		0	OP I	Deductible	/
	Deductible	Medical	Rx	OOP Type	
Settings	Medical &	Medical &	Medical &	Stacked	
	Calc	ulate			
			62.09%	0.992	
			02.05/6	0.332	



SILVER DEDUCTIBLE

AV from AVC = 69.9%

Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 66.79%/65.83% = 1.0146 x .6991 = 70.9% *1.001 (MH/SA Copay Adj) = 71.0%

Adjusted AV = 71.0%

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	_		HSA/HRA Option			red Network Op	otion			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗆		Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:	\$0.00		Tier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?				, , , , ,	2nd	Tier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tie				_						
	Medical	1 Plan Benefit D	Combined	-	Medical	2 Plan Benefit Drug	Combined			
Deductible (\$		Drug \$500.00	Combined		iviedicai	Drug	\$6,500.00			
Coinsurance (%, Insurer's Cost Share)		50.00%	50.00%				60.00%			
MOOP (\$		00.00	30.0070				\$8,700.00			
MOOP if Separate (\$,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
		•	•			•				
Click Here for Important Instructions		Tie	er 1			Tie	er 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay appli	es only after
	Deductible?	Coinsurance?	different	separate		Coinsurance?	different	separate		ctible?
Medical	☐ All	All All			All	☐ All			☐ All	☐ All
Emergency Room Services	Ø			\$250.00					V	
All Inpatient Hospital Services (inc. MH/SUD)	V	V								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$40.00						
X-rays)				\$90.00						
Specialist Visit	U			\$90.00		Ш				
Mental/Behavioral Health and Substance Use Disorder Outpatient Services				\$40.00						
Imaging (CT/PET Scans, MRIs)	V	✓								
Speech Therapy		П		\$90.00					П	
	†				1					
Occupational and Physical Therapy				\$50.00						
Preventive Care/Screening/Immunization			100%							
Laboratory Outpatient and Professional Services	V	<u>v</u>			H					
X-rays and Diagnostic Imaging	✓	✓								
Skilled Nursing Facility	V	✓				Ō				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	V	✓								
	_ _	_ 								
Outpatient Surgery Physician/Surgical Services	□ All	□ All			□ All	 □ All			□ All	
Drugs Generics				\$15.00	L All					
Preferred Brand Drugs	V	Ö		\$70.00		Ä			v	
Non-Preferred Brand Drugs	V	v		570.00						
Specialty Drugs (i.e. high-cost)	<u> </u>	<u> </u>								
Options for Additional Benefit Design Limits:			Plan Description	n:						
Set a Maximum on Specialty Rx Coinsurance Payments?	. 🗆		Name:	2025 Silver Opt	ion 2					
Specialty Rx Coinsurance Maximum	\$0		Plan HIOS ID:	2025 Silver Opt	ion 2					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10)			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
#Visits (1-10)										
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays (1-10)										
Output	. 0	J								
Calculate										
Status/Error Messages:	Standard On-Exc	hange Individual	Silver Plans must	t meet a [0, +2] n	ercent de mini	mis range: Calcu	lation Successfu	I.		
Actuarial Value:	69.91%					0-,				
Metal Tier:	Silver Off-Exchai	nge and Small Gro	oup Market							
				deductible and h	nave no copay.	Any service wit	h this cost-sharir	ng structure is	covered at 100% b	y the plan in the
Additional Notes:	deductible range	. NOTE: Office-v	isit-specific cost-	sharing is applyi	ng to x-rays in	office settings.				
Calculation Time:	1.6562 seconds									
Draft 2025 AV Calculator										



Silver Deductible, Continued

HDHP Model – Without Prescription Drug Adjustments:

	culate' anytime					rop down box, and press 'Calculate'.
		•	•			:
	t the model run					
A messag	ge box will appe	ar to indica	te that the	calculation	s are done.	
		Medical	Rx			
Individ	dual Deductible	3,500	500			
Fan	nily Deductible	7,000	1,000			
Individual	Out-of-Pocket	9,200	9,200			
Family	Out-of-Pocket	18,400	18,400			
·						
Coinsuranc	e (50% or Less)	41%	39.44%			
	,					
		Costs	that Accun	nulate		
		00313			Deductible	1
		Deductible	_	Rx	OOP Type	•
	Settings	Medical &				
	Settings	Wiedical &	ivicultar &	Wiedical &	Stacked	1.00
						1.00
		Color	ulate .			
		Calco	liate			
				65.83%	1.007	



Silver Deductible, Continued

HDHP Model – With Prescription Drug Adjustments:

Press 'Ca	alculate' anytime d	an input or o	dropdown:	selection is	chanaed.	
	at the model run-	•				ssina speed.
	age box will appe		-			
Amesse	age box will appe	ar to maical	e that the	- arearation	die done.	
		Medical	Rx			
Indiv	idual Deductible		500			
	amily Deductible	_,	1,000			
	diffiny Deductible	7,000	1,000			
Individu	l ual Out-of-Pocket	9,200	1,500			
	ily Out-of-Pocket	-,	3,000			
i dilli	ily out-of-rocket	10,400	3,000			
Coincura	nce (50% or Less)	41%	39.44%			
Compara	1100 (3070 OI LESS)	41/0	33.4470			
		Costs	that Accum	nulate		
		COSES			Deductible	/
		Deductible		Rx	OOP Type	
	Settings	Medical &			Stacked	
	octings	Wicarda &	Wicarcar &	nx only	Stacked	1.00
						1.00
		Calcu	ılate			
				66.79%	1.007	



BRONZE DEDUCTIBLE (WITH PHARMACY LIMIT)

AV from AVC = 61.0%

Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 61.73%/60.91% = 1.013 x .6095 = 61.8%

Adjusted AV = 61.8%

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗌	Tiered	Network Plan?	2 🗆			
Apply Skilled Nursing Facility Copay per Day?		Annual Cantail		\$0.00	1st T	ier Utilization	: 100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contril	oution Amount:	\$0.00	2nd 7	ier Utilization	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	✓									
Desired Metal Tier	Bronze 🔻									
	Tier	1 Plan Benefit De	esign		Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$6,450.00	\$1,100.00					\$6,500.00			
Coinsurance (%, Insurer's Cost Share)	50.00%	40.00%	50.00%				60.00%			
MOOP (\$)	\$9,20	00.00				•	\$8,700.00			
MOOP if Separate (\$)				_						
					1					
Click Here for Important Instructions		Tie					ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to	Subject to	Coinsurance, if	Copay, if	Copay applie	
	Deductible?	Coinsurance?	different	separate		Coinsurance?	different	separate	deduct	
Medical	☐ All	☐ All			All	☐ All			☐ All	_ All
Emergency Room Services	V	✓								
All Inpatient Hospital Services (inc. MH/SUD)	V	✓								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	✓			\$35.00					✓	
X-rays)	l									
Specialist Visit	V			\$90.00					V	
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓			\$35.00					✓	
Services				333.00						
Imaging (CT/PET Scans, MRIs)	V	☑								
Speech Therapy	☑			\$90.00					V	
	✓			\$45.00					✓	
Occupational and Physical Therapy				Ş45.00						
Preventive Care/Screening/Immunization			100%							
Laboratory Outpatient and Professional Services	V	V								
X-rays and Diagnostic Imaging		✓								
Skilled Nursing Facility	V	V								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
					_	_				
Outpatient Surgery Physician/Surgical Services	V	<u> </u>								
Drugs	☐ All	☐ All			All	All			☐ All	All
Generics				\$15.00						
Preferred Brand Drugs	V			\$85.00					V	
Non-Preferred Brand Drugs	V	<u></u>				<u> </u>				
Specialty Drugs (i.e. high-cost)	V	V				Ш				
Options for Additional Benefit Design Limits:	_	1	Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Bronze RX						
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2025 Bronze RX	Limit Option 2					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0									
Output										
Calculate										
Status/Error Messages:	Expanded Bronze	Standard (58% t	o 65%), Calculati	on Successful.						
Actuarial Value:	60.95%									
Metal Tier:	Bronze									
							th this cost-sharin	g structure is co	overed at 100% by	the plan in the
Additional Notes:	deductible range	. NOTE: Office-v	isit-specific cost-	sharing is applying	ng to x-rays in o	ffice settings.				
Calculation Time:	1.4297 seconds									
Draft 2025 AV Calculator										



Bronze Deductible (Continuing, with pharmacy limit), Continued

HDHP Model – Without Prescription Drug Adjustments:

Press 'Calculate' anytime a	n input or a	lropdown s	election is	changed.	
Note that the model run-ti	ime will var	y based on	the compu	iters proces	sing speed.
A message box will appea	r to indicat	e that the o	alculation	are done.	
	Medical	Rx			
Individual Deductible	6,450	1,100			
Family Deductible	12,900	2,200			
Individual Out-of-Pocket	9,200	9,200			
Family Out-of-Pocket	18,400	18,400			
oinsurance (50% or Less)	44%	50%			
	Costs	that Accun	nulate		
		00	OP I	Deductible	/
	Deductible	Medical	Rx	OOP Type	
Settings	Medical &	Medical &	Medical 8	Stacked	
	Calcu	ulate			
I	I I		60.91%	0.99388	



Bronze Deductible (Continuing, with pharmacy limit), Continued

HDHP Model – With Prescription Drug Adjustments:

Enter valu	es in the blue cells be	elow, choos	e a setting	option fro	m the drop	down box, and press 'Calculate'.
Press 'Ca	lculate' anytime an i	nput or dro	pdown sele	ection is ch	anged.	
Note the	at the model run-time	will vary b	ased on th	e compute	rs processin	g speed.
A messo	ige box will appear t	o indicate t	hat the cald	culations a	re done.	
		Medical	Rx			
Inc	dividual Deductible	6,450	1,100			
	Family Deductible	12,900	2,200			
	-					
Indiv	idual Out-of-Pocket	9,200	1,600			
Fa	amily Out-of-Pocket	18,400	3,200			
Coinsu	rance (50% or Less)	44%	50%			
		Costs	that Accun	nulate		
			00	OP [Deductible	/
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical &	Medical &	Rx Only	Stacked	2
				•		
		Calcu	ulate			
				61.73%	0.99388	



SILVER HDHP - EMBEDDED MOOP CSR - 73%

AV from AVC = 75.7%

Adjusted AV = 73.5%

User Inputs for Plan Parameters		_								
Use Integrated Medical and Drug Deductible?			HSA/HRA Option		Tie	red Network Op	otion			
Apply Inpatient Copay per Day?		HSA/HRA Employ	yer Contribution?	? 🗌		Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contrib	oution Amount:	\$0.00	1st 7	ier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Allildar Collette	oution Amount.	\$0.00	2nd 1	ier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				-						
		1 Plan Benefit De				2 Plan Benefit D				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$1,800.00				\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			70.00%				60.00%			
MOOP (\$)			\$5,900.00				\$8,700.00			
MOOP if Separate (\$)										
Click Here for Important Instructions		Tie	-1			т:	er 2		Tier 1	Tier 2
CHECK HETE TOT IMPORTANT MISTIGLIONS	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to		Coinsurance, if	Copay, if	Copay applie	
Type of Benefit	Deductible?	Coinsurance?	different	separate		Coinsurance?	different	separate	deduct	
Medical	□ All	□ All	unierent	3c parate	All	All	unierent	Separate	□ All	All All
Emergency Room Services	✓	✓								
All Inpatient Hospital Services (inc. MH/SUD)	V	V							Ä	
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and										
X-rays)	✓	✓	90%							
Specialist Visit	✓	✓								
Mental/Behavioral Health and Substance Use Disorder Outpatient										
Services	✓	✓	90%							
Imaging (CT/PET Scans, MRIs)	V	✓								П
Speech Therapy	·	<u>.</u>			ä	H				ä
эресси петару										
Occupational and Physical Therapy	✓	~								
Preventive Care/Screening/Immunization	П		100%							
Laboratory Outpatient and Professional Services	V	V	100%							
X-rays and Diagnostic Imaging	Ž	Ž			H	H				
Skilled Nursing Facility	V	V			ä	ä			ä	ä
Skilled Nulsing racinty										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	~								
Outpatient Surgery Physician/Surgical Services	☑	7								
Drugs	□ All	☐ All			All	All			□ All	□ All
Generics	V	П		\$10.00					V	
Preferred Brand Drugs	☑			\$40.00	1	Ä			✓	Ä
Non-Preferred Brand Drugs	V	<u> </u>	50%						Ō	Ö
Specialty Drugs (i.e. high-cost)	☑	☑	50%						П	Ä
Options for Additional Benefit Design Limits:			Plan Description	n:						
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	2025 Silver HDH	IP 73					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2025 Silver HDH						
Set a Maximum Number of Days for Charging an IP Copay?		1	Issuer HIOS ID:	2025						
# Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?		1								
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?	_									
# Copays (1-10):										
Output		3								
Calculate										
Status/Error Messages:	Error: Result is o	utside of [-2, +2] ;	percent de minin	nis variation.						
Actuarial Value:	75.70%									
Metal Tier:										
	NOTE: One or mo	ore services are n	ot subject to the	deductible and h	ave no copav.	Any service wit	h this cost-sharin	g structure is o	overed at 100% by	the plan in the
Additional Notes:		e. NOTE: Office-v						-	,	
•			•		-	-				
Calculation Time:	1.3633 seconds									
Draft 2025 AV Calculator	. ,									



Silver HDHP - Embedded MOOP CSR - 73%, Continued

HDHP Model – Normalization:

Enter values in the blue ce	ells below, o	choose a se	etting optic	on from the	drop down box, and press 'Calculate'.
Press 'Calculate' anytime	an input o	r dropdow	n selection	is changed	
Note that the model ru	n-time will	vary based	on the cor	nputers pro	ocessing speed.
A message box will appe	ear to indic	ate that th	ne calculati	ons are dor	ne.
	Medical	Rx			
Individual Deductible	1,800	1,800			
Family Deductible	3,600	3,600			
Individual Out-of-Pocket	5,900	5,900			
Family Out-of-Pocket	11,800	11,800			
Coinsurance (50% or Less)	26%	36%			
	Costs	that Accur	nulate		
		0	OP [Deductible	/
	Deductible	Medical	Rx	OOP Type	
Settings	Medical &	Medical &	Medical &	Stacked	5
	Calcu	ulate			
				75.70%	
			75.70%	0.99888	



Silver HDHP - Embedded MOOP CSR - 73%, Continued

HDHP Model – Adjusted Actuarial Value:

Enter values in the blue c	ells below,	choose a se	etting optic	on from the	drop down box, and press 'Calculate'.
Press 'Calculate' anytime	an input o	r dropdow	n selection	is changed	l.
Note that the model ru	n-time will	vary based	on the co	mputers pro	ocessing speed.
A message box will app	ear to indic	ate that th	ne calculati	ions are doi	ne.
	Medical	Rx			
Individual Deductible	1,800	1,650			
Family Deductible	3,600	3,300			
Individual Out-of-Pocket	5,900	1,650			
Family Out-of-Pocket	11,800	3,300			
Coinsurance (50% or Less)	26%	36%			
	Costs	that Accur	nulate		
		0	OP	Deductible	/
	Deductible	Medical	Rx	OOP Type	
Settings	Medical &	Medical &	Rx Only	Aggregate	
			·		
	Calc	ulate			
			73.46%	0.99888	
			73.4070	0.55000	



SILVER HDHP - EMBEDDED MOOP CSR - 77%

AV from AVC = 79.5%

Adjusted AV = 77.5%

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	✓ HSA/HRA Options			Tie	red Network O	ption				
Apply Inpatient Copay per Day?	ay? 🗌 HSA/HRA E		ployer Contribution?		Tiered Network Plan?					
Apply Skilled Nursing Facility Copay per Day?			oution Amount:	\$0.00	1st Tier Utilization:					
Use Separate MOOP for Medical and Drug Spending?				*****	2nd 1	Fier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				1	_					
	Medical	1 Plan Benefit Do	Combined	1	Medical	2 Plan Benefit I Drug	Combined			
Deductible (\$)	iviedicai	Drug	\$1,800.00	-	iviedicai	Drug	\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			70.00%				60.00%			
MOOP (\$)			\$4,700.00				\$8,700.00			
MOOP if Separate (\$)			¥ 1/1 COLOR	1			70,.00.00			
			•		•	•	•			
Click Here for Important Instructions	Tier 1			Tier 2				Tier 1	Tier 2	
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay applie	
<u> </u>	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	deduc	
Medical	□ All	☐ All			All	All			□ All	All
Emergency Room Services	V	▽			<u> </u>					
All Inpatient Hospital Services (inc. MH/SUD)		<u>V</u>				Ш			Ш	
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	✓	✓	90%							
X-rays) Specialist Visit	V	☑								
Mental/Behavioral Health and Substance Use Disorder Outpatient										
Services	✓	✓	90%							
Imaging (CT/PET Scans, MRIs)	☑	✓								
Speech Therapy	V	V								
	✓	✓				П				П
Occupational and Physical Therapy									U	
Preventive Care/Screening/Immunization			100%							
Laboratory Outpatient and Professional Services	V	V								
X-rays and Diagnostic Imaging	✓	▽								
Skilled Nursing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
Outpatient Surgery Physician/Surgical Services	Ø	V								
Drugs	☐ All	☐ All			☐ All	☐ All			☐ All	☐ All
Generics	V			\$10.00					V	
Preferred Brand Drugs	V			\$40.00					V	
Non-Preferred Brand Drugs	V	V	50%							
Specialty Drugs (i.e. high-cost)	V	V	50%							
Options for Additional Benefit Design Limits:		1	Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Silver HDF						
Specialty Rx Coinsurance Maximum: Set a Maximum Number of Days for Charging an IP Copay?	\$0		Plan HIOS ID: Issuer HIOS ID:	2025 Silver HDF 2025	1P //					
#Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?			Ave version.	2025_10						
#Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0									
Output										
Calculate										
Status/Error Messages:	Calculation Succe	esstul.								
Actuarial Value:	79.45%									
Metal Tier:	Gold	ro consicos ara -	ot cubioct to the	doductible and b	2210 DO CODO::	Any consise	h this cost shari-	a etructuro :	overed at 100% by	the plan in the
Additional Notes:	deductible range						ans cost-sndfin	5 structure IS C	overeu at 100% Dy	are plantin the
Additional Notes:	academore range		ion specific cost-	onaning is applyi	₆ to x-iays III C	e settings.				
Calculation Time:	1.582 seconds									
Draft 2025 AV Calculator	2.502 3CC011d3									



Silver HDHP – Embedded MOOP CSR – 77%, Continued

HDHP Model – Normalization:

Enter value	es in the blue ce	ells below, o	choose a se	etting optio	n from the	drop down box, and press 'Calculate'.
Press 'Cal	culate' anytime	an input o	r dropdow	n selection	is changed	l.
Note the	at the model ru	n-time will	vary based	on the cor	nputers pro	ocessing speed.
A messa	ge box will app	ear to indic	ate that th	ne calculati	ons are doi	ne.
		Medical	Rx			
Individ	lual Deductible	1,800	1,800			
Far	nily Deductible	3,600	3,600			
Individual	Out-of-Pocket	4,700	4,700			
Family	Out-of-Pocket	9,400	9,400			
Coinsuranc	e (50% or Less)	26%	36%			
		Costs	that Accur	nulate		
			0	OP [Deductible	/
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical &	Medical &	Medical &	Stacked	5
	_					
		Calcu	ulate			
					79.45%	
				79.46%	1.21013	



Silver HDHP – Embedded MOOP CSR – 77%, Continued

HDHP Model – Adjusted Actuarial Value:

Enter val	ues in the blue ce	ells below, o	choose a se	etting optic	on from the	drop down box, and press 'Calculate'.
Press 'Co	alculate' anytime	an input o	r dropdow	n selection	is changed	l.
Note th	nat the model ru	n-time will	vary based	on the co	mputers pro	ocessing speed.
A mess	age box will app	ear to indic	ate that th	ne calculati	ions are dor	ne.
		Medical	Rx			
Indivi	dual Deductible	1,800	1,650			
Fa	mily Deductible	3,600	3,300			
Individua	al Out-of-Pocket	4,700	1,650			
Fami	ly Out-of-Pocket	9,400	3,300			
Coinsuran	ce (50% or Less)	26%	36%			
		Costs	that Accun	nulate		
			00	OP I	Deductible	/
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical &	Medical &	Rx Only	Aggregate	6
		Calc	ulate			
				77.45%	1.21013	



SILVER HDHP - EMBEDDED MOOP CSR - 87%

AV from AVC = 87.7%

Adjusted AV = 87.2%

User Inputs for Plan Parameters		-								
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution?	· 🗆		Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contril	bution Amount:	\$0.00		Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?		7 tilliour contri	outron 7 milount.	\$0.00	2nd 1	Tier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				-						
		1 Plan Benefit De		4		2 Plan Benefit				
	Medical	Drug	Combined	4	Medical	Drug	Combined			
Deductible (\$)			\$1,650.00				\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			100.00%	1			60.00%			
MOOP (\$)			\$1,650.00				\$8,700.00			
MOOP if Separate (\$)			ı							
Click Here for Important Instructions		Tie	vr 1			т.	er 2		Tier 1	Tier 2
Chick here for important histractions	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to		Coinsurance, if	Copay, if		es only after
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		ctible?
Medical	☐ All	☐ All			All	☐ All			☐ All	☐ All
Emergency Room Services	V									
All Inpatient Hospital Services (inc. MH/SUD)	V									
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and										
X-rays)	✓									
Specialist Visit	V									
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓									
Services										
Imaging (CT/PET Scans, MRIs)	V					<u> </u>				
Speech Therapy	V									
	✓									
Occupational and Physical Therapy			100%							
Preventive Care/Screening/Immunization	<u> </u>		100%			H			П	
Laboratory Outpatient and Professional Services	<u>v</u>	H			H	H			H	H
X-rays and Diagnostic Imaging	<u>v</u>									
Skilled Nursing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓									
Outpatient Surgery Physician/Surgical Services	☑	П								
Drugs	□ All	□ All			☐ All	□ All			□ All	□ All
Generics	V									
Preferred Brand Drugs	V									
Non-Preferred Brand Drugs	☑					Ō				
Specialty Drugs (i.e. high-cost)	V									
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Silver HDH	IP 87					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:	2025 Silver HDH	IP 87					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays? #Copays (1-10):										
Output # Copays (1-10).	. 0									
Calculate										
Status/Error Messages:	Error: Result is or	utside of I-2 +21	nercent de minim	nis variation						
Actuarial Value:	87.69%									
Metal Tier:										
	NOTE: One or mo	ore services are n	ot subject to the	deductible and h	nave no copav.	Any service wi	th this cost-sharin	g structure is o	overed at 100% b	y the plan in the
Additional Notes:									inputs for those s	
	. 0				.,					
Calculation Time:	1.4062 seconds									
Draft 2025 AV Calculator										



Silver HDHP - Embedded MOOP CSR - 87%, Continued

HDHP Model – Normalization:

Enter values in the blue co	ells below.	choose a se	ettina optio	on from the	e drop down box, and press 'Calculate'.
Press 'Calculate' anytime				-	·
Note that the model ru					
A message box will app					• •
	Medical	Rx			
Individual Deductible	1,650	1,650			
Family Deductible	3,300	3,300			
Individual Out-of-Pocket	1,650	1,650			
Family Out-of-Pocket	3,300	3,300			
Coinsurance (50% or Less)	0%	0%			
		-			
	Costs	that Accun			
				Deductible	
	Deductible		Rx	OOP Type	
Settings	Medical &	Medical &	Medical &	Stacked	5
	Colo	ulate .			
	Calc	ulate			
				87.69%	
			87.70%	1.17138	



Silver HDHP - Embedded MOOP CSR - 87%, Continued

HDHP Model – Adjusted Actuarial Value:

Enter value	s in the blue ce	ells below, (choose a se	etting optio	on from the	drop down box, and press 'Calculate'.
Press 'Calc	culate' anytime	an input o	r dropdow	n selection	is changed	l.
Note tha	t the model ru	n-time will	vary based	on the co	mputers pro	ocessing speed.
A messag	ge box will app	ear to indic	ate that th	ne calculati	ions are dor	ne.
		Medical	Rx			
Individu	ual Deductible	1,650	1,650			
Fam	nily Deductible	3,300	3,300			
Individual	Out-of-Pocket	1,650	1,650			
Family	Out-of-Pocket	3,300	3,300			
Coinsurance	e (50% or Less)	0%	0%			
		Costs	that Accun	nulate		
			0	OP	Deductible ,	/
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical &	Medical &	Rx Only	Aggregate	6
		Calc	ulate			
				87.21%	1.17138	



SILVER HDHP - EMBEDDED MOOP CSR - 94%

AV from AVC = 94.4%

Adjusted AV = 94.4%

User Inputs for Plan Parameters		-								
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution?	? 🗆		Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contril	oution Amount:	\$0.00		ier Utilization:				
Use Separate MOOP for Medical and Drug Spending?		7 tilliour contri	Jacion 7 miloune.	Ģ0.00	2nd 1	ier Utilization:	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				-						
		1 Plan Benefit De		_		2 Plan Benefit				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$650.00				\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			100.00%	4			60.00%			
MOOP (\$)			\$650.00	1		1	\$8,700.00			
MOOP if Separate (\$)			I				ı			
Click Here for Important Instructions		Tie	r 1			T.	ier 2		Tier 1	Tier 2
CHEK HETE TOT IMPORTANCE MISTIGLETONS	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to		Coinsurance, if	Copay, if		es only after
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		ctible?
Medical	☐ All	☐ All			All	All			☐ All	☐ All
Emergency Room Services	✓									
All Inpatient Hospital Services (inc. MH/SUD)	✓									
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and										
X-rays)	✓									
Specialist Visit	V									
Mental/Behavioral Health and Substance Use Disorder Outpatient	•									
Services										
Imaging (CT/PET Scans, MRIs)	<u> </u>									
Speech Therapy	V									
	✓									
Occupational and Physical Therapy			100%							
Preventive Care/Screening/Immunization	□		100%			H			П	
Laboratory Outpatient and Professional Services	V	H			H	H			H	H
X-rays and Diagnostic Imaging Skilled Nursing Facility	V	ä							-	
Skilled Nursing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓									
Outpatient Surgery Physician/Surgical Services	7									
Drugs	☐ All	☐ All			☐ All	All			☐ All	A⊪
Generics	✓		"							
Preferred Brand Drugs	✓									
Non-Preferred Brand Drugs	V									
Specialty Drugs (i.e. high-cost)	V									
Options for Additional Benefit Design Limits:		-	Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Silver HDH	P 94					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:	2025 Silver HDH	P 94					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
#Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of Copays?										
# Copays (1-10):										
Output	. 0	J								
Calculate										
Status/Error Messages:	Error: Result is o	utside of [-2, +2]	percent de minim	nis variation.						
Actuarial Value:	94.37%									
Metal Tier:										
	NOTE: One or mo	ore services are n	ot subject to the	deductible and h	ave no copay.	Any service wi	th this cost-sharin	g structure is o	overed at 100% b	y the plan in the
Additional Notes:							ponents, overrid			
Calculation Time:	1.5039 seconds									
Draft 2025 AV Calculator										



Silver HDHP – Embedded MOOP CSR – 94%, Continued

HDHP Model – Normalization:

Enter values in the blue ce	ells below,	choose a se	etting optic	on from the	drop down box, and press 'Calculate'.
Press 'Calculate' anytime	an input o	r dropdow	n selection	is changed	l.
Note that the model ru	n-time will	vary based	on the cor	nputers pr	ocessing speed.
A message box will appe	ear to indic	ate that th	ne calculati	ons are do	ne.
	Medical	Rx			
Individual Deductible	650	650			
Family Deductible	1,300	1,300			
Individual Out-of-Pocket	650	650			
Family Out-of-Pocket	1,300	1,300			
Coinsurance (50% or Less)	0%	0%			
	Costs	that Accun	nulate		
		00	OP [Deductible	/
	Deductible	Medical	Rx	OOP Type	
Settings	Medical &	Medical &	Medical &	Stacked	5
	Calc	ulate			
				94.37%	
				34.3/70	
			94.37%	1.17388	
			34.3770	1.1/300	



Silver HDHP - Embedded MOOP CSR - 94%, Continued

HDHP Model – Adjusted Actuarial Value:

Enter valu	ues in the blue ce	ells below,	choose a se	etting optio	on from the	drop down box, and press 'Calculate'.
Press 'Co	alculate' anytime	an input o	r dropdow	n selection	is changed	l.
Note th	nat the model ru	n-time will	vary based	on the co	mputers pro	ocessing speed.
A mess	age box will app	ear to indic	ate that th	ne calculati	ions are doi	ne.
		Medical	Rx			
Indivi	dual Deductible	650	650			
Fa	mily Deductible	1,300	1,300			
Individua	al Out-of-Pocket	650	650			
Famil	ly Out-of-Pocket	1,300	1,300			
Coinsuran	ce (50% or Less)	0%	0%			
		Costs	that Accun	nulate		
			00	OP I	Deductible	/
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical &	Medical &	Rx Only	Stacked	6
		Calc	ulate			
				94.35%	1.17388	
				2	2.27000	




SILVER DEDUCTIBLE CSR - 73%

AV from AVC = 73.1%

Adjustments

 HDHP Model with drug adjustments / HDHP Model without drug adjustments = 69.73%/68.98% = 1.011 x 73.1% = 73.9% * 1.001 (MH/SA Copay Adj) = 73.9%

Adjusted AV = 73.9%





Silver Deductible CSR – 73%, Continued

HDHP Model – Without Prescription Drug Adjustments:

Enter valu	ues in the blue cell:	s below, ch	oose a sett	ing option j	from the dr	op down box, and press 'Calculate'.
Press 'Co	ılculate' anytime a	n input or a	lropdown s	election is	changed.	
Note th	at the model run-	time will va	ry based oi	n the comp	uters proce	essing speed.
A messo	age box will appea	r to indicat	e that the	calculations	s are done.	
		Medical	Rx			
Ind	ividual Deductible	3,150	450			
	Family Deductible	6,300	900			
	•					
Individ	lual Out-of-Pocket	6,950	6,950			
Far	nily Out-of-Pocket	13,900	13,900			
	•		•			
Coinsura	ance (50% or Less)	41%	39%			
	,					
		Costs	that Accun	nulate		
					Deductible	/
		Deductible		Rx	OOP Type	
	Settings	Medical &	Medical &			5
						_
		Calcu	ulate			
				68.98%	0.998875	



Silver Deductible CSR - 73%, Continued

HDHP Model – With Prescription Drug Adjustments:

Enter values in the blue cell	s below, ch	oose a sett	ing option j	from the dr	op down box, and press 'Calculate'.
Press 'Calculate' anytime a	n input or o	dropdown s	election is	changed.	
Note that the model run-	time will va	ry based oi	n the comp	uters proce	essing speed.
A message box will appea	r to indicat	e that the	calculation	s are done.	
	Medical	Rx			
Individual Deductible	3,150	450			
Family Deductible	6,300	900			
Individual Out-of-Pocket	6,950	1,300			
Family Out-of-Pocket		2,600			
•					
Coinsurance (50% or Less)	41%	39%			
	Costs	that Accun	nulate		
	00313			Deductible	1
	Deductible		Rx	OOP Type	•
Settings	Medical &			Stacked	2
octings	ivicultur o	Wicalcal &	na Only	Stuckeu	
	Calc	ulate			
		and te			
			69.73%	0.998875	



SILVER DEDUCTIBLE CSR - 77%

AV from AVC = 77.2%

Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 71.26%/70.57% = 1.01 x 77.2% = 77.9% * 1.001 (MH/SA Copay Adj) = 77.9%

Adjusted AV = 77.9%

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗆	Tiered Network Plan?					
Apply Skilled Nursing Facility Copay per Day?				40.00	1st Tier Utilization: 100%					
Use Separate MOOP for Medical and Drug Spending?		Annual Contril	oution Amount:	\$0.00	2nd	Tier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier	Gold ▼									
		1 Plan Benefit De	esign		Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$2,950.00	\$350.00	Combined		IVICUICAI	Diug	\$6,500.00			
Coinsurance (%, Insurer's Cost Share)	50.00%	50.00%	50.00%				60.00%			
MOOP (\$)		50.00	30.00%	-			\$8,700.00			
	\$6,3	50.00					\$8,700.00			
MOOP if Separate (\$)										
Click Here for Important Instructions		Tie					er 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to		Coinsurance, if	Copay, if	Copay applies	
	Deductible?	Coinsurance?	different	separate		Coinsurance?	different	separate	deducti	
Medical	☐ All	All			All	All			☐ All	All
Emergency Room Services	V			\$200.00						
All Inpatient Hospital Services (inc. MH/SUD)	V	☑								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$30.00	П	П				
X-rays)				\$30.00						
Specialist Visit				\$60.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient									_	
Services				\$30.00						
Imaging (CT/PET Scans, MRIs)	v	7							П	П
Speech Therapy				\$60.00						
Occupational and Physical Therapy				\$35.00						
Preventive Care/Screening/Immunization	П	П	100%							
Laboratory Outpatient and Professional Services		U	100%		l R					
	V	<u> </u>			l H					
X-rays and Diagnostic Imaging	V	✓				H				
Skilled Nursing Facility	<u> </u>	<u> </u>								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
	v	☑								П
Outpatient Surgery Physician/Surgical Services]					
Drugs	☐ All	☐ All			All	All			☐ All	All
Generics				\$15.00						
Preferred Brand Drugs	V			\$60.00		Щ			V	
Non-Preferred Brand Drugs	✓	₹								Ш
Specialty Drugs (i.e. high-cost)	V	✓								
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Silver Ded	uct 77					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2025 Silver Ded	uct 77					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	V			-						
#Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0									
Output	- 0									
Calculate										
	Error Deculation	steido of F2 +21	norcont de	aic variation						
Status/Error Messages:	Error: Result is o	utside of [-2, +2]	percent de minin	iis variation.						
Actuarial Value:	77.15%									
Metal Tier:										
							th this cost-sharin	g structure is o	overed at 100% by t	he plan in the
Additional Notes:	deductible range	. NOTE: Office-v	isit-specific cost-	sharing is applying	ng to x-rays in o	office settings.				
Calculation Time:	1.4453 seconds									
Draft 2025 AV Calculator										



Silver Deductible CSR – 77%, Continued

HDHP Model – Without Prescription Drug Adjustments:

						op down box, and press 'Calculate'.
Press 'Co	alculate' anytime a	n input or o	dropdown s	election is	changed.	
Note th	nat the model run-	time will va	ry based oi	n the comp	uters proce	essing speed.
A mess	age box will appea	r to indicat	e that the	calculation	s are done.	
		Medical	Rx			
Ind	ividual Deductible	2,950	350			
	Family Deductible	5,900	700			
Individ	lual Out-of-Pocket	6,350	6,350			
Far	mily Out-of-Pocket	12,700	12,700			
Coinsura	ance (50% or Less)	38%	38%			
	,					
		Costs	that Accun	nulate		
			00	OP I	Deductible	/
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical &	Medical &	Medical &		5
						_
		Calc	ulate			
				70.57%	0.998875	



Silver Deductible CSR - 77%, Continued

HDHP Model – With Prescription Drug Adjustments:

Enter values in the blue cells	s below, ch	oose a sett	ing option j	from the dr	op down box, and press 'Calculate'.	
Press 'Calculate' anytime a	n input or o	dropdown s	election is	changed.		
Note that the model run-	time will vo	ry based o	n the comp	uters proce	essing speed.	
A message box will appea	r to indicat	e that the	calculation	s are done.		
	Medical	Rx				
Individual Deductible	2,950	350				
Family Deductible	5,900	700				
Individual Out-of-Pocket	6,350	1,200				
Family Out-of-Pocket	12,700	2,400				
Coinsurance (50% or Less)	38%	38%				
, ,						
	Costs	that Accun	nulate			
		0	OP I	Deductible /		
	Deductible	Medical	Rx	OOP Type		
Settings	Medical &	Medical &	Rx Only	Stacked	2	
	Calc	ulate				
			74 055	0.0000==		
			71.26%	0.998875		



SILVER DEDUCTIBLE CSR - 87%

AV from AVC = 87.4%

Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 83.74%/83.37% = 1.004 x 87.4%= 87.8%

Adjusted AV = 87.8%

AVC Screen Shot:

Draft 2025 AV Calculator

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗆	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		A I Contail		¢0.00	1st T	ier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	bution Amount:	\$0.00	2nd T	ier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier	Gold ▼									
	Tier	1 Plan Benefit D	esign		Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)		\$250.00					\$6,500.00			
Coinsurance (%, Insurer's Cost Share)	60.00%	50.00%	60.00%				60.00%			
MOOP (\$)		00.00	00.0070	1			\$8,700.00			
MOOP if Separate (\$)		0.00					\$0,700.00			
woor it separate (2)							ı			
Click Here for Important Instructions		Tie	er 1			Ti	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay applie	s only after
Type of Benefit	Deductible?	Coinsurance?	different	separate		Coinsurance?		separate	deduct	
Medical	☐ All	☐ All			All	☐ All			□ All	All
Emergency Room Services	✓			\$125.00					✓	
All Inpatient Hospital Services (inc. MH/SUD)	▽	✓				П				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	1	***************************************								
X-rays)				\$10.00						
Specialist Visit				\$30.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient				\$10.00						
Services		_		\$10.00					П	
Imaging (CT/PET Scans, MRIs)	✓	V								
Speech Therapy				\$30.00						
				\$12.00		П				
Occupational and Physical Therapy				Ç12.00	_				_	_
Preventive Care/Screening/Immunization			100%							
Laboratory Outpatient and Professional Services	y V	✓								
X-rays and Diagnostic Imaging	V	V								
Skilled Nursing Facility	V	₹.								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	V	V								
Outpatient Surgery Physician/Surgical Services	- 2	_ 7				_				
	□ All	□ All			□ All	□ All			□ All	
Drugs				\$10.00						
Generics	V	H		······		H			V	
Preferred Brand Drugs	V	✓		\$50.00		H			ä	
Non-Preferred Brand Drugs	<u>v</u>					H			H	
Specialty Drugs (i.e. high-cost)	•	✓							Ш	
Options for Additional Benefit Design Limits:		1	Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Silver Ded						
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2025 Silver Ded	uct 87					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):			AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	✓									
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of	_									
Copays?										
# Copays (1-10):	0									
Output										
Calculate										
Status/Error Messages:	Error: Result is or	utside of [-2, +2]	percent de minin	nis variation.						
Actuarial Value:	87.43%									
Metal Tier:										
	NOTE: One or mo	ore services are n	ot subject to the	deductible and h	ave no copay.	Any service wi	th this cost-sharin	g structure is c	overed at 100% by	the plan in the
Additional Notes:	deductible range	. NOTE: Office-v	isit-specific cost-	sharing is applyin	ng to x-rays in o	ffice settings.				
Calculation Time:	1.4375 seconds									



Silver Deductible CSR - 87%, Continued

HDHP Model – Without Prescription Drug Adjustments:

Enter valu	ues in the blue cells	s below, ch	oose a sett	ing option j	from the dr	op down box, and press 'Calculate'.
Press 'Co	alculate' anytime a	n input or a	dropdown s	election is	changed.	
Note th	at the model run-	time will va	ry based oi	n the comp	uters proce	essing speed.
A mess	age box will appea	r to indicat	e that the	calculation	s are done.	
		Medical	Rx			
Ind	ividual Deductible	1,275	250			
	Family Deductible	2,550	500			
Individ	lual Out-of-Pocket	2,500	2,500			
Far	nily Out-of-Pocket	5,000	5,000			
	,	•				
Coinsura	ance (50% or Less)	28%	36%			
	,					
		Costs	that Accun	nulate		
					Deductible	/
		Deductible		Rx	OOP Type	•
	Settings	Medical &	Medical &			5
		Calc	ulate			
				83.37%	0.998875	



Silver Deductible CSR - 87%, Continued

HDHP Model – With Prescription Drug Adjustments:

Enter val	ues in the blue cells	s below, ch	oose a sett	ing option j	from the dr	op down box, and press 'Calculate'.
Press 'Co	alculate' anytime a	n input or a	dropdown s	election is	changed.	
Note th	hat the model run-	time will va	ry based o	n the comp	uters proce	essing speed.
A mess	age box will appea	r to indicat	e that the	calculation	s are done.	
		Medical	Rx			
Ind	lividual Deductible	1,275	250			
	Family Deductible	2,550	500			
Individ	dual Out-of-Pocket	2,500	450			
Far	mily Out-of-Pocket	5,000	900			
Coinsura	ance (50% or Less)	28%	36%			
	,					
		Costs	that Accun	nulate		
					Deductible	/
		Deductible		Rx	OOP Type	
	Settings	Medical &			Stacked	2
						_
		Calc	ulate			
				83.74%	0.998875	



SILVER DEDUCTIBLE CSR - 94%

AV from AVC = 94.6%

Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 94.02%/93.83% = 1.002 x 94.6% = 94.8%

Adjusted AV = 94.8%

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Employ	yer Contribution?	? 🗆	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?				40.00	1st 7	Fier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contril	bution Amount:	\$0.00	2nd 1	Fier Utilization:	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier										
		1 Plan Benefit De	esion		Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined	1	Medical	Drug	Combined			
Deductible (\$)		\$0.00	Combined		ivicultai	Diug	\$6,500.00			
Coinsurance (%, Insurer's Cost Share)	90.00%	70.00%	90.00%				60.00%			
MOOP (\$)		00.00	50.00%				\$8,700.00			
		J0.00					\$6,700.00			
MOOP if Separate (\$)										
Click Here for Important Instructions		Tie	1			-	ier 2		Tier 1	Tier 2
Click Here for important instructions	6.11				6.1.					
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to		Coinsurance, if	Copay, if	Copay applie	
**	Deductible?	Coinsurance?	different	separate		Coinsurance?	different	separate	deduct	
Medical	☐ All	☐ All			☐ All	All			☐ All	All
Emergency Room Services	V			\$75.00					V	
All Inpatient Hospital Services (inc. MH/SUD)	V	V								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$5.00						
X-rays)	ш	П		33.00					Ц	
Specialist Visit				\$15.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient				ćr. 00						
Services				\$5.00						
Imaging (CT/PET Scans, MRIs)	V	☑								
Speech Therapy		П		\$15.00						
Occupational and Physical Therapy				\$6.00						
Preventive Care/Screening/Immunization	П	П	100%							
Laboratory Outpatient and Professional Services		V	20070			-			П	
X-rays and Diagnostic Imaging	V	V			H	H				H
	V	V							ä	
Skilled Nursing Facility									ш	
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
	V	☑								П
Outpatient Surgery Physician/Surgical Services					0					_
Drugs	☐ All	☐ All		<u> </u>	All	All			☐ All	All
Generics				\$5.00						
Preferred Brand Drugs	V			\$20.00						
Non-Preferred Brand Drugs	V	V				Ш				
Specialty Drugs (i.e. high-cost)	V	V								
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2025 Silver Ded	uct 94					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2025 Silver Ded	uct 94					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2025						
# Days (1-10):	0		AVC Version:	2025_1a						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	V									
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0									
Output		ı								
Calculate										
Status/Error Messages:	Frrom Result is or	itside of [-2 ±2]	percent de minin	nis variation						
Actuarial Value:	94.64%	acside of [-2, +2]	persent de million	variation.						
Metal Tier:	J-1.04/0									
IVICLAL LICE.	NOTE: One a			dadattleta.a			ala alain nana ala		aa.a.d at 1000/ !	Abo alon in the
							ui uiis cost-snarin	ig structure is c	overed at 100% by	trie plan in the
Additional Notes:	ueuuctibie range	INUTE: UTTICE-V	risit-specific cost-	snaring is applying	ig to x-rays in c	nnce settings.				
Calculation Time:	1.6055 seconds									
Draft 2025 AV Calculator										



Silver Deductible CSR - 94%, Continued

HDHP Model – Without Prescription Drug Adjustments:

nter valu	ies in the blue cells	s below, ch	oose a sett	ing option f	rom the dr	op down box, and press 'Calculate'.			
ress 'Ca	lculate' anytime a	n input or a	dropdown s	election is a	changed.				
Note th	at the model run-t	time will va	ry based oi	n the comp	uters proce	essing speed.			
A messo	age box will appea	r to indicat	e that the	calculations	are done.				
		Medical	Rx						
Indi	ividual Deductible	300	0						
1	Family Deductible	600	0						
Individ	ual Out-of-Pocket	1,100	1,100						
Fan	nily Out-of-Pocket	2,200	2,200						
Coinsura	nce (50% or Less)	8%	20%						
		Costs	that Accun	nulate					
	0				OOP Deductible /				
		Deductible	Medical	Rx	OOP Type				
	Settings	Medical &	Medical &	Medical &	Stacked				
		Calcu	ulate						
-									
				93.83%	0.998875				



Silver Deductible CSR - 94%, Continued

HDHP Model – With Prescription Drug Adjustments:

Enter valu	ues in the blue cells	s below, ch	oose a sett	ing option j	from the dr	op down box, and press 'Calculate'.		
Press 'Co	ılculate' anytime a	n input or a	dropdown s	election is	changed.			
Note th	at the model run-t	time will va	ry based oi	n the comp	uters proce	essing speed.		
A mess	age box will appea	r to indicat	e that the	calculation	s are done.			
		Medical	Rx					
Ind	ividual Deductible	300	0					
	Family Deductible	600	0					
Individ	lual Out-of-Pocket	1,100	250					
Far	nily Out-of-Pocket	2,200	500					
	,	_,						
Coinsura	ance (50% or Less)	8%	20%					
-	(2070 0. 2022)		2070					
		Costs	that Accun	nulate				
				OOP Deductible /				
	Deductible Medical			Rx	OOP Type	•		
	Settings	Medical &			Stacked	2		
	Settings	Wiedical &	iviculcal &	IX OTHY	Stacked			
		Calc	ulate					
		Cuic	diate					
				94.02%	0.998875			

Certification of Compliance

I hereby certify that I have reviewed the applicable filing requirements for this filing and the filing complies with all applicable statutory and regulatory provisions for the state of Vermont.

Print Name: Karla Austen Title: Chief Financial Officer & Executive Vice President